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A B S T R A C T
Background
Serious illness is oKen characterised by physical/psychological problems, family support needs, and high healthcare resource use.
Hospital-based specialist palliative care (HSPC) has developed to assist in better meeting the needs of patients and their families and
potentially reducing hospital care expenditure. There is a need for clarity on the e,ectiveness and optimal models of HSPC, given that
most people still die in hospital and also to allocate scarce resources judiciously.
Objectives
To assess the e,ectiveness and cost-e,ectiveness of HSPC compared to usual care for adults with advanced illness (hereaKer patients)
and their unpaid caregivers/families.
Search methods
We searched CENTRAL, CDSR, DARE and HTA database via the Cochrane Library; MEDLINE; Embase; CINAHL; PsycINFO; CareSearch;
National Health Service Economic Evaluation Database (NHS EED) and two trial registers to August 2019, together with checking of
reference lists and relevant systematic reviews, citation searching and contact with experts to identify additional studies.
Selection criteria
We included randomised controlled trials (RCTs) evaluating the impact of HSPC on outcomes for patients or their unpaid caregivers/
families, or both. HSPC was defined as specialist palliative care delivered by a palliative care team that is based in a hospital providing
holistic care, co-ordination by a multidisciplinary team, and collaboration between HSPC providers and generalists. HSPC was provided
to patients while they were admitted as inpatients to acute care hospitals, outpatients or patients receiving care from hospital outreach
teams at home. The comparator was usual care, defined as inpatient or outpatient hospital care without specialist palliative care input at
the point of entry into the study, community care or hospice care provided outside of the hospital setting.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. We assessed risk of bias and extracted data. To account for use of
di,erent scales across studies, we calculated standardised mean di,erences (SMDs) with 95% confidence intervals (CIs) for continuous
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data. We used an inverse variance random-e,ects model. For binary data, we calculated odds ratio (ORs) with 95% CIs. We assessed the
evidence using GRADE and created a 'Summary of findings' table.
Our primary outcomes were patient health-related quality of life (HRQoL) and symptom burden (a collection of two or more symptoms). Key
secondary outcomes were pain, depression, satisfaction with care, achieving preferred place of death, mortality/survival, unpaid caregiver
burden, and cost-e,ectiveness. Qualitative data was analysed where available.
Main results
We identified 42 RCTs involving 7779 participants (6678 patients and 1101 caregivers/family members). Twenty-one studies were with
cancer populations, 14 were with non-cancer populations (of which six were with heart failure patients), and seven with mixed cancer and
non-cancer populations (mixed diagnoses).
HSPC was o,ered in di,erent ways and included the following models: ward-based, inpatient consult, outpatient, hospital-at-home or
hospital outreach, and service provision across multiple settings which included hospital. For our main analyses, we pooled data from
studies reporting adjusted endpoint values. Forty studies had a high risk of bias in at least one domain.
Compared with usual care, HSPC improved patient HRQoL with a small e,ect size of 0.26 SMD over usual care (95% CI 0.15 to 0.37; I2 =
3%, 10 studies, 1344 participants, low-quality evidence, higher scores indicate better patient HRQoL). HSPC also improved other person-
centred outcomes. It reduced patient symptom burden with a small e,ect size of -0.26 SMD over usual care (95% CI -0.41 to -0.12; I2 = 0%,
6 studies, 761 participants, very low-quality evidence, lower scores indicate lower symptom burden). HSPC improved patient satisfaction
with care with a small e,ect size of 0.36 SMD over usual care (95% CI 0.41 to 0.57; I2 = 0%, 2 studies, 337 participants, low-quality evidence,
higher scores indicate better patient satisfaction with care). Using home death as a proxy measure for achieving patient's preferred place
of death, patients were more likely to die at home with HSPC compared to usual care (OR 1.63, 95% CI 1.23 to 2.16; I2 = 0%, 7 studies, 861
participants, low-quality evidence). Data on pain (4 studies, 525 participants) showed no evidence of a di,erence between HSPC and usual
care (SMD -0.16, 95% CI -0.33 to 0.01; I2 = 0%, very low-quality evidence). Eight studies (N = 1252 participants) reported on adverse events
and very low-quality evidence did not demonstrate an e,ect of HSPC on serious harms. Two studies (170 participants) presented data
on caregiver burden and both found no evidence of e,ect of HSPC (very low-quality evidence). We included 13 economic studies (2103
participants). Overall, the evidence on cost-e,ectiveness of HSPC compared to usual care was inconsistent among the four full economic
studies. Other studies that used only partial economic analysis and those that presented more limited resource use and cost information
also had inconsistent results (very low-quality evidence).
Quality of the evidence
The quality of the evidence assessed using GRADE was very low to low, downgraded due to a high risk of bias, inconsistency and
imprecision.
Authors' conclusions
Very low- to low-quality evidence suggests that when compared to usual care, HSPC may o,er small benefits for several person-centred
outcomes including patient HRQoL, symptom burden and patient satisfaction with care, while also increasing the chances of patients
dying in their preferred place (measured by home death). While we found no evidence that HSPC causes serious harms, the evidence was
insu,icient to draw strong conclusions. Although these are only small e,ect sizes, they may be clinically relevant at an advanced stage of
disease with limited prognosis, and are person-centred outcomes important to many patients and families. More well conducted studies
are needed to study populations with non-malignant diseases and mixed diagnoses, ward-based models of HSPC, 24 hours access (out-of-
hours care) as part of HSPC, pain, achieving patient preferred place of care, patient satisfaction with care, caregiver outcomes (satisfaction
with care, burden, depression, anxiety, grief, quality of life), and cost-e,ectiveness of HSPC. In addition, research is needed to provide
validated person-centred outcomes to be used across studies and populations.
P L A I N   L A N G U A G E   S U M M A R Y
Eectiveness and cost-eectiveness of hospital-based specialist palliative care (HSPC) for adults with advanced illness and their
unpaid caregivers
Review question
How e,ective is hospital-based specialist palliative care for adults with a terminal illness and their unpaid caregivers, and is it cost-e,ective?
Why is this question important?
Palliative care aims to improve the quality of life of people who have a terminal illness (a disease that cannot be cured and is likely to
lead to death). It seeks to help patients, their unpaid caregivers and families manage symptoms that cause distress (for example, pain)
and to meet patients’ and unpaid caregivers’ needs for psychological, social and spiritual support. Palliative care is known as an ‘holistic’
approach, because it considers the ‘whole’ person and their support network – not just the illness and its symptoms. It usually involves a
team of people that can include physicians, nurses, pharmacists, other allied health professionals, social workers, chaplains or volunteers.
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A growing number of hospitals are setting up specialist palliative care services (known as hospital-based specialist palliative care (HSPC)).
HSPC can be provided:
- either in the hospital itself – for inpatients or outpatients;
- or as 'hospital-at-home' – which means that the hospital team visits patients in the community;
- or across multiple settings (for example, hospital and home).
To find out whether HSPC benefits patients and their unpaid caregivers, and how cost-e,ective it is, we reviewed the evidence from
research.
How did we identify and evaluate the evidence?
First, we searched for all relevant studies in the medical literature. We specifically looked for:
- randomised controlled studies: these are studies where people are randomly divided into di,erent treatment groups. This type of study
provides the most robust evidence about the e,ects of a treatment;
- studies that compared HSPC to either hospital care without specialist palliative care; care received in the community; or hospice care
outside hospital.
We compared the results, and summarised the evidence from all the studies. Finally, we assessed how certain the evidence was. We
considered factors such as the way studies were conducted, study sizes, and consistency of findings across studies. Based on our
assessments, we categorised the evidence as being of very low, low, moderate or high certainty.
What did we find?
We found 42 studies that involved a total of 6678 patients and 1101 caregivers or family members. The patients were su,ering from: cancer
(21 studies); an advanced illness that was not cancer (14 studies); and a combination of cancer and non-cancer (mixed) diagnoses (7
studies). Patients in six of the 14 non-cancer studies had heart failure. Almost half (19) of the studies were set in the USA. Thirteen studies
reported information on the costs of HSPC.
The evidence from the studies we found suggests that, when compared to usual care:
- HSPC may slightly improve patients’ health-related quality of life, their overall symptom burden and their satisfaction with care;
- HSPC may increase the chances of people dying in their preferred place of death.
It is unclear what the e,ects of HSPC are on pain, caregivers’ burden, or unwanted events. This is because the evidence we found was
not robust (very low-certainty evidence). Similarly, because the evidence relating to costs was of very low certainty, it is unclear how cost-
e,ective HSPC is.
What does this mean?
When compared with usual care, HSPC may slightly improve a patient’s quality of life, symptom burden and their satisfaction with care. It
may also increase their chances of dying at home. However, future research is likely to change these findings, since they are based on low-
certainty evidence. We need further studies to evaluate the e,ect of HSPC on other outcomes, such as pain, caregivers’ burden, unwanted
events and cost-e,ectiveness.
How-up-to date is this review?
The evidence in this Cochrane Review is current to August 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Hospital-based specialist palliative care compared to usual care for adults with advanced illness and their caregivers/
families
Hospital-based specialist palliative care compared to usual care for adults with advanced illness and their unpaid caregivers/families
Patient or population: adults with advanced illness and their unpaid caregivers/families
Setting: hospital and home
Intervention: hospital-based specialist palliative care
Comparison: usual care
Anticipated absolute effects* (95% CI)Outcomes












Patient health-related quality of life
(HRQoL) i, SD units
(higher scores indicate better quality of
life)
Follow-up: range two weeks after hospi-
talisation to 13 months
Mean (SD) ranging from -45.4 (26.83)
to 131.14 (26.62)
SMD 0.26 SDs higher





Patient symptom burden assessed with
generalised measuresii, SD units
(lower scores indicate lower symptom
burden)
Follow-up: range two weeks after hospi-
talisation to 13 months
Mean (SD) ranging from -19.3 (4.2) to
268.59 (201.65)
SMD 0.26 SDs lower






Patient satisfaction with care iii, SD units
(higher scores indicate better patient sat-
isfaction)
Follow-up: range 3 months to 6 months
Mean (SD) ranging from 6.4 (1.1) to
68.37 (9.03)
SMD 0.36 SDs higher





Achieving patient preferred place of
death (measured by number of patients
with home death)
Follow-up: range 1 month to 13 months





















































































































































































Pain iv , SD units
(lower scores indicate less pain)
Follow-up: range 8 weeks to 6 months
Mean (SD) ranging from 2.2 (3.7) to
28.19 (32.81)
SMD 0.16 SDs lower






Unpaid caregiver burden v
Follow-up: 6 months
Only two studies reported adjusted endpoint values but we could not pool
them in a meta-analysis. They both found no between-group difference be-





Cost and cost-effectiveness Of 13 studies reporting costs of HSPC, nine studies found no difference be-
tween HSPC and usual care and two studies favoured HSPC over usual care.
The difference in cost was unclear in one study, while another study reported
mixed findings with lower cost of hospitalisation in favour of HSPC but no dif-
ference in the cost of emergency room visit.







*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; OR: Odds ratio; RCT: randomised controlled trial; RR: Risk Ratio; SMD: standardised mean difference
i. Assessed with the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), Functional Assessment of
Cancer Therapy - Bone Marrow Transplant (FACT-BMT), Functional Assessment of Cancer Therapy - General Measure (FACT-G), Functional Assessment of Cancer Therapy –
Lung scale (FACT-L), Functional Assessment of Chronic Illness therapy for Palliative Care (FACIT-Pal), Functional Assessment of Chronic Illness Therapy - Spiritual Well-being
Scale (FACIT-Sp), McGill Quality of Life Questionnaire (McGill QoL questionnaire) and Minnesota Living with Heart Failure Questionnaire (MLHF questionnaire).
ii. Assessed with the Edmonton Symptom Assessment Scale (ESAS) or a modified form of it, severity subscale of the Memorial Symptom Assessment Scale (MSAS), symptom
impact subscale of the Quality of Life at End of life (QUAL-E), Rotterdam Symptom Checklist (RSC - Physical Symptoms Score) and lung cancer subscale of the FACT-L.
iii. Assessed with 16-item Family Satisfaction with Care - Patient Version (FAMCARE-P16) and Modified City of Hope Patient Questionnaires - Place of Care Environment Scale
(MCOHPQ - Place of Care Environment Scale).
iv. Assessed with pain item of EORTC QLQ-C30 and Brief Pain Inventory (BPI).
v. Assessed with Montgomery-Borgatta Caregiver Burden Scale and Zarit Burden Inventory
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect











































































































































































b We downgraded by 1 level due to inconsistency between our main meta-analysis and sensitivity analyses.
c We downgraded by 1 level for imprecision due to the small number of participants.
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B A C K G R O U N D
The global burden of disease has increased, and this change is
placing considerable strain on healthcare systems internationally
(Bloom 2016). Most adults develop one or more chronic illnesses
with which they may live for many years before they die. For
a minority of patients with serious illness, the time following
diagnosis is characterised by a stable period of relatively good
functional and cognitive performance, followed by a predictable
and short period of functional and clinical decline. The time
following diagnosis may also be characterised by months to
years of physical and psychological symptom distress, progressive
functional dependence and frailty, considerable family support
needs and high healthcare resource use (Evans 2019; Prince
2015). In addition to increased clinical complexity, the rise of
ageing populations has led to considerable healthcare costs
globally. This has occurred despite e,orts to reduce acute hospital
care expenditure in many high-income countries, including, for
example, in the USA (Kashihara 2012), and the UK (Imison 2017;
Lafond 2014), by shiKing care from the hospital setting to primary
care and the community.
It could be argued that increased sta,ing costs and the introduction
or expansion of novel services in hospitals and the community,
such as specialist palliative care, plays a role in this increased
expenditure. Hospital-based palliative care encompasses palliative
care interventions that are delivered by specialist palliative care
teams based in a hospital to patients with advanced (C-TAC 2015),
life-limiting (Palliative Care Australia 2005), or life-threatening
illness (NCP 2013), which is likely to compromise their quality of life
(WHOQOL Group 1995). The care is provided to the patient while
they are admitted as inpatients to acute care hospitals, outpatients
or patients receiving care from hospital outreach teams at home.
Between 2000 and 2016, the prevalence of specialist palliative care
in hospitals with 50 or more beds increased by 178% in USA, from
25% of hospitals in 2000 to 75% in 2016 (CAPC 2018). Furthermore,
the growth of specialist palliative care in acute hospitals is likely to
continue in the foreseeable future as most older adults (≥ 65 years
old) die in hospitals (Broad 2013), most deaths in hospital occur
due to terminal illness (Pivodic 2016), and also because deaths
in institutional care persist into older stages of life, with one in
five centenarians dying in hospital (Evans 2014). In the UK, it has
been estimated that by 2040 about 160,000 more people yearly are
likely to have palliative care needs, including pain management
in chronic illnesses and end-of-life care in hospitals, hospices and
at home (Etkind 2017). Cost-e,ective commissioning of end-of-life
resources has been highlighted as a priority (PHE 2017). Preliminary
evidence shows that palliative care improves clinical outcomes
and quality of care (Higginson 2003). Furthermore, palliative care,
which includes bereavement care and preparatory grief work, has
the potential to help unpaid caregivers access the care they need
related to the death of a loved one (Grande 2017).
The numbers of inpatient hospital palliative care teams are
increasing (CAPC 2018; Meier 2011). This is occurring in response
to unmet palliative care needs of inpatients and their unpaid
caregivers (Meier 2011), yet clarity around e,ective models of
care are needed. This Cochrane Review will provide much-
needed clarity regarding the e,ectiveness and cost-e,ectiveness of
hospital-based specialist palliative care. In the review, five di,erent
models of hospital-based specialist palliative care were specified
due to its evolving nature and also to make the findings more
relevant to clinical practice. The models of hospital-based specialist
palliative care eligible are ward-based models, inpatient consulting
models, outpatient models, hospital-at-home or hospital outreach
models (hereaKer outreach model) and service provision across
multiple settings which included hospital. The review findings
will have the potential to aid the future development, funding
and implementation of hospital-based specialist palliative care.
This may help transform services, which have mostly developed
locally in culturally responsive ways in relation to local needs and
populations (Higginson 2003; Kamal 2013). Therefore, the review
will help deliver hospital-based specialist palliative care services
in the midst of increased ageing populations that present with
complex clinical needs against a backdrop of fiscal constraint and
increased healthcare utilisation.
Description of the condition
Population-based estimates of palliative care have indicated
which populations require this service (Murtagh 2014), including
those with malignant neoplasms and non-malignant and
other health-related conditions, specifically: heart disease,
including cerebrovascular disease, renal disease, liver disease,
respiratory disease, neurodegenerative disease (Huntington’s
disease, Parkinson’s disease, multiple sclerosis, motor neuron
disease, multi-system degeneration, progressive supranuclear
ophthalmoplegia, Alzheimer's dementia and senility) and HIV/
AIDS. Patients with any of these conditions and their unpaid
caregivers were considered for inclusion in this review.
Description of the intervention
The intervention of interest is hospital-based specialist palliative
care (HSPC). In this review, hospital-based specialist palliative care
encompasses the following essential components:
• care co-ordinated by a multiprofessional or multidisciplinary
team;
• collaboration between specialist palliative care providers and
generalist providers; and
• holistic care (NCP 2013).
HSPC refers to care that is provided with the input of specialist
palliative care providers to patients while they are admitted as
inpatients to acute care hospitals, outpatients or patients receiving
care from hospital outreach teams at home. The models of
HSPC eligible for inclusion include ward-based models, inpatient
consulting models, outpatient models, hospital outreach models
and service provision across multiple settings which included
hospital. Ward-based models encompassed care provision to
patients and their families on a palliative care ward in hospital.
Inpatient consulting models encompassed care provision to
patients and their families by an inpatient consult team while
they are admitted as inpatients to acute hospitals. Outpatient
models comprised care provision to hospital outpatients and
their families. Hospital-at-home or hospital outreach into the
community involved care provision by hospital outreach teams in
the patient's home as well as service provision across multiple
settings including hospital.
The intervention aims to prevent or relieve physical, psychological,
social and spiritual problems. It is provided to patients who have
a malignant and/or non-malignant condition who may or may not
be at the end of their life (Dixon 2015). Recognising the importance
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of the informal unpaid caregiver, palliative care also aims to meet
the psychological, social and spiritual needs of unpaid caregivers.
(Grande 2017).
At the heart of palliative care is the belief that every person is
unique, autonomous and that they have the right to continue
to live and enjoy quality of life even though they are diagnosed
with an advanced, life-limiting or life-threatening illness. Specialist
palliative care is di,erentiated from generalist palliative care.
Specialists are likely to have received higher specialist training
in palliative care work and services focus mainly or exclusively
on patients with palliative care needs; whereas for generalists,
provision of palliative care is a component of their service provision
(Dixon 2015) and they will not have received higher specialist traing
in palliative care. Specialist care is mostly provided to patients
with advanced, life-limiting or life-threatening illness who present
with complex needs (NHS England 2016). Complexity, although
sometimes di,icult to define, involves clinical complexity and
its interaction with the confidence or ability of the lead clinical
team (generalists) to address the presenting need. Complexity may
involve intertwined and multiple factors which may include related
age, the serious nature of illness, social or familial backgrounds,
and/or the nature of a symptom (e.g. the usualness or intractable
nature of the symptom) (Palliative Care Australia 2005; Quill 2013).
Pre-bereavement interventions are also specialist palliative care
interventions administered to prevent or manage bereavement-
related physical, psychological, social and spiritual problems
experienced by unpaid caregivers prior to the death of the patient
(Aoun 2017; Breen 2014). We included specialist palliative care
interventions involving pre-bereavement interventions either to
the unpaid caregiver alone or together with the patient.
How the intervention might work
Although positive outcomes, such as symptom reduction,
improved quality of care and care co-ordination, and reduced
hospital costs, can result from hospital-based specialist palliative
care, qualitative methods such as interviews and empirical
testing using randomised controlled trials have yet to definitively
establish how hospital-based specialist palliative care might
work. Therefore, any descriptions of how hospital-based specialist
palliative care may work are speculative. That acknowledged,
hospital-based specialist palliative care may work with patients by
the following:
• directly improving symptoms (including physical and
psychological symptoms, such as uncertainty and feelings of
loss) through specialist interventions and holistic care (Temel
2010);
• improving care quality by delivering or facilitating improved
care co-ordination and person-centred holistic care (Daveson
2014; Pinnock 2011);
• reducing futile medical interventions by mitigating against
disease-modifying priorities through optimal communication
and shared decision-making practice (Harris 2013
• addressing holistic needs that span multimorbidity (Burge
2012); and
• reducing unnecessary hospital costs through significant
reduction in pharmaceutical, laboratory and intensive care unit
costs (May 2014);
In addition, findings from published a systematic review (Harding
2012), RCTs (Allen 2008; Hudson 2005), and a before-and-aKer study
(Lichtenthal 2011), indicated that the intervention may work for
unpaid caregivers prior to the death of the patient through the
following mechanisms:
• emphasising the positive aspects of caregiving by
providing relevant information, guidance and instruction. The
intervention may also work by providing unpaid caregivers with
individual support to see problems di,erently, draw out their
optimism, helping them to plan and by providing them with
access to expert information;
• improving the unpaid caregiver’s understanding of their
experiences and role to result in increased caregiving
competencies and knowledge;
• aiding their interpretation of their circumstance and
normalising their emotional responses to caregiving demands;
• enabling their involvement in care planning, where possible;
• engaging both patients and unpaid caregivers in a life review
within consultations which may work to reduce unpaid
caregivers’ stress; and
• ensuring timely assessment of needs, adaptive coping and
access to needs-based care through pre-bereavement work.
The intervention may therefore also work via a preventive
mechanism.
Why it is important to do this review
A previous systematic review by Higginson 2002 showed that
hospital-based palliative care improved clinical outcomes and
quality of care and can reduce hospital costs. However, this review
was small (nine studies) and only included cancer patients. A recent
review in hospital, hospice or community settings by Gaertner
2017 showed that specialist palliative care led to improvement
in quality of life with significant benefits for patients with cancer
receiving specialist palliative care early. The results for pain
and other outcomes were inconclusive. Another review by Haun
2017 showed that early palliative care interventions resulted in
improved quality of life and lower symptom intensity compared
with the control condition. Survival and levels of depression did
not di,er significantly between the early palliative care group and
control group.
Since the publication of these systematic reviews, there have been
at least six newly published RCTs on hospital-based specialist
palliative care and no review on its di,erent models. In addition,
the models of palliative care are continuously evolving. Recent
UK government (DoH 2008), and commissioning guidance (NCPC
2012), have recommended that there ought to be delivery of a 24/7
palliative care service. However, the End of Life Care Audit 2016
showed that of the 142 acute NHS trusts in England participating,
only 37% had specialist palliative care services available out-of-
hours and this service varied with level of contact (telephone or
on-site visiting) and health professional involved (specialist nurse,
junior doctor or consultant) (RCP 2016). The research priorities
identified by the James Lind Alliance highlighted the need for
research into identifying the core palliative care services needed
and the best way of providing palliative care outside of working
hours (JLA 2015). This Cochrane Review addresses these priorities.
It is important that, following the Liverpool Care Pathway and
Neuberger review, we examine the most e,ective methods and
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models of hospital-based specialist palliative care in order to
ensure that there is an evidence-based approach to its delivery
(Crown 2013).
A Cochrane Review has provided valuable evidence synthesis
on the e,ectiveness and cost-e,ectiveness of home palliative
care services (Gomes 2013). However, there is no such available
evidence for specialist palliative care in hospital inpatient,
outpatient, outreach and services provided across multiple
settings. Furthermore, the numbers of hospital-based specialist
palliative care teams are increasing (CAPC 2018; Meier 2011). This
is occurring in response to unmet palliative needs of patients
and their unpaid caregivers (Meier 2011), yet clarity regarding
the e,ective components of the intervention is needed. This
review may therefore assist with providing much-needed solutions
to problems, and clarity regarding the e,ectiveness and cost-
e,ectiveness of the component parts of hospital-based specialist
palliative care. In essence, the review may address some of the
problems encountered by contemporary healthcare systems and
services, service-users, clinicians, policy-makers, researchers and
commissioners.
O B J E C T I V E S
To assess the e,ectiveness and cost-e,ectiveness of hospital-based
specialist palliative care compared to usual care for adults with
advanced illness and their unpaid caregivers/families.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Due to the increasing numbers of RCTs in palliative and end-of-
life care, and also because they are the most robust experimental
design, this review only included RCTs (including cluster-unit
randomised trials). We used established approaches to include
and analyse RCTs following the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a).
All studies evaluated e,ectiveness regarding one or more of our
primary or secondary outcomes. In the economic component of
the review, we included studies conducted alongside (or as part of)
the main e,ectiveness trial and ones that also met the eligibility
criteria for the e,ectiveness component. Full economic evaluation
(i.e. cost-e,ectiveness analyses, cost-utility analyses, cost-benefit
analyses); partial economic evaluations (i.e. cost analyses, cost-
description studies, cost-outcome descriptions); and studies that
reported more limited information, such as estimates of resource
use or costs associated with service use, were eligible for inclusion.
Types of participants
• Adult (≥ 18 years) patients receiving hospital-based specialist
palliative care:
* these patients were diagnosed with advanced, life-limiting or
life-threatening illness (malignant or non-malignant), which
was likely to compromise their quality of life in some way;
* diseases and health-related conditions included (with
the corresponding International Classification of Diseases
(ICD-10)) malignant neoplasms (ICD-10 codes: C00-C97)
and non-malignant and other health-related conditions,
specifically: heart disease, including cerebrovascular disease
(ICD-10 codes: I00-I52, I60-69), renal disease (ICD-10 codes:
N17, N18, N28, I12, I13), liver disease (ICD-10 codes: K70-K77),
respiratory disease (ICD-10 codes: J06-J18, J20-22, J40-47,
J96), neurodegenerative disease (Huntington’s disease
(ICD-10 code: G10), Parkinson's disease (ICD-10 code: G20),
multiple sclerosis (ICD-10 code: G35), motor neuron disease
(ICD-10 code: G12.2)), multi-system degeneration (ICD-10
code: G90.3), progressive supranuclear ophthalmoplegia
(ICD-10 code: G23.1), Alzheimer’s dementia and senility
(ICD-10 codes: F01, F03, G20, R54), and HIV/AIDS (ICD-10
codes: B20-B24)); and
• unpaid caregivers, including those who had received a pre-
bereavement intervention from one or more hospital-based
specialist palliative care sta, in order to manage or alleviate
bereavement-related problems prior to the death of the
inpatient: unpaid caregivers are likely to be family, friends or
significant others associated with the patient (Payne 2010a;
Payne 2010b).
Types of interventions
Hospital-based Specialist Palliative Care (herein HSPC) varies
between settings and countries. In order to allow for these
di,erences, we included studies that described HSPC as "palliative
care, generic palliative care, hospice care (provided in hospital
settings) or specialist palliative care". It was delivered by a specialist
palliative care team or by a "specialist palliative care", "palliative
care" or "hospice outreach (based in hospital settings)" sta,
member. In order to account for di,erences in specialist palliative
care between countries, and also because of the sometimes limited
details provided on the specialist training of palliative care teams,
we decided to include studies where training/clinical experience
in specialist palliative care was made explicit as well as those
that simply stated the involvement of a palliative care team;
eligibility was informed by activity of delivering specialist palliative
care rather than level of specialist training (Luckett 2014). Higher
specialist training in palliative care was also accepted if the authors
described the professionals as palliative care experts or specialists
(for example, palliative care physician or nurse) or if they had
obtained clinical competencies and professional characteristics
required for the delivery of specialist palliative care through clinical
experience (NCPC 2012). The intervention was provided to adults
receiving hospital inpatient, outpatient, outreach or HSPC as part
of wider services, and their unpaid caregivers/families.
We included studies of HSPC compared with usual care. Usual
care was defined as inpatient or outpatient hospital care without
specialist palliative care input (e.g. oncological care) at the point
of entry into the study, community care (e.g. primary or specialist
care provided in the patient’s place of residence) or hospice
care provided outside of the hospital setting. Usual care patients
may receive specialist palliative care aKer entry into the study
if requested by the patient, their families or clinicians, however
specialist palliative care should not be a routine part of usual
care. We extracted descriptive data on what was involved in each
intervention.
Similar to a Cochrane Review that examined home palliative care
(Gomes 2013), we excluded trials that evaluated hospital palliative
care practitioners’ provision of only a biomedical component of
palliative care (e.g. oxygen therapy) as this does not encompass the
holistic nature of palliative care assessment or treatment.
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Types of outcome measures
We developed the primary and secondary outcomes for this review
from previous reviews regarding the e,ectiveness of palliative care
and those that we thought to be clinically relevant (Gomes 2013;
Gysels 2004; Higginson 2003; Higginson 2010). The outcomes reflect
the multicomponent nature of palliative care and the provision of
both direct (e.g. face-to-face delivery of patient care) and indirect
(e.g. concerning practitioners' prescribing rationale) patient care,
and care for unpaid caregivers/families while the patient is still
alive. We chose to measure health-related quality of life and
symptom burden reported as adjusted endpoint values as our
primary outcomes. We selected health-related quality of life and
symptom burden as primary outcomes because the major focus of
palliative care is to improve quality of life while providing optimal
management of symptoms (Dixon 2015).
Primary outcomes
• Patient health-related quality of life, measured using validated
assessment scales which may be generic and disease/condition-
specific health-related quality of life measures; and
• Patient symptom burden, specifically, a collection of two
or more symptoms which could be physical (e.g. pain),
psychological (e.g. anxiety, depression), social or spiritual
domains, either patient or proxy-reported through validated
generalised assessment scales.
Secondary outcomes
• Patient satisfaction with care through validated assessment
scales;
• Caregiver/family satisfaction with care through validated
assessment scales;
• Achieving patient's preferred place of care;
• Achieving patient's preferred place of death;
• Patient mortality/survival;
• Pain measured using validated assessment scales;
• Patient anxiety and depression measured using validated
assessment scales;
• Breathlessness measured using validated assessment scales;
• Adverse events in participants and unpaid caregivers;
• Unpaid caregiver symptom control, specifically physical,
psychological (e.g. anxiety and depression), social or spiritual
domains, reported through validated assessment scales and
burden, including emotional strain, burden, distress, mastery
or positive aspects of caregiving through validated assessment
scales;
• Unpaid caregiver pre- and post-bereavement outcomes,
reported using validated outcome scales of multidimensional
caregiving experiences (strain, distress, positive appraisals, and
family well-being), caregiver prolonged grief, multidimensional
grief responses (despair, panic behaviour, blame and anger,
detachment, disorganisation and personal growth), quality of
life.
• Resource use: institutional care services use (e.g. emergency
department (ED) or accident and emergency (A&E), intensive
care unit use, inpatient stay, care in nursing homes (or
skilled nursing homes) etc.), outpatient clinic services use (e.g.
palliative care visits in outpatient settings, consultation with
experts in outpatient settings), community care services use
(e.g. contact with general practitioners, district nurses, home
care, hospice care at home etc.), unpaid caregiver's care, and
medications and other resources;
• Costs and cost-e,ectiveness: costs were calculated based on
resource use and unit costs of services, while cost-e,ectiveness
was measured using e.g. incremental cost-e,ectiveness ratios
of costs and condition-specific outcome measures or quality-
adjusted life years (QALYS) or an equivalent.
Search methods for identification of studies
We identified studies through electronic searches, handsearching,
electronic citation tracking, personal contact and searching of grey
literature. We did not place restrictions on language; we assessed
non-English papers with the assistance of a native speaker.
Electronic searches
We identified studies by searching the databases listed below, using
a combination of key terms and MeSH terms:
• Cochrane Library:
* Cochrane Central Register of Controlled Trials (CENTRAL);
Issue 8 of 12, 2019
* Cochrane Database of Systematic Reviews (CDSR); Issue 8 of
12, 2019
* Database of Abstracts of Reviews of E,ects (DARE), Issue 2 of
4, 2015;
* Health Technology Assessment (HTA), Issue 4 of 4, 2016;
* National Health Service Economic Evaluation Database (NHS
EED), Issue 2 of 4, 2015;
• MEDLINE & MEDLINE-in-Process (OVID), 1947 to 27 August 2019;
• Embase (OVID), 1974 to 27 August 2019;
• CINAHL (EBSCO),1982 to 28 August 2019;
• PsycINFO (OVID), 1806 to 28 August 2019;
• CareSearch, Australian Government's Department of Health and
Ageing (http://www.caresearch.com.au/) (from inception to 12
September 2019).
We could not carry out more recent searches in DARE, HTA and
NHS EED because they are no longer updated. We also could not
carry out a search of the health economic database EURONHEED
as it is no longer available. We refined our search strategies with
the assistance of the Information Specialist of the Cochrane Pain,
Palliative and Supportive Care Review Group. Please see Appendix
1 for the MEDLINE search strategy in OVID and Appendix 2, Appendix
3, Appendix 4, Appendix 5 and Appendix 6 for all other search
strategies.
Searching other resources
We searched clinicaltrials.gov (www.clinicaltrials.gov) and the
World Health Organisation (WHO) International Clinical Trials
Registry Platform (ICTRP) (http://apps.who.int/trialsearch/) for
ongoing trials on 12 September 2019 (search term: palliative).
Handsearching
We screened the reference lists of all included studies, and three
relevant systematic reviews (Haun 2017; Gaertner 2017; Gomes
2013), for additional studies.
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Electronic citation tracking
We used the "Citation tacking" option in MEDLINE for lateral
searching on the included studies, as recommended for palliative
care reviews (Payne 2010a).
Personal contact
We contacted 15 experts in the field for unpublished and ongoing
trials. We also contacted study authors for additional information
where necessary.
Data collection and analysis
Selection of studies
Two review authors (AO and SB) independently screened all titles
and abstracts identified in our electronic searches. If, aKer reading
the abstract, doubt persisted regarding the eligibility of the study,
we retrieved the full-text articles for further assessment and again
the two reviewers independently assessed these full-text articles.
We resolved disagreements by discussion and consensus. We
reported our study selection process using a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram (Liberati 2009) in Figure 1, as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a).
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Figure 1.   PRISMA flow diagram.
 
Data extraction and management
Two reviewers (AO and SB) independently extracted data from all
included studies using a piloted data extraction form (Appendix
7), that we further developed for economic evaluation based on
the format and guidelines used to produce structured abstracts of
economic evaluations for inclusion in the NHS EED. We entered
data into Review Manager (RevMan) (RevMan 2014). We resolved
any disagreements by discussion and consensus. Given that the
review included some studies by the review authors, we did
not involve these authors in the assessment of or extraction of
data from their studies. The data extraction form has been used
previously for a review on the e,ectiveness of home palliative care
(Gomes 2013). We adapted the form for this review regarding HSPC.
We collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
collected characteristics of the included studies in su,icient detail
to populate a 'Characteristics of included studies' table.
Assessment of risk of bias in included studies
Two reviewers (AO and SB)independently assessed risk of
bias for each included study, using the criteria outlined in
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the Cochrane Handbook for Systematic Reviews of Interventions
(Chapter 12, Schunemann 2011), with any disagreements resolved
by discussion. We completed a 'Risk of bias' table for each included
study using the 'Risk of bias' tool for randomised controlled studies
in RevMan (RevMan 2014).
We assessed the following for each included study:
• Random sequence generation (checking for possible selection
bias). We assessed the method used to generate the allocation
sequence as:
* low risk of bias (any truly random process, e.g. random
number table; computer random number generator); or
* unclear risk of bias (method used to generate sequence not
clearly stated);
* we excluded studies that used a non-random process (e.g.
odd or even date of birth; hospital or clinic record number).
• Allocation concealment (checking for possible selection bias).
The method used to conceal allocation to interventions prior to
assignment determines whether intervention allocation could
have been foreseen in advance of, or during recruitment, or
changed aKer assignment. We assessed the methods as:
* low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes); or
* unclear risk of bias (method not clearly stated);
* we excluded studies that did not conceal allocation.
• Blinding of participants and personnel (checking for possible
performance bias) (subjective). We assessed the methods used
to blind study participants and personnel from knowledge
of which intervention a participant received for subjective
outcomes (e.g. quality of life, pain, breathlessness). We grouped
all subjective outcomes as being at high risk of bias if blinding
was unsuccessful. When the study did not include subjective
outcomes, we leK this domain blank. We assessed the methods
as:
* low risk of bias (blinding of participants and key study
personnel ensured, and unlikely that the blinding could have
been broken);
* unclear risk of bias (insu,icient information to permit
judgement of ‘low risk’ or ‘high risk’);
* high risk of bias (no blinding or incomplete blinding; blinding
of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome
is likely to be influenced by lack of blinding).
• Blinding of participants and personnel (checking for possible
performance bias) (objective). We assessed the methods used to
blind study participants and personnel from knowledge of which
intervention a participant received for objective outcomes (e.g.
mortality, length of stay in hospital, number of readmissions).
When the study did not include objective outcomes, we leK this
domain blank. We assessed the methods as:
• low risk of bias (objective outcomes are unlikely to be
influenced by lack of blinding and we treated these outcomes
as a 'low risk of bias' even if blinding was unsuccessful or not
carried out);
• unclear risk of bias (insu,icient information to permit
judgement of ‘low risk’ or ‘high risk’); or
• we did not rate a high risk of bias for an objective outcome.
• Blinding of outcome assessment (checking for possible
detection bias) (subjective). We assessed the methods used to
blind outcome assessors from knowledge of which intervention
a participant received for subjective outcomes. We grouped all
subjective outcomes as being at high risk of bias if blinding
was unsuccessful. When the study did not include subjective
outcomes, we leK this domain blank. We assessed the methods
as:
* low risk of bias (blinding of outcome assessment ensured,
and unlikely that the blinding could have been broken);
* unclear risk of bias (insu,icient information to permit
judgement of ‘low risk’ or ‘high risk’); or
* high risk of bias (no blinding of outcome assessment;
blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is
likely to be influenced by lack of blinding).
• Blinding of outcome assessment (checking for possible
detection bias) (objective). We assessed the methods used to
blind outcome assessors from knowledge of which intervention
a participant received for objective outcomes. Objective
outcomes are unlikely to be influenced by lack of blinding and
we rated these outcomes as a 'low risk of bias' even when
blinding was unsuccessful or not carried out. When the study did
not include objective outcomes, we leK this domain blank. We
assessed the methods as:
• low risk of bias (e.g. no blinding of outcome assessment, but
the review authors judge that the outcome measurement is
not likely to be influenced by lack of blinding; blinding of
outcome assessment ensured, and unlikely that the blinding
could have been broken);
• unclear risk of bias (insu,icient information to permit
judgement of ‘low risk’ or ‘high risk’); or
• we did not rate a high risk of bias for an objective outcome.
• Selective reporting (checking for reporting bias). We assessed
whether primary and secondary outcome measures were
prespecified and whether these were consistent with those
reported. We assessed the methods as:
* low risk of bias (protocol is available and all of the study’s
prespecified primary and secondary outcomes that are of
interest in the review have been reported in the prespecified
way);
* unclear risk of bias (insu,icient information to permit
judgement of ‘low risk’ or ‘high risk’, including, when the
protocol is not available); or
* high risk of bias (protocol is available and some prespecified
outcomes were not reported; one or more primary outcomes
were reported using measurements, analysis methods
or subsets of the data (e.g. subscales) that were not
prespecified; one or more reported primary outcomes were
not prespecified).
• Incomplete outcome data (checking for possible attrition bias
due to the amount, nature and handling of incomplete outcome
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data). We assessed the methods used to deal with incomplete
data as:
* low risk (< 10% of participants did not complete the study or
used ‘baseline observation-carried-forward’ analysis);
* unclear risk of bias (used 'last-observation-carried-forward'
analysis or when the number of dropouts was not reported);
or
* high risk of bias (used 'completer' analysis).
• Other bias (other sources of bias). We also assessed whether
groups were balanced at baseline and whether di,erences at
baseline were controlled for. We assessed the studies as:
* low risk of bias (e.g. if there were no baseline di,erences or if
observed di,erences were controlled for);
* unclear risk of bias (e.g. if there were baseline di,erences and
it was unclear if the di,erences were significant and also if
they were controlled for); or
* high risk of bias (e.g. if there were di,erences that were not
controlled for).
• Size of study (checking for possible biases confounded by small
size). We assessed studies as being at:
* low risk of bias (≥ 200 participants per treatment arm);
* unclear risk of bias (50 to 199 participants per treatment
arm; 50 to 199 participants in one treatment arm and ≥ 200
participants in another treatment arm; < 50 participants in
one treatment arm and 50 to 199 participants in another
treatment arm); or
* high risk of bias (< 50 participants per treatment arm).
Quality assessment in studies with a cost/cost-eectiveness
component
We classified health economics studies per the design of the health
economic study (e.g. full economic evaluation, partial economic
evaluation) and the design of the study generating the e,ectiveness
data of the health economic study (e.g. a single study design, a
synthesis of several studies). For full economic evaluations, we
assessed the risk of bias in results of the single e,ectiveness
study on which the full economic evaluation study was based
and methodological quality of the full economic evaluation study.
We used as checklists the BMJ Checklist for authors and peer
reviewers of economic submissions (Drummond 1996), and the
Consensus on Health Economic Criteria (CHEC) list for assessment
of methodological quality of economic evaluations (Evers 2005).
For assessment of the quality of relevant economic modelling
studies, we planned to use tools such as the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) statement
(Husereau 2013), and the Quality Appraisal Checklist for Economic
Evaluations (NICE 2012), supplemented by the Philips Checklist
(Philips 2004). We could not apply these planned methods in this
review as we did not identify any relevant economic modelling
studies for inclusion; we plan to use these tools for future updates
of the review, where appropriate.
Measures of treatment eect
If appropriate, we undertook meta-analysis of the primary
and secondary outcomes using RevMan (RevMan 2014). Given
that eligible studies were conducted with di,erent populations,
countries and years, and that they included di,erent models of
HSPC, we had to incorporate the assumption of heterogeneity in
the meta-analysis of our outcomes. We used the inverse variance
random-e,ects model for meta-analysis. This method summarises
e,ect sizes from studies by calculating the weighted mean of the
e,ect sizes using the inverse variance of the individual studies as
weights (Lee 2016).
We combined data from the RCTs for the primary outcomes (patient
health-related quality of life and patient symptom burden) and
expressed the pooled e,ect as standardised mean di,erence (SMD)
for HSPC compared to usual care; values greater than 0 indicated
better patient health-related quality of life with HSPC, and less
than 0 indicated worse health-related quality of life. By contrast, for
symptom burden, values greater than 0 indicated higher symptom
burden and less than 0 reduced symptom burden.
We used a P value of 0.05 as the cut-o, value to determine statistical
significance and we presented data as e,ect size with 95% CIs.
We did not combine change values with endpoint values in our
meta-analysis because we pooled the data using SMD (Deeks 2011).
Furthermore, we pooled adjusted endpoint values presented for
patient health-related quality of life and patient symptom burden
as our main analyses because adjusted endpoint values control for
di,erences and provide the most precise and least biased estimates
of treatment e,ects (Deeks 2011). Where possible, we conducted
similar meta-analyses for the other outcomes with the exception
of achieving preferred place of death (measured as home deaths)
where we expressed the pooled e,ect as an odds ratio (OR) for
HSPC compared to usual care; values greater than 1 indicated
increased odds of achieving preferred place of death with HSPC,
and less than 1 indicated decreased odds. Even though we used ORs
to detect treatment e,ect, we also presented findings as risk ratios
(RRs) (or relative risk) in order to aid the use and interpretation
of the findings by end users. We used the Mantel-Haenszel (M-H)
method in the meta-analysis for achieving preferred place of death.
In order to combine di,erent instruments in which an increase in
score indicates improvement or an increase in score is worse in the
same meta-analysis, we multiplied the mean values from one set of
studies by -1 to ensure that all the scales were in the same direction.
In order to interpret subgroup di,erences in our subgroup analyses,
we considered the test for subgroup di,erences and also checked
for confidence interval overlap. Where P values were < 0.05 in the
test for subgroup di,erences, we considered this to be evidence of a
subgroup e,ect. However, we were cautious in the interpretation of
our subgroup analyses where there were a small number of studies
and participants.
We considered that a SMD of 0.2 to < 0.5 constituted a small e,ect,
0.5 to < 0.8 a moderate e,ect and ≥ 0.8 constituted a large e,ect
(Cohen 1988).
Economic data
We presented characteristics of the included health economics
studies, such as year of study; details of interventions and
comparators; study design; data sources; jurisdiction and setting;
analytic perspective and time horizon, in the 'Characteristics
of included studies' table as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We summarised characteristics and results of included economic
evaluations using additional tables, supplemented by a narrative
summary that compared and evaluated methods used and
principal results between studies. Where possible, we presented
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point estimates of measures of items of resource use and cost with
associated measures of uncertainty for both the intervention and
its comparators, as well as point estimates of incremental costs and
cost-e,ectiveness, again with associated measures of uncertainty.
We converted costs to Great British Pounds (GBP) (2018) based on
Purchasing Power Parities (PPP) and gross domestic product (GDP)
deflators.
Unit of analysis issues
We addressed issues in the analysis of studies with particular
characteristics, for example cluster-randomised trials, in our
meta-analysis. We highlighted whether cluster-randomised trials
presented their intra-cluster correlation coe,icient (ICC) and if
they made adjustment for clustering. Where studies adjusted for
clustering, we used the data they presented in the meta-analysis.
However, where the authors did not present their ICC or adjust
for clustering, we contacted the authors for an estimate of the
ICC. Where authors did not respond, we estimated an ICC from a
previous Cochrane review (Shepperd 2011) and used it to adjust for
clustering in order to allow for inclusion of the study in our meta-
analysis. We carried out sensitivity analysis to test the estimate we
used for clustering. The Cochrane Handbook for Systematic Reviews
of Interventions suggests that decisions that may be somewhat
unclear should be tested using sensitivity analysis (Higgins 2011a).
Dealing with missing data
When sample sizes and mean (SD) were missing, we did not
carry out imputations or estimate the missing values for meta-
analysis. Rather, as recommended by the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a), we contacted
study authors to request additional data. Where studies had
missing intervention data (such as number of sta, involved and
skills and so on), we assessed the potential impact of these missing
data on the findings of the review in the 'Discussion' section of
the review. We sought clarity from study authors regarding study
population, analysis and interventions, where required.
Assessment of heterogeneity
We examined and assessed heterogeneity through the following
three measures:
• inspecting the studies to examine for plausible areas of
heterogeneity based on clinical factors that may influence
findings of our meta-analysis;
• inspecting the forest plots;
• using the I2 statistics to examine the extent and impact of
heterogeneity between included studies (Higgins 2011a).
Assessment of reporting biases
In order to detect and manage reporting bias, we took the following
steps to attend to:
• multiple (publication) bias by contacting study authors to
ascertain whether duplication had occurred;
• location bias by searching relevant national and international
trial registries for all relevant studies (e.g. CENTRAL);
• language bias by including studies published in languages other
than English; and
• outcomes reporting (including non-publication of economic
evaluation outlined in the protocol) through comparing the
findings in eligible studies with published protocols, where
available. Where published protocols were unavailable, we
asked study authors to supply them.
In addition, where there were more than 10 included studies in
our meta-analysis, we used funnel plots and visually inspected
them for asymmetry/symmetry as a means of exploring whether
there was evidence that study size (precision) was associated
with e,ect size. Where possible, we also conducted relevant
tests for asymmetry influenced by data type (e.g. continuous or
dichotomous), to assist with examining publication bias and to
overcome any reliance on visual inspection (Lau 2006). When we
observed asymmetry, we considered publication bias as one (of
several) plausible explanations (Sterne 2001).
Data synthesis
Where eligible studies were not su,iciently homogenous to permit
meta-analysis, we extracted quantitative data (means, standard
deviations, frequencies and proportions, test coe,icients, 95% CIs
and e,ects sizes, where available) and we employed techniques
used in narrative synthesis to analyse the data, including:
• tabulation, which involved inserting the main elements of
extracted data into a table format;
• textual descriptions, which involved collating a summary
description of each included study (part of Characteristics of
included studies);
• clustering of group textual descriptions according to attributes;
and
• vote counting to determine how oKen certain attributes were
reported (Rodgers 2009).
Where possible, we included qualitative data from nested or
embedded qualitative studies where qualitative data were used as
part of the trial to explore stakeholder views and experiences of
the intervention. We analysed these through narrative synthesis
methods.
Quality of the evidence
Two review authors independently rated the quality of the
outcomes. We used the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) system to rank the quality of
the evidence using the GRADEprofiler Guideline Development Tool
soKware (GRADEpro GDT 2015) and the guidelines provided in the
Cochrane Handbook (Chapter 12, Higgins 2011a).
The GRADE approach uses five considerations (study limitations,
consistency of e,ect, imprecision, indirectness and publication
bias) to assess the quality of the body of evidence for each outcome
(Chapter 12, Higgins 2011a). The GRADE system uses the following
criteria for assigning grades of evidence:
• high: we are very confident that the true e,ect lies close to that
of the estimate of the e,ect.
• moderate: we are moderately confident in the e,ect estimate;
the true e,ect is likely to be close to the estimate of e,ect, but
there is a possibility that it is substantially di,erent.
• low: our confidence in the e,ect estimate is limited; the true
e,ect may be substantially di,erent from the estimate of the
e,ect.
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• very low: we have very little confidence in the e,ect estimate;
the true e,ect is likely to be substantially di,erent from the
estimate of e,ect.
The GRADE system uses the following criteria for assigning a quality
level to a body of evidence (Chapter 12, Higgins 2011a):
• high: randomised trials; or double-upgraded observational
studies;
• moderate: downgraded randomised trials; or upgraded
observational studies;
• low: double-downgraded randomised trials; or observational
studies;
• very low: triple-downgraded randomised trials; or downgraded
observational studies; or case series/case reports.
Factors that may decrease the quality level of a body of evidence
are:
• limitations in the design and implementation of available
studies suggesting high likelihood of bias;
• indirectness of evidence (indirect population,
intervention,control, outcomes);
• unexplained heterogeneity or inconsistency of results (including
problems with subgroup analyses);
• imprecision of results (wide CIs);
• high probability of publication bias.
Factors that may increase the quality level of a body of evidence are:
• large magnitude of e,ect;
• all plausible confounding would reduce a demonstrated e,ect
or suggest a spurious e,ect when results show no e,ect;
• dose-response gradient.
We downgraded the quality of the evidence by one (−1) or two (−2)
if we identified:
• serious (−1) or very serious (−2) limitation to study quality;
• important inconsistency (−1);
• some (−1) or major (−2) uncertainty about directness;
• imprecise or sparse data (−1);
• high probability of reporting bias (−1).
'Summary of findings' table
We included a 'Summary of findings' table to present the main
findings in a transparent and simple tabular format. The table
summarised the comparison of HSPC versus usual care (which
could be inpatient or outpatient hospital care without specialist
palliative care input (e.g. oncological care) at the point of entry to
the study, community care (e.g. primary or specialist care provided
in the patient’s place of residence), and hospice care provided
outside of the hospital setting). The table included key information
concerning the quality of the evidence, the magnitude of e,ect of
the interventions examined, and the sum of available data on the
outcomes patient health-related quality of life, patient symptom
burden, patient satisfaction with care, achieving patient preferred
place of death (measured by number of patients with home death),
pain, unpaid caregiver burden, and cost/cost-e,ectiveness.
Subgroup analysis and investigation of heterogeneity
As part of our primary objective, we identified the e,ective
components and determined the comparative e,ectiveness of
HSPC for adults with advanced illness and their unpaid caregivers/
families. We compared the resources and costs associated with
these services and determined their cost-e,ectiveness; compared
e,ectiveness by disease type (e.g. malignant and non-malignant
groups), and country; and we examined other sources of
heterogeneity and the applicability of meta-analysis.
Where possible, we performed subgroup analysis using the
following components known to influence the e,ectiveness of
specialist palliative care:
• disease type, including malignant, non-malignant and mixed
malignant and non-malignant disease (mixed diagnoses);
• frailty associated with advanced age;
• HSPC team composition (e.g. physician-led, nurse-led
versus multidisciplinary team-led palliative care services
and organisation (e.g. 24-hour access (out-of-hours) versus
temporally restricted access)) and taxonomy of the components;
• models of HSPC (ward-based model, inpatient consult model,
outpatient model, outreach model and service provision across
multiple settings);
• early palliative care versus late palliative care to assess the
e,ectiveness of hospital-based palliative care applied early in
the course of a life-threatening disease from palliative care
delivered mainly with high symptom burden or in the terminal
phase of illness. To be classified as early palliative care, early
palliative care intent had to be stated explicitly or reflected
in the sample composition, i.e. most participants had to be
enrolled shortly aKer diagnosis of advanced disease (Haun
2017). Anything besides this, we classified as late palliative care;
and
• country of origin.
Sensitivity analysis
We carried out sensitivity analyses to explore a number of our
methodological decisions.
We conducted sensitivity analysis to assess our decision to use
an estimate of intracluster-correlation coe,icient (ICC) we had
obtained from a previous Cochrane review (Shepperd 2011) to
adjust for clustering in one of the cluster-RCTs (McCorkle 2015). The
authors did not respond to our request for the ICC from their study.
Given that combining endpoint scores and change scores is not
recommended when using standardised mean di,erences (SMDs)
and also that Cochrane does not recommend pooling adjusted and
unadjusted estimates together
(Deeks 2011), we pooled studies presenting adjusted endpoint
scores as our main meta-analysis while we carried out sensitivity
analyses with studies reporting unadjusted endpoint scores,
adjusted change scores and unadjusted change scores.
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R E S U L T S
Description of studies
Also see the Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies tables.
Results of the search
We identified 15,927 records from our electronic searches and
an additional 55 records from other sources. AKer removing
duplicates, two authors independently screened the titles and
abstracts of 10,774 records, excluded 10,132 records and selected
642 for full-text reading. We classed 476 records as not relevant (e.g.
systematic reviews, study design).
We included 42 studies reported in 106 records (91 full papers
and 15 abstracts), ranging from one to ten records per study (see
Included studies). Of the remaining records, we excluded 25 with
reasons (see Excluded studies); 34 are ongoing studies, and one




All the studies we included were RCTs, comprising one cluster-RCT
(McCorkle 2015), one cluster-randomised crossover trial (Ma 2019)
and eight fast-track RCTs (Bajwah 2015; Bakitas 2015; Edmonds
2010; Farquhar 2014; Farquhar 2016; Higginson 2009; Higginson
2014; McWhinney 1994). The remaining 32 RCTs had a parallel
design.
Sample sizes
Sample sizes in included studies ranged from 30 to 621 participants.
The length of recruitment in included studies varied between 10
months and 50 months. In total, we included data from studies
involving 7779 participants (6678 adults with advanced illness and
1101 unpaid caregivers/family members). Thirty-three studies had
power calculations (details in 'Characteristics of included studies').
Nine studies were powered on quality of life only (Bekelman 2018;
El-Jawahri 2016; Franciosi 2019; Groenvold 2017; Rogers 2017;
Tattersall 2014; Temel 2010; Temel 2017; Vanbutsele 2018). Ma 2019
was powered on proportion of patients transitioning to do-not-
resuscitate and do-not-intubate (DNR/DNI). In addition to quality of
life, Bakitas 2015 also performed calculations on depression, Solari
2018 on symptom burden, O'Riordan 2019 on pain, while Bakitas
2009 and Sidebottom 2015 included depression and symptom
burden. Farquhar 2014 and Farquhar 2016 were powered on
distress due to breathlessness, Brannstrom 2014 on symptom
burden, Brumley 2007 on cost, Carson 2016 on depression and
anxiety, Grudzen 2016 on time to palliative care, Janssens 2019
on hospital admission, Rodin 2019 on traumatic stress symptoms,
Bajwah 2015, Edmonds 2010 and Higginson 2009 on the Palliative
care Outcome Scale (POS), Lowther 2015 on the African Palliative
care Outcome Scale (APOS), Higginson 2014 on Chronic Respiratory
Disease Questionnaire (CRDQ) mastery domain, Hopp 2016 and
Ozcelik 2014 on palliative outcomes and palliative care service
respectively, McWhinney 1994 on pain and nausea and Woo 2019
on pain and depression.
Eight studies were well-powered at recruitment and also at
the primary point of analyses (Carson 2016; Edmonds 2010;
Farquhar 2016; Higginson 2014; Ma 2019; Ozcelik 2014; Solari 2018;
Temel 2017). Fourteen studies were underpowered at recruitment
stage (i.e. participants enrolled) by three participants (Brumley
2007; Groenvold 2017; Hopp 2016), four (Grudzen 2016), eight
(Rodin 2019), 19 (Nottelmann 2018), 25 (O'Riordan 2019), 30
(Tattersall 2014), 50 (Rogers 2017), 74 (McWhinney 1994), 78
(Bakitas 2009), 111 (Janssens 2019), 153 (Bakitas 2015) and 268
(Sidebottom 2015). In one of the underpowered studies (Rogers
2017), the data and safety monitoring board in consultation with
the sponsoring agency recommended a sample size reduction
due to enrollment rates, a mortality rate that was lower than
predicted and observed outcomes di,erences at the intermediate
time point. Reasons provided for underpowered studies included
slower than anticipated accrual, resource constraints, early deaths,
problems with recruitment and low compliance rate for completion
of questionnaires. The remaining 11 studies included the numbers
that they had planned to recruit but dropped below the required
numbers by the first time point of analyses (i.e. following baseline
assessment and aKer receiving the intervention or control). These
studies were underpowered by two participants (Brannstrom
2014), three participants (El-Jawahri 2016), five participants each
(Bajwah 2015; Higginson 2009), six participants each (Lowther
2015; Farquhar 2014), 13 participants (Temel 2010), 22 participants
(Vanbutsele 2018), 29 participants (Franciosi 2019), 60 participants
(Woo 2019) and 70 participants (Bekelman 2018). Nine studies
did not report any power calculation (Ahronheim 2000; Cheung
2010; Gade 2008; Jingfen 2017; Kane 1984; Mendoza-Galindo 2018
(abstract only); McCa,rey 2013; McCorkle 2015; Wallen 2012) (see
Figure 2 for a graphical representation of the power of included
studies at recruitment and follow-up). Overall, 14 studies examined
post-intervention assessments in more than 100 participants.
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Figure 2.   A figure describing the power of included studies at recruitment and follow-up
 
Setting
Nineteen studies were carried out in USA. Six studies took place
in the UK (Bajwah 2015; Edmonds 2010; Farquhar 2014; Farquhar
2016; Higginson 2009; Higginson 2014), and three studies occurred
in Australia (Cheung 2010; McCa,rey 2013; Tattersall 2014). One
study was conducted in Sweden (Brannstrom 2014), two in
Denmark (Groenvold 2017; Nottelmann 2018), one in Switzerland
(Janssens 2019), one in Belgium (Vanbutsele 2018), two in Italy
(Franciosi 2019; Solari 2018), and one in Turkey (Ozcelik 2014).
McWhinney 1994 and Rodin 2019 were carried out in Canada, while
Woo 2019 was undertaken in South Korea. Lowther 2015 took place
in Kenya and Jingfen 2017 was conducted in China. Mendoza-
Galindo 2018 (abstract only) was carried out in Mexico.
Thirty studies recruited from hospital settings. Three of these
studies recruited from intensive care units (ICU) (Carson 2016;
Cheung 2010; Ma 2019). Of these 30 studies, Ahronheim 2000
recruited patients with advanced dementia from Mount Sinai
Hospital, Bajwah 2015 recruited from a specialist interstitial lung
disease centre, Janssens 2019 from patients followed by Geneva
University Hospitals on long-term oxygen therapy (LTOT) and/or
home non-invasive ventilation (NIV) as well as those hospitalised
for acute exacerbation of Chronic Obstructive Oulmonary Disease
(COPD) in the general internal medicine and geriatric wards,
Lowther 2015 from outpatient HIV clinics in a community hospital,
McCorkle 2015 from disease-specific multidisciplinary clinics at a
cancer hospital, O'Riordan 2019 from new inpatient admissions to
the medicine and cardiology services, Solari 2018 from three Italian
multiple sclerosis centres and Franciosi 2019 from outpatient and
inpatient settings at five Italian cancer centres. Seven studies
recruited from oncology centres or clinics (Groenvold 2017; Rodin
2019; Tattersall 2014; Temel 2010; Temel 2017; Vanbutsele 2018;
Woo 2019). Bakitas 2009 and Bakitas 2015 recruited from oncology
clinics of a cancer centre and a,iliated outreach clinics and the
Veterans A,airs Medical Centre (VAMC).
Eleven studies recruited from primary care and/or secondary
care. For example, Gade 2008 recruited from community medical
services and inpatient units, while McWhinney 1994 recruited
through family physicians and home care nurses. Brumley 2007
received referrals from discharge planners, primary care physicians
and other specialty physicians, whereas Rogers 2017 enrolled both
hospitalised patients and recently discharged patients who were
at high risk of rehospitalisation. Higginson 2009 received referrals
from local health and social care professionals. Edmonds 2010
received referrals from health and social care professionals and, in
a few instances, through voluntary organisations and self-referral.
Mendoza-Galindo 2018 (abstract only) did not present the setting
where recruitment took place..
Participants
Twenty-one studies were carried out with patients who had severe/
advanced cancer or their unpaid caregivers/family members or
both (Bakitas 2009; Bakitas 2015; El-Jawahri 2016; Farquhar
2014; Franciosi 2019; Groenvold 2017; Grudzen 2016; Jingfen
2017; Kane 1984; McCorkle 2015; McWhinney 1994; Mendoza-
Galindo 2018 (abstract only); Nottelmann 2018; Ozcelik 2014; Rodin
2019; Tattersall 2014; Temel 2010; Temel 2017; Vanbutsele 2018;
Wallen 2012; Woo 2019). A range of cancers were included in
these studies comprising solid and non-solid tumour cancers.
Seven studies involved both cancer and non-cancer populations
(mixed populations) (Brumley 2007; Carson 2016; Cheung 2010;
Gade 2008; Higginson 2014; Ma 2019; McCa,rey 2013), while
the remaining 14 studies had only non-cancer populations. The
non-cancer populations were those with interstitial lung disease
(Bajwah 2015), heart failure (Bekelman 2018; Brannstrom 2014;
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
Hopp 2016; O'Riordan 2019; Rogers 2017; Sidebottom 2015), HIV
(Lowther 2015), dementia (Ahronheim 2000), multiple sclerosis
(Edmonds 2010; Higginson 2009; Solari 2018), COPD (Janssens
2019) and a combination of COPD (83%) and other non-malignant
diseases (Farquhar 2016). Two studies were with rural populations
(Bakitas 2009; Bakitas 2015), while Hopp 2016 was with a
predominantly African-American population (92%). Thirty-five
studies were conducted or first published from 2010 onwards, with
89% taking place within the last six years (see Characteristics of
included studies for details).
Mean/median age ranged from 38.3 to 85.6 years. About the
same number of males and females were included in most
studies. However, five studies had between 69% and 82% females
(Ahronheim 2000; Edmonds 2010; Higginson 2009; Lowther 2015;
Ozcelik 2014), whereas nine studies had 60% to 98% males (Bajwah
2015; Bakitas 2009; Bekelman 2018; Brannstrom 2014; Farquhar
2016; Franciosi 2019; Kane 1984; Rodin 2019; Vanbutsele 2018).
Ahronheim 2000 had the highest percentage of females (82%). Kane
1984 who recruited at a Veterans Administration hospital included
predominantly male veterans. Wallen 2012 did not provide the
gender distribution in their population. Unpaid caregivers/family
members included in studies tended to be mainly females. Nine
of the 16 studies involving unpaid caregivers/families described
one or more of their characteristics: they were mainly spouses
and women, and had a median/mean age ranging from 51 to 65.6
years. In five studies, between 16% and 43% of patients lived alone
(Farquhar 2014; Farquhar 2016; Higginson 2009; McCorkle 2015;
Vanbutsele 2018).
Sixteen studies had survival as an inclusion criterion. Life
expectancy specified in these studies ranged from > 72 hours to
24 months. Eight studies specifically stated that they included
newly diagnosed patients (Bakitas 2015; Franciosi 2019; McCorkle
2015; Nottelmann 2018; Rodin 2019; Temel 2010; Temel 2017; Woo
2019). Exclusion criteria included the presence of severe mental
illness (Bakitas 2009; Bakitas 2015; Hopp 2016; Jingfen 2017;
Temel 2017), and palliative care/hospice involvement previously or
at present/request for palliative care involvement (Bajwah 2015;
Carson 2016; Cheung 2010; Franciosi 2019; Grudzen 2016; Ma
2019; Nottelmann 2018; Rodin 2019; Sidebottom 2015; Solari 2018;
Tattersall 2014; Temel 2010; Temel 2017; Vanbutsele 2018). In three
studies, patients without surrogate decision-makers were excluded
(Carson 2016; Cheung 2010; Solari 2018), while Gade 2008 excluded
patients if they had impaired cognitive status and no surrogate.
Janssens 2019 and Rodin 2019 excluded patients with moderate or
severe cognitive impairment.
Intervention
Hospital Based Specialist Palliative Care (HSPC)
We included di,erent models of HSPC in this review. Some were
new interventions evaluated through feasibility/pilot studies or
early phase trials (e.g. Bajwah 2015; Cheung 2010; Edmonds 2010;
Higginson 2009; Nottelmann 2018; Rodin 2019); others had existed
for some time. Services were based in hospitals, with three studies
in hospital ICUs (Carson 2016; Cheung 2010; Ma 2019), and three in
palliative care centres/units of hospitals (Groenvold 2017; Jingfen
2017; McWhinney 1994). The hospice programme in Kane 1984
was located in a Veterans Administration hospital. Most served
urban and suburban populations. Both Bakitas 2009 and Bakitas
2015 evaluated telephone-based hospital interventions for rural
populations.
The HSPC models in the 42 included studies were:
• ward-based services. This was provided by only Jingfen 2017;
• inpatient consult or advisory services. This was provided by 10
studies: Ahronheim 2000; Carson 2016; Cheung 2010; El-Jawahri
2016; Gade 2008; Grudzen 2016; Hopp 2016; Ma 2019; Ozcelik
2014; Sidebottom 2015;
• outpatient services. This was provided by six studies: Lowther
2015; Mendoza-Galindo 2018 (abstract only); Nottelmann 2018;
Tattersall 2014, Temel 2010; Woo 2019;
• hospital outreach services. This was provided by five studies:
Bajwah 2015; Brannstrom 2014; Janssens 2019; McWhinney
1994; Solari 2018; and
• service provision across multiple settings including hospital.
This was provided by 20 studies: Bakitas 2009; Bakitas 2015;
Bekelman 2018; Brumley 2007; Edmonds 2010; Farquhar 2014;
Farquhar 2016; Franciosi 2019; Groenvold 2017; Higginson
2009; Higginson 2014; Kane 1984; McCa,rey 2013; McCorkle
2015; O'Riordan 2019; Rodin 2019; Rogers 2017; Temel 2017;
Vanbutsele 2018; Wallen 2012.
In order to be included in this review, one of the criteria was
that care should be co-ordinated by a multidisciplinary team.
Consequently, all the studies included a multidisciplinary HSPC
team either as the core team providing the intervention or a
multidisciplinary team was included as needed. Seven studies
included HSPC teams led by nurses (Bajwah 2015; Bakitas 2009;
Lowther 2015; McCa,rey 2013; Nottelmann 2018; Tattersall 2014;
Vanbutsele 2018), while none of the studies included HSPC teams
that were physician-led. In one study, it was unclear who was
leading the HSPC (Mendoza-Galindo 2018 (abstract only)). Multi-
disciplinary team members ranged from two to eight professionals,
mainly comprising nurses, physicians and sometimes social
workers.
Five studies had HSPC that had 24 hours access (out-of-hours
care). The hospital outreach service provided by McWhinney 1994
included 24 hours on-call service, while another hospital outreach
service organised the intervention in close co-operation with out-
of-hours palliative advanced home care (Brannstrom 2014). In
McCa,rey 2013, services traversed multiple settings, including
hospital and nursing services, and were provided up to 24 hours
a day at home for up to five days. Brumley 2007 involved service
provision across multiple settings including hospital and also
included 24 hours on-call service. The inpatient consult service
provided by Gade 2008 included a palliative care physician on call
aKer hours.
Thirty-one studies either included certified experts in palliative
care or those described as palliative care clinicians (without
being explicit about their training). For example, Bakitas 2015
included a board-certified palliative care clinician and advanced
practice palliative care nurse specialists, while Gade 2008 included
a multiprofessional team comprising a palliative care physician,
nurse, hospital social worker and chaplain. Janssens 2019 included
a palliative care team comprising nurses with experience in
palliative care and a physician specialised in palliative care.
Furthermore, Higginson 2009 evaluated a new short-term specialist
palliative care intervention involving one to three contacts
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provided by a core team of a part-time consultant in palliative
medicine, part-time palliative care nurse, psychosocial worker and
administrator comprising consultation and shared care with other
care providers. Bajwah 2015, Edmonds 2010 and Nottelmann 2018
were also new palliative care services. Bajwah 2015 was developed
for people with interstitial lung disease and involved a hospital-
to-home case conference attended by the palliative care nurse
who organised it and di,erent healthcare professionals, while
the service in Edmonds 2010 comprised a part-time consultant
in palliative medicine with a special interest in neurological
conditions, a part-time clinical nurse specialist and a full time
administrator. Nottelmann 2018 was a palliative rehabilitation
service delivered by a specialised palliative care team consisting
of physicians, nurses, physiotherapists, psychologists, a part time
social worker, dietician, occupational therapist, and chaplain. In
Franciosi 2019, the palliative care intervention was provided across
multiple settings and involved nurses working full time in palliative
care as well as double-boarded certified oncologists and palliative
care physicians. A palliative care physician and nurse that were
separate from the haematology team provided the intervention in
Rodin 2019. Other multidisciplinary team members were involved
as needed. Sidebottom 2015 assessed inpatient palliative care
for patients with heart failure. The inpatient palliative care team
included four physicians who were board-certified in hospice and
palliative medicine, two clinical nurse specialists board-certified in
advanced practice palliative care nursing, a chaplain and a social
worker. The remaining 11 studies only stated the involvement of
professionals who delivered specialist level interventions without
any details on their training or whether they were palliative
care clinicians (Ahronheim 2000; Cheung 2010; Groenvold 2017;
Grudzen 2016; Hopp 2016; Jingfen 2017; McCa,rey 2013; Mendoza-
Galindo 2018 (abstract only); O'Riordan 2019; Ozcelik 2014; Woo
2019).
Early palliative care was evaluated in 19 studies (Bakitas 2009;
Bakitas 2015; El-Jawahri 2016; Franciosi 2019; Groenvold 2017;
Grudzen 2016; Higginson 2014; Janssens 2019; Ma 2019; McCorkle
2015; Mendoza-Galindo 2018 (abstract only); Nottelmann 2018;
Rodin 2019; Tattersall 2014; Temel 2010; Temel 2017; Vanbutsele
2018; Wallen 2012; Woo 2019). Early palliative care intent either
had to be stated explicitly or most participants had to enrolled
shortly aKer diagnosis of advanced disease. Bakitas 2009 included
patients who were within eight to 12 weeks of a new diagnosis
of advanced cancer, while Bakitas 2015 included patients with
advanced cancer who were within 30 and 60 days of diagnosis.
McCorkle 2015 recruited patients with a late-stage cancer diagnosis
within 100 days, whereas Temel 2010 included patients with
metastatic lung cancer diagnosed within the previous eight weeks.
Similarly, four studies included patients who were within eight
weeks of diagnosis of advanced cancer (Franciosi 2019; Nottelmann
2018; Temel 2017; Woo 2019). Temel 2017 recruited patients
with incurable lung or non-colorectal Gastrointestinal cancer,
while Franciosi 2019 recruited patients with non-small cell lung
cancer, pancreatic, gastric or biliary tract cancer. Nottelmann 2018
involved patients diagnosed with non-resectable solid cancer,
and Woo 2019 recruited those with a diagnosis of advanced or
metastatic pancreatic or biliary tract cancer. Vanbutsele 2018
included patients who were within the first 12 weeks of a new
primary tumour or had a diagnosis progression. In El-Jawahri
2016, the intention was early palliative care and the intervention
was delivered during hospitalisation for haematopoietic stem
cell transplantation (HCT) care. Groenvold 2017 initiated their
palliative care intervention earlier than would otherwise have been
the case among patients with advanced cancer, while Grudzen
2016 assessed early referral to palliative care for emergency
department patients with advanced cancer. Rodin 2019 delivered
early palliative care interventions to patients newly diagnosed
with acute leukaemia. Wallen 2012 began an early palliative
care intervention postoperatively for patients with advanced
cancer. Tattersall 2014 included ambulatory patients with newly-
detected incurable metastatic cancer. Higginson 2014 evaluated
early palliative care integrated with respiratory services for patients
with a range of malignant and non-malignant advanced diseases
(mixed populations) and refractory breathlessness. Janssens 2019
assessed early palliative care for patients with severe and very
severe COPD over a one-year period while Mendoza-Galindo 2018
(abstract only) stated that their intervention was an early palliative
care intervention for patients with newly-diagnosed or relapsed
metastatic breast cancer. Ma 2019 involved early triggered palliative
care consultation within 48 hours of ICU admission.
Eleven studies were theoretically grounded: case conference/
management (Bajwah 2015; Ozcelik 2014), chronic care model
(Bakitas 2009), person-centred palliative care (Brannstrom 2014),
palliative care approach (Farquhar 2014; Farquhar 2016), hospice
(Brumley 2007; Kane 1984), knowledge-belief-action model
(Jingfen 2017), trauma-focussed cognitive behavioural therapy
(Rodin 2019), and palliative care and physiotherapy approach
(Higginson 2014). Two studies were modelled aKer hospice
programmes (Brumley 2007; Kane 1984).
Twenty-three studies included HSPC that provided some level
of unpaid caregiver/family support ranging from meeting with
unpaid caregivers/families to discuss care options to education/
counselling or provision of psychological interventions aimed at
supporting patient and unpaid caregiver/family dyads.
Taxonomy of the components of HSPC
We assessed the components of HSPC in the studies included in
this review using the principles and domains of palliative care
highlighted by Zimmermann 2019. Zimmermann 2019 developed
a conceptual framework highlighting the domains and principles
of team-based outpatient early palliative care for patients with
cancer. This framework is based on palliative care theory (Doyle
1998; WHO 2002; Zimmermann 2004; Zimmermann 2012), review
of previous palliative care interventions (Zimmermann 2008) and
practice guidelines (Cancer Care Ontario 2016; NCCN 2016). This
framework was chosen above others such as the Holistic Common
Assessment (National End of Life Care Programme 2010), which
is used for comprehensive palliative care assessment, because
the essential elements of the framework are consistent with the
need for early provision of palliative care in collaboration with the
multidisciplinary team, and also because it is based on the needs
of the patient and their family, rather than on prognosis.
The four domains are coping and support, decision-making,
symptom control and future planning, while the four principles are
that care is flexible, attentive, patient- and family-centred.
Components of HSPC in studies that either included certified experts
in palliative care or those described as palliative care clinicians
Thirty-one studies either included certified experts in palliative
care or those described as palliative care clinicians. Eight studies
were only patient-centred (Brannstrom 2014; Rodin 2019; Rogers
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2017; Sidebottom 2015; Tattersall 2014; Temel 2017; Vanbutsele
2018; Wallen 2012), while Carson 2016 was only family-centred
because the intervention was a palliative care-led meeting for
families of patients in the medical intensive care unit. Twenty-
two studies were both patient-centred and family-centred (Bajwah
2015; Bakitas 2009; Bakitas 2015; Bekelman 2018; Brumley 2007;
Edmonds 2010; El-Jawahri 2016; Farquhar 2014; Farquhar 2016;
Franciosi 2019; Gade 2008; Higginson 2009; Higginson 2014;
Janssens 2019; Kane 1984; Lowther 2015; Ma 2019; McCorkle 2015;
McWhinney 1994; Nottelmann 2018; Solari 2018; Temel 2010). For
instance, the HSPC intervention in Bajwah 2015 was individualised
to each patient and carer, while Vanbutsele 2018 described the use
of semi-structured monthly consultations by palliative care nurses
that allowed for individualised care. Bekelman 2018 described
collaboration between patients and the nurse as they both agreed
on the symptom to focus on.
Palliative care in all 31 studies except Kane 1984 involved provision
of care that was flexible and attentive to the needs of patients
and/or their families as they allowed for the involvement of other
members of the healthcare team in order to address these needs.
We mapped the 31 studies to the four domains highlighted above.
We added care co-ordination as an additional domain because the
need for co-ordinated care for those with advanced disease is not
always delivered and this can result in increased hospitalisations
and suboptimal clinical outcomes (Higginson 2003; Walsh 2011)
(see Table 1 under Additional tables for the domains covered in
the studies and Figure 3 for the percentage of studies assessing
di,erent domains).
 
Figure 3.   A figure showing the domains of HSPC in the studies that either included certified experts in palliative
care or those described as palliative care clinicians
 
Symptom control
This involved assessment and management of symptoms. Twenty-
eight studies highlighted that the HSPC intervention included
symptom or needs assessment and management. In two studies,
this was unclear (McWhinney 1994; Solari 2018), while it appeared
that Carson 2016 did not address this domain.
Decision-making
This domain involved assessing patient and their family's
understanding of illness, assessing individual and cultural values/
beliefs or assessing goals of care and regularly reviewing them.
Twenty-three studies included HSPC that addressed one or more
aspects of decision-making. One study included HSPC that did
not focus on decision-making as the intervention was targeted at
managing patients’ physical and psychological symptoms during
hospitalisation (El-Jawahri 2016). A further five studies of HSPC
did not involve this domain (Higginson 2009; Kane 1984; Rodin
2019; Tattersall 2014; Wallen 2012). In two studies, this was unclear
(McWhinney 1994; Solari 2018).
Future planning
Future planning involved discussing concerns and preferences for
end-of-life care, making a will, power of attorney and decisions
about resuscitation. Half of the studies (n = 16) included HSPC
that involved planning for the future, while this was unclear in two
studies (McWhinney 1994; Solari 2018). The remaining 13 studies
did not include this domain in delivery of HSPC (Bekelman 2018;
Brannstrom 2014; Carson 2016; El-Jawahri 2016; Franciosi 2019;
Ma 2019; McCorkle 2015; Rodin 2019; Tattersall 2014; Temel 2010;
Temel 2017; Vanbutsele 2018; Wallen 2012).
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Coping and support
This involved establishing a therapeutic relationship, facilitating
coping with advanced illness and spiritual support, providing
emotional and practical support, addressing family needs and
bereavement care.
All 31 studies involved HSPC that had one or more elements of this
domain. In particular, three studies included HSPC that specifically
highlighted bereavement care or involved a bereavement co-
ordinator as needed (Bakitas 2009; Brumley 2007; Higginson 2009).
Bakitas 2009 provided a bereavement follow-up call to the unpaid
caregiver as part of the HSPC intervention, while Higginson 2009
described HSPC that provided bereavement support when needed.
Brumley 2007 described HSPC that included a bereavement co-
ordinator, as needed. Furthermore, Bekelman 2018 included a topic
on grief and loss as part of the counselling session in their HSPC
intervention.
In addition to the areas described above, we assessed the provision
of spiritual care. Thirteen studies include HSPC provided spiritual
care or support (Bajwah 2015; Brannstrom 2014; Brumley 2007;
Carson 2016; Higginson 2014; Janssens 2019; Kane 1984; Lowther
2015; Nottelmann 2018; Rogers 2017; Sidebottom 2015; Vanbutsele
2018; Wallen 2012).
Care co-ordination
Although Zimmermann 2019 did not include care co-ordination as
a domain in their conceptual framework, we decided to include
this domain. Over half of the studies (n = 19) involved HSPC that
provided care co-ordination (Bajwah 2015; Bakitas 2009; Bakitas
2015; Bekelman 2018; Brannstrom 2014; Brumley 2007; Edmonds
2010; Franciosi 2019; Higginson 2009; Higginson 2014; Janssens
2019; Ma 2019; McCorkle 2015; Nottelmann 2018; Rogers 2017;
Sidebottom 2015; Temel 2010; Temel 2017; Vanbutsele 2018), while
this was unclear in two studies (McWhinney 1994; Solari 2018). In
10 studies, it appeared that the HSPC intervention did not include
this domain.
The main domains of care in the HSPC intervention in the 31
studies were symptom control, coping and support, and decision-
making. At least half of the studies included HSPC that provided
care co-ordination and future planning. Besides McWhinney 1994
and Solari 2018, the remaining studies addressed at least two
domains.
Components of HSPC in studies that were unclear about palliative care
training
Eleven studies were unclear about the palliative care training
of those who delivered the HSPC intervention (Ahronheim 2000;
Cheung 2010; Groenvold 2017; Grudzen 2016; Hopp 2016; Jingfen
2017; McCa,rey 2013; Mendoza-Galindo 2018 (abstract only);
O'Riordan 2019; Ozcelik 2014; Woo 2019) (see Table 2 under
Additional tables for the domains covered in the studies and
Figure 4 for the percentage of studies assessing di,erent domains).
Four of these studies were only patient-centred (Groenvold 2017;
Hopp 2016; O'Riordan 2019; Woo 2019), while Ahronheim 2000
was only family-centred. Three studies were both patient- and
family-centred (Grudzen 2016; Jingfen 2017; Ozcelik 2014). In three
studies, this was unclear (Cheung 2010; McCa,rey 2013; Mendoza-
Galindo 2018 (abstract only)).
 
Figure 4.   A figure showing the domains of HSPC in studies that were unclear about palliative care training
 
Palliative care provision was flexible in all the 11 studies, with the
involvement of the multidisciplinary team as required to address
the needs of patients and/or their families. In 10 studies, the
palliative care providers were attentive to the needs of patients
and their families, while this was unclear in Mendoza-Galindo
2018 (abstract only). Mendoza-Galindo 2018 (abstract only) only
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reported that the intervention was provided by a palliative team,
which included psychological, nutritional and symptom support.
We assessed the domains of HSPC included in these studies as
follows:
Symptom control
Eight studies highlighted the issue that the HSPC intervention
included symptom or needs assessment and management. In three
studies, this was unclear (Cheung 2010; Groenvold 2017; McCa,rey
2013).
Decision-making
Three studies involved one or more aspects of decision-making
(Grudzen 2016; Hopp 2016; Jingfen 2017), while this was unclear
in three studies (Cheung 2010; Groenvold 2017; McCa,rey 2013). It
appeared five studies did not involve this domain (Ahronheim 2000;
Mendoza-Galindo 2018 (abstract only); O'Riordan 2019; Ozcelik
2014; Woo 2019).
Future planning
Five studies involved planning for the future (Ahronheim 2000;
Grudzen 2016; Hopp 2016; O'Riordan 2019; Ozcelik 2014), while
this was unclear in three studies (Cheung 2010; Groenvold 2017;
McCa,rey 2013). Three studies did not include this domain (Jingfen
2017; Mendoza-Galindo 2018 (abstract only); Woo 2019).
Coping and support
Eight studies involved one or more elements of this domain,
while three studies were unclear (Cheung 2010; Groenvold 2017;
McCa,rey 2013). O'Riordan 2019 further involved the provision of
spiritual care.
Care co-ordination
Only McCa,rey 2013 involved care co-ordination, while eight
studies did not. It was unclear whether two studies included this
domain (Cheung 2010; Groenvold 2017).
The main domains of care in the HSPC intervention in studies
with unclear training were symptom control, coping and support,
and future planning. Very few studies involved decision-making
and care co-ordination. Besides three studies where the domains
were unclear, the remaining eight studies addressed at least two
domains.
When compared to studies that included experts or those described
as palliative care clinicians, studies with unclear palliative care
training oKen did not include decision-making and care co-
ordination. There was also less focus on symptom control, and
coping and support in studies with unclear palliative care training.
Both groups were similar in the extent to which they focussed on
future planning.
Controls
HSPC was compared with usual care. Overall, there was poor
description of usual care in most studies with no information or
very little information provided. For example, Ahronheim 2000
only stated that the control group was treated by the primary
care team without palliative care input, and Cheung 2010 stated
that control group received usual ICU care without palliative care
consultation. Among studies providing some level of detail on
usual care, it appeared usual care was varied, probably reflecting
the local context as well as di,erences in health systems. For
example, in the Kenyan study by Lowther 2015, those in the
usual care group received care from nurses without experience in
palliative care from the HIV clinic, consisting of monthly clinical
assessments once antiretroviral therapy (ART) was established. In
the Swiss study by Janssens 2019, patients receiving usual care
had no contact with the palliative care team. Specialised nurses
provided regular home visits to patients under long-term oxygen
therapy (LTOT) and/or home non-invasive ventilation (NIV). In the
Belgian study by Vanbutsele 2018, usual oncology care in all the
participating departments was provided by a multidisciplinary
team, including oncologists, other medical specialists, social
workers, psychologists, dieticians and specialist nurses. All patients
with advanced cancer usually have an introductory consultation
with a specialist nurse trained in oncological care, a dietician,
and a psychologist at the start of their treatment. Follow-up
consultations were at the patient's discretion. The palliative care
team was only involved on demand and oKen late in the disease
trajectory, and their services were not systematically o,ered
to all patients from oncology departments. Usual care in the
South Korean study by Woo 2019 comprised anticancer and
symptom control treatments and consultation with psychiatric and
pain specialists. In Bajwah 2015, a UK study, the control group
remained under interstitial lung disease (ILD) specialist care which
included input from ILD physicians, ILD clinical nurse specialist,
occupational therapists, physiotherapists and oxygen assessment
and treatment services. All patients were also able to access
inpatient ILD treatment, as needed. The control group received the
intervention aKer four weeks. In Higginson 2014, the control group
received usual care services according to UK guidance. AKer six
weeks, the control group was o,ered the intervention. Similarly, in
Solari 2018, usual care involved health and social services provided
by the Italian National Health Service and dyads were o,ered the
intervention at the end of the study.
In 20 studies, usual care included involvement of palliative
care professionals if needed (Bajwah 2015; Bakitas 2009; Bakitas
2015; Bekelman 2018; Carson 2016; El-Jawahri 2016; Franciosi
2019; Groenvold 2017; Grudzen 2016; Ma 2019; McCa,rey 2013;
McWhinney 1994; Rodin 2019; Rogers 2017; Tattersall 2014; Temel
2010; Temel 2017; Vanbutsele 2018; Wallen 2012; Woo 2019), and,
in one study, usual care incorporated hospice care (Brumley 2007).
Wallen 2012 reported that the usual care group was permitted to
cross over to the intervention arm if standard pain and symptom
management was inadequate to meet their needs.
Outcomes
Our primary outcomes of patient health-related quality of life
(HRQoL) and their symptom burden (assessed using generalised
measures) were assessed by 10 and six studies reporting adjusted
endpoint values, respectively. Of the 10 studies assessing patient
HRQoL, nine were with cancer populations, and one with non-
cancer populations. Nine of the 10 studies involved early palliative
care (Bakitas 2009; Bakitas 2015; El-Jawahri 2016; McCorkle 2015;
Rodin 2019; Tattersall 2014; Temel 2010; Temel 2017; Vanbutsele
2018). All six studies that reported symptom burden were with
cancer populations and they involved early palliative care (Bakitas
2009; Bakitas 2015; El-Jawahri 2016; Rodin 2019; Tattersall 2014;
Temel 2010).
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Other patient outcomes reported included individual symptoms
(pain, anxiety, depression, post-traumatic stress disorder,
breathlessness, fatigue, nausea/vomiting, appetite loss, sleep
disturbance), traumatic stress symptoms, mortality (death at
home, hospital and ICU), survival, advanced care planning,
functional independence, achieving preferred place of care or
death, satisfaction with care, physical function, psychological,
social and spiritual well-being, nutrition, and cognitive status.
Unpaid caregiver outcomes assessed in studies included
satisfaction with care, symptom control (e.g. anxiety, depression),
HRQoL, burden, coping, distress with patients' symptoms, and
grief.
Economic data
We included 31 studies in the economic component of this review
as they compared the resource use and/or costs/cost-e,ectiveness
between HSPC and usual care alongside clinical e,ectiveness. We
restricted the economic component of the review to economic
analyses conducted alongside the studies meeting eligibility
criteria for the e,ectiveness component of the review. Of the 31
studies, four studies were full economic evaluations that compared
the costs and e,ects of the intervention and control group between
baseline and follow-up (Farquhar 2014; Farquhar 2016; Higginson
2009; McCa,rey 2013), five partial economic evaluations that
compared only costs and outcomes without reporting incremental
changes or decision criteria (Brumley 2007; Gade 2008; Higginson
2014; Kane 1984; Temel 2010), and 22 studies reported more limited
resource use/cost information.
The studies measured resource use associated with care received
in the intervention and the control group. Use of the following
resources was assessed: institutional care services use (e.g.
emergency department (ED) or accident and emergency (A&E),
intensive care unit use, inpatient stay, care in nursing homes (or
skilled nursing homes)); outpatient clinic use (e.g. palliative care
visits in outpatient settings, consultation with experts in outpatient
settings); community care services use (e.g. GP contacts, nurse
visits, home care, hospice care at home); unpaid caregiver care;
medications and other resource use. Thirteen studies calculated
the costs associated with resource utilisation (Brannstrom 2014;
Brumley 2007; Farquhar 2014; Farquhar 2016; Gade 2008; Higginson
2009; Higginson 2014; Kane 1984; Ma 2019; McCa,rey 2013;
Mendoza-Galindo 2018 (abstract only); Ozcelik 2014; Temel 2010).
Four studies reported the results of cost-e,ectiveness analysis
using relevant outcome measures (palliative outcome, unpaid
caregiver burden, quality-adjusted life years (QALYs)) (Farquhar
2014; Farquhar 2016; Higginson 2009; McCa,rey 2013), and hospital
costs or total costs. Results of cost-e,ectiveness analyses were
reported by incremental cost-e,ectiveness ratios (ICERs) and/or
costs per QALY (point estimates or cost-e,ectiveness planes). The
four studies reported ICERs, cost/QALY, or cost-e,ectiveness planes
from cost-e,ectiveness analysis.
Excluded studies
We excluded 25 studies for the following reasons: studies were not
RCTs (n = 8), usual care included palliative care as part of routine
care (n = 5), studies did not conceal their allocation sequence (n
= 3), intervention was not delivered by a multidisciplinary team
(n = 7), intervention was not HSPC (n = 1), and study included
hospices based outside hospital settings (n = 1) (see Characteristics
of excluded studies).
Studies awaiting classification
We could not classify one study due to insu,icient information
to clarify the nature of the palliative care team and setting (see
Characteristics of studies awaiting classification).
Ongoing studies
We identified 34 ongoing studies (see Characteristics of ongoing
studies).
Risk of bias in included studies
We assessed risk of bias using the Cochrane 'Risk of bias' tool
(see Figure 5 and Figure 6) (Higgins 2011b). Across trials, we
assessed risk of bias for all outcomes in all the domains specified
for RCTs in the Cochrane Handbook (Higgins 2011b). The domains
we covered were selection bias (random sequence generation
and allocation concealment), performance, detection, attrition and
reporting biases. We also assessed 'size of study' as a potential risk
of bias. Under the 'other bias' domain, we assessed whether groups
were balanced at baseline and also if di,erences at baseline were
adjusted for.
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Ahronheim 2000 ? ? + + ? ? + ?
Bajwah 2015 + + - + - + - - ? ?
Bakitas 2009 + ? - + - + ? - + +
Bakitas 2015 + ? - + + + + + + ?
Bekelman 2018 + + - + + + + - ? ?
Brannstrom 2014 + ? - + - + - - + -
Brumley 2007 + ? - + + + + ? ? ?
Carson 2016 + + - + ? + - - + +
Cheung 2010 + + - + - + - + ? -
Edmonds 2010 + + - - + - + -
El-Jawahri 2016 + ? - + - + + - + ?
Farquhar 2014 + + - + - - + ?
Farquhar 2016 + + - + + - + ?
Franciosi 2019 + + - + + + + + ? ?
Gade 2008 + ? - + ? + + ? - +
Groenvold 2017 + + - + + + + - + ?
Grudzen 2016 ? + - + ? + + - + ?
Higginson 2009 + + - - ? + + -
Higginson 2014 + + - + ? + - - + ?
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Figure 5.   (Continued)
Higginson 2014
Hopp 2016 ? ? + + - ? + -
Janssens 2019 + + - + - + + - + -
Jingfen 2017 + ? ? ? ? ? ? + ?
Kane 1984 ? ? - + ? + - ? + ?
Lowther 2015 ? ? - - ? - ? ?
Ma 2019 ? + + + - - + ?
McCaffrey 2013 ? ? + + + - ? -
McCorkle 2015 + ? - ? - - ? ?
McWhinney 1994 + + - + - ? ? ?
Mendoza-Galindo 2018 (abstract only) ? ? ? ? ? ? ? ? ? -
Nottelmann 2018 + + - + ? + ? ? ? ?
O'Riordan 2019 ? ? - ? - - - -
Ozcelik 2014 ? ? - ? + ? ? -
Rodin 2019 + + - + - + + - + -
Rogers 2017 ? ? - + - + - - + ?
Sidebottom 2015 ? ? - + ? + - ? + ?
Solari 2018 + + - + + + + - ? ?
Tattersall 2014 + + - + - + - + + ?
Temel 2010 ? ? - + - + + - + ?
Temel 2017 + + - - - - + ?
Vanbutsele 2018 + + - + - + + ? + ?
Wallen 2012 ? ? - ? - - + ?
Woo 2019 ? ? - + ? + + ? + ?
 
 
Figure 6.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias), subjective outcomes
Blinding of participants and personnel (performance bias), objective outcomes
Blinding of outcome assessment (detection bias), subjective outcomes
Blinding of outcome assessment (detection bias), objective outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
Size of study
0% 25% 50% 75% 100%




Twenty-seven studies were randomised and provided adequate
description of the sequence generation process. We therefore
judged them to be at low risk of bias. However, we judged 15
studies to be at unclear risk of bias due to insu,icient description of
the sequence generation process (Ahronheim 2000; Grudzen 2016;
Hopp 2016; Kane 1984; Lowther 2015; Ma 2019; McCa,rey 2013;
Mendoza-Galindo 2018 (abstract only); O'Riordan 2019; Ozcelik
2014; Rogers 2017; Sidebottom 2015; Temel 2010; Wallen 2012; Woo
2019).
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Allocation concealment
Authors of 21 studies did not provide adequate information on
how they concealed the allocation and so we judged them to
be at unclear risk of bias (Ahronheim 2000; Bakitas 2009; Bakitas
2015; Brannstrom 2014; Brumley 2007; El-Jawahri 2016; Gade 2008;
Hopp 2016; Jingfen 2017; Kane 1984; Lowther 2015; McCa,rey 2013;
McCorkle 2015; Mendoza-Galindo 2018 (abstract only); O'Riordan
2019; Ozcelik 2014; Rogers 2017; Sidebottom 2015; Temel 2010;
Wallen 2012; Woo 2019). We judged 21 studies as having a low risk of
bias because the methods used to conceal the allocation sequence
were described.
Blinding
As stated in the methods, we assessed blinding for subjective and
objective outcomes separately.
Blinding of participants and personnel (subjective outcomes)
None of the studies that reported on subjective outcomes blinded
participants. We judged two studies as having an unclear risk of
bias because they did not state whether participants and personnel
were blinded (Jingfen 2017; Mendoza-Galindo 2018 (abstract only)),
while we gave the remaining 36 studies a high risk of bias because
they did not carry out blinding. Four studies did not include
subjective outcomes and we therefore did not assess this domain
in these studies (Ahronheim 2000; Hopp 2016; Ma 2019; McCa,rey
2013) and we leK the domain blank. Generally, in palliative care
research, blinding of participants and personnel is not possible or
feasible due to the nature of palliative care interventions which
involve service provision by a multidisciplinary team (Piggott 2004),
and also because of ethical considerations as patients need to be
informed about the intervention.
Blinding of participants and personnel (objective outcomes)
We judged 29 studies to be at low risk of bias because we considered
that lack of blinding of participants and personnel was unlikely
to a,ect the objective outcomes they assessed. We could not
assess this domain in 12 studies because they did not include
objective outcomes (Edmonds 2010; Farquhar 2014; Farquhar
2016; Higginson 2009; Jingfen 2017; Lowther 2015; McCorkle 2015;
McWhinney 1994; O'Riordan 2019; Ozcelik 2014; Temel 2017; Wallen
2012) and so we therefore leK this domain blank. We gave Mendoza-
Galindo 2018 (abstract only) an unclear risk of bias because
the authors did not state whether blinding of participants and
personnel occurred.
Blinding of outcome assessment (subjective outcomes)
We judged nine studies as having a low risk of bias because they
blinded outcome assessors (Bakitas 2015; Bekelman 2018; Brumley
2007; Farquhar 2014; Farquhar 2016; Franciosi 2019; Groenvold
2017; McWhinney 1994; Solari 2018). We assessed 14 studies as
having an unclear risk of bias rating (Carson 2016; Gade 2008;
Grudzen 2016; Higginson 2014; Jingfen 2017; Kane 1984; McCorkle
2015; Mendoza-Galindo 2018 (abstract only); Nottelmann 2018;
O'Riordan 2019; Ozcelik 2014; Sidebottom 2015; Wallen 2012; Woo
2019) because it was unclear whether outcome assessors were
blinded, while we gave 15 studies a high risk of bias rating because
they did not blind outcome assessors. Some authors of studies
with a high risk of bias stated explicitly that they did not blind
outcome assessors (e.g. Vanbutsele 2018), while others stated that
they were open-label or non-blinded studies (e.g. Bakitas 2009;
Janssens 2019; Rodin 2019; Temel 2017).
We could not assess this domain in four studies because they did
not include subjective outcomes (Ahronheim 2000; Hopp 2016; Ma
2019; McCa,rey 2013) so we therefore leK this domain blank.
Blinding of outcome assessment (objective outcomes)
We assessed 29 studies as having a low risk of bias because they
blinded outcome assessors, while we rated two studies as having an
unclear risk of bias (Jingfen 2017; Mendoza-Galindo 2018 (abstract
only)) due to lack of clarity on whether outcome assessors were
blinded. We could not rate the remaining 11 studies because they
did not include objective outcomes (Edmonds 2010; Farquhar 2014;
Farquhar 2016; Higginson 2009; Lowther 2015; McCorkle 2015;
McWhinney 1994; O'Riordan 2019; Ozcelik 2014; Temel 2017; Wallen
2012) and so we leK this domain blank.
Incomplete outcome data
Twenty-nine of the 42 included studies reported almost identical
attrition rates in the intervention and control groups (Bajwah
2015; Bakitas 2009; Bekelman 2018; Brumley 2007; Carson 2016;
Edmonds 2010; El-Jawahri 2016; Farquhar 2014; Farquhar 2016;
Franciosi 2019; Gade 2008; Groenvold 2017; Grudzen 2016;
Higginson 2009; Higginson 2014; Hopp 2016; Janssens 2019; Kane
1984; Lowther 2015; Ma 2019; McCa,rey 2013; McCorkle 2015;
O'Riordan 2019; Rogers 2017; Sidebottom 2015; Solari 2018; Temel
2017; Wallen 2012; Woo 2019). The level of attrition ranged from
1% to 93%. Reasons given for attrition included clinical sta, missed
patient (n = 1, note all 'n's are studies), death (n = 27), deterioration/
severe illness (n = 4), did not receive intervention (n = 1), did not
complete (n = 3), feeling too well (n = 1), form mailed but not
returned (n = 3), hospitalised or too ill/hospitalised/hospice (n = 2),
lack of interest (n = 1), lost to follow-up (n = 2), migrated (n = 1),
not eligible aKer enrollment (n = 1), overwhelmed (n = 1), patients
could not be reached (n = 2), passive withdrawal (n = 1), protocol
violation (n = 1), refused to participate (n = 5), transfer of care (n =
3), treated at another facility (n = 1), unable to attend appointments
and unavailable (n = 1), unknown reason (n = 2), withdrawal of
consent (n = 16) and went on holiday (n = 1).
We judged 17 studies as having a high risk of bias. For example,
we assessed Brannstrom 2014 as having a high risk of bias because
attrition was not balanced across the intervention and control
groups with 77.8% completers in the intervention and 88.9%
completers in the control group. Missing data were also excluded
from the analysis in this study. Similarly, in McCorkle 2015, missing
data were not included in the analysis. McCorkle 2015 had 55%
completers in the intervention and 70% completers in the control
group. We gave Tattersall 2014 a high risk of bias rating due to high
attrition as only 18.3% of intervention group and 30% of control
completed the study and reasons for non-completion were not
stated. In McWhinney 1994, a high attrition rate was reported at one
month (36%). However, the attrition rate in each of the treatment
arms (intervention and control) was not stated. Janssens 2019 had
a 16% death rate at 12 months but did not indicate the number of
deaths in each of the treatment arms.
We judged 18 studies as having a low risk of bias (Bakitas
2015; Bekelman 2018; Brumley 2007; Edmonds 2010; El-Jawahri
2016; Farquhar 2016; Franciosi 2019; Gade 2008; Groenvold 2017;
Grudzen 2016; Janssens 2019; McCa,rey 2013; Ozcelik 2014; Rodin
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2019; Solari 2018; Temel 2010; Vanbutsele 2018; Woo 2019). In
Bekelman 2018, there were 79% completers in both intervention
and control groups with 14 (8.9%) and 12 (7.6%) being unaccounted
for in the intervention and control groups, respectively. Given
that missing data were included in the analysis using maximum
likelihood estimates, we gave a low risk of bias rating. Franciosi
2019 had 63.4% completers in the intervention group and 62.6%
completers in the control group. We rated it as having a low risk
of bias because an imputation method was used for missing data
as described in the FACIT Administration and Scoring Guidelines.
Rodin 2019 had 59% completers in the intervention group and 95%
completers in the control group. In spite of this di,erence, we gave
a low risk of bias rating because missing data were included in the
analysis.
We judged the remaining seven studies as having an unclear risk of
bias (Ahronheim 2000; Bakitas 2009; Higginson 2009; Jingfen 2017;
Lowther 2015; Mendoza-Galindo 2018 (abstract only); Nottelmann
2018). Examples of reasons for unclear risk of bias ratings were
inclusion of missing data in primary outcome analysis but not
secondary outcome analysis (Bakitas 2009) and study was an
abstract and provided no information on attrition (Mendoza-
Galindo 2018 (abstract only).
Selective reporting
We judged only five studies as having a low risk of bias (Bakitas
2015; Cheung 2010; Franciosi 2019; Higginson 2009; Tattersall 2014)
because all prespecified outcomes were reported, while we gave 13
studies an unclear risk of bias either because their study protocols
were not available or study protocols were available but only an
abstract had been published. We gave 24 studies a high risk of
bias for a number of reasons (for example. Bajwah 2015; Bekelman
2018; Carson 2016; Edmonds 2010; Janssens 2019; Rodin 2019;
Solari 2018; Temel 2010; Vanbutsele 2018; Wallen 2012): some
prespecified outcomes were not reported (for example, Edmonds
2010; Wallen 2012; Rodin 2019; Solari 2018); some outcomes in
published papers were not stated a priori in the protocol/trial
registry (for example, Brannstrom 2014; Janssens 2019); or because
outcomes specified as primary outcomes in the protocol/trial
registry were reported as secondary outcomes in published papers
(for example, Bakitas 2009). We gave Temel 2017 a high risk of
bias because it used a terminal decline joint modelling approach
in modelling the trend in outcomes backward from death. This
approach was not prespecified in the protocol.
Other potential sources of bias
Overall, we judged 27 studies as having a low risk of bias in this
domain because the studies either appeared free of other biases
or controlled for confounders in their analyses. For example, in
Bakitas 2015, although the intervention group had significantly
less education, higher weekly alcoholic beverage use, and higher
clinical trial enrollment, the intention to treat analyses were
adjusted for baseline values. Similarly, in Brannstrom 2014, the
intervention and control groups were balanced with respect to
baseline characteristics except for mean age. However, we gave a
low risk of bias rating because the authors controlled for age in
their analysis. We gave two studies a high risk of bias rating because
the authors stated that there were baseline di,erences which
were not adjusted for (Gade 2008; O'Riordan 2019). In 13 studies,
we rated an unclear risk of bias because there were baseline
di,erences and it was unclear if any adjustment was carried out for
the di,erences (e.g. Bajwah 2015; Bekelman 2018; Brumley 2007;
Cheung 2010; Franciosi 2019; McCorkle 2015). We gave McWhinney
1994 an unclear risk of bias because the sample characteristics at
baseline were not reported.
Size of study
We assessed the size of studies in order to check for possible
biases confounded by small size. We assessed 11 studies as
having a high risk of bias because they included fewer than 50
participants in each treatment group (Brannstrom 2014; Cheung
2010; Edmonds 2010; Higginson 2009; Hopp 2016; Janssens 2019;
McCa,rey 2013; Mendoza-Galindo 2018 (abstract only); O'Riordan
2019; Ozcelik 2014; Rodin 2019). Three studies included greater
than 200 participants in each treatment group and we rated them
as having a low risk of bias (Bakitas 2009; Carson 2016; Gade 2008).
We gave the remaining 28 studies an unclear risk of bias rating
because they had between 50 and 199 participants in one of the
treatment groups or both groups. For example, Bekelman 2018 had
157 participants in the intervention group and 157 participants in
the control group.
Quality assessment for cost-eectiveness studies
For full economic evaluations (Farquhar 2014; Farquhar 2016;
Higginson 2009; McCa,rey 2013), we assessed risk of bias in
results of the single e,ectiveness study on which the full economic
evaluation study was based (see Figure 5 and Figure 6 for 'Risk
of bias' assessment). We judged Farquhar 2014, Farquhar 2016
and Higginson 2009 to be at low risk of selection bias due to
adequate description of the sequence generation process and
allocation concealment. We gave McCa,rey 2013 an unclear risk of
bias rating because there was insu,icient information about the
random sequence generation process and allocation concealment.
Three of the studies reported on subjective outcomes but did
not blind participants (Farquhar 2014; Farquhar 2016; Higginson
2009). Consequently, we gave the three studies a high risk of bias
rating under 'blinding of participants and personnel (subjective
outcomes)'. McCa,rey 2013 did not include subjective outcomes;
we therefore leK this domain blank. Besides McCa,rey 2013, the
remaining three studies did not include objective outcomes and we
leK the domain 'blinding of participants and personnel (objective
outcomes)' blank. We gave McCa,rey 2013 a low of risk under
'blinding of participants and personnel (objective outcomes)'
because lack of blinding was unlikely to lead to bias in objective
outcomes such as place of death.
We judged Farquhar 2014 and Farquhar 2016 to be at a low risk
of bias for blinding of outcome assessment (subjective outcomes)
because they blinded outcome assessors, while we gave Higginson
2009 a high risk of bias due to lack of blinding. McCa,rey 2013 did
not include subjective outcomes and we therefore leK this domain
blank. McCa,rey 2013 included objective outcomes and we rated
a low risk of bias for blinding of outcome assessment (objective
outcomes) because lack of blinding was unlikely to a,ect objective
outcomes. We leK this domain blank in Farquhar 2014, Farquhar
2016 and Higginson 2009 because they did not include objective
outcomes.
We judged Farquhar 2016 and McCa,rey 2013 as having a low
risk of bias for incomplete outcome data (attrition bias), while
we assessed Higginson 2009 as having an unclear risk of bias
because the number of patients analysed di,ered from the number
of patients randomly assigned to the intervention and control
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groups. We assessed Farquhar 2014 as having a high risk of bias
in this domain due to exclusion of missing data from the analysis.
With the exception of Higginson 2009, we rated a high risk of
bias for selective reporting (reporting bias) in the remaining three
studies because all outcomes in the protocol/trial registry were not
reported in the publication.
We gave a low risk of bias rating for 'other bias' in all studies
except McCa,rey 2013. In McCa,rey 2013, it was unclear whether
the di,erences between the intervention and control groups were
controlled for. We assessed Farquhar 2014 and Farquhar 2016 as
having an unclear risk of bias for 'size of study', and Higginson 2009
and McCa,rey 2013 as having a high risk of bias due to sample sizes
below 50 in the intervention and control groups.
BMJ Checklist for authors and peer reviews of economic
submissions
The methodological quality of the 13 studies that examined total
costs varied across the di,erent areas assessed (see Appendix 8).
We assessed methodological quality using the BMJ Checklist for
authors and peer reviewers of economic submissions (Drummond
1996). Given that they used di,erent methods and reported on
di,erent resources used by patients, we could not pool their data
in a meta-analysis. All the studies were clear about their research
question. We considered all the studies to have provided the
rationale for choosing the alternatives they compared because they
all compared HSPC (or HSPC in addition to usual care) with usual
care. However, only eight of them stated the economic importance
of the research question. Six studies stated the form of economic
evaluation used. The viewpoint of the analysis was stated only
in three studies (Higginson 2009; McCa,rey 2013; Sahlen 2016
(linked to Brannstrom 2014)). All studies were clear about the
source of e,ectiveness estimates used. Besides Mendoza-Galindo
2018 (abstract only), they all provided details on the design and
results of their e,ectiveness study. The primary outcome for the
economic evaluation was clearly stated in seven studies (Farquhar
2014; Farquhar 2016; Gade 2008; Higginson 2009; Higginson
2014; McCa,rey 2013; Sahlen 2016 (linked to Brannstrom 2014)).
Quantities of resources were not reported separately from their
unit costs in four studies (Ma 2019; Mendoza-Galindo 2018 (abstract
only); Ozcelik 2014; Sahlen 2016 (linked to Brannstrom 2014)). In
Brumley 2007, this was unclear because the authors described
how the costs were derived but did not present the unit costs.
Details of currency of price adjustments for inflation or currency
conversion were not provided in any of the studies. The relevance of
productivity changes to the study question was also not discussed
in any of the studies. All studies except Mendoza-Galindo 2018
(abstract only) stated the time horizon of costs and benefits. They
all addressed the research question with conclusions following
from their findings. Gade 2008, Higginson 2009, Higginson 2014,
McCa,rey 2013 and Sahlen 2016 (linked to Brannstrom 2014)
provided details of statistical tests and confidence intervals.
Consensus on Health Economic Criteria (CHEC) list
We also used the CHEC list to assess the methodological quality
of economic evaluations (see Appendix 9). Overall, 13 studies met
seven to 16 (out of 19) quality items on the list. Five items were
considered to have been met by all studies: clear description of
study population; a well-defined research question in answerable
form; identification of important and relevant outcomes for
each alternative; appropriate measurement of outcomes; and
conclusion following the reported data. All studies but Mendoza-
Galindo 2018 (abstract only) discussed the generalisation of results
to other settings or patient group and chose the appropriate
time horizon to include relevant costs and outcomes. Eleven
of 13 studies used the appropriate economic study design to
answer the stated objective with the exception of Brumley
2007 and Brannstrom 2014. All studies except McCa,rey 2013
and Mendoza-Galindo 2018 (abstract only) discussed the ethical
and distributional issues appropriately. Only two studies clearly
described the competing alternatives (Higginson 2014; Ozcelik
2014), and three studies were considered to have appropriately
chosen a perspective for the study (Higginson 2014; McCa,rey
2013; Temel 2010). Valuing outcomes appropriately was achieved
only in five studies (Farquhar 2014; Farquhar 2016; Kane 1984;
McCa,rey 2013; Temel 2010). No study needed nor clearly stated
the discounting methods.
Eects of interventions
See: Summary of findings 1 Hospital-based specialist palliative
care compared to usual care for adults with advanced illness and
their caregivers/families
Primary outcomes
Patient Health-related Quality of Life (HRQoL)
Ten studies contributed adjusted endpoint data to the main meta-
analysis on patient HRQoL (Bakitas 2009; Bakitas 2015; El-Jawahri
2016; McCorkle 2015; O'Riordan 2019; Rodin 2019; Tattersall
2014; Temel 2010; Temel 2017; Vanbutsele 2018). We also pooled
nine studies reporting unadjusted endpoint data (Bajwah 2015;
Brannstrom 2014; El-Jawahri 2016; Franciosi 2019; Gade 2008;
Higginson 2014; Jingfen 2017; McCorkle 2015; Rogers 2017), and
nine studies presenting unadjusted change data in our sensitivity
analyses (Bajwah 2015; Bekelman 2018; El-Jawahri 2016; Grudzen
2016; Ozcelik 2014; Rogers 2017; Sidebottom 2015; Temel 2010;
Temel 2017). We further carried out sensitivity analyses to explore
the e,ect of using 0.02 in adjusting for clustering in McCorkle
2015 among studies that reported adjusted endpoint data and
unadjusted endpoint data. Only Solari 2018 reported adjusted
change data.
Of the remaining 19 studies that were not in any of the meta-
analyses, 10 did not report on patient HRQoL (Ahronheim 2000;
Brumley 2007; Carson 2016; Cheung 2010; Higginson 2009; Kane
1984; Ma 2019; McCa,rey 2013; Mendoza-Galindo 2018 (abstract
only); Wallen 2012), six presented data on di,erent domains of
HRQoL (Edmonds 2010; Farquhar 2014; Farquhar 2016; Groenvold
2017; Janssens 2019; Lowther 2015), one assessed HRQoL only
at baseline but not at follow-up (Hopp 2016), while one study
only reported that there was "no significant di,erence" without
presenting data (McWhinney 1994). Nottelmann 2018 assessed
HRQoL but did not present analysable data.
Pooled data from 10 studies reporting adjusted endpoint data
(main meta-analysis) with 1344 participants showed that HSPC was
beneficial at improving patient HRQoL when compared to usual
care (SMD 0.26, 95% CI 0.15 to 0.37; I2 = 3%; Analysis 1.1). Positive
SMDs indicate better patient HRQoL while negative SMDs indicate
lower patient HRQoL. The e,ect size obtained (0.26) is small based
on conventional standards (Cohen 1988).
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We carried out sensitivity analysis with studies that reported
adjusted endpoint data to assess the impact of using an estimate of
0.02 in adjusting for clustering in McCorkle 2015. We found similar
results to the main analysis, in favour of HSPC (SMD 0.29, 95% CI
0.18 to 0.40; I2 = 0%; n = 9 studies; N = 1280 participants; Analysis
1.2). Sensitivity analysis using unadjusted endpoint values led to
a larger di,erence between groups but the confidence intervals
were wider and there was greater heterogeneity (SMD 0.41, 95% CI
0.11 to 0.70; I2 = 83%; n = 9 studies; N = 1201 participants; Analysis
1.3). When McCorkle 2015 was removed, HSPC was still better than
usual care in improving HRQoL (SMD 0.46, 95% CI 0.13 to 0.78; I2
= 85%; n = 8 studies; N = 1137 participants; Analysis 1.4). When
we pooled unadjusted change values, we also found benefit with
HSPC (SMD 0.67, 95% CI 0.16 to 1.18; I2 = 95%; n = 9 studies; N =
1278 participants; Analysis 1.5). The results from these sensitivity
analyses supported that from the main analyses.
Solari 2018 was the only study that presented adjusted change
data and it assessed patient HRQoL using the Schedule for the
Evaluation of Individual Quality of Life - Direct Weighting (SEIQoL-
DW) (range, 0 to 100, 100 = best HRQoL). It found no between-group
di,erence between HSPC and usual care both at three months and
six months. At three months, mean change in the HSPC group was
-0.9 (95% CI -6.8 to 5.1) and -3.7 (95% CI -17.6 to 10.3) in the usual
care group with a di,erence of 2.8 (95% CI -12.2 to 17.8) between
the groups. At six months, mean change in the HSPC group was 0.8
(95% CI -5.3 to 6.9) and that in the usual care group was -4.0 (95% CI
-21.1 to 13.1) with a di,erence of 4.8 (95% CI -13.2 to 22.7) between
the groups.
Across the studies in the meta-analyses, we combined di,erent
scales assessing patient HRQoL by calculating SMDs. Table 3 under
Additional tables describes the HRQoL scales and the dimensions
they covered. The studies used di,erent scales for measuring
patient HRQoL (Kings Brief Interstitial Lung Disease in Bajwah 2015;
Functional Assessment of Chronic Illness therapy for Palliative
Care, FACIT-Pal, in Bakitas 2009, Bakitas 2015 and Rogers 2017;
Kansas City Cardiomyopathy Questionnaire (KCCQ) in Bekelman
2018; EQ-5D in Brannstrom 2014; Functional Assessment of Cancer
Therapy-Bone Marrow Transplant, FACT-BMT, in El-Jawahri 2016;
Functional Assessment of Chronic Illness Therapy - Spiritual Well-
being Scale, FACIT-Sp, in Rodin 2019; Modified City of Hope Patient
Questionnaires in Gade 2008; Functional Assessment of Cancer
Therapy-General Measure, FACT-G, in Franciosi 2019; Grudzen 2016
and McCorkle 2015; Chronic Respiratory Disease Questionnaire-
Health Related Quality of lIfe (CRQ HRQL) in Higginson 2014;
European Organisation for the Research and Treatment of Cancer
Quality of Life Questionnaire Core 30, EORTC QLQ-C30 (Chinese
version), in Jingfen 2017; EORTC QLQ-C30 in Ozcelik 2014 and
Vanbutsele 2018; Minnesota Living with Heart Failure Questionnaire
(MLHF) in O'Riordan 2019 and Sidebottom 2015; Schedule for the
Evaluation of Individual Quality of Life - Direct Weighting (SEIQoL-
DW) in Solari 2018; McGill Quality of Life Questionnaire in Tattersall
2014; Functional Assessment of Cancer Therapy – Lung scale,
FACT-L, in Temel 2010; Functional Assessment of Cancer Therapy -
General scale, FACT-G, in Temel 2017).
Four studies used more than one scale to measure patient HRQoL
(Bajwah 2015; Brannstrom 2014; Higginson 2014; Rogers 2017). In
particular, Brannstrom 2014 only showed data obtained using the
EQ-5D and not that from the KCCQ. Consequently, data from the
EQ-5D was used in the meta-analysis. Higginson 2014 assessed
HRQoL using the CRQ HRQL and the EQ-5D. We only used data
from the CRQ HRQL in the meta-analysis because unlike the EQ-5D
(Williams 1995), a generic health-related quality of life measure, it
is more specific to chronic respiratory disease (Guyatt 1987). Rogers
2017 assessed HRQoL using the FACIT-Pal and the KCCQ and both
were presented as primary outcomes. Given that the FACIT-Pal has
more extensive validation in palliative populations, we used it in the
meta-analysis.
Overall, the funnel plot suggested some asymmetry (Figure 7).
Egger's test for asymmetry resulted in a P value of 0.02. However,
given evidence of publication of negative studies in the funnel plot,
this asymmetry is not necessarily indicative of publication bias. We
did not carry out subgroup analysis due to low heterogeneity (I2 =
3%) in our main meta-analysis.
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Figure 7.   Funnel plot of comparison: 1 Patient health-related quality of life, outcome: 1.1 HSPC versus usual care on
patient HRQoL: adjusted endpoint values.










Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence on patient HRQoL to low due to a high risk of bias across
studies (-2 levels as a result of very serious study limitations: high
risk of bias for selection, performance, detection, attrition and
reporting bias) (see Summary of findings 1).
Patient symptom burden (as a collection of two or more
symptoms)
We pooled six studies that reported adjusted endpoint data as
the main meta-analysis on patient symptom burden (Bakitas 2009;
Bakitas 2015; El-Jawahri 2016; Rodin 2019; Tattersall 2014; Temel
2010). We pooled six studies that reported unadjusted endpoint
values (Bajwah 2015; El-Jawahri 2016; Gade 2008; Higginson 2014;
Lowther 2015; McCorkle 2015), four studies presenting adjusted
change values (Edmonds 2010; McCorkle 2015; Sidebottom 2015;
Solari 2018), and six studies that reported unadjusted change
values in our sensitivity analyses (Bajwah 2015; Bekelman 2018;
El-Jawahri 2016; Higginson 2009; Ozcelik 2014; Temel 2010). We
further carried out sensitivity analyses to explore the e,ect of using
0.02 in adjusting for clustering in McCorkle 2015 among studies that
reported unadjusted endpoint data and adjusted change data.
Pooled data from six studies with 761 participants reporting
adjusted endpoint values showed that HSPC was beneficial at
reducing patient symptom burden compared to usual care (SMD
-0.26, 95% CI -0.41 to -0.12; I2 = 0%; Analysis 2.1). Negative SMDs
indicate benefit (lower symptom burden) and positive SMDs reflect
higher symptom burden.
Sensitivity analysis in the six studies (N = 833 participants) that
reported unadjusted endpoint values showed a pooled e,ect of
SMD -0.17 (95% CI -0.54 to 0.20; I2 = 83%; Analysis 2.2). Among
studies that reported unadjusted endpoint values, we carried out
another sensitivity analysis to assess the impact of using 0.02 in
adjusting for clustering in McCorkle 2015 and had similar findings
(SMD -0.19, 95% CI -0.62 to 0.24; I2 = 87%; n = 5 studies; N = 769
participants; Analysis 2.3). When we considered adjusted change
values, the pooled e,ect was a SMD of -1.31 (95% CI -3.27 to 0.64;
I2 = 98%; n = 4 studies; N = 353 participants; Analysis 2.4). When
we excluded McCorkle 2015 from the studies that reported adjusted
change values, we found a pooled e,ect of SMD -1.79 (95% CI -4.29
to 0.70; I2 = 98%; n = 3 studies; N = 289 participants; Analysis 2.5).
When we considered unadjusted change values, the pooled e,ect
from the studies was a SMD of -0.44 (95% CI -0.94 to 0.06; I2 = 88%;
n = 6 studies; N = 641 participants; Analysis 2.6).
Of the remaining 25 studies that were not in any of the meta-
analyses, 20 did not report on patient symptom burden (Ahronheim
2000; Brumley 2007; Carson 2016; Cheung 2010; Franciosi 2019;
Farquhar 2014; Farquhar 2016; Groenvold 2017; Grudzen 2016;
Hopp 2016; Jingfen 2017; Ma 2019; McCa,rey 2013; McWhinney
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1994; Mendoza-Galindo 2018 (abstract only); Nottelmann 2018;
Rogers 2017; Temel 2017; Vanbutsele 2018; Woo 2019), two studies
reported that there were "no significant di,erences" between
intervention and control groups but they did not present data
(Brannstrom 2014; Kane 1984), while O'Riordan 2019 did not
present data from the Edmonton Symptom Assessment Scale
(ESAS). Wallen 2012 did not present analysable data, while
Janssens 2019 only assessed patient symptom burden using the
Edmonton Symptom Assessment Scale (ESAS) in the intervention
group.
Across the studies that we pooled in the meta-analyses, we
combined di,erent generalised measures of patient symptom
burden by applying SMDs. Included studies used the following
measures in assessing patient symptom burden: Palliative care
Outcome Scale (POS) or a modified form of it in Bajwah 2015,
Edmonds 2010, Higginson 2009, Higginson 2014 and Solari 2018;
African POS in Lowther 2015; Edmonton Symptom Assessment
Scale (ESAS) or a modified form of it in Bakitas 2009, El-Jawahri
2016, Ozcelik 2014 and Sidebottom 2015; symptom impact subscale
of the Quality of Life at End of life (QUAL-E) in Bakitas 2015; General
Symptom Distress Scale in Bekelman 2018; physical area scale
of the Modified City of Hope Patient Questionnaires (MCOHPQ)
in Gade 2008; Symptom Distress Scale (SDS) in McCorkle 2015
and Wallen 2012; Rotterdam Symptom Checklist (RSC - Physical
Symptoms Score) in Tattersall 2014; lung cancer subscale (LCS)
of the FACT-L in Temel 2010 and Memorial Symptom Assessment
Scale (MSAS) in Rodin 2019. Only the severity subscale of the MSAS
reported by Rodin 2019 was used in the meta-analysis.
Given that there were fewer than 10 included studies in the main
meta-analysis of studies that presented adjusted endpoint values,
we did not use funnel plots or carry out tests for funnel plot
asymmetry. We also did not carry out subgroup analysis due to lack
of heterogeneity I2 = 0%) in our main meta-analysis.
Quality of the evidence
Within the GRADE approach, we downgraded the quality of the
evidence for patient symptom burden to very low due to a high
risk of bias across studies (-2 levels as a result of very serious
study limitations: high risk of bias for selection, performance,
detection, attrition and reporting bias and inconsistency: -1 level
due to di,erences between our main meta-analysis and sensitivity
analyses) (see Summary of findings 1).
Secondary outcomes
Patient satisfaction with care
Eight studies assessed the e,ect of HSPC on patient satisfaction
with care (Brumley 2007; Gade 2008; Jingfen 2017; Kane 1984;
O'Riordan 2019; Ozcelik 2014; Rodin 2019; Wallen 2012). We
excluded three of the studies from the synthesis because they used
measures that had not been validated (Jingfen 2017; O'Riordan
2019; Ozcelik 2014), while one study did not present analysable
data (Wallen 2012). We excluded Janssens 2019 because the
authors did not state the outcome measure used in assessing
satisfaction with the intervention. The remaining four studies with
733 participants used validated measures (Brumley 2007; Gade
2008; Kane 1984; Rodin 2019). However, we could not include
Brumley 2007 and Kane 1984 in our meta-analysis because Brumley
2007 presented odds ratio while Kane 1984 only presented P values.
Gade 2008 and Rodin 2019 reported adjusted endpoint values and
found evidence in favour of HSPC (SMD 0.36, 95% CI 0.14 to 0.57;
I2 = 0%; N = 337 participants; Analysis 3.1). Positive SMDs indicate
better patient satisfaction while negative SMDs indicate lower
patient satisfaction. Gade 2008 used the Modified City of Hope
Patient Questionnaires (MCOHPQ) Place of Care Environment Scale
and the Doctors, Nurses/Other Care Providers Communication
scale for assessing patient satisfaction with care. The MCOHPQ
Place of Care Environment scale addressed experiences receiving
pain management and symptom relief, psychological and social
support, discharge planning, and end-of-life planning, while the
Doctors, Nurses/Other Health Care Providers Communication scale
addressed the level of caring and respect a patient felt from
their providers, as well as the opportunity, ease, and the level of
understanding the patient had with their providers. Only data from
the MCOHPQ Place of Care Environment scale was used in the
meta-analysis. Rodin 2019 assessed patient satisfaction with care
using the 16-item Family Satisfaction with Care - Patient Version
(FAMCARE-P16).
Brumley 2007 found a 3.37 higher odds of satisfaction in the HSPC
group compared to control group (P = 0.03). Brumley 2007 used the
Reid-Gundlach Satisfaction with Services instrument for assessing
patient satisfaction. Kane 1984 found di,erences in satisfaction
scores (P < 0.01) with HSPC patients expressing more satisfaction
than control patients in two of the three areas examined. The
two areas were interpersonal care and involvement in care. Kane
1984 used the Interpersonal Care scale adapted from the Ware
scale (Ware 1979), a physical environment scale from McCa,ree
and Harkins (McCa,ree 1976) and involvement-in-care questions
adapted from the National Cancer Institute’s Hospice Study (Baker
1981). Kane 1984 reported that these measures have been shown
to be reliable and valid for patients with terminal cancer. No study
reported decreased satisfaction of care in the HSPC group.
Due to small numbers in our main meta-analysis with adjusted
endpoint values, we could not carry out subgroup analysis and we
did not use funnel plots or carry out tests for funnel plot asymmetry.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for patient satisfaction to low due to a high risk of bias in
some domains in the two studies (-2 levels as a result of very serious
study limitations: high risk of performance, detection, reporting,
attrition, size of study and other biases) (see Summary of findings
1).
Unpaid caregiver satisfaction with care
Four studies assessed the e,ect of HSPC on family satisfaction
with care (Carson 2016; Cheung 2010; Kane 1984; Ozcelik 2014).
We excluded Cheung 2010 and Ozcelik 2014 from the synthesis
because they used non-validated family satisfaction measures.
Carson 2016 and Kane 1984 used validated measures with a total of
408 participants.
Carson 2016 was the only study that presented adjusted
endpoint values, with family satisfaction assessed using the Family
Satisfaction in the Intensive Care Unit (FS-ICU) survey (range, 0 to
100, 100 = best unpaid caregiver satisfaction). It found no between-
group di,erence between HSPC and usual care. The mean (95% CI)
satisfaction in the HSPC group was 81.1 (78.3 to 83.9) while that in
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the usual care group was 84.3 (81.3 to 87.3), with a di,erence of -3.1
(-7.3 to 1.0) between groups (P = 0.13).
Kane 1984 did not present their data. They only reported P values
in favour of the HSPC group in two of the five cohorts they
assessed. Kane 1984 assessed family satisfaction with care using
the Interpersonal Care scale adapted from the Ware scale (Ware
1979), a physical environment scale based on that of McCa,ree
and Harkins (McCa,ree 1976), and involvement-in-care questions
adapted from the National Cancer Institute’s Hospice Study (Baker
1981).
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for unpaid caregiver satisfaction with care to very low due
to a high risk of bias across studies (-2 levels as a result of very
serious study quality limitations: high risk of bias for performance,
attrition and reporting biases and inconsistency: -1 level due to
heterogeneity in study findings).
Achieving patient preferred place of death (measured by number
of patients with home death)
Given that most people in developed countries prefer to die at
home (Gomes 2012), we used number of home deaths as a proxy
measure for achieving patient preferred place of death.
Pooled data from seven studies with 861 analysed participants
showed that those receiving HSPC had higher odds of home deaths
compared to those receiving usual care (OR 1.63, 95% CI 1.23 to
2.16; I2 = 0%; Analysis 4.1). The odds ratio of 1.63 translates to a
risk ratio of 1.22 (95% CI 1.08 to 1.39). This implies an increase in
the relative risk of home deaths of 22% (95% CI 8% to 39%) when
compared to usual care.
Kane 1984 reported that in the intervention group, only 3% of
deaths occurred at home with almost 60% dying in the inpatient
hospice, while in the control group, 7% of deaths occurred at home
with almost 80% dying in hospital. The actual number of deaths
was not given but the authors stated that the di,erence between
intervention and control group was not "statistically significant".
Janssens 2019 reported two home deaths but did not state whether
they occurred in the HSPC group or control group.
The remaining 33 studies did not report on home death.
Given that there were fewer than 10 included studies in the meta-
analysis, we did not use funnel plots or carry out tests for funnel plot
asymmetry. In addition, we could not carry out subgroup analysis
due to lack of heterogeneity (I2 = 0%) in our meta-analysis.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for achieving patient preferred place of death to low
due to a high risk of bias across studies (-2 levels as a result
of very serious study limitations: high risk of bias for selection,
performance, detection, attrition and reporting bias) (see Summary
of findings 1).
Achieving patient preferred place of care
Only one study by Bajwah 2015 (n = 47 participants) reported
on this outcome. Bajwah 2015 was a fast-track RCT. Patients
in the intervention group received HSPC immediately aKer
randomisation, while the control group received HSPC four weeks
aKer randomisation. Consequently, both the intervention and
control group received HSPC. Results at the end of the study
showed that all eight patients (100%) who died in the intervention
group achieved their preferred place of care, while 11 patients
(84%) in the control group who received HSPC aKer four weeks
achieved this.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for achieving preferred place of care to very low due to
a high risk of bias in di,erent domains (-2 levels as a result of
very serious study limitations: high risk of bias for performance,
detection, attrition and reporting bias and imprecision: -1 level due
to limited number of studies and participants).
Mortality/survival
Thirty-six studies with 7103 participants reported on mortality/
survival (Ahronheim 2000; Bajwah 2015; Bakitas 2009; Bakitas
2015; Bekelman 2018; Brannstrom 2014; Brumley 2007; Carson
2016; Cheung 2010; Edmonds 2010; El-Jawahri 2016; Farquhar
2014; Farquhar 2016; Franciosi 2019; Gade 2008; Groenvold 2017;
Grudzen 2016; Higginson 2009; Higginson 2014; Hopp 2016;
Janssens 2019; Kane 1984; Lowther 2015; Ma 2019; McCa,rey 2013;
McCorkle 2015; McWhinney 1994; O'Riordan 2019; Rogers 2017;
Sidebottom 2015; Solari 2018; Tattersall 2014; Temel 2010; Temel
2017; Vanbutsele 2018; Woo 2019) (see Table 4 under Additional
tables). We decided against pooling of their hazard ratios in a meta-
analysis due to methodological limitations in the included studies.
Three studies did not report on the number of deaths (Mendoza-
Galindo 2018 (abstract only); Ozcelik 2014; Wallen 2012), while
Nottelmann 2018 only reported number of deaths in the HSPC
group. Rodin 2019 reported that there were no deaths during the
study, while this was unclear in the foreign language study because
it was not described (Jingfen 2017).
Ten of these studies reported on deaths in the HSPC and control
group without presenting survival time and they found no between-
group di,erence in number of deaths (Ahronheim 2000; Bekelman
2018; Brannstrom 2014; Cheung 2010; Franciosi 2019; Higginson
2009; Hopp 2016; Ma 2019; McCa,rey 2013; Rogers 2017), while
Sidebottom 2015 reported no association between study group
assignment and death within six months aKer adjustment for age,
gender, and marital status (Hazard Ratio: 1.90 (95% CI: 0.88, 4.09); P
= 0.101). Sidebottom 2015 reported 14 deaths (12.1%) in the HSPC
group and 5 deaths (4.3%) in the control group.
In 11 studies, it was unclear if there was any di,erence in mortality
because the P values were not presented (Bajwah 2015; Edmonds
2010; El-Jawahri 2016; Farquhar 2014; Farquhar 2016; Lowther
2015; McCorkle 2015; McWhinney 1994; O'Riordan 2019; Solari
2018; Temel 2017). McWhinney 1994 only presented the total
number of deaths at one month (36 (24.7%)) but did not report the
numbers in the HSPC and control group.
In the studies that reported survival time, there was probably
little to no e,ect of HSPC on survival (Bakitas 2009; Bakitas 2015;
Carson 2016; Gade 2008; Groenvold 2017; Grudzen 2016; Kane 1984;
Janssens 2019; Vanbutsele 2018; Woo 2019).
In Bakitas 2009, median survival (95% CI) in the HSPC group was 14
months (10.6 to 18.4) and 8.5 months (7 to 11.1) in control with a
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P value of 0.14. There were 112 deaths (69.6%) in the HSPC group
and 119 deaths (73.9%) in the control group. The Cox proportional
hazards model estimate demonstrated a reduced relative risk of
death (Hazard Ratio (HR): 0.67 (95% CI: 0.496 to 0.906), P = 0.009)
in the HSPC group during the first year of the study and a greater
relative risk aKer one year (HR, 1.56 (95% CI: 0.908 to 2.655)).
In Bakitas 2015, a fast-track RCT in which the intervention group
was o,ered HSPC immediately, while the control group received
HSPC aKer three months, median survival by the end of data
collection in the intervention group was 18.3 months and 11.8
months in the control group who began HSPC three months later.
Kaplan-Meier curves illustrated a 15% di,erence in survival at 1
year (HSPC, 63% versus control, 48%; P = 0.038). However, the
overall log-rank test P value was 0.18, suggesting a convergence in
overall survival aKer 12 months. At one year, there were 109 deaths
(52.7%) but numbers in intervention and control groups were not
reported.
Carson 2016 reported a median survival (95% CI) of 19 (12 to 37)
days in the HSPC group and 23 (12 to 39) days in control group (P =
0.51). There was no di,erence in 90-day survival (HR, 0.95 (95% CI:
0.65 to 1.38), P = 0.96). Post hoc adjustment for baseline activities of
daily living and study site did not alter the outcome (HR,1.01 (95%
CI: 0.69 to 1.47), P = 0.96).
In Grudzen 2016, median survival (95% CI) in the HSPC group was
289 days (128 to 453) and 132 days (80 to 302) in control with a P
value of 0.2. At one year, 41 participants (59.4%) had died in the
HSPC group and 44 (65.7%) had died in the control group. However,
there was no di,erence between the groups (P = 0.20).
Janssens 2019 was not clear about whether they were reporting
mean or median survival. Survival in the HSPC group was 454 days
(95% CI: 382 to 525) and 425 days (95% CI: 339 to 509) in the
control group (log-rank test, P = 0.91). During the follow-up period
in Janssens 2019, there were four deaths (15.4%) in the HSPC group
and four deaths (17.4%) in the control group.
Kane 1984 reported no di,erence in survival between HSPC and the
control group as the survival curves were similar.
In Gade 2008, median survival (IQR) was 30 days (6 to 104) in the
HSPC group and 36 days (13 to 106) in the control group (P = 0.08).
There were 173 deaths (63%) in the HSPC group and 132 deaths
(56%) in the control group during the study period.
Groenvold 2017 reported that survival time did not di,er between
HSPC and the control group. Median survival in the HSPC group was
323 days and 364 days in the control group (P = 0.16, but in the
adjusted analysis P = 0.39). There were 25 deaths (27%) in the HSPC
group and 22 deaths (23%) in the control group.
Woo 2019 reported that there was no di,erence in survival between
HSPC and usual care but did not present any data.
Vanbutsele 2018 found the median survival (95% CI) in the HSPC
group to be 312 days (190 to 434) and 343 days (253 to 433) in the
control group (P = 0.97).
Sidebottom 2015 reported no association between study group
assignment and death within six months aKer adjusting for age,
gender and marital status (P = 0.10).
Higginson 2014 and Temel 2010 found evidence in favour of
HSPC for longer survival compared to usual care. Higginson 2014
was a fast-track RCT in which the intervention group received
HSPC immediately while those in the control group were o,ered
HSPC aKer six weeks. Survival was calculated from the time of
randomisation to the time of death, if death occurred during the
study period, or to the time of censoring. Median survival (range)
from randomisation to the time of censoring was 745 (338 to
1075) days in the intervention group compared to 711 (345 to
1045) in the control group who received HSPC aKer six weeks
(P = 0.048). In subgroup analysis, this pattern was not recorded
for patients with cancer (P = 0.97); but it became more marked
for patients with diseases other than cancer (P = 0.01). Temel
2010 reported that median survival (95% CI) was 11.6 months
(6.4 to 16.9) in the HSPC group and 8.9 months (6.3 to 11.4) in
control (log rank P = 0.02). AKer adjustment for age, sex, and
baseline Eastern Cooperative Oncology Group performance status,
the group assignment remained a predictor of survival (hazard ratio
for death in the standard care group, 1.70; 95% CI, 1.14 to 2.54; P =
0.01).
By contrast, Brumley 2007 and Tattersall 2014 reported greater
survival (SD) in the control group compared to the HSPC group.
Brumley 2007 reported a mean (SD) survival of 242 (SD:200) days in
the control group compared to 196 (SD:164) days in those receiving
HSPC (P = 0.03). However, results of the Kaplan-Meier survival
analysis did not show di,erences in survival time between study
groups (P = 0.08). The authors also highlighted 75% death among
participants but the percentages in the HSPC and control groups
were not stated. In Tattersall 2014, there were 39 (65%) deaths in
the HSPC group and 31 (51.7%) in the control group at 12 months.
Tattersall 2014 found the median survival (95% CI) in the HSPC
group to be 7 months (5.2 to 9.8) compared to 11.7 months (9.8
to 18.8) in the control group (log rank P = 0.014). The estimated
hazard ratio was 1.6 (95% CI:1.1 to 2.3; P = 0.015). This estimate
changed to 1.5 (95% CI 0.99 to 2.2; P = 0.06) when adjusted for the
oncologist’s baseline estimate of likely survival, diagnosis, months
since diagnosis, and gender.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for mortality/survival to very low due to a high risk of
bias across studies (-2 levels as a result of very serious study
limitations: high risk of bias for selection, performance, detection,
attrition, reporting and other biases and inconsistency: -1 level due
to variability in study findings).
Pain
We pooled data from four studies (n = 525 participants) that
reported adjusted endpoint values for pain as the main meta-
analysis. The meta-analysis showed that HSPC may lead to little to
no di,erence in pain relief (SMD -0.16, 95% CI -0.33 to 0.01; I2 = 0%;
Analysis 5.1). Positive SMDs indicate more pain while negative SMDs
indicate lower pain (benefit). Only Woo 2019 reported unadjusted
endpoint values and it assessed pain using the Brief Pain Inventory.
It found no di,erence in mean pain scores between HSPC and
usual care (P = 0.22). However, sensitivity analysis with studies
reporting adjusted change values showed evidence in favour of
HSPC (SMD -0.47, 95% CI -0.74 to -0.20, I2 = 0%; n = 2 studies; N =
218 participants; Analysis 5.2).
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When we carried out sensitivity analysis using unadjusted change
values, we found no evidence of a di,erence between HSPC and
usual care (SMD -0.93, 95% CI -3.05 to 1.19; I2 = 97%; n = 2 studies;
N = 291 participants; Analysis 5.3).
Although we had initially specified that we would treat pain
as a binary outcome in our published protocol (Bajwah 2017),
this was not possible as most studies presented pain as a
continuous outcome. Studies such as Tattersall 2014 reported on
the percentage of patients with pain, while Lowther 2015 presented
pain data as medians. Kane 1984 reported that there was no
di,erence in pain between the intervention and control group
over time but did not present data. Also, McWhinney 1994 stated
that there were "no clinically or statistically significant di,erences"
between the intervention and control groups but did not report
their data. The remaining 30 studies did not report on pain.
We combined di,erent scales assessing pain by calculating SMDs.
Across the studies in these meta-analyses, we combined di,erent
measures for assessing pain (PEG derived from the Brief Pain
Inventory (BPI) in Bekelman 2018; pain item of the EORTC QLQ-C30
in Groenvold 2017 and Vanbutsele 2018; pain item of the POS in
Higginson 2009; pain severity on the BPI in O'Riordan 2019, Rodin
2019 and Woo 2019; pain item of the ESAS in Ozcelik 2014 and
Sidebottom 2015).
Given that there were fewer than 10 included studies in our main
meta-analysis on pain using adjusted endpoint values, we did not
use funnel plots or carry out tests for funnel plot asymmetry. In
addition, we could not carry out subgroup analysis due to lack of
heterogeneity (I2 = 0%) in our main meta-analysis with adjusted
endpoint values.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for pain to very low due to a high risk of bias across studies
(-2 levels as a result of very serious study limitations: high risk of
bias for performance, attrition and other bias and inconsistency:
-1 level due to di,erences between our main meta-analysis and
sensitivity analyses) (see Summary of findings 1).
Patient anxiety and depression
Patient anxiety
We pooled data from five studies (N = 384 participants) that
reported adjusted endpoint values as the main meta-analysis. The
five studies used the anxiety subscale of the Hospital Anxiety and
Depression Scale (HADS-A) for assessing anxiety (seven items; 0 to
21 scale, 21 = maximum distress). HSPC showed no evidence of
di,erence with a mean di,erence of -0.63 points when compared
to usual care (95% CI -2.22 to 0.96; I2 = 76%; Analysis 6.1). Negative
mean di,erence (MD) indicates benefit (lower anxiety) and positive
MD reflects harm (higher anxiety).
We carried out sensitivity analysis to test the estimate we used in
adjusting for clustering in McCorkle 2015 and found evidence in
favour of HSPC (MD -1.60, 95% CI -2.56 to -0.65; I2 = 17%; n = 4
studies; N = 320 participants; Analysis 6.2).
Evidence from the sensitivity analysis of studies that reported
unadjusted endpoint values produced a mean di,erence of -0.90
between HSPC and usual care (95% CI -2.52 to 0.71; I2 = 67%; n
= 4 studies; N = 273 participants; Analysis 6.3). Included studies
measured anxiety using the HADS-A. When we removed McCorkle
2015, the mean di,erence was -1.48 (95% CI -3.52 to 0.56; I2 = 71%;
n = 3 studies; N = 209 participants; Analysis 6.4).
Sensitivity analysis with studies that presented unadjusted change
values showed an e,ect in favour of HSPC (SMD -0.62; 95% CI -1.02
to -0.21; I2 = 74%; n = 4 studies; N = 496 participants; Analysis
6.5). SMD was used in pooling the estimates because the four
studies used di,erent scales for measuring anxiety. Bajwah 2015
and El-Jawahri 2016 used the HADS-A, Bekelman 2018 used the
Generalised Anxiety Disorder-7 (GAD-7), while Ozcelik 2014 used
the anxiety subscale of the Edmonton Symptom Assessment Scale
(ESAS)).
Only Sidebottom 2015 (n = 167 participants) reported adjusted
change values and it assessed anxiety using the anxiety subscale
of the ESAS (using a visual scale line, 0 to 10, 10 = worst possible).
It found that anxiety scores improved by a mean of 1.27 points
in the HSPC group and 0.89 in the control group at three months
(di,erence 0.38, P = 0.017) aKer adjusting for age, gender, and
marital status di,erences between study groups. This di,erence
was already evident at one month (P = 0.007).
Five studies also assessed patient anxiety but they could not be
included in the meta-analysis for the following reasons: Kane 1984
did not provide data on anxiety but rather it only stated the P values,
Temel 2010 only presented the percentage of patients with anxiety
at the primary point of analysis, Temel 2017 did not provide data
but stated that scores did not di,er between the intervention and
control groups at 12 weeks or 24 weeks, Solari 2018 reported no
di,erence between groups for change at three and six months but
did not present usable data and Vanbutsele 2018 presented an odds
ratio at 12, 18 and 24 weeks. This study did not find any evidence of
a di,erence between groups at these di,erent time points.
The remaining 26 studies did not report on patient anxiety.
Given that there were fewer than 10 included studies in the main
meta-analysis on patient anxiety using adjusted endpoint values,
we did not use funnel plots or carry out tests for funnel plot
asymmetry.
Subgroup analysis on patient anxiety
We carried out the following subgroup analyses on patient anxiety.
Eect of HSPC on patient anxiety in dierent populations
Among studies that reported adjusted endpoint values, we
carried out subgroup analysis to assess the e,ect of HSPC on
patient anxiety in di,erent populations. Three studies with 275
participants were with cancer populations and two with non-
cancer populations (N = 109 participants). Subgrouping according
to patient population explained heterogeneity in the non-cancer
population subgroup (I2 = 0%), but not the cancer population
subgroup (I2 = 87%) (Analysis 6.6). There was no evidence of a
subgroup e,ect (P = 0.90, I2 = 0%). This finding may be spurious due
to the small number of studies and participants in the subgroups.
When McCorkle 2015 was excluded from the cancer population
subgroup, heterogeneity (I2) reduced to 24% (Analysis 6.7). No
subgroup di,erence was observed (P = 0.29, I2 = 10%).
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Eect of dierent models of HSPC on patient anxiety
Four studies (N = 227 participants) that involved service provision
across multiple settings and one study by El-Jawahri 2016 with an
inpatient consult model (N = 157 participants) reported adjusted
endpoint values. We could not carry out subgroup analysis because
of the limited number of studies in the inpatient consult model
subgroup.
Eect of 24 hours access (out-of-hours care) on patient anxiety
None of the studies had provision for 24 hours access.
Eect of early palliative care versus late palliative care on patient
anxiety
Among studies that reported adjusted endpoint data, two studies
with 221 participants provided HSPC early and three with
163 participants provided it late. Subgrouping only explained
heterogeneity in the late palliative care subgroup (I2 = 0%), but
not the early palliative care subgroup (I2 = 94%) (Analysis 6.8).
There was no evidence of a subgroup e,ect (P = 0.90, I2 = 0%).
When McCorkle 2015 was removed from the early palliative care
subgroup, only El-Jawahri 2016 was remaining in the subgroup and
we could not carry out any further analysis.
Eect of nurse led multi-disciplinary team versus multidisciplinary led
team services on patient anxiety
All five studies (N = 384 participants) that reported adjusted
endpoint values were MDTservices not led by nurses with a pooled
mean di,erence of -0.63 between HSPC and usual care (95% CI
-2.22 to 0.96; I2 = 76%; Analysis 6.9). AKer removal of McCorkle 2015,
there was evidence in favour of HSPC when compared to usual care
(MD -1.60, 95% CI -2.56 to -0.65; I2 = 17%; n = 4 studies; N = 320
participants; Analysis 6.10).
Eect of HSPC on patient anxiety in dierent countries
Among studies that reported adjusted endpoint values, three (N
= 251 participants) were carried out in USA and two (N = 133
participants) in the UK. Subgrouping by country only explained
heterogeneity in the UK studies (I2 = 0%), but not the USA studies
(I2 = 88%) (Analysis 6.11). Subgroup analysis showed no di,erence
across the two countries (P = 0.66, I2= 0%). This analysis is unlikely
to detect a subgroup di,erence due to the small number of
studies and participants in the subgroups. When McCorkle 2015
was removed from the USA subgroup, I2 was 52% in the subgroup
(Analysis 6.12) and there was no evidence of a subgroup e,ect and
heterogeneity (P = 0.77, I2 = 0%).
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for patient anxiety to very low due to a high risk of bias
across studies (-2 levels as a result of very serious study limitations:
high risk of bias for selection, performance, detection, attrition and
reporting biases and inconsistency: -1 level due to unexplained
heterogeneity).
Patient depression
We pooled data from eight studies (N = 1096 participants) reporting
adjusted endpoint values for our main meta-analysis on patient
depression. The results showed that HSPC improved depression
when compared to usual care (SMD -0.22, 95% CI -0.34 to -0.10;
I2 = 0%; Analysis 8.1). Negative SMDs indicate benefit (lower
depression) and positive SMDs reflect harm (higher depression).
We carried out sensitivity analysis with five studies (N = 350
participants) presenting unadjusted endpoint values and found
a pooled estimate of SMD -0.25 (95% CI -0.55 to 0.04; I2 = 47%;
Analysis 8.2). We carried out sensitivity analysis to assess the
impact of using an estimate of 0.02 in adjusting for clustering in
McCorkle 2015 and found evidence in favour of HSPC (SMD -0.34,
95% CI -0.65 to -0.03; I2 = 42%; n = 4 studies; N = 286 participants;
Analysis 8.3).
Only two studies (McCorkle 2015, Sidebottom 2015) with 231
participants contributed data to the sensitivity analysis using
adjusted change values with a pooled estimate of MD -0.32 (95%
CI -1.10 to 0.45; I2 = 92%; Analysis 8.4). The sensitivity analysis
using unadjusted change values showed evidence in favour of HSPC
(SMD -0.38, 95% CI -0.58 to -0.18; I2 = 12%; n = 4 studies; N = 488
participants; Analysis 8.5).
Three studies also presented binary data and we pooled them using
odds ratio (El-Jawahri 2016; Temel 2010; Woo 2019). We found
evidence of lower odds of patient depression with HSPC compared
to usual care (OR 0.38, 95% CI 0.21 to 0.68; I2 = 32%; n = 3 studies; N
= 338 participants; Analysis 8.6). The odds ratio of 0.38 translates to
a risk ratio of 0.55, implying that the risk of patient depression was
0.55 times lower with HSPC compared to usual care.
Four studies assessed patient depression but we excluded them
from the main meta-analysis because they did not present
analysable data (Kane 1984; Solari 2018; Vanbutsele 2018; Wallen
2012). Kane 1984 described no between-group di,erence between
intervention and control group but did not provide the data.
Solari 2018 reported that they found no di,erence between
groups at three and six months but did not present analysable
data, Vanbutsele 2018 presented only odds ratios and the
corresponding 95% CIs for the two measures it used in assessing
depression (HADS-D and PHQ-9). There was no di,erence between
intervention and control groups at 12, 18 and 24 weeks in
Vanbutsele 2018. Wallen 2012 assessed depression but did not
present data on it at baseline and follow-up. The remaining 21
studies did not report on patient depression.
Studies included in the meta-analyses used di,erent scales in
assessing depression (Becks Depression Inventory-II (BDI-II) in
Rodin 2019; depression subscale of the Hospital Anxiety and
Depression Scale (HADS-D) in Bajwah 2015, El-Jawahri 2016,
Farquhar 2014, Farquhar 2016, Higginson 2014, O'Riordan 2019,
Rogers 2017; Patient Health Questionnaire (PHQ-9) in Bekelman
2018, Grudzen 2016, McCorkle 2015, Sidebottom 2015 and Temel
2017; depression subscale of the Edmonton Symptom Assessment
Scale (ESAS) in Ozcelik 2014; Centre for Epidemiological Studies -
Depression Scale (CES-D) in Bakitas 2009, Bakitas 2015 and Woo
2019). El-Jawahri 2016 and Temel 2017 also assessed depression
using the PHQ-9.
Given that there was no heterogeneity in our main meta-analysis (I2
= 0%), we did not carry out any subgroup analysis. There were fewer
than 10 studies that reported adjusted endpoint values in the main
meta-analysis, and we did not use funnel plots or carry out tests for
funnel plot asymmetry.
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Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for patient depression to very low due to a high risk of bias
across studies (-2 levels as a result of very serious study limitations:
high risk of bias for selection, performance, detection, attrition
and reporting biases and inconsistency: -1 level due to di,erences
between our main meta-analysis and sensitivity analyses).
Patient breathlessness
We pooled data from five studies reporting adjusted endpoint
values for our main meta-analysis on patient breathlessness with
a pooled estimate of SMD -0.04 (95% CI -0.19 to 0.12; I2 = 0%, N
= 616 participants; Analysis 12.1). Negative SMDs indicate benefit
(reduced breathlessness) and positive SMDs reflect worsened
breathlessness. The five studies used di,erent instruments and
reported on di,erent breathlessness domains. For instance,
Farquhar 2014 and Farquhar 2016 both assessed distress due to
breathlessness and breathlessness mastery using a Numeric Rating
Scale (NRS) and the mastery domain of the Chronic Respiratory
Questionnaire (CRQ), respectively; Groenvold 2017 and Vanbutsele
2018 assessed breathlessness intensity using the dyspnoea item of
EORTC QLQ-C30; O'Riordan 2019 assessed breathlessness intensity
using the BORG scale. For Farquhar 2014 and Farquhar 2016, we
used only data for distress due to breathlessness assessed with the
NRS in our meta-analysis because it was the primary outcome. We
did not di,erentiate between di,erent breathlessness domains in
our meta-analysis due to small numbers.
Sensitivity analysis carried out with the two studies (N = 128
participants) presenting unadjusted endpoint values showed a
pooled estimate in favour of HSPC (SMD -0.35, 95% CI -0.70 to -0.00;
I2 = 0%; Analysis 12.2).
Only Sidebottom 2015 presented adjusted change values. It
assessed breathlessness using the dyspnoea item of ESAS (using
a visual scale line, 0 to 10, 10 = worst possible) and found that
breathlessness scores improved by a mean of 2.8 points in the HSPC
group and 1.7 in the control group at 3 months (di,erence 1.08, P <
0.001) aKer adjusting for age, gender, and marital status di,erences
between study groups. This di,erence was evident at one month
with a mean di,erence of 1.10 (P < 0.001).
Sensitivity analysis with the two studies that reported unadjusted
change values showed a pooled estimate of SMD -0.47 (95% CI -1.55
to 0.61; I2 = 90%, N = 292 participants; Analysis 12.3).
A study by Tattersall 2014 also recorded this outcome but did not
present analysable data. The remaining 31 studies did not report
on breathlessness.
Studies included in the meta-analyses used di,erent scales in
assessing breathlessness: D-12 in Bajwah 2015; Memorial Symptom
Assessment Scale in Bekelman 2018; Numeric Rating Scale (NRS)
for distress due to breathlessness in Farquhar 2014 and Farquhar
2016; dyspnoea item of EORTC QLQ-C30 in Groenvold 2017 and
Vanbutsele 2018; breathlessness mastery domain of the Chronic
Respiratory Disease Questionnaire (CRQ mastery) in Higginson
2014; BORG scale in O'Riordan 2019; dyspnoea item of ESAS in
Ozcelik 2014 and Sidebottom 2015.
Due to lack of heterogeneity (I2 = 0%) in our main meta-analysis,
we could not carry out subgroup analysis. Given that there were
fewer than 10 included studies in the main meta-analysis on
breathlessness using adjusted endpoint values, we did not use
funnel plots or carry out tests for funnel plot asymmetry.
Quality of the evidence
Within the Grade approach, we downgraded the quality of evidence
for breathlessness to very low due to a high risk of bias across
studies (-2 levels as a result of very serious study limitations: high
risk of bias for selection, performance, detection, attrition and
reporting biases, imprecision: -1 level due to wide 95% CI around
the e,ect estimates that included both benefit and harm and
inconsistency: -1 level due to di,erences between our main meta-
analysis and sensitivity analyses).
Adverse events in patients and unpaid caregivers
Eight studies with 1252 participants reported on adverse events
(Bajwah 2015; Bekelman 2018; Groenvold 2017; Higginson 2014;
Lowther 2015; Rodin 2019; Solari 2018; Tattersall 2014) (see Table
5 under Additional tables). Two of these studies involved unpaid
caregivers (Bajwah 2015; Higginson 2014).
Six studies (N = 976 participants) reported no harmful e,ect
(Bajwah 2015; Bekelman 2018; Groenvold 2017; Higginson 2014;
Lowther 2015; Rodin 2019).
One study by Tattersall 2014 (N = 120 participants) found that more
patients in the HSPC group had the mild adverse event of poorer
appetite (P = 0.04) compared to the control group.
Solari 2018 (N = 156 participants) reported 15 serious
adverse events in 13 patients in the HSPC group and
seven in seven patients in the control group (P = 0.78).
Serious adverse events reported included aspiration pneumonia,
generalised anxiety, breathing di,iculty, urine retention/infection,
anarthria, contact dermatitis, dysphagia, vomiting, bladder
catheter malfunctioning, fever, arrhythmia, necrotising fasciitis,
traumatic wound, macrohaematuria, constipation, abdominalgia
and bronchitis. Three patients in the HSPC group died but this was
considered to be unrelated to the intervention.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for adverse events to very low due to a high risk of bias
across studies (-2 levels as a result of very serious study limitations:
high risk of bias for performance, detection, attrition and reporting
bias and inconsistency: -1 level due to variability in the results).
Unpaid caregiver symptom control
Unpaid caregiver anxiety
Only Carson 2016 (N = 312 participants) presented adjusted
endpoint values. Carson 2016 assessed unpaid caregiver anxiety
using the HADS-A (seven items; 0 to 21 scale, 21 = maximum
distress). Carson 2016 reported no di,erence in the unpaid
caregiver anxiety in the HSPC group compared to the control group
at three months on adjusting for baseline and multiple respondents
(mean (95% CI): 7.2 (6.6 to 7.9) versus 6.4 (5.7 to 7.1), mean
di,erence was 0.8 (95% CI: -0.1 to 1.8), P = 0.09). Adjustments for
three variables (baseline, multiple respondents and study sites)
and six variables (baseline, multiple respondents, study sites, race,
sex and primary/additional surrogate) also produced similar results
with P values of 0.11 and 0.12, respectively.
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Only Bajwah 2015 and Carson 2016 with 351 participants provided
unadjusted endpoint data with a pooled estimate of MD -0.71 (95%
CI -4.27 to 2.85; I2 = 77%; Analysis 7.1). Both studies used the HADS-
A in assessing unpaid caregiver anxiety. A negative MD indicates
benefit (lower unpaid caregiver anxiety) and a positive MD reflects
harm (higher unpaid caregiver anxiety).
Four studies recorded this outcome but did not present analysable
data (El-Jawahri 2016; Farquhar 2014; Farquhar 2016; Kane 1984).
El-Jawahri 2016 and Farquhar 2016 did not present the number of
participants in the intervention and control group at the primary
point of analysis. Farquhar 2014 reported that there was little
change in carer outcomes but did not present data, while Kane
1984 found di,erences in favour of HSPC in three of the five cohorts
examined but did not present usable data.
The remaining 36 studies did not report on unpaid caregiver
anxiety.
Given that we had only one study that presented adjusted endpoint
values, we could not carry out any further analysis.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for unpaid caregiver anxiety to very low due to a high
risk of bias (-2 levels as a result of very serious study limitations:
high risk of bias for performance, attrition and reporting biases, and
imprecision: -1 level due to the small number of participants).
Unpaid caregiver depression
Two studies (N = 413 participants) reported on unpaid caregiver
depression and also presented adjusted endpoint values. They
found that HSPC had little to no e,ect on unpaid caregiver
depression (SMD -0.02, 95% CI -0.21 to 0.18; I2 = 0%; Analysis 9.1).
Negative SMDs indicate benefit (lower depression) and positive
SMDs reflect harm (higher depression).
Sensitivity analysis with the three studies that reported unadjusted
endpoint values resulted in a SMD of -0.29 (95% CI -0.70 to 0.12; I2 =
63%; n = 3 studies; N = 420 participants; Analysis 9.2).
Bajwah 2015, (N = 35 unpaid caregiver participants), was the only
study that presented unadjusted change values on the HADS-D
(seven items; 0 to 21 scale, 21 = maximum distress). It found a
30% mean decrease in unpaid caregiver depression scores from
baseline at four weeks for the HSPC group while for controls, unpaid
caregiver depression increased by one point. The e,ect size (95%
CI) at four weeks was -0.7 (-1.3 to 0.0). Between the period when the
control group received HSPC (four weeks) and eight weeks, mean
(SD) depression improved in the control group from 9.6 (4.9) to 7.2
(3.9).
Four studies reported on unpaid caregiver depression but did not
present usable data (El-Jawahri 2016; Farquhar 2014; Farquhar
2016; Kane 1984). In El-Jawahri 2016, the number of participants in
the intervention and control groups at the primary point of analysis
was not reported. Farquhar 2014, Farquhar 2016 and Kane 1984 did
not present their data. The remaining 34 studies did not report on
unpaid caregiver depression.
Studies included in the meta-analyses used di,erent scales in
assessing unpaid caregiver depression (Bajwah 2015 and Carson
2016 used the depression subscale of the HADS (HADS-D); Bakitas
2015 used the CES-D; Bekelman 2018 assessed depression using the
Patient Health Questionnaire-8 (PHQ-8)).
We could not carry out subgroup analysis due to lack of
heterogeneity in our main meta-analysis (I2 = 0%). Given that there
were fewer than 10 included studies in the meta-analysis on unpaid
caregiver depression, we did not use funnel plots or carry out tests
for funnel plot asymmetry.
Quality of the evidence
Within the Grade approach, we downgraded the quality of evidence
for unpaid caregiver depression to very low due to a high risk of bias
(-2 levels as a result of very serious study limitations: high risk of
bias for performance, attrition and reporting bias and imprecision:
-1 level due to wide 95% CIs around the e,ect estimates that
included both benefit and harm).
Unpaid caregiver burden
Two studies with 170 participants presented adjusted endpoint
values (Dionne-Odom 2015a (linked to Bakitas 2015); Bekelman
2018)). However, we could not pool them together in a meta-
analysis due to how they presented their data. Dionne-Odom 2015a
assessed unpaid caregiver burden using the Montgomery-Borgatta
Caregiver Burden (MBCB) scale and presented results for three
di,erent subscales of the MBCB, namely, the objective burden scale
(range, 6 to 30; 30 indicates worst level of interference with the
unpaid caregiver's private, social, recreational time and normal
daily routine), stress burden scale (range, 4 to 20; 20 indicates worst
level of strained emotional demands related to caregiving) and the
demand scale (range, 4 to 20; > 15 indicates worst level of caregiver
strain by his or her caregiving demands). Bekelman 2018 assessed
unpaid caregiver burden using the Zarit Burden Inventory (ZBI)
(range, 0 to 88; 88 indicates highest burden).
On the objective burden scale of the MBCB, the mean unpaid
caregiver burden scores for the HSPC group was 0.3 points higher
(range 6 to 30; 30 indicates worst) than that of the control group
with adjustment for patient death (P = 0.64). On the stress burden
scale of the MBCB, the mean caregiver burden scores for the HSPC
group was 0.5 points lower (range, 4 to 20; 20 indicates worst) than
the control group with adjustment for patient death (P = 0.29).
There was no di,erence in the mean caregiver burden score with
adjustment for patient death on the demand scale of the MBCB (P
= 0.97). Bekelman 2018 reported a mean (SE) caregiver burden of
12.9 (1.3) in the HSPC group and 14.8 (1.4) in the control group at
12 months (P = 0.30).
Two studies (N = 108 participants) reported unadjusted endpoint
data but we could not pool them in a meta-analysis (Bajwah 2015;
Dionne-Odom 2015a (linked to Bakitas 2015)). Dionne-Odom 2015a
reported the following results: on the objective burden scale of the
MBCB, the mean caregiver burden scores for the HSPC group was
0.3 points higher (range 6 to 30; 30 indicates worst) than that of the
control group (P = 0.62). On the stress burden scale of the MBCB, the
mean caregiver burden scores for the HSPC group was 0.6 points
lower (range, 4 to 20; 20 indicates worst) than that of the control
group. There was no di,erence between HSPC and control group in
the mean caregiver burden score on the demand scale of the MBCB
(P = 0.99). Bajwah 2015 assessed unpaid caregiver burden using the
ZBI (range, 0 to 88; 88 indicates highest burden), and reported a
mean (SD) unpaid caregiver burden of 22.3 (15.3) in the fast-track
group and 31.7 (17.3) for the control group at four weeks. AKer
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the control group was o,ered HSPC between four weeks and eight
weeks, mean (SD) unpaid caregiver burden reduced to 25.4 (13.4).
We carried out sensitivity analysis with the three studies that
reported adjusted change values and found evidence in favour of
HSPC (MD = -3.88, 95% CI -5.95 to -1.80; I2 = 0%; N = 128 participants;
Analysis 11.1). All three studies assessed unpaid caregiver burden
using the ZBI.
Bajwah 2015 (N = 39 participants) was the only study that presented
unadjusted change values. Bajwah 2015 reported a 0.1 mean
increase in unpaid caregiver burden score from baseline to four
weeks for 16 intervention unpaid caregivers while for 23 unpaid
caregivers in the control group, unpaid caregiver burden decreased
by a 0.1 point. The e,ect size (95% CI) at four weeks was -0.6 (-1.2
to 0.1).
Bakitas 2009 reported on unpaid caregiver burden but did not
present usable data for the meta-analysis. The remaining 36 studies
did not report on unpaid caregiver burden.
We did not carry out any further analysis on unpaid caregiver
burden due to limited number of studies.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for unpaid caregiver burden to very low due to a high risk
of bias across studies (-2 levels as a result of very serious study
limitations: high risk of bias for performance and reporting bias and
imprecision: -1 level due to small number of participants).
Unpaid caregiver pre- and post-bereavement outcomes
Unpaid caregiver grief
Only Dionne-Odom 2016 (linked to Bakitas 2015) with 44
participants provided usable data for unpaid caregiver grief.
Dionne-Odom 2016 assessed unpaid caregiver grief using the
Prigerson Inventory of Complicated Grief - Short Form (PG 13) and
reported a non-signifacnt di,erence in the mean unpaid caregiver
grief score in the HSPC group that was 2.2 points lower (range,
11 to 55; 55 indicates highest grief) than that of the control group
(P = 0.21). There was no evidence of a di,erence on adjusting for
religious preference (P = 0.40), baseline depression levels (P = 0.51)
and patient hospice use (P = 0.51).
Quality of the evidence
We downgraded the quality of the evidence on unpaid caregiver
grief to low due to a high risk of bias (-1 level as a result of serious
study limitations: high risk of performance bias and imprecision: -1
level due to small number of participants).
Unpaid caregiver quality of life
Only Dionne-Odom 2015a (linked to Bakitas 2015) with 69
participants reported adjusted endpoint data on unpaid caregiver
quality of life with no evidence of benefit of HSPC over usual
care. Dionne-Odom 2015a assessed unpaid caregiver quality of life
using the unpaid caregiver Quality of Life (CQOL) Index (range, 0
to 140; 140 indicates worse CQOL), and found a non-significant
improvement in the mean unpaid caregiver quality of life score
in the HSPC group that was two points better than that of the
control group at three months with adjustment for patient death (P
= 0.39). In decedents' unpaid caregivers, a terminal decline analysis
indicated a mean di,erence of -4.9 points between HSPC group and
control (P = 0.07).
Sensitivity analysis in two studies (N = 105 participants) that
reported unadjusted endpoint values showed a pooled e,ect in
favour of HSPC (MD = 6.11, 95% CI 0.42 to 11.81; I2 = 0%; Analysis
10.1). A positive MD indicates better unpaid caregiver quality of life
and a negative MD reflects lower unpaid caregiver quality of life.
The two studies assessed unpaid caregiver quality of life using the
unpaid caregiver Quality of Life (CQOL) Index (range, 0 to 140; 140
indicates worse CQOL).
In addition, Bajwah 2015 with 36 participants also presented
unadjusted change values and assessed unpaid caregiver quality
of life using the CQOL index. Bajwah 2015 found a non-significant
2.5 point mean improvement (range, 0 to 140; 140 indicates worse
CQOL) in unpaid caregiver quality of life from baseline at four weeks
for the HSPC group while for controls, unpaid caregiver quality of
life improved by 0.7 points. The e,ect size (95% CI) at four weeks
was -0.4 (-1.1 to 0.2). At eight weeks, the mean (SD) score for the
HSPC group was 58.3 (15.6), while that for the control group was
60.2 (23.9).
The remaining 39 studies did not report on unpaid caregiver quality
of life.
We could not perform any further analysis due to the limited
number of studies.
Quality of the evidence
Within the Grade approach, we downgraded the quality of the
evidence for unpaid caregiver quality of life to low due to a high
risk of bias (-1 level as a result of serious study limitations: high risk
of bias for performance bias and imprecision: -1 level due to small
number of participants).
Resource use
It was not possible to combine data for resource use or costs due to
di,erences in measurement and reporting, such as type of analysis,
tools used, assessment time points or time horizon and statistics
reported. Consequently, we provided a narrative synthesis on the
economic studies.
Thirty-one studies compared resource use or costs or both
between the treatment groups in di,erent ways. Three studies
collected information on resource use and/or costs by chart
review (Ahronheim 2000; Kane 1984; Bakitas 2009), while four
studies collected resource use data from patients using either
the Client Services Receipt Inventory (CSRI) or a modified form
of it (Farquhar 2014; Farquhar 2016; Higginson 2009; Higginson
2014). Eight studies used medical/health records (Grudzen 2016;
Ma 2019; Rogers 2017; Sidebottom 2015; Tattersall 2014; Temel
2010; O'Riordan 2019; Vanbutsele 2018). Four studies used a
combination of methods (Bekelman 2018; Bakitas 2015; Janssens
2019; Rodin 2019). Bekelman 2018 collected data from medical
records and supplemented these with patient or family self-
report, while Janssens 2019 collected data from medical records
as well as contact with patients and their GPs. Rodin 2019
collected data from patients and their medical charts. Bakitas
2015 used patient self-report for hospital and intensive care unit
days and emergency department visits, while decedents' data
for the period between the last patient-reported assessment and
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death, and chemotherapy use in last 14 days were obtained from
medical records. In Ozcelik 2014, a patient expenditure record
form was created to capture resources and their costs. Brumley
2007 obtained resource use for each patient retrospectively
from the non-profit HMO mainframe database, while Gade 2008
used standard data extract protocols to extract information from
the managed care organisation’s (MCO) database. Methods for
collecting resource use information were unclear in nine RCTs
(Brannstrom 2014; Cheung 2010; Carson 2016; El-Jawahri 2016;
Groenvold 2017; McCa,rey 2013; Mendoza-Galindo 2018 (abstract
only); Temel 2017; Woo 2019).
We considered resource use in the following areas: institutional
care services use, outpatient clinic services use, community care
services use, unpaid caregiver's care, and medications and other
resources.
Institutional care services use
Thirty studies compared the e,ect of HSPC and usual care
on institutional care use. Eight studies assessed emergency
department (ED) visits (Bakitas 2009; Bakitas 2015; Brumley 2007;
Janssens 2019; Ma 2019; Mendoza-Galindo 2018 (abstract only);
Rogers 2017; Temel 2010), and their results were inconsistent (see
Table 6 under Additional tables). Two of the studies reported
fewer ED visits in favour of the HSPC group (Brumley 2007; Ma
2019). Brumley 2007 found that 20% of intervention group patients
had ED visits compared to 33% of control group patients (P =
0.01). Linear regression adjusting for survival, age and severity of
illness showed the intervention reduced ED visits by 0.35 visits
(P = 0.02). Ma 2019 reported fewer post-discharge ED visits in the
HSPC group compared to the control group (1.3% versus 12.5%;
P = 0.0067). Four of the remaining six studies described little to
no di,erence between HSPC and control group (Bakitas 2009;
Bakitas 2015; Janssens 2019; Mendoza-Galindo 2018 (abstract
only)). In particular, Janssens 2019 initially reported that patients
in the HSPC group were twice as likely to be admitted to the
emergency ward for respiratory failure compared to the control
group (incidence rate ratio (95% CI): 2.05 (1.11 to 3.94); P = 0.014).
However, aKer correction for multiple testing, there was no longer
any evidence of a di,erence. Two studies reported fewer ED visits in
the HSPC group compared to the control group but did not present
their P values (Rogers 2017; Temel 2010).
Nine studies assessed ICU use (see Table 7 under Additional
tables). Six studies of these studies assessed ICU days (Bakitas
2009; Bakitas 2015; Carson 2016; Cheung 2010; Kane 1984; Ma
2019), and three assessed number of ICU admissions (Gade 2008;
Grudzen 2016; Janssens 2019). Five of the six studies assessing
ICU days found no di,erence between HSPC and control group
(Bakitas 2009; Bakitas 2015; Carson 2016; Cheung 2010; Ma 2019).
Kane 1984 reported slightly shorter mean number of ICU days
per patient in the HSPC group compared to the control group
(0.2 versus 0.3) but did not report P values. Gade 2008, Grudzen
2016 and Janssens 2019 reported contrasting results regarding ICU
admission. Janssens 2019 compared number of ICU admissions for
respiratory failure between HSPC and control groups in the year
before study inclusion (7 versus 7; incidence rate ratio 0.88, 95%
CI: 0.26 to 2.96; P = 0.82) and also during the study (5 versus 1;
incidence rate ratio 4.42, 95% CI: 0.49 to 20.92; P = 0.16), but did
not find any evidence of a di,erence. On the other hand, Gade 2008
found evidence in favour of HSPC in reduction in ICU admissions.
The median number of ICU admissions in the HSPC group was
12 while in the control group it was 21 (P = 0.04). Grudzen 2016
reported that no di,erence between the treatment arms in the
number of ICU admissions during the index-admission (P > 0.99)
and also at 180 days (P > 0.99).
Carson 2016 and Ma 2019 provided details on resource use in the
ICU and their findings were varied (see Table 8 under Additional
tables). Carson 2016 found no di,erence in use of the following
resources between HSPC and control group in the ICU: dialysis
(median (IQR): 13 (10) versus 15 (12); P = 0.64), mechanical
ventilation (median (IQR): 40 (31) versus 33 (26); P = 0.41), nutrition
(median (IQR): 18 (14) versus 21 (17); P = 0.60) and vasopressors
(median (IQR): 18 (14) versus 19 (15); P = 0.86). Ma 2019 reported
lower use of tracheostomy (1% versus 7.8%; P = 0.035) and fewer
median (IQR) number of days on mechanical ventilation (4 (3 to 7)
versus 6 (3 to 13); P = 0.042) in the ICU in the HSPC group compared
to the control group.
Kane 1984 further reported reduced mean number of nursing home
days per patient in favour of the HSPC group (HSPC 1 and control
11.4, P < 0.05).
Twelve studies provided mixed results on hospital admissions
(Ahronheim 2000; Bekelman 2018; Brannstrom 2014; Brumley 2007;
Farquhar 2014; Farquhar 2016; Janssens 2019; Ma 2019; Mendoza-
Galindo 2018 (abstract only); Rogers 2017; Sidebottom 2015; Temel
2010) (see Table 9 under Additional tables). Four studies found
no di,erence in the number of hospital admissions between
HSPC and the control group (Ahronheim 2000; Bekelman 2018; Ma
2019; Sidebottom 2015). Ma 2019 initially described fewer hospital
readmissions in the intervention group compared to the control
group (17.3% versus 33.3%; P = 0.024). Hospital admission for
respiratory failure during the study was almost twice as oKen in
the HSPC group compared to the control group (Incidence rate
ratio 1.87, 95% CI: 1.04 to 3.48, P = 0.026). However, aKer the
Benjamini and Hochberg correction for multiple testing, there was
no longer any evidence of a di,erence in the number of hospital
admissions during the study period. Sidebottom 2015 reported no
association between study group assignment and 30-day inpatient
readmission (adjusting for age, gender, and marital status) (P
= 0.50). Janssens 2019 described a non-significant increase in
hospital admissions for respiratory failure in the HSPC group
compared to the control group in the year before the study (24
versus 18; P = 0.60) and also during the study period (38 versus 18;
P = 0.026). Two studies found fewer hospital admissions in favour
of the HSPC group (Brannstrom 2014; Brumley 2007). Brannstrom
2014 found fewer mean (SD) number of hospitalisations in the HSPC
group compared to the control group (0.42 (0.60) versus 1.47 (1.81);
P = 0.009). Brumley 2007 found fewer hospital admissions in the
intervention group compared to the control group (36% versus
59%, P < 0.001). Three studies further reported fewer hospital
admissions in the HSPC group but they did not present their
P values (Farquhar 2014; Mendoza-Galindo 2018 (abstract only);
Temel 2010). Farquhar 2014 reported 7% inpatient admissions in
the HSPC group compared to 12% in the control group, while
Mendoza-Galindo 2018 (abstract only) found that 48% of patients
in HSPC group had hospital admissions compared to 51% in the
control group. Temel 2010 described fewer hospital admissions in
the HSPC group compared to the control group from enrollment
to death (73.5% versus 76.8%) and also within 30 days of death
(36.7% versus 53.6%). By contrast, Farquhar 2016 reported more
inpatient admissions in the HSPC group compared to the control
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group (15% versus 11%), but did not report the P value. In Rogers
2017, there was more hospitalisation for heart failure during the
study in the HSPC group (30.7% versus 29.3%; P value was not
reported), more hospitalisation for non-heart failure cardiovascular
conditions (16% versus 13%; P value was not reported) and fewer
hospitalisations for non-cardiovascular conditions (10.7% versus
24%; P value was not reported).
Length of hospital admission was assessed in 17 studies
(Ahronheim 2000; Bakitas 2009; Bakitas 2015; Brannstrom 2014;
Brumley 2007; Carson 2016; Cheung 2010; El-Jawahri 2016; Gade
2008; Grudzen 2016; Higginson 2009; Higginson 2014; Kane 1984;
Ma 2019; Mendoza-Galindo 2018 (abstract only); Ozcelik 2014;
Temel 2010) (see Table 10 under Additional tables). Nine studies
found no di,erence in length of admission between HSPC and
the control group (Ahronheim 2000; Bakitas 2009; Carson 2016;
Cheung 2010; Gade 2008; Grudzen 2016; Ma 2019; Mendoza-Galindo
2018 (abstract only); Ozcelik 2014). Bakitas 2015 described fewer
hospitalisation days in the HSPC group (0.69 (95% CI 0.4 to 1.18)
versus 1.39 (95% CI 0.97 to 1.97); P = 0.03) but not in decedents
in the HSPC group (0.95 (95% CI 0.61 to 1.46) versus 1.3 (95% CI
0.91 to 1.86); P = 0.26). Brannstrom 2014 reported that the mean
(SD) number of days spent in hospital was lower in the HSPC group
compared to the control group (2.9 (8.3) versus 8.5 (12.4), P = 0.011).
The number of days spent in the Department of Medicine-Geriatrics
(100, range 1 - 45 versus 242, range 2 - 46) and Surgery (0 versus 56)
were also lower in the HSPC group, but not in other departments
(3, range 1 - 2 versus 7 range 1 - 6). Brumley 2007 reported fewer
hospital days in the HSPC group. Linear regression adjusted for
survival, age and severity of illness showed that the intervention
reduced hospital days by 4.36 (P < 0.001). Kane 1984 reported on
total inpatient days as well as general medicine, hospice, intensive
care unit and intermediate care inpatient days. The mean number
of total inpatient days per patient did not di,er between HSPC and
control group (51 versus 47.5). However, Kane 1984 found fewer
mean days of general medical inpatient care (HSPC 13.2 and control
20.7, P < 0.05) and intermediate inpatient care per patient (HSPC
8.3 and control 26.5, P < 0.05). Four studies described fewer hospital
days in the HSPC group compared to the control group but did not
report their P values (El-Jawahri 2016; Higginson 2009; Higginson
2014; Temel 2010). El-Jawahri 2016 reported the median duration
of hospitalisation in the HSPC group to be 20 (range: 12 to 102 days)
and that in the control group to be 21 (13 to 40). Institutional days
(hospital admission) was reported to be increased in the control
group by Higginson 2009. Higginson 2014 reported mean hospital
days of 4.5 (6.8) in the HSPC group and 4.6 (7.6) in the control
group, while Temel 2010 reported the number of inpatient days
from enrollment to death to be 5 (range: 0 to 50) in the HSPC group
and 7 (range: 0 to 45) in the control group.
Palliative care visits during hospitalisation was further compared
between HSPC and usual care in two studies (El-Jawahri 2016;
Tattersall 2014) (see Table 11 under Additional tables). El-Jawahri
2016 reported that HSPC patients had at least two palliative care
visits during the first two weeks of their hospitalisation (median
4; range, 2-7), while two control patients received a palliative
care consultation (P values were not reported). Tattersall 2014
highlighted that 86% of patients in the HSPC group had palliative
care contact during hospitalisation compared to 78% of control
group patients (P = 0.37).
With the exception of days spent in nursing homes reported in one
study to be in favour of HSPC, the overall evidence on institutional
care use was inconsistent.
Outpatient clinic services use
Seven studies provided inconsistent evidence on the e,ect of HSPC
compared to usual care on outpatient clinic visits (Brannstrom
2014; Higginson 2009; Groenvold 2017; Rogers 2017; Temel 2010;
Temel 2017; Vanbutsele 2018) (see Table 12 under Additional
tables). One of these studies reported fewer outpatient clinic visits
in favour of HSPC (Brannstrom 2014). Brannstrom 2014 found fewer
physician visits, nurse visits, phone calls and prescriptions in the
HSPC group compared to the control group. Another study by
Vanbutsele 2018 reported a di,erence in favour of the control group
for number of consultations with a psychologist at 18 weeks (P =
0.02), but not at 24 weeks. Three studies described more contacts
with palliative care teams in the HSPC group compared to the
control group, but did not present P values (Groenvold 2017; Temel
2010; Temel 2017). Temel 2017 highlighted more palliative care
visits in the HSPC group compared to the control group (mean
(range): 6.54 (0 to 14) versus 0.89 (0 to 7)). Temel 2010 reported that
all the patients assigned to HSPC, except for one patient who died
shortly aKer enrollment, had at least one visit with the palliative
care service by the 12th week. The average number of visits in the
palliative care group was 4 (range, 0 to 8). Ten patients who received
usual care (14%) had a palliative care consultation in the first 12
weeks of the study, with seven patients having one visit and three
having two visits. In Groenvold 2017, 138 patients had at least one
face-to-face contact with the HSPC team compared to 13 patients in
the control group. Groenvold 2017 further reported no di,erence in
mean (SD) number of specialists visits between HSPC and control
group (4.9 (8.1) versus 7.0 (9.1); P = 0.25).
Higginson 2009 described fewer hospital specialist visits in the
HSPC group (8 patients (35%)) compared to control group (16
patients (76%)), but P values were not reported. Rogers 2017
reported more mean (SD) total number of clinic encounters in
the HSPC group compared to control group (21.9 (1.99) versus
20.8 (1.92)), but did not present P values. There were more visits
to the rehabilitation clinic in the HSPC group compared to the
control group (mean (SD): 1.4 (0.68) versus 0.9 (0.48)) and fewer
cardiology visits in the HSPC group compared to control group
(mean (SD): 2.3 (0.55) versus 3.2 (1.0)). Woo 2019 reported that
similar proportions of patients in the HSPC group and control group
consulted with a psychiatrist (12% versus 12%), but did not present
P values. Tattersall 2014 reported more contacts with palliative care
physicians in the HSPC group compared to the control group by the
end of the study (51 patients (85%) versus 8 patients (13.3%)) and
also in the last month of life (16 patients (26.7%) versus 6 patients
(10%)). However, the P values were not reported.
Community care services use
Fourteen studies compared community care services use between
the HSPC group and control group and their findings were
inconsistent (Bakitas 2009; Bakitas 2015; Brannstrom 2014;
Brumley 2007; Farquhar 2014; Farquhar 2016; Gade 2008; Grudzen
2016; Higginson 2009; Kane 1984; McCa,rey 2013; Rogers 2017;
Sidebottom 2015; Temel 2010) (see Table 13 under Additional
tables). The studies reported on a range of community services.
Two UK studies by the same author found di,erent results for mean
number (SD) of GP contacts for cancer (Farquhar 2014), and non-
cancer populations (Farquhar 2016). Farquhar 2014 reported the
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mean number of GP contacts to be slightly higher in the control
group (1.3 (0.5)) compared to the HSPC group (1.2 (0.6)) in cancer
populations, while Farquhar 2016 found the mean number of GP
contacts to be slightly higher in the HSPC group (1.8 (1.2)) compared
to the control group (1.6 (0.7)) in non-cancer populations. However,
these studies did not provide their P values. Higginson 2009
described di,erences in contact with GPs, district/practice nurse,
multiple sclerosis (MS) nurse and social services, but the P values
of the results were not reported.
A study set in the USA by Gade 2008 found longer median length of
stay in hospice favouring the HSPC group (24 days) compared to the
control group (12 days) (P = 0.04), while two USA studies found no-
between group di,erences (Brumley 2007; Temel 2010). Grudzen
2016 and Bakitas 2015 reported no between-group di,erences in
hospice use at 180 days. Sidebottom 2015 found no evidence of
an association between group assignment and hospice use within
six months adjusting for age, gender and marital status in USA. Ma
2019 highlighted more transfers to hospice care in the HSPC group
compared to usual care (18.6% versus 4.9%; P = 0.0026).
Brannstrom 2014 further reported more nurse visits in the HSPC
group compared to the control group (1075 versus 230, P = 0.000)
in Sweden. By contrast, this study found that phone calls and
prescriptions by doctors were more common in the control group
(108 versus 231) while physician visits were similar (194 versus 201).
Kane 1984 and McCa,rey 2013 both reported more days spent at
home in the HSPC group compared to the control group, but did not
present P values. Kane 1984 reported a mean of 44.8 days at home
per patient while that in the control group was 37.9 days at home
per patient. In McCa,rey 2013, the HSPC group spent a mean of 13.1
days (95% CI 8.5 to 17.7) at home compared to 12.1 days (95% CI 5.9
to 18.4) in the control group.
Rogers 2017 reported on the frequency of interaction between
patients and primary care providers and found fewer interactions
in the HSPC group (mean (SD): 4.4 (0.93)) compared to the control
group (mean (SD): 5.2 (0.82)). The authors did not present the P
values.
Unpaid caregiver's care
Higginson 2009 and Farquhar 2014 reported on the e,ect of
HSPC and usual care on the support provided by informal unpaid
caregivers (see Table 14 under Additional tables). Increased care by
informal unpaid caregivers was reported by Higginson 2009 with
more hours of informal care provided in the control group. The
P value was not reported. Farquhar 2014 reported more use of
informal care in the control group compared to the HSPC group.
However, the P value was not also stated.
Medication and other resources
Seventeen studies either reported on the use of medications or
other resources, or both (Ahronheim 2000; Bakitas 2009; Bakitas
2015; Brumley 2007; Carson 2016; Farquhar 2014; Farquhar 2016;
Groenvold 2017; Higginson 2009; Janssens 2019; Kane 1984; Ma
2019; Markgren 2016 (linked to Brannstrom 2014); O'Riordan
2019; Rodin 2019; Rogers 2017; Temel 2010) (see Table 15 under
Additional tables). Markgren 2016 (part of Brannstrom 2014)
assessed the number of patients receiving the target doses of
medications based on current guidelines for heart failure among
HSPC and control group patients. This study found that the number
of patients treated with mineralocorticoid receptor antagonists
(MRAs) di,ered between groups, and increased from 10 (28%) of
36 patients to 15 (48%) of 31 patients in the HSPC arm compared
with 13 (35%) of 36 patients to 13 (39%) of 33 patients in the control
group. The change in number of patients receiving full target
doses of the angiotensin-converting enzymes inhibitors (ACEIs)/
angiotensin receptor blockers (ARBs), beta-blockers and MRAs was
higher in the HSPC arm than in the control arm (P = 0.009).
Conversely, O'Riordan 2019 found no evidence of a di,erence in use
of guideline-driven heart failure treatments such as beta-blockers
and ACEIs/ARBs. Similarly, Janssens 2019 did not find any evidence
of a di,erence between HSPC and the control group in antibiotics
use (P = 0.819). Temel 2010 reported a di,erence in aggressive end-
of-life care among decedents with 33% (16 of 49 patients) of those
in the HSPC group and 54% (30 of 56 patients) in the control group
receiving aggressive end-of-life care (P = 0.05). Aggressive end-of-
life care was defined as chemotherapy within 14 days before death,
no hospice care, or admission to hospice three days or less before
death.
Kane 1984 further reported more use of chemotherapy in the HSPC
group, with a mean of 1.3 patients receiving chemotherapy in the
HSPC group compared to 0.49 in the control group (P = 0.03).
More patients in the HSPC group (mean: 0.09) also received major
surgical procedures compared to the control group (mean: 0.01)
(P < 0.05). Bakitas 2015 reported no between-group di,erence in
chemotherapy use in the last two weeks of life.
Ahronheim 2000 reported lower use of intravenous therapy for the
entire admission among 61 (66%) of 92 admissions in the HSPC
group compared to 79 (81%) of 98 admissions in the control group
in patients with advanced dementia. On the other hand, the study
reported no evidence of a di,erence in use of other resources
such as feeding tubes, mechanical ventilation, tracheostomy,
systemic antibiotics, days with restraints, mechanical restraints
and cardiopulmonary resuscitation. In Ma 2019, the HSPC group
had fewer ventilator days (median 4 versus 6; P = 0.042) and
tracheostomies performed (1% versus 7.8%; P = 0.035), while there
was no between-group di,erence in mechanical ventilation, use
of vasopressors, haemodialysis, cardiopulmonary resuscitation.
Carson 2016 found no between-group di,erence in ventilator days
between the HSPC and control group.
Higginson 2009 reported di,erences in resource use such as
primary/secondary care, use of specialist wards, occupation
therapist/physiotherapist, palliative care nurse, dietician,
chiropodist, day centre and respite care. However, the P values
of the di,erences were not reported. Rogers 2017 reported
more hospital encounters with the HSPC team (mean (SD): 2.5
(0.45) versus 2.4 (0.35)) and telephone contacts (mean (SD): 12.6
(1.2) versus 10.6 (0.88)) in the HSPC group compared to the
control group, but did not present P values. Groenvold 2017 also
highlighted the face that 116 patients in the HSPC group had at
least one telephone contact with the HSPC team compared to nine
patients in the control group. However, they did not report their P
value.
Bakitas 2009 and Brumley 2007 reported no evidence of a di,erence
in referral to palliative care/hospice care. Bakitas 2009 reported
that 34 (235) of 145 patients were referred to palliative care in the
HSPC group compared to 39 (29%) of 134 patients in the control
group (P = 0.34), while 6 (3.7%) of 161 patients in the HSPC group
and 4 (2.5%) of 161 patients in the control group were referred to
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hospice care (P = 0.75). Brumley 2007 presented results on hospice
referral for only one of the sites in their study and reported that
25% of patients in the HSPC group were referred to hospice care
compared to 36% of patients in the control group (P = 0.15). Rodin
2019 described more referrals to palliative care (22 patients (100%)
versus 1 patient (5%)), but not psychiatry (1 patient (4.5%) versus
1 patient (5%)) in the HSPC group compared to the control group.
The P values for the di,erences were not reported. There was no
di,erence in referral to social work between HSPC and control
group (22 patients (100%) versus 20 patients (100%)).
Other resource use with no between-group di,erences include
hospital discharge disposition (Carson 2016). Farquhar 2014 and
Farquhar 2016 reported di,erences between HSPC and the control
group in use of services provided by nurses, social care, other
health professionals and other hospital services but the P values for
di,erences were not reported.
Certainty of the evidence
Within the Grade approach, we downgraded the certainty of
evidence for resource use to very low due to a high risk of bias
across studies (-2 levels as a result of very serious study limitations:
high risk of bias for performance, detection, attrition, reporting, size
of study and other bias and inconsistency: -1 level due to variability
in results) (Summary of findings 1).
Costs and cost-eectiveness of HSPC
Thirteen economic studies with 2103 participants reported on
cost. The utilisations included were: ED or A&E visits; inpatient
and outpatient hospital care; home and community care; care
in nursing homes (or skilled nursing homes); inpatient stay;
day care in hospice; hospice care at home; informal care;
drugs and equipment. Four studies reported the results of cost-
e,ectiveness analysis using relevant outcome measures (palliative
outcome, unpaid caregiver’s burden, quality-adjusted-life-years)
and hospital costs or total costs (Farquhar 2014; Farquhar 2016;
Higginson 2009; McCa,rey 2013). Results of cost-e,ectiveness
analyses were reported by ICERs and/or costs per QALY (point
estimates or cost-e,ectiveness planes).
Two studies found evidence of lowered cost with HSPC (Brumley
2007; Gade 2008). When compared to usual care, Mendoza-
Galindo 2018 (abstract only) reported a reduction in the cost of
hospitalisation days in the HSPC group. However, no di,erence
was found between groups in the cost of emergency room visits.
In Brannstrom 2014, this was unclear as no P value was presented
for the di,erence in cost between HSPC and usual care. We
identified four full economic studies (Farquhar 2014; Farquhar
2016; Higginson 2009; McCa,rey 2013). The evidence on the cost-
e,ectiveness of HSPC compared to usual care was inconsistent.
With the exception of Mendoza-Galindo 2018 (abstract only), all
other studies had applied more robust methodology since the first
relevant study we identified which compared the costs of HSPC and
conventional care among cancer patients (Kane 1984). Kane 1984
provided services across multiple settings and was carried out in
the USA. The HSPC group had lower total costs when compared
to conventional care. However, the authors reported that the
di,erence was "not significant". The estimated mean expenditure
per patient was reported to be US dollars (USD) 15,263 (converts to
Great British Pounds (GBP) 29,058 in 2018) in the HSPC group and
USD 15,493 (converts to GBP 29,496 in 2018) in the conventional
care group. Resource use was measured in hospital stays, hospice
stays, surgical procedures, chemotherapy and radiotherapy, and
costs were calculated using di,erent assumptions. However,
di,erence in survival (days since enrollment in the study) as well
as other factors (e.g. age, severity of diseases) which might be
associated with costs, were not adjusted for.
Brumley 2007 compared resource use and costs between the HSPC
and usual care group versus usual care only among terminally ill
patients with mixed cancer and non-cancer diagnoses in the USA
involved service provision across multiple settings. A wider range of
resource use was reported from the health insurance database: the
number of ED visits, physician o,ice visits, hospital days, hospice
days, skilled nursing facility days, home health and palliative visits
and palliative physician home visits. Service utilisation was lower in
the HSPC group than usual care group even aKer controlling for age,
survival and severity measured using the Palliative Performance
Scale. Stay in hospital decreased by 4.36 days and ED visits by 0.35.
Due to the di,erence in the survival (days on service), mean costs
per patient were adjusted using regression analysis, controlling for
survival, age, severity of illness and primary disease. Mean costs
per patient in the intervention group were much lower (Australian
dollars (AUD) 12,670, SD AUD 12,523; converts to GBP 8383, SD GBP
8285 in 2018), compared with the usual care group (AUD 20,222,
SD AUD 30,026; converts to GBP 13,379, SD GBP 19,866 in 2018).
Average daily costs per patient were also lower in the intervention
group (AUD 95.30, converts to GBP 63.05 in 2018) compared to the
usual care group (AUD 212.80, converts to GBP 140.76 in 2018) (P =
0.02).
Gade 2008 used the health insurance database to extract resource
use and unit cost of services of hospitalised patients with life-
limiting illnesses (mixed cancer and non-cancer diagnoses), who
were randomly assigned to the HSPC intervention or usual care.
Included utilisations were ED visits, clinic and hospital outpatient
visits, home health visits, hospital admission, skilled nursing facility
admissions and prescriptions. The cost of the palliative care team
was calculated as the intervention cost. HSPC patients stayed
longer in hospice aKer the index hospitalisation (24 days) than
usual care patients (12 days) however this was a non-significant
di,erence (P = 0.08), and had shorter ICU stays on readmission (12
times versus 21 times, P = 0.04) and lower total healthcare costs
(USD 14,486, converts to GBP 15,013 in 2018 versus USD 21,252,
converts to GBP 22,025 in 2018, P = 0.001). Gade 2008 involved an
inpatient consult model and was a USA study.
Temel 2010 examined the e,ectiveness of early palliative care
integrated with standard oncologic care among patients with newly
diagnosed metastatic non–small-cell lung cancer, where standard
oncologic care alone was a comparator. It was an outpatient model
of HSPC that took place in the USA. Data on health utilisations and
end-of-life care were collected from the medical records: anticancer
therapy, medication prescriptions, referral to hospice, hospital
admissions and ED visits. Patients in standard care received more
aggressive end-of-life care (54% [30 of 56 patients] versus 33% [16
of 49 patients], P = 0.05), and had non-significant longer stays in
hospice care (median 11 days versus 4 days, P = 0.09) than the
intervention group. Patients in the HSPC group used more palliative
care and less aggressive care while there was greater improvement
in quality of life and survival in this group than control. However,
this was not conclusive because the sample size of the study did
not allow the statistical power to test the di,erences in service
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utilisation. Detailed analyses of costs and cost-e,ectiveness were
conducted and reported later although lacking in statistical power
to detect the di,erence in Greer 2016 (linked to Temel 2010)).
Comparisons of costs per day alive and costs for the last 30 days
were made between HSPC and the usual care group and the cost-
e,ectiveness per life year saved was calculated. Total costs per day
were on average lower in the HSPC group. However, this was a
non-significant di,erence (mean di,erence USD 117, SE USD 74;
converts to GBP 103, SE GBP 65 in 2018, P = 0.13). Total costs for the
last 30 days were also reduced non-significantly (mean di,erence
USD 2527, SE USD 3311; converts to GBP 2230, SE GBP 2922 in 2018,
P = 0.44). The cost-e,ectiveness ratio was USD 41,938 per life year
saved. There was a non-signifant increase in use of hospice care
(mean di,erence USD -1053, SE USD 538; converts to GBP -929, SE
GBP 475 in 2018, P = 0.07) and less use of chemotherapy (mean
di,erence USD 757, SE USD 365; converts to GBP 668, SE GBP 322 in
2018, P = 0.03) for the last 30 days.
Higginson 2014 examined the e,ectiveness of the early
introduction of palliative care among patients with chronic
breathlessness in the UK. The intervention (HSPC) was provided
across multiple settings and patients had mixed cancer and non-
cancer diagnoses. Patients were randomly assigned either to the
HSPC group or to usual care. Resource use was collected using
the Client Services Receipt Inventory (CSRI) on health, voluntary,
and social care received over the past three months at baseline
and since the last interview at six weeks follow-up. Limited results
on resource use and costs were reported: hospital inpatient stays
(mean 4.5, SD 6.8 in BSS; mean 4.6, SD 7.6 in control) and costs of
formal care use (mean GBP 1422, 95% CI: 897 to 2101; converts to
GBP 1611, 95% CI: 1016 to 2380 in 2018 in Breathlessness Support
Service (BSS) group; mean GBP 1408, 95% CI: 899 to 2023; converts
to GBP 1595, 95% CI: 1018 to 2292 in 2018 in control group). There
was no between-group di,erence between the two groups.
Brannstrom 2014 compared service use between patients
randomised to the integrated palliative advanced home care and
heart failure care (PREFER) intervention and usual care among
patients with severe chronic heart failure in Sweden. The PREFER
intervention involved an outreach model of HSPC. Resource use
collected included hospital admissions, inpatient days, physician
and nurse visits, phone calls and drug prescriptions. The HSPC
group had fewer hospitalisations than the control group (0.42 ± 0.60
versus 1.47 ± 1.81, P = 0.009) and the length of stay in hospital was
also shorter in patients receiving the intervention (mean 2.9, SD 8.3
versus mean 8.5, SD 12.4, P = 0.011). The total days or total contacts
per study arm were compared between HSPC and the control group
and additional cost analysis was reported in Sahlen 2016 (linked
to Brannstrom 2014). QALY gain was 0.25 years between baseline
and the end of intervention across the HSPC group (P = 0.025). Over
six months, total cost was Swedish Krona (SEK) 1.4 million (EUR
140,000, converts to GBP 126,132 in 2018) in the HSPC group (n = 36)
and SEK 2.0 million (EUR 205,000, converts to GBP 180,188 in 2018)
in the control group (n = 26), and the di,erence SEK 600,000 (EUR
61,000, converts to GBP 54,056 in 2018) was the saving achieved by
providing the intervention in addition to usual heart failure care.
Ozcelik 2014 compared duration of hospitalisation and direct cost
between HSPC and usual care in Turkey. It was an inpatient
consult model of HSPC. A patient cost record form was used to
document cost. This form was created by listing direct health
expenditure, which consisted of all expenses incurred while in
hospital. Direct expenses assessed included medicines used from
the start of the patient’s stay in hospital, medical equipment,
laboratory and diagnosis tests, consultations, professional care,
and hospital stay expenses (including those of companions). On
the patient’s discharge from hospital, costs were recorded on the
form by obtaining the expenses list from the clinic secretary. Mean
(SD) direct cost in the HSPC group was USD 68,869 (SD 48.522)
(converts to GBP 60,154 (GBP 42,382) in 2018) and USD 81,076
(72,700) (converts to GBP 70,816 (GBP 63,500) in 2018) in the control
group (P = 0.76). There was no evidence of a di,erence in the
duration of hospitalisation (P = 0.07), with a mean (SD) length of
stay in hospital of 9.4 (6.27) days in the HSPC group and 13.9 (11.5)
days in the control group.
The first study using robust cost-e,ectiveness analysis (CEA)
method among papers we identified was by Higginson 2009. This
was the CEA alongside a feasibility trial of a new HSPC service
among patients with multiple sclerosis (MS) in the UK, randomised
into either fast-track of the new intervention or control of usual
care. Higginson 2009 involved service provision across multiple
settings. Costs were measured in health, social and voluntary
services, and informal care provided by family or friends was also
included for the analysis from a broad perspective. As the usual
unit costs were applied for the formal services, ‘shadow price’ was
used for the informal care. CEA used the di,erences in costs and
outcomes (palliative care outcome scale (POS-8) and Zarit Burden
Inventory (ZBI)) between baseline and follow-up at 12 weeks. Total
costs for 12 weeks measured at follow-up were lower in the fast-
track intervention group than usual care group by GBP 1789 (95%
CI: GBP -5224 to GBP 1902); converts to GBP 2424 (GBP -7077 to
GBP 2577) in 2018. When inpatient care and informal care were
excluded, mean service costs for 12 weeks were GBP 1195 lower
for the intervention group (95% CI GBP -2916 to GBP 178); converts
to GBP 1619 (GBP -3950 to GBP 241) in 2018. Cost-e,ectiveness
planes showed that 33.8% of replications for POS-8 indicated
that patients in the intervention group had lower cost and better
outcomes than in the control group, and 54.9% had lower cost but
worse outcomes. For ZBI, 47.3% of replications showed lower costs
and better outcomes while 48% indicated higher costs and better
outcomes.
McCa,rey 2013 estimated incremental net monetary benefit (INMB)
and cost-e,ectiveness acceptability curves (CEACs) for one extra
day at home in an RCT among patients with mixed cancer and non-
cancer diagnoses with complex or unstable symptom management
and high care needs in Australia. McCa,rey 2013 provided services
across multiple settings. Data on resource use were prospectively
collected and costed including: days at home, specialist palliative
care service use, acute hospital and palliative care unit inpatient
days, and outpatient visits. Intervention costs were calculated
based on sta, administration, travel and direct patient contact
time, overheads and consumables. The analysis was conducted
from a healthcare provider perspective and bootstrapping was
used to calculate the confidence intervals around INMB and CEACs.
Total costs were AUD 6452 (95% CI AUD 4469 to AUD 8586) (converts
to GBP 5750 (95% CI GBP 3983 to GBP 7652) in 2018) in the HSPC
group and AUD 5425 (95% CI AUD 2404 to AUD 8531) (converts to
GBP 4835 (GBP 2142 to GBP 7602) in 2018) in the control group.
The increment costs between the two groups was AUD 1027 (95%
CI AUD -2612 to AUD 4738) (converts to GBP 915.22 (95% CI GBP
-2327.71 to 4222.32). When the INMB of one more day at home
was compared with varying threshold values, HSPC was preferred
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to usual care beyond AUD 1068. Sensitivity analyses with di,erent
inclusion ranges of costs (using hospital inpatient costs only and
excluding high cost outliers) indicated that HSPC was preferred
above AUD 2547 (converts to GBP 2270 in 2018) and AUD 846
(converts to GBP 754 in 2018). It was concluded that HSPC had a
potential to be cost-e,ective, especially in trials with longer follow-
up. The meaning of the threshold value for one extra day at home
remains for future research.
Farquhar 2014 and Farquhar 2016 reported the cost-e,ectiveness
of the Breathlessness Intervention Service (BIS), a multidisciplinary
complex intervention underpinned by a palliative care approach
for patients with advanced cancer and advanced non-malignant
disease separately. The BIS was a model of HSPC where service
provision traversed multiple settings in the UK. In Farquhar 2014,
data from patients with advanced cancer were analysed from a
societal perspective by including costs of informal care. Total health
and social costs, including informal care for eight weeks prior to
the baseline assessment, in the HSPC group were GBP 6137 (SD
GBP 6099) which converts to GBP 6952 (GBP 6909) in 2018 and GBP
5461 (SD GBP 6099) which converts to GBP 6186 (GBP 6909) in 2018
for usual care. Costs between baseline and follow-up at two weeks
were GBP 794 (SD GBP 866) which converts to GBP 899 (SD GBP
981) in 2018 for HSPC and GBP 1121 (SD GBP 1635) which converts
to GBP 1270 (SD GBP 1852) in 2018 for usual care. Intervention
costs for HSPC were GBP 119 (SD GBP 62) which converts to GBP
135 (SD GBP 70) in 2018. Total costs were GBP 354 lower for HSPC
(95% CI: GBP -1020 to GBP 246) which converts to GBP 401 (95%
CI: GBP -1155 to GBP 279) in 2018 and incremental QALY-gain was
0.0002 years (95% CI, −0.001 to 0.002), aKer controlling for baseline.
The chance of HSPC being lower in total costs and providing better
outcomes in terms of reduced distress due to breathlessness was
80.9% according to cost-e,ectiveness planes and 16.4% for higher
costs and better outcomes. It was 50.9% for the chance of HSPC
being lower in total costs and greater in QALY, and 11% for higher
costs and a greater QALY gain.
An NHS perspective was taken in the analysis of data from the UK
study of patients with advanced non-malignant disease in Farquhar
2016. Total health and social costs for eight weeks prior to the
baseline assessment in the HSPC group was GBP 1952 (SD GBP
3290) which converts to GBP 2211 (SD GBP 3727) in 2018 and
GBP 3630 (SD GBP 5588) which converts to GBP 4112 (SD GBP
6330) in 2018 for usual care. Costs between baseline and follow-
up at four weeks were GBP 1371 (SD GBP 2948) which converts
to GBP 1553 (SD GBP 3339) in 2018 for HSPC and GBP 659 (SD
GBP 1253) which converts to GBP 746 (SD GBP 1419) in 2018 for
usual care. Intervention costs for HSPC were GBP 156 (SD GBP 80)
which converts to GBP 177 (SD GBP 91) in 2018. With adjusting
for baseline, total costs were GBP 799 higher for HSPC (95% CI:
GBP -237 to GBP 1904) which converts to GBP 905 (95% CI: GBP
-268 to GBP 2157) in 2018 and the HSPC group gained 0.003 extra
QALYs (95% CI: –0.001 to 0.007). A cost per QALY for HSPC was GBP
266,333 (converts to GBP 301,692 in 2018). The chance of HSPC
being lower in total costs and greater in QALYs was 7% according to
cost-e,ectiveness planes. There was an 86.5% likelihood of HSPC
being higher in total costs and greater in QALY gain. The HSPC
intervention appeared to be cost-e,ective among patients with
cancer but not among those with non-malignant disease.
Mendoza-Galindo 2018 (abstract only) compared resource use and
costs between the early palliative care (EPC) group and usual care
in patients with cancer diagnoses in Mexico. The study involved
an outpatient model of HSPC. Resource use assessed included
number/days of hospitalisation and emergency room (ER) visits as
well as their cost. The number of ER visits in the EPC group was
39 while that in the control group was 50 (P = 0.074). There was
also no di,erence in the number of hospitalisations (48% versus
51%) and days of hospitalisation (78 versus 90 days; P = 0.808)
among both groups. Median cost associated with ER visits were
non-significantly lower in the EPC group (USD 21.99: converts to
GBP 16.97 in 2018) compared to usual care (USD 46.35: converts
to GBP 35.76 in 2018) (P = 0.081). The authors further reported
lower median cost of hospitalisation days in favour of EPC (USD
167.57: converts to GBP 129.30 in 2018) compared to usual care
(USD 295.05: converts to GBP 227.66 in 2018) (P = 0.015).
Ma 2019 assessed resource use and operating costs between an
early palliative care intervention and usual care for patients in
the ICU setting in USA. It was an inpatient consult model of
HSPC. Resources used were extracted from patients' electronic
medical records, including mechanical ventilation, vasopressors,
haemodialysis, tracheostomy, cardiopulmonary resuscitation, ED
visits, hospital readmission, hospital duration and ICU duration.
Early palliative care patients had fewer ventilator days (median 4
versus 6; P = 0.042), tracheostomies performed (1% versus 7.8%; P
= 0.035), postdischarge emergency department visits (1.3% versus
12.5%; P = 0.007), days on mechanical ventilation (median (IQR)
4 (3 - 7) versus 6 (3 - 13); P = 0.042) and hospital readmissions
(17.3% versus 33.3%; P = 0.0024). There was no di,erence between
the intervention and control group in ICU length of stay (median 5
versus 5.5 days), numbers on mechanical ventilation (53.6% versus
56.9%; P = 0.64), numbers on vasopressors (48.5% versus 50%; P =
0.83), days on vasopressors (median 3 versus 3; P = 0.91), numbers
on haemodialysis (15.5% versus 23.5%; P = 0.15), numbers receiving
cardiopulmonary resuscitation (5.2% versus 6.9%; P = 0.61) and
hospital length of stay (median 10 versus 11 days). Analysis of
operating costs was conducted though lacking in statistical power
to detect the di,erence. Intervention patients had lower medical
ICU (USD 9860 (converts to GBP 7608.08 in 2018) versus USD 15,660
(converts to GBP 12,083.42 in 2018); P = 0.004) and pharmacy costs
(USD 3430 (converts to GBP 2646.62 in 2018) versus USD 5850
(converts to GBP 4513.92 in 2018); P = 0.016) per patient compared
with the control group. However, the total operating cost per
patient was not di,erent between intervention and control group
(USD 37,310 (converts to GBP 28,788.78 in 2018) versus USD 45,790
(converts to GBP 35,332.04 in 2018); P = 0.14). An estimated USD
880 (converts to GBP 679.02) of the intervention group’s per patient
total operating cost was due to the added cost of the palliative care
consultation.
Quality of the evidence
Within the Grade approach, we downgraded the quality of evidence
for cost and cost-e,ectiveness to very low due to a high risk of bias
across studies (-2 levels as a result of very serious study limitations:
high risk of bias for performance, detection, attrition, reporting, size
of study and other bias and inconsistency in the direction of the
results: -1 level due to variability in results) (Summary of findings 1).
Synthesis of nested or embedded qualitative studies that
explored stakeholders' views and experiences of HSPC
Ten studies with a total of 322 participants (245 patients, 20 carers,
9 HSPC team members, 29 physicians (including oncologists), 14
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oncology nurse practitioners, one consultant in interstitial lung
disease, one clinical nurse specialist in interstitial lung disease,
one community matron, one community palliative care nurse and
one general practitioner) also had qualitative components that
were used to explore stakeholders' views and experiences of HSPC
(Bajwah 2015; Farquhar 2014; Farquhar 2016; Hopp 2016; Veron
2018 (linked to Janssens 2019); Lowther 2018 (linked to Lowther
2015); Maloney 2013 (linked to Bakitas 2009); Giovannetti 2018
(linked to Solari 2018); Talabani 2017 (linked to Brannstrom 2014);
Wallen 2012) (see Table 16 under Additional tables). The number
of patients interviewed by Wallen 2012 was unclear. However, a
study (Slota 2014 linked to Wallen 2012) reporting the same data by
the authors stated that 34 patients were involved in the qualitative
analysis.
Data collection was mainly through semi-structured interviews.
However, Slota 2014 (linked to Wallen 2012) collected their data
using open-ended questions on a questionnaire, while Hopp 2016
qualitatively reviewed clinical records. Approaches to data analysis
in these studies included content analysis, framework analysis and
thematic analysis. Slota 2014 (linked to Wallen 2012) stated that
they used thematic analysis while another study that reported
the same data by the authors stated that they used transcript-
based analysis. Bajwah 2015 reported using a constant comparison
approach within framework analysis, while Hopp 2016 did not state
their approach.
Four studies were HSPC models involving service provision across
multiple settings (Farquhar 2014; Farquhar 2016; Maloney 2013
(linked to Bakitas 2009); Wallen 2012), and another four were
hospital outreach services (Bajwah 2015; Talabani 2017 (linked to
Brannstrom 2014); Veron 2018 (linked to Janssens 2019); Solari
2018). Lowther 2018 (linked to Lowther 2015) was an outpatient
HSPC model while Hopp 2016 was an inpatient consult model.
Data from the studies were synthesised into two themes: valued
components and challenges to HSPC provision.
Participants valued the patient and family-centredness of the HSPC
intervention as it helped to address the varied needs of patients
and their unpaid caregivers/families. Benefits described included
better symptom control, e,ective communication and shared
decision-making, psychosocial support and coping, respectful
and compassionate care, supporting role maintenance and
empowerment, reduced isolation, and improved use of devices.
HSPC facilitated e,ective communication and shared decision-
making as patients and their unpaid caregivers/families had control
over the care the patient received. They were able to ask questions,
they were listened to and were able to receive the support they
needed. Shared decision-making and the psychosocial support
provided as part of HSPC was therapeutic for patients and their
unpaid caregivers/families, and also reassured them that they were
not alone. Patients particularly valued services they received in
the secure environment of their homes, and the involvement and
support of their families. In addition to the care delivered, the
process of delivery of care was also considered to be important.
For instance, patients and their unpaid caregivers/families noted
that the palliative care professionals were approachable, attentive
and supportive. HSPC further facilitated care planning and the
discussion of advanced care plans.
Although HSPC was viewed favourably by participants in these
studies, there was also evidence that some participants questioned
its usefulness. For instance, in Veron 2018 (linked to Janssens
2019), there were mixed reactions among advanced COPD patients
about the value of the HSPC intervention. Authors described poor
recollection of the HSPC consultation by patients who tended not
to consider themselves to be sick. They ascribed their functional
limitations to health problems other than COPD. Patients in this
study avoided talking about the future and end-of-life issues and
wanted to focus on the present. Also in Hopp 2016, participants
expressed concerns that HSPC might prevent them from receiving
more aggressive interventions and many did not want to discuss
advanced directives.
Patients and their unpaid caregivers/families found the information
provided during the HSPC intervention to be useful, as it ensured
a better understanding of illness and treatment options. Patients
and their unpaid caregivers/families valued the multidisciplinary
nature of the HSPC team and their specialist expertise. Healthcare
professionals such as oncologists tended to describe better patient
care resulting from integration of palliative care with oncology at
the time of diagnosis of advanced cancer.
Challenges to HSPC provision in these studies were identified,
including lack of referral to HSPC by other health professionals,
perception of palliative care as being synonymous with imminent
death, lack of willingness to engage with palliative care,
organisational barriers (e.g. insu,icient services) and issues with
the experimental study design (e.g. inadequate length of the HSPC
intervention).
D I S C U S S I O N
Summary of main results
Studies on the e,ectiveness of HSPC in patients with an advanced
illness have yielded evidence of low quality and very low quality
indicating small benefits for patient HRQoL and symptom burden,
respectively. Due to very low- to low-quality evidence, we are
uncertain about the true e,ect of HSPC on these outcomes. The
results of the 10 studies including a total of 1344 participants
indicate that, when compared to usual care, HSPC may improve
patient HRQoL on average by 0.26 SMD (95% CI 0.15 to 0.37; I2 =
3%). Positive SMDs indicate better patient HRQoL while negative
SMDs indicate lower patient HRQoL. Data from the six studies,
including a total of 761 participants, suggests that HSPC may
reduce patient symptom burden on average by -0.26 SMD over
usual care (95% CI -0.41 to -0.12; I2 = 0%). Negative SMDs indicate
benefit (lower symptom burden) and positive SMDs reflect higher
symptom burden. Data from the two studies, including a total of 337
participants, suggests that HSPC may improve patient satisfaction
with care on average by 0.36 SMD over usual care (95% CI 0.14 to
0.57; I2 = 0%; low-quality evidence). Positive SMDs indicate better
patient satisfaction with care while negative SMDs indicate lower
patient satisfaction with care. By conventional criteria, these e,ects
are considered small.
Very low-quality evidence from one study including 312
participants suggests that when compared to usual care, there
was no evidence of e,ect of HSPC on unpaid caregiver satisfaction
with care. We used home death as a proxy measure for achieving
patient's preferred place of death and we found low-quality
evidence favouring home death in those that received HSPC.
Results from the seven studies (N = 861 participants) favoured HSPC
which is reflected in 1.63 higher odds of home death (95% CI 1.23
to 2.16; I2 = 0%). Very low-quality evidence from one study of 47
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participants showed that when HSPC was involved, patients were
more likely to achieve their preferred place of care.
We found no di,erence in mortality/survival between HSPC and
usual care in 36 studies (N = 7103 participants) (very low-quality
evidence). Very low-quality evidence from four studies (N = 525
participants) measuring pain also showed no evidence of e,ect
of HSPC (SMD -0.16, 95% CI -0.33 to 0.01; I2 = 0%). Positive
SMDs indicate more pain while negative SMDs indicate lower pain
(benefit). As a result of the very low-quality evidence, we are
uncertain about the e,ect of HSPC on mortality/survival and pain.
Very low-quality evidence from five studies (N = 384 participants)
suggests that there is no di,erence in patient anxiety when HSPC is
compared to usual care (MD -0.63, 95% CI -2.22 to 0.96; I2 = 76%).
Negative mean di,erences (MDs) indicate benefit (lower anxiety)
and positive MDs reflect higher anxiety. However, eight studies
(N = 1096 participants) found that HSPC may improve patient
depression on average with a small e,ect size of -0.22 SMD (95% CI
-0.34 to -0.10; I2 = 0%; very low-quality evidence). Negative SMDs
indicate benefit (lower depression) and positive SMDs reflect higher
depression. We found no evidence of e,ect on unpaid caregiver
anxiety and depression. However, there was only very low-quality
evidence from one study that assessed unpaid caregiver anxiety
(N = 312 participants), and two studies (N = 413 participants) that
reported on unpaid caregiver depression (SMD -0.02, 95% CI -0.21
to 0.18; I2 = 0%).
The data we pooled from five studies (N = 616 participants)
that reported adjusted endpoint values and constituted very
low-quality evidence indicated no evidence of e,ect of HSPC
on breathlessness when compared to usual care (SMD -0.04,
95% CI -0.19 to 0.12; I2 = 0%). Negative SMDs indicate benefit
(reduced breathlessness) and positive SMDs reflect worsened
breathlessness.
Of the eight studies (N = 1252 participants) that reported on adverse
events, six described no adverse events while the remaining two
described more adverse events in the HSPC group compared to
the control group. While we found no evidence that HSPC causes
serious harms, the evidence was very low quality and insu,icient
to draw strong conclusions.
We could not pool data from the two studies (n = 170 participants)
that reported adjusted endpoint data for unpaid caregiver burden.
Both studies suggested that HSPC may make little to no di,erence
to unpaid caregiver burden (very low-quality evidence).
Only one study in 44 participants assessed unpaid caregiver grief
and also reported adjusted endpoint values. Similarly, one study in
69 participants assessed unpaid caregiver quality of life and also
presented adjusted endpoint values. There was no evidence of a
di,erence between HSPC and usual care on unpaid caregiver grief
and quality of life (low-quality evidence).
Very low-quality evidence suggests that the e,ect of HSPC
compared to usual care on resource utilisation, cost and cost-
e,ectiveness is inconclusive. The evidence on resource use was
varied across the di,erent areas assessed. Two studies found
reduced cost with HSPC when compared to usual care, while one
study found a reduction in the cost of hospitalisation days but no
di,erence in the cost of emergency room visits. The di,erence in
cost was unclear in one study, while the remaining nine studies
indicated no di,erence between HSPC and usual care. It was
hard to tell if the costs were shiKed to other settings (e.g. from
acute sector to community) when data on resource utilisation
were limited to hospital. Regarding cost-e,ectiveness, the evidence
from the full economic studies was also inconsistent. One study
reported cost-e,ectiveness planes of the palliative care outcome
scale (POS-8) and unpaid caregiver burden (ZBI) against total
costs, and found that 34% and 47% of bootstrapped di,erences in
costs and outcomes indicated lower costs and better outcomes for
the intervention. Another study also presented cost-e,ectiveness
planes with bootstrapping, where 66% of replicated combinations
of costs and outcomes of distress due to breathlessness (NRS)
against total cost indicated lower costs and better outcomes.
However, another study found that the intervention was not cost-
e,ective: the incremental cost-e,ective ratio (ICER) was 266,333
per QALY, and there was only about a 7% likelihood of lower
cost and higher QALYs. The last cost-e,ectiveness study calculated
incremental net monetary benefit (INMB) of HSPC and found that
the intervention was cost-e,ective when the willingness to pay
threshold was larger than AUD 1,027 (converts to GBP 915 in 2018)
for one extra day at home.
Evidence from the qualitative studies that explored views and
experiences of HSPC by stakeholders suggested that HSPC was
beneficial as it ensured personalised and holistic care for patients
and their families, while also fostering open communication,
shared decision-making, respectful and compassionate care and
psychosocial support. A previous systematic review also found
these areas to be important by patients and their families for end-
of-life care in the hospital setting (Virdun 2015). Patients found the
specialist expertise and multidisciplinary nature of the HSPC teams
to be helpful, and there was oncologists' support for early palliative
care for patients with newly diagnosed advanced stage cancer.
The main domains of palliative care addressed in the studies
that either included certified experts in palliative care, or those
described as palliative care clinicians, were symptom control,
coping and support, and decision-making. Some of the studies
also addressed care co-ordination and future planning. With the
exception of future planning, studies that were unclear about
palliative care training of those delivering the HSPC intervention
had less focus on symptom control, decision-making, care co-
ordination and coping and support when compared to those that
included certified experts in palliative care.
Overall completeness and applicability of evidence
We had a highly sensitive electronic search strategy in addition
to contacting experts in order to locate grey literature and
unpublished studies. As a result, we had a large number of
references to screen. Given our intensive search strategy, we are
of the opinion that we captured the breadth of evidence on HSPC
so far. In particular, we were able to identify 42 RCTs including
one foreign language study (Chinese). This allowed us to report
on the e,ect of HSPC on di,erent outcomes. It is noteworthy that
the number of studies reporting on di,erent outcomes varied,
especially, as we decided to report adjusted endpoint values as our
main meta-analysis. We decided to present adjusted values as our
main meta-analysis because they control for di,erences, and also
provide the most precise and least biased estimates of treatment
e,ects. Although we had indicated that we would be carrying out
subgroup analyses by disease type, HSPC team composition (e.g.
physician-led versus nurse-led versus MDT-led services and 24-hour
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access versus temporarily restricted access), models of HSPC and
country of origin in order to explain heterogeneity, we could only
carry out subgroup analyses on one outcome (patient anxiety)
due to low to no heterogeneity in the main meta-analysis in other
outcomes. The results of subgroup analysis should be interpreted
with caution due to the small number of studies available and
the exploratory nature of this approach. We had indicated that we
would be carrying out a subgroup analysis using frailty associated
with advanced age. However, no study reported on frailty. In
addition, there is a need for better reporting of the findings of
studies. We could not include some studies in the meta-analysis
because they did not present analysable data.
Most of the studies were conducted in hospitals with specialised
palliative care teams and were largely carried out in the US and
UK. Regulatory environment can have a significant impact on the
provision and impact of HSPC on hospitals, patients and unpaid
caregivers. For example, in the US, non-hospital palliative care
is provided through a large number of varied private for profit
and non-profit entities whose e,ectiveness and success may vary
significantly. This aspect of the service also makes the hospital
to home-based care transition di,icult and lacking in continuity
of care. In addition, palliative care, health policy and resources
in developed countries di,er from what is obtainable in low- and
middle-income countries where resources are somewhat limited
and palliative care at its infancy (WPCA/WHO 2014). The results
obtained from these highly developed healthcare systems may not
be applicable to low resource settings. The majority of our included
studies were for populations of cancer patients and, importantly,
this review has shown that HSPC is being extended to other patient
populations.
Quality of the evidence
Besides Ahronheim 2000 and Jingfen 2017, a foreign language
study, we judged all other studies as having a high risk of bias in at
least one domain. Nine studies had a high risk of bias in four or more
domains (Bajwah 2015; Brannstrom 2014; Cheung 2010; Edmonds
2010; Janssens 2019; O'Riordan 2019; Rodin 2019; Rogers 2017;
Temel 2017). We carried out sensitivity analyses using unadjusted
endpoint values and (un)adjusted changes and the results from
these analyses sometimes supported the results we obtained from
our main analysis.
Using the GRADE approach, the quality of the evidence ranged
from very low to low across di,erent outcomes. Generally, we
downgraded the evidence mainly due to serious/very serious
study limitations (high risk of bias), inconsistency resulting from
unexplained heterogeneity and imprecision due to small numbers
of participants.
There were di,erences across studies in the models of HSPC
and usual care, patient population, outcome measures and time
point of primary analysis. The evidence for mortality/survival was
also quite varied. This di,erence could have resulted because
of the diverse patient populations in the studies as well as the
heterogeneous models of the intervention.
This review provided evidence of low quality concerning the
e,ectiveness of HSPC on the primary outcomes of patient
HRQoL and patient symptom burden. Given the low quality of
the evidence, the findings should be interpreted circumspectly.
Findings from ongoing studies and other future studies may assist
in further strengthening the certainty of the e,ect estimates on the
e,ectiveness of HSPC.
Potential biases in the review process
Given that decisions taken during the process of conducting a
systematic review and meta-analysis may be a,ected by subjective
decisions (Shrier 2008), it is important to consider potential
biases that may have occurred. Generally, the methods of a
systematic review provide for transparency and standardisation
thereby enhancing reproducibility of the process. For most of our
outcomes such as patient HRQoL and patient symptom burden, we
combined studies reporting adjusted endpoint data as our main
meta-analyses. We pooled these studies using standardised mean
di,erences (SMDs) because they used di,erent scales. Restricting
our main meta-analyses to studies reporting adjusted endpoint
data reduced the number of studies we could pool together.
We could not include some studies in our meta-analyses because
they did not present analysable data. Outcomes that were not
reported in a usable format may be systematically di,erent from
those that were included in the meta-analyses, thereby introducing
selective outcome reporting bias (Higgins 2011b). We followed
the GRADE approach in assessing the quality of the evidence
for di,erent outcomes. Although the GRADE approach may not
always ensure consistency of conclusions, we believe it o,ers the
advantage of a systematic and transparent process of judging the
quality of the evidence (Guyatt 2011).
An important step in minimising bias in systematic reviews is to
address publication bias. Publication bias a,ects the validity and
generalisability of the findings of a meta-analysis (Lin 2017). In
order to reduce the possibility of publication bias, we searched
electronic databases, carried out citation tracking, handsearched
relevant studies and reviews and contacted experts for grey
literature and unpublished studies. We drew on a comprehensive
search strategy with input from the information specialist from
the PaPaS Group in order to minimise our chances of missing
out relevant studies. We believe that this synthesis includes an
unbiased sample that covers the populations targeted by this
review. Nonetheless, we cannot rule out time-lag bias, that is, when
the results of negative trials take longer to publish when compared
to positive trials (Sterne 2011).
In order to include studies in this review, the intervention had to
have been delivered by a multidisciplinary team. Our definition of
a multidisciplinary team was quite broad encompassing studies
where di,erent professionals delivered the intervention to those
where one single professional led the service and included other
professionals, as needed. We excluded studies such as Maltoni 2016
and Schenker 2018 because they did not meet our definition of a
multidisciplinary team. Further, we excluded studies such as Brims
2019 and Wong 2016 because palliative care was an integral part
of routine usual care. Our decision to include studies where the
training of the palliative care team was unclear, with eligibility
informed by activity of delivering specialist palliative care rather
than level of specialist training, might have implications for the
e,ect estimates we found, with the possibility of smaller e,ect sizes
in the review. Also, in almost half of the studies (n = 20), there was
palliative care involvement in the control group. This could have
resulted in a smaller e,ect of the intervention in these studies.
Due to di,erences in the reporting of the cost-e,ectiveness results
and also the dearth of cost-e,ectiveness studies in this review, we
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could not carry out subgroup analysis to explore di,erences in cost-
e,ectiveness across countries.
We included studies where the authors stated that the intervention
they provided was early palliative care or where this was their
intention. Given that the definition of early palliative care is still an
area of ongoing debate (Haun 2017), there is a need for consensus
on its definition. In order to make our review more relevant for
clinical practice and policy makers, we made some changes to the
protocol such as expansion of the remit of our review from only
inpatient specialist palliative care to five di,erent HSPC models,
limiting eligible studies to only RCTs and change of our primary
outcome from pain to two primary outcomes, patient HRQoL
(previously, a secondary outcome in the protocol) and patient
symptom burden. We carried out these changes before we began
data extraction and analysis. Consequently, the changes were not
post hoc. We have provided a full description of the changes we
made to the protocol under Di,erences between protocol and
review.
As in a previous Cochrane Review on the e,ectiveness of early
palliative care for adults with advanced cancer (Haun 2017),
we provided a description of the quality of the evidence for
our outcomes rather than on providing clinical guidance. We
have presented quality ratings for each outcome and have not
determined the quality across outcomes. Given that it has been
suggested that the lowest quality rating of the primary outcome(s)
should be applied to the overall quality rating across studies
(Guyatt 2013), the evidence for HSPC would be considered as very
low. However, as recognised in Haun 2017 and also in this review,
this rating is likely biased and we need larger and well-conducted
studies to establish the e,ectiveness of HSPC.
Agreements and disagreements with other studies or
reviews
Four relevant systematic reviews have been published prior to this
review (Dalgaard 2014; Gaertner 2017; Haun 2017; Higginson 2002).
Three of these reviews included HSPC while Haun 2017 assessed
the e,ectiveness of early palliative care for cancer patients only.
None of these previous reviews included all the RCTs in our
review. Our Cochrane Review is the first to assess the e,ectiveness
and cost-e,ectiveness of HSPC on diverse outcomes in a broad
population consisting of people with cancer, non-cancer and mixed
diagnoses.
Dalgaard 2014 assessed the best methods for early identification
of palliative trajectories in patients with cancer, chronic heart
failure and COPD, while also identifying preconditions for early
integration of general palliative care in hospitals and outcomes
for patients and relatives. This review included only one of the
seminal papers on early palliative care by Temel 2010 which found
that early integration of palliative care with standard oncology care
for patients with non-small-cell lung cancer (NSCLC) led to better
quality of life and mood as well as longer survival. This review
concluded that evidence about outcomes was sparse and mostly
related to cancer populations receiving specialised palliative care.
Gaertner 2017 assessed the e,ect of specialist palliative care on
quality of life and other outcomes in adults with advanced illness
in hospital, hospice or community settings. This review included
eight RCTs that we also identified in our review and concluded
that "specialist palliative care was associated with a small e,ect on
quality of life and might have most pronounced e,ects for patients
with cancer who received such care early". The review found that
the results for pain and other secondary outcomes (fatigue, nausea,
dyspnoea, psychosocial variables (distress, depression, anxiety,
spiritual well-being, social well-being, and satisfaction), survival
time, place of death, cost of care, and attrition (or completion rate))
were inconclusive.
Haun 2017 assessed the e,ectiveness of early palliative care on
di,erent outcomes such as HRQoL, depression, symptom intensity
and survival among patients with advanced cancer. This review
included six RCTs that were also part of our review and concluded
that "early palliative care interventions may have more beneficial
e,ects on HRQoL and symptom intensity among patients with
advanced cancer than among those given usual/standard cancer
care alone". The authors found only small e,ect sizes. The e,ects
on mortality and depression were uncertain. The authors further
stated that results should be interpreted with caution due to
the very low-to low-quality of the evidence and between-study
di,erences regarding participant populations, interventions, and
methods.
Higginson 2002 is the oldest review that was relevant. Its
objective was to assess whether hospital-based palliative care
teams improved the process or outcomes of care for patients and
families at the end-of-life through a qualitative meta-synthesis and
quantitative meta-analysis. It did not include any of the studies
in our review and there was only one RCT. The authors found
a small positive e,ect for hospital-based palliative care teams.
Higginson 2002 further highlighted the need for better designed
studies comparing di,erent models of HSPC as well as the use of
standardised outcome measures for assessing symptoms.
Our review agrees with these past reviews in some respect
especially with regards to HRQoL. We found evidence that HSPC
may be e,ective in improving HRQoL of patients and patient
symptom burden with small e,ect sizes. We also found that HSPC
may lead to benefits on some of the secondary outcomes we
assessed: better patient satisfaction, achieving patient preferred
place of death (measured by number of home deaths) and
improvement in patient depression. Quality of the evidence ranged
from very low to low. Similar to our review, the review by Gaertner
2017 found a small e,ect of specialist palliative care on HRQoL
(SMD 0.16, 95% CI 0.01 to 0.31; n = 7 studies with 1218 participants;
moderate-quality evidence). The Cochrane Review by Haun 2017
also showed a small e,ect of early palliative care on HRQoL (SMD
0.27, 95% CI 0.15 to 0.38; n = 7 studies with 1028 participants; low-
quality evidence).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For patients and carers
Available evidence of very low- to low-quality suggests that patients
with advanced illness may benefit from HSPC with respect to small
improvements in patient HRQoL and symptom burden, and HSPC
may improve patient satisfaction, patient depression, and increase
the chances of patients dying in their preferred place (measured
by home death). There is limited evidence of the e,ect on unpaid
caregiver grief as this has not been well studied. While we found no
evidence that HSPC causes serious harms, the evidence was very
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low quality and insu,icient to draw strong conclusions. Patients
could approach their clinicians and request referral to HSPC.
For clinicians
Although we found evidence that HSPC may improve patient
HRQoL, symptom burden, patient depression, patient satisfaction
with care and may improve the chances that patients achieve their
preferred place of death (measured by home death), the certainty
of the evidence was very low to low. Despite the limited quality
of the evidence, HSPC may be considered in practice for patients
with advanced diseases. From a practitioner's perspective, some
previous reviews have reported definitive success of palliative care
in prolonging life. Results from our review do not support increased
survival with HSPC but HSPC may increase the chances of a home
death. Very low-quality evidence did not demonstrate an e,ect of
HSPC on serious harms. Therefore, clinicians may consider o,ering
HSPC on a case-by-case basis to address patient HRQoL and
symptom burden, but refrain from claiming these interventions will
improve survival. More research is needed before solid conclusions
can be drawn.
For policy makers
Given that population-based projections have indicated that
palliative care needs will increase in the future (Sleeman 2019),
one area that policy makers could prioritise is the further
commissioning of HSPC. Importantly, our review showed that
those receiving HSPC may have 1.63 higher odds of dying in their
preferred place (measured by home death), in addition to benefits
for patient HRQoL and symptom burden. The 1.63 higher odds
translates to an increase in the relative risk of dying in the patient's
preferred place of 22% (8% to 39%). Very low-quality evidence did
not demonstrate an e,ect of HSPC on serious harms. There is an
urgent need for well-powered high-quality RCTs on the e,ect of
HSPC in populations with non-cancer and mixed diagnoses, ward-
based care, 24 hours access (out-of-hours care), achieving patient
preferred place of care, patient satisfaction with care, unpaid
caregiver outcomes (satisfaction with care, burden, depression,
anxiety, grief, quality of life) and cost-e,ectiveness. Of note, there
were no studies looking at the e,ectiveness of HSPC on broader
e,ects in hospitals such as patient flow and readmission rates.
For funders of the intervention
When compared to usual care, HSPC may improve patient HRQoL,
symptom burden, patient satisfaction, patient depression, while
also helping patients die in their preferred place (measured by
home death). We suggest that the evidence should be interpreted
cautiously until more RCTs are available. Very low-quality evidence
did not demonstrate an e,ect of HSPC on serious harms. It appears
that HSPC carried no greater cost than usual care.
Implications for research
General
This review has shown that there is a need for larger and well-
conducted RCTs assessing di,erent models of HSPC in non-cancer
and mixed populations. Compared with cancer studies, RCTs
involving populations with non-cancer and mixed diagnoses are
fewer. Also, this review found only few RCTs assessing ward-based
HSPC models and 24 hours access (out-of-hours care), and no
study assessing relatively new constructs such as frailty or a focus
on multimorbidity. These are areas for exploration in future RCTs
that are su,iciently powered to detect di,erences between the
intervention and control groups. There is also an urgent need
for studies to consider the varied regulatory environment and
conduct more systems-wide research looking at HSPC spanning
more than one setting and how integrated HSPC across hospital
and community changes outcomes and costs. It is paramount that
more RCTs are carried out in low- and middle-income countries
with a good description of the intervention and usual care in
order to expand the existing evidence base. More RCTs on the
e,ectiveness of HSPC on other outcomes besides patient HRQoL
and symptom burden are also needed. For instance, patient
satisfaction with care, achieving patient preferred place of care,
unpaid caregiver outcomes (e.g. satisfaction with care, burden,
depression, anxiety, grief, quality of life) and cost-e,ectiveness
should be further explored. There is an urgent need for more
cost-e,ectiveness studies on HSPC as we only identified four such
studies in this review. A clearer definition of early palliative care by
the palliative care community would assist future RCTs evaluating
it to be more focussed.
Design
Future RCTs need to be larger, well-designed and well-conducted,
with high-quality reporting of their methods. Interventions should
be described clearly under the di,erent models we have proposed
for HSPC. To strengthen the internal validity of e,ect estimates,
future studies need to be rigorous in both design and delivery, and
should be based on su,icient power. To ensure fidelity of delivery
of the intervention, detailed descriptions of the components of the
intervention should be provided in the methods, including training
of sta, involved in the provision of HSPC. In addition, the delivery
of HSPC (including frequency and duration of treatment), receipt of
HSPC, and enactment of HSPC should be clearly described. Where
possible, usual care groups should not include access to HSPC and
where this does happen, there should be clear documentation.
Where possible, investigators should aim to control for selection
bias (i.e. to ensure adequate allocation concealment), performance
bias (i.e. to blind study participants) and detection bias (i.e. to blind
outcome assessors). However, this will continue to be a challenge
in this area. With respect to settings, interventions that span acute
and community settings are needed.
Concerning heterogeneity of samples, there is a need to investigate
disease-homogenous samples to better account for disease-
specific trajectories and multimorbidity.
In addition, future studies should also consider e,ectiveness-
implementation hybrid designs, combining elements of clinical
e,ectiveness and implementation research to enhance public
health impact (Curran 2012). In particular, strategies to encourage
implementation of evaluation findings should be incorporated and
be based on a scientific understanding of the behaviours that
need to change, the relevant decision-making processes, and the
barriers and facilitators of change. This will speed the translation of
research findings into routine practice.
Measurement
Patient HRQOL and symptom burden are appropriate outcomes
that appear to be sensitive to change and can be recommended
for routine collection. However, most of the available quality
of life measures do not include domains that have been found
to be important in palliative populations such as existential or
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spiritual domains (Cohen 2001; Roscoe 2010), and this could
potentially underestimate the e,ect of HSPC. Further, many of
the HRQOL measures have been validated on the assumption
that scores deteriorate towards death and so exhibit floor e,ects
in palliative care. In addition, they are not individualised. Pain,
whilst an appropriate primary outcome in studies of participants
with malignancies, does not appear to be an appropriate outcome
for studies of participants with non-malignant diagnoses. Better
outcome measures are needed, which are person-centred and can
be used across studies.
It is also important that RCTs report adequately on outcomes
they stated in their protocol in order to avoid selective outcome
reporting bias. There is a need for more studies reporting adjusted
endpoint data. It appears that consensus is needed by palliative
care researchers on whether endpoint scores or change scores are
the most informative for this population. The ongoing focus on
improvement of outcomes may be leading to discounting of the
e,ectiveness of HSPC in the important clinical outcome of slowing
deterioration compared to usual care.
Concerning economic measurements, data sources such as health
insurance database and hospital medical records are more reliable
and accurate but the information on services in community and/or
at home (including delivery of care by unpaid caregivers) requires
di,erent approaches. For example, hospital records (e.g. Hospital
Episode Statistics) linked with community service data (e.g. Clinical
Practice Research Datalink) would help understand the change
of resource use and its implication on costs/cost-e,ectiveness.
Moreover, future studies need primary data collection from
patients or family members, using tools such as the Client Service
Receipt Inventory providing information on delivery of care by
unpaid caregivers as well as health and social care.
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Who led PC intervention: Multidisciplinary team
Core team: Clinical nurse specialist/certified geriatrician
Participants Country and regions: USA, New York
Recruitment: Eligible patients admitted to Mount Sinai Hospital over a 3-year period were identified
through daily rounds by the palliative care team nurse. Patients were assessed by the palliative care
nurse as to appropriateness for inclusion.
Inclusion criteria: Patients were eligible if they had advanced dementia and had been hospitalised for
acute illness. Advanced dementia was defined as Functional Assessment Staging Tool (FAST) of stage 6
or greater, with a stable baseline neurological deficit for at least 1 month.
Exclusion criteria: Not described
Number of patients: N = 99 (48 intervention and 51 control)
Diseases: Advanced dementia
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Patient characteristics: Mean age in years (range): 83.9 (63 - 99) years in intervention group, 85.6 (72 -
100) years in control group; 77.1% female in intervention group, 86.3% female in control group.
Deaths at end of study (N (%)): N = 24: 12 (25%) intervention and 12 (23.5%) control
Withdrawals/other dropouts (N (%)): Not reported
Interventions Name: Inpatient palliative care vs usual hospital care
Type: Training in palliative care unclear
Service base: Mount Sinai Hospital, a tertiary care referral centre and teaching hospital for Mount Sinai
School of Medicine
Team: Consisted of master's level clinical nurse specialist and one or more attending level, certified
geriatricians who held academic appointments in the Departments of Medicine and Geriatrics
Intervention condition: The intervention consisted of palliative care consultation by the team nurse
and physician investigator, who then visited the patient and discussed management with available
members of the primary healthcare team in the hospital on a daily basis, excluding weekends. The
palliative care team also met with family unpaid caregivers or other surrogates when they were avail-
able and attempted to arrange meetings after hours. If face-to-face meetings could not be arranged,
discussions were held over the phone. During encounters with health professionals or family unpaid
caregivers, the palliative care team discussed various care options. The goal of the intervention was
to maximise patient comfort with avoidance of painful or invasive treatments, including hospital ad-
mission, diagnostic tests, and invasive procedures, unless needed for symptom control. Recommenda-
tions regarding palliative care interventions were made to the hospital inpatient team but contact be-
tween or after hospitalisations were generally with the family. On readmission, the patient was identi-
fied through a computerised system. Consent to continue in the study was obtained from the surrogate
by phone, and the inpatient providers were contacted.
Duration: Time of initial randomisation until final discharge or in-hospital death







Use of nonpalliative procedures
Do-not-resuscitate (DNR) orders and cardiopulmonary resuscitation (CPR)
Systemic antibiotics




Whether a decision was made to adopt an overall palliative care plan
Assessment points: After informed consent, complete history was obtained and physician examina-
tion performed. After this baseline evaluation, patients were randomised and outcomes assessed until
Ahronheim 2000  (Continued)
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final discharge or in-hospital death. Date of death for patients who survived the hospitalisation was as-
certained by telephone follow-up.
Resource use/costs Number of hospital admissions
Number of rehospitalisations
Mean length of stay post-randomisation
Time horizon: Start of hospitalisation to final discharge or in-hospital death
Notes Funding source: This work was supported by grants from The Greenwall Foundation and The Kornfeld
Foundation.
Declarations of interest among primary researchers: Apart from funding, no further study author
disclosure statements were made.
Power considerations: Not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "patients were randomly assigned to either the
intervention or to the control group".









Low risk Comment: participants and personnel were not blinded but this is unlikely to
lead to bias in the outcomes.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "in order to maintain blindness for the research
assistant during data gathering from the chart, consultation did not include
written notes on the chart... A research assistant blinded to randomization sta-
tus gathered information from the charts of patients in both arms of the study;
data obtained included demographic characteristics, advance directives, co-





Unclear risk Comment: number of dropouts were not reported.
Selective reporting (re-
porting bias)
Unclear risk Comment: protocol was not available.
Other bias Low risk Comment: study appeared to be free of other biases.
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Study characteristics
Methods Design: RCT
Fast-track phase II RCT
Who led PC intervention: Nurse-led intervention
Core team: PC specialist nurse. The patient, their carer, hospital-2-home nurse, general practitioner,
community matron/district nurse, respiratory nurse, community palliative care nurse (and any other
relevant health or social care professional) were invited to attend the case conference.
Participants Country and regions: UK, London
Recruitment: October 2011 to October 2013. Patients with a clinical diagnosis of advanced idiopathic
fibrotic lung disease (IPF by American Thoracic Society/European Respiratory Society criteria or fibrotic
nonspecific interstitial pneumonia) were recruited from the inpatient and outpatient settings in a spe-
cialist ILD centre (Royal Brompton Hospital, London). Where possible, patient and carer dyads were re-
cruited.
Inclusion criteria: Patients included were considered to have end-stage disease as judged by either
high resolution CT or composite physiologic index scores. A subsequent amendment allowed recruit-
ment of patients considered to have end-stage disease clinically who were too unwell to complete pul-
monary function tests. To be included, patients and carers had to be > 18 years old, possess sufficient
mental capacity and be able to complete questionnaires in English.
Exclusion criteria: Patients/informal unpaid caregiver
i) Any patient/informal unpaid caregiver unable to give informed consent
ii) Any patient/informal unpaid caregiver less than 18 years of age
iii) Participants who are unable to understand/speak English
iv) Participants who are remaining as an inpatient in the hospital or being transferred to another inpa-
tient facility (e.g. hospice unit, for terminal care)
v) Participants whose prognosis is less than 1 week or judged too unwell by the research team to take
part in serial interviews
Number of patients: N = 53 (26 intervention and 27 control)
Diseases: Idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia
Patient characteristics: Mean age in years (SD): 67.1 (10.9) years in intervention group, 70.6 (10.3)
years in control group; 23% female in intervention group, 33% female in control group
Number of unpaid caregivers: N = 45 (19 intervention and 26 control)
unpaid caregivercharacteristics: Mean age in years (SD): 61.3 (14) years in intervention group, 60.3
(13.1) years in control group; 68% female in intervention group, 77% female in control group
Deaths at end of study (N (%)): Total N = 10: 1 (3.8%) intervention and 9 (33.3%) control
Withdrawals/other dropouts (N (%)): Total N = 12: 6 (23.1%) intervention and 6 (22.2%) control
Interventions Name:.Case conference intervention (hospital-2-home) delivered alongside best standard care vs stan-
dard care
Type: Specialist palliative care. Included a palliative care specialist nurse who delivered the interven-
tion. The nurse had received training on delivery of the intervention from specialist nurses delivering
the cancer hospital-2-home intervention
Service base: Hospital
Bajwah 2015 
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Team: A palliative care specialist nurse delivered the intervention. The patient, their carer, hospi-
tal-2-home nurse, general practitioner, community matron/district nurse, respiratory nurse and com-
munity palliative care nurse (and any other health or social care professional involved in their care or
identified as important by the patient) were invited to attend the case conference.
Intervention condition: The hospital-2-home intervention was delivered alongside best standard
care. The fast-track group received the intervention after 1 week, the waiting list group after 4 weeks.
The intervention aimed to provide a quality comprehensive palliative care assessment and streamlin-
ing of transfer of data between specialist and community settings improving co-ordination of care and
communication while codifying responsibility for the patient, carer and health professionals. The Hos-
pital-2-Home intervention included a case conference (multiprofessional and holistic) and a care plan
(care individualised to each patient and carer). A palliative care specialist nurse who had received train-
ing on the intervention delivered it. Clinical supervision was provided to assist in identifying and advis-
ing on strategies to address problems compromising effective management of the palliative care con-
cerns of these patients and carers. During the case conference, current and anticipated palliative care
concerns (physical, psychological, social and spiritual concerns) were discussed. An action plan was
agreed upon for each concern and a responsible healthcare professional allocated for each item. The
individualised care plan was then communicated to the patient and carer and health and social care
professionals.
Duration: 8 weeks
Control condition: All patients received best standard care throughout the study: Patients remained
under ILD specialist care for the full duration of the study. Referrals to community health professionals
(as deemed necessary by the ILD team) continued throughout the study. These could include referrals
to community nursing (such as community matron or district nurses), respiratory services and commu-
nity palliative care teams.
Outcomes Primary outcome:
Palliative Care Outcome Scale (POS) assessed by the patient
Secondary outcome:
POS assessed by the carer
Breathlessness assessed using the D12 and MRC breathlessness scale
Symptom control assessed using POS
Quality of life of patients assessed using the Kings Brief Interstitial Lung Disease (KBILD) questionnaire
and the St Georges Respiratory Questionnaire (SGRQ)
Quality of life of carers assessed using the unpaid caregiver Quality of Life Index
Patient anxiety and depression assessed using the Hospital Anxiety and Depression Scale
Carer anxiety and depression assessed using the Hospital Anxiety and Depression Scale
Carer burden assessed using the Zarit Burden Inventory
Preferred place of care and death
Patient use of other services
Consent and recruitment rates
Percentage of patients in the fast-track group receiving case conferences within 14 days
Assessment points: After consent and baseline interview, patients were randomised to fast-track or
waiting list groups. Primary and secondary outcome data were collected by postal questionnaire at
baseline in both groups. Subsequent time points were 4 weeks and 8 weeks after receiving the inter-
vention in the fast-track group and just before receiving the intervention and 4 weeks after receiving
the intervention in the waiting list group.
Bajwah 2015  (Continued)
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Resource use/costs Patient use of other services
Carer's assessment of patient's use of services
Notes Funding source: This study was funded partly by a grant from Marie Curie. The remainder of the fund-
ing was from the Royal Marsden and Royal Brompton Palliative Care Research Fund which is funded
from charitable sources.
Declarations of interest among primary researchers: No competing interest was declared by the au-
thors.
Power considerations: FiKy-two patients were needed to enable estimation of change in POS between
baseline and 4 weeks with accurate precision (assuming a SD of 2, a 95% CI for the difference between
the fast-track and waiting list groups would be 2.2 units wide, i.e. mean difference ± 1.1 units).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "after consent and baseline interview, patients
were randomised to fast-track or waiting list groups... Treatment allocation
(fast-track/waiting list group) was by computer generated random permuted
blocks (by the Institute of Cancer Research) with stratification dependent on
severity of patient Palliative Care Outcome Scale (POS) at baseline (patients




Low risk Quote from main publication: "treatment allocation (fast-track/waiting list
group) was by computer generated random permuted blocks (by the Institute
of Cancer Research) with stratification dependent on severity of patient Pallia-
tive Care Outcome Scale (POS) at baseline (patients with a POS score ≥ 28 were
classed as severe)".










Low risk Information registered for this trial, NCT01450644, reported there was no
masking (open-label).
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in the objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Comment: no blinding
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Information registered for this trial, NCT01450644, reported there was no
masking (open-label).





High risk N = 23 (88.5%) completers in intervention group vs N = 21/24 (77.8%/88.9%)
completers in control group. In intervention group, loss to follow-up occurred
due to death (N = 1), withdrawal (N = 1) and went on holiday (N = 1). In con-
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trol group, loss to follow-up occurred due to death (N = 6). Patients lost to fol-
low-up were excluded from analysis.
Selective reporting (re-
porting bias)
High risk Comment: some of the outcomes in the protocol were not reported e.g. cost.
Furthermore, some outcomes reported in the study were not prespecified in
the protocol e.g. carer's burden and end-of-life preferences.
Other bias Unclear risk Comment: there were differences between the intervention and control
groups at baseline in patients' age, gender, ethnicity, percentage with comor-
bidities. However, it was unclear if these differences were significant as no sta-
tistical test was carried out. It was also unclear if they were controlled for.






Methods Design: RCT (multisite)
Who led PC intervention: Nurse-led palliative care intervention
Core team: Advanced practice palliative care nurse specialists. Intervention participants and their un-
paid caregiver were invited to attend monthly group shared medical appointments (SMAs) led by a
certified palliative care physician and nurse practitioner. Palliative care–certified nurse practitioner
and physician, psychologists, and other team members, met biweekly to review the advanced practice
nurses’ audiotaped educational sessions and to provide feedback on difficult patient management is-
sues.
Participants Country and regions: USA, New Hampshire and Vermont
Recruitment: November 2003 to May 2007. Research assistants (RAs) at the cancer centre and the Vet-
erans Affairs Medical Center (VAMC) attended weekly gastrointestinal (GI), genitourinary (GU), breast,
and thoracic cancer management meetings (tumour boards) in which newly diagnosed patients were
discussed. The RAs also reviewed clinic schedules to identify potentially eligible patients. The clinician
then approached the patients to obtain permission for the RA to provide them with more information
about the study. From affiliated outreach clinics, following discussion of the study with clinic sta,, the
main study site was informed of a potentially interested patient.
Inclusion criteria: Patients identified at the Norris Cotton Cancer Centre’s tumour boards with a life-
limiting cancer (prognosis of approximately 1 year) were eligible if they were within 8 to 12 weeks of a
new diagnosis of gastrointestinal tract (unresectable stage III or IV), lung (stage IIIB or IV non–small cell
or extensive small cell), genitourinary tract (stage IV), or breast (stage IV and visceral crisis, lung or liver
metastasis, oestrogen receptor negative [ER−], human epidermal growth factor receptor 2 positive [Her
2 neu + ]) cancer. Patients were asked to select a unpaid caregiver to participate in the study. Patients
who did not select a unpaid caregiver were not excluded.
Exclusion criteria: Patients with impaired cognition (< 17 on a modified Mini-Mental State Examina-
tion), an Axis I psychiatric disorder (schizophrenia, bipolar disorder), or active substance use were ex-
cluded.
Number of patients enrolled (survival outcomes sample): N = 322 (161 intervention and 161 control)
Number of patients (patient outcomes sample): N = 279 (145 intervention and 134 control)
Diseases: Gastrointestinal tract (42%), lung (33%), genitourinary tract (13%) and breast cancer (11%)
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Patient characteristics: Mean age in years (SD): 65.4 (10.3) years in intervention group, 65.2 (11.7)
years in control group; 37.9% female in intervention group, 41.8% female in control group.
Number of unpaid caregivers enrolled: N = 220 (116 intervention and 104 control)
Number of unpaid caregivers ( unpaid caregiveroutcomes sample): N = 198 (108 intervention and 90
control)
unpaid caregivercharacteristics ( unpaid caregiveroutcomes sample): Mean age in years (SD): 58
(11.9) years in intervention group, 59.9 (13) years in control group; 76.9% female in intervention group,
77.8% female in control group
Deaths at end of study (survival outcomes sample) (N (%)): N = 231: 112 (69.6%) intervention and
119 (73.9%) control
Withdrawals/other dropouts from enrollment (N (%)): N = 100: 45 (28%) intervention and 55 (34.2%)
control
Withdrawals/other dropouts (patient outcome sample) (N (%)): N = 57: 29 (20%) intervention and 28
(20.9%) control
Interventions Name: Advanced practice palliative care nurse specialist-administered palliative care intervention con-
current with anti-cancer treatment for patients with advanced cancer and a unpaid caregiver vs usual
care (project ENABLE II).
Early PC: Randomised controlled trial of a palliative care intervention compared with usual care for
persons newly diagnosed with advanced cancer (8 to 12 weeks of a new diagnosis)
Type: Specialist palliative care. Included advanced practice palliative care nurse specialists
Service base: Oncology clinics of the National Cancer Institute-designated comprehensive cancer
centre and affiliated outreach clinics, and the academically affiliated Veterans Affairs Medical Center
(VAMC)
Provider of service: Advanced practice palliative care nurse specialists
Intervention condition: The intervention, based on the chronic care model, used a case management,
educational approach to encourage patient activation, self-management, and empowerment. A man-
ualised, telephone-based format was used to improve access to palliative care in a rural population.
One of 2 advanced practice nurses with palliative care specialty training conducted 4 initial structured
educational and problem-solving sessions and at least monthly telephone follow-up sessions until the
participant died or the study ended. A bereavement follow-up call was made to the unpaid caregiver.
The nurses began all contacts with an overall assessment by administering the Distress Thermometer,
an 11-point rating scale (0-10) of distress. If distress intensity was > 3, the nurses explored the sources
of distress and identified if the participant would like to apply the problem-solving approach to ad-
dress his or her issues. The education manual, contained the 4 modules of problem-solving, commu-
nication and social support, symptom management, advance care planning and unfinished business,
and an appendix listing supportive care resources. Following the 4 formal sessions, the advanced prac-
tice nurse was available by telephone and also contacted the participant (or unpaid caregiver) at least
monthly (until the participant’s death) to follow-up on active issues and to assess the need for referral
to appropriate care resources. Additionally, intervention participants and their unpaid caregiver were
invited to attend monthly group shared medical appointments (SMAs).
Duration: Enrollment until death or study completion
Control condition: Participants assigned to usual care were allowed to use all oncology and support-
ive services without restrictions including referral to the institutions’ interdisciplinary palliative care
service. The cancer centre site has a consultative interdisciplinary palliative care team (PCT) comprised
of a physician and nurse practitioners which provided care for both inpatient and outpatients. Oncol-
ogists could refer patients for assessment by this team while patients were receiving anticancer treat-
ments. Patients and family members were often followed through death and bereavement.
Outcomes Primary outcomes:
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Patient-reported quality of life measured by the Functional Assessment of Chronic Illness Therapy-Pal-
liative Care (FACIT-Pal)
Symptom intensity measured by a modified Edmonton Symptom Assessment Scale (ESAS)
Resource use
Secondary outcomes:
Mood measured by the Center for Epidemiological Studies Depression Scale (CES-D)
unpaid caregiver burden measured by the Montgomery Borgatta unpaid caregiver Burden Scale




Baseline assessment was followed by randomisation. Outcomes were assessed at baseline, 1 month,
and every 3 months until death or study completion.
Resource use/costs Number of days in the hospital
Number of days in the intensive care unit (ICU)
Number of emergency department visits
Time horizon: Enrollment until death or study completion
Notes Funding source: This study was supported by National Cancer Institute grant R01 CA101704.
Declarations of interest among primary researchers: No financial disclosure was reported.
Power considerations: The original target sample size of 400 was chosen to provide 80% power to de-
tect treatment effects of at least 0.35 SDs for scores on the Functional Assessment of Chronic Illness
Therapy for Palliative Care, ESAS, and CES-D based on a t-test comparing the treatment groups with re-
spect to the last observed value with a 2-sided value of.01. However, at the planned study completion
date, the final total study enrollment was 322 due to slightly slower accrual than anticipated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from publication: "participants were randomised equally into either
the intervention or the usual care group using computer-generated random
numbers. There were separate randomisation schemes for the cancer center
and the VAMC participants (in order to ensure an equal distribution of patients
in intervention and control groups from each of these primary sites). Partici-
pants from all other sites randomised according to the cancer center scheme,
as large numbers of participants were not anticipated. Randomisation was
blocked using random block sizes and was also stratified by diagnosis (lung,
breast, and GI and GU cancers) to control for differential effects of treatment




Unclear risk Quote from main publication: "referring clinicians were neither informed nor
formally blinded to participant assignment".
Comment: allocation concealment was not adequately described.
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Low risk Information obtained from the trial registry indicated it was open-label.
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Comment: no blinding
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Information obtained from the trial registry indicated it was open-label.
Comment: lack of blinding of outcome assessment was unlikely to lead to bias




Unclear risk N = 113 (77.9%) in intervention group vs N = 105 (78.4%) in control group com-
pleted > 1 follow-up. In the intervention group, 29 (20%) patients withdrew
and 19 (13.1%) died. In the control group, 28 (20.9%) withdrew and 28 (20.9%)
died. Missing data were included in primary outcome analysis.
Comment: although missing data were included in primary outcome analysis,
they were not included in secondary outcome analysis.
Selective reporting (re-
porting bias)
High risk Comment: one outcome (problem-solving skills) included on the trial registry
was not reported in the publication. Trial Registration no is NCT00253383. Fur-
thermore, quality of care (After Death Bereaved Family Member Interview) was
stated as a primary outcome on the trial registry but reported as a secondary
outcome in the publication.
Other bias Low risk Comment: study appeared to be free of other biases.
Size of study Low risk Comment: each of the groups had above 200 participants (patients and unpaid





Methods Design: RCT (multisite RCT)
Fast-track RCT
Who led PC intervention: Multidisciplinary team
Core team: Board-certified palliative care clinician/advanced practice palliative care nurse
Participants Country and regions: USA. Lebanon, New Hampshire and White River Junction, Vermont
Recruitment: October 2010 to March 2013. Research co-ordinators reviewed all outpatient clinicians’
schedules and tumour board lists using eligibility criteria to identify potential participants.
Inclusion criteria: English-speaking, age > 18 years with advanced-stage solid tumour or haematologic
malignancy, oncologist-determined prognosis of 6 to 24 months, and able to complete baseline ques-
tionnaires; data supplement provides detailed criteria. After providing signed consent, patient par-
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ticipants were asked to select a unpaid caregiver, defined as “someone who knows you well and is in-
volved in your medical care,” to participate; however, patients were not excluded if they did not identi-
fy a unpaid caregiver.
Exclusion criteria: Exclusions included impaired cognition (Callahan score < 4), active axis I psychiatric
disorder (schizophrenia, bipolar) or substance use disorder, uncorrectable hearing disorder, or unreli-
able telephone service. There were no formal unpaid caregiver exclusion criteria.
Number of patients: N = 207 (104 intervention and 103 control)
Diseases: Lung (N = 88, 43%), breast (N = 23, 11%), gastrointestinal tract (N = 50, 24%), other solid tu-
mour (N = 20, 10%), genitourinary tract (N = 16, 8%) and haematologic malignancy (N = 10, 5%).
Patient characteristics: Mean age in years (SD): 64.03 (10.3) years in intervention group, 64.6 (9.6)
years in control group; 46% female in intervention group, 49% female in control group
Number of unpaid caregivers: N = 122 (61 intervention and 61 control)
unpaid caregivercharacteristics: Mean age in years (SD): 61 (11.6) years in intervention group, 57.9
(11.9) years in control group; 77% female in intervention group, 80.3% female in control group
Number of unpaid caregivers who completed after-death questionnaires: N = 44 (19 intervention
and 25 control)
unpaid caregivercharacteristics for those who completed after-death questionnaires: Mean age in
years (SD): 62.1 (11.9) years in intervention group, 61.2 (8.6) years in control group; 78.9% female in in-
tervention group, 88% female in control group
Deaths at end of study (N (%)): N = 17: 2 (2.9%) intervention and 14 (13.6%) control
Withdrawals/other dropouts (N (%)): N = 77: 42 (40.4%) intervention and 35 (34%) control
Interventions Name: Early palliative care alongside standard oncology care (ENABLE III telehealth concurrent PC
model with standard oncology care) vs standard oncology care
Early PC: Early palliative care was defined as initiating palliative care within 30 to 60 days of diagnosis.
Type: Specialist palliative care. Included a board-certified palliative care clinician and advanced prac-
tice palliative care nurse specialists.
Service base: National Cancer Institute cancer centre, a Veterans Affairs Medical Centre, and commu-
nity outreach clinics
Provider of service: Board-certified palliative care clinician and an advanced practice palliative care
nurse
Intervention condition: ENABLE includes initial in-person, standardised outpatient palliative care
consultation by a board-certified palliative care clinician and six structured weekly telephone coaching
sessions by an advanced practice nurse using a manualised curriculum (i.e. Charting Your Course: An
Intervention for Patients With Advanced Cancer). Sessions one to three focussed on problem-solving,
symptom management, self-care, identification and co-ordination of local resources, communication,
decision-making, and advance care planning. Sessions four to six comprised Outlook, a life-review ap-
proach that encourages participants to frame advanced illness challenges as personal growth opportu-
nities. After the six Charting Your Course sessions, monthly follow-up calls reinforced prior content and
identified new challenges or care co-ordination issues. The principal investigator, reviewed all PC con-
sultation notes, and digitally recorded nurse coach sessions for protocol adherence. She met with the
nurse coaches weekly to review and provide feedback on difficult cases. There was also a unpaid care-
giver-specific intervention (such as cultivating communication skills with patient and healthcare clini-
cians).
Duration: Enrollment until death or study completion
Control condition: Usual oncology care, provided to all patients, was directed by a medical oncologist
and consisted of anticancer and symptom control treatments and consultation with oncology and sup-
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portive care specialists, including a clinical PC team. The latter was provided whenever requested, re-
gardless of group assignment.
Outcomes Outcomes:
Patient-reported quality of life measured by the Functional Assessment of Chronic Illness Therapy-Pal-
liative Care (FACIT-Pal) and Treatment Outcome Index
unpaid caregiver QoL measured by the CGQOL Scale-Cancer (CQOL-C)
Symptom impact measured by the Quality of life at end-of-life symptom impact subscale
Patient and unpaid caregiver mood measured by the Center for Epidemiological Studies Depression
Scale (CES-D)
One year and overall survival
Location of death
unpaid caregiver grief measured by the Prigerson Inventory of Complicated Grief-Short Form (PG13)
unpaid caregiver burden measured by the Montgomery–Borgatta CG Burden (MBCB) Scale
Assessment points:
Randomisation was done and then assessments were carried out. Subsequent to signed informed con-
sent, research co-ordinators administered questionnaires by telephone at baseline; at 6, 12, 18, and 24
weeks; and every 12 weeks thereafter until death or study completion.
Resource use/costs Patient-reported hospital and intensive care unit (ICU) days and emergency department (ED) visits
Chemotherapy use in last 14 days
Time horizon: Enrollment until death or study completion
Notes Funding source: Supported by Grant No. R01NR011871-01 from the National Institute for Nursing Re-
search; by a Cancer and Leukemia Group B Foundation Clinical Scholar Award; by the Foundation for
Informed Medical Decision-Making; by Grants No. P30CA023108, UL1 TR001086, and R03NR014915; an
NIH/NINR Small Research Grant 1R03NR014915-01 (Zhigang Li); by Norris Cotton Cancer Center pilot
funding; by the Dartmouth-Hitchcock Section of Palliative Medicine; by a National Palliative Care Re-
search Center Junior Career Development Award (M.A.B.); by Grant No. 5R25CA047888 from the Uni-
versity of Alabama at Birmingham Cancer Prevention and Control Training Program (J.N.D.-O.); and by
Mentored Research Scholar Grant No. MRSG 12-113-01-CPPB in Applied and Clinical Research from the
American Cancer Society (K.D.L.)
Declarations of interest among primary researchers: Authors stated that they had no relationship to
disclose.
Power considerations: Authors calculated a target sample size of 360 to provide 80% power to detect
a 6-point difference in the FACIT-Pal and 2.5-point difference in the CES-D based on a t-test comparing
the 3-month group differences with a two-sided value of.05 using ENABLE II standard deviations of 17
for the FACIT-Pal and seven for the CES-D. However at the planned study completion date, the final en-
rollment was 207 because of slower than anticipated accrual. On the basis of the final sample size, the
3-month detectable differences were: FACIT-Pal, 7.7 points; CES-D, 3.2 points.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "random assignment was on a one-to-one basis
using computer-generated randomly permuted treatment assignments with
randomly assigned block sizes of two and four stratified by disease (six cate-
gories) and enrollment site (four clinics)".
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Low risk Participants and personnel were not blinded.
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Low risk of bias due to blinding of data collectors
Blinding of outcome as-
sessment (detection bias),
objective outcomes






Low risk N = 59 (56.7%) completers in intervention group vs N = 54 (52.4%) completers
in control group. In the intervention group, 12 (11.5%) patients did not receive
the intervention (did not start intervention (N = 9) and died before start (N =
3)) and 33 (31.7%) discontinued intervention for various reasons such as not
interested (N = 14), passive withdrawal (N = 6), overwhelmed (N = 6), moved
care (N = 3), too ill (N = 2), too well (N = 1) and no reason (N = 1). In the control
group, 22 (21.4%) patients did not receive allocated intervention (did not start
intervention (N = 8) and died before start (N = 14)) and 27 (26.2%) discontinued
intervention for various reasons such as not interested (N = 11), passive with-
drawal (N = 4), overwhelmed (N = 3), moved care (N = 3), too ill (N = 1), too well
(N = 5) and no reason (N = 0). Missing data were included in analysis. Maximum
likelihood estimates used
Comment: low risk of bias
Selective reporting (re-
porting bias)
Low risk All outcomes were reported.
Other bias Low risk Quote from main publication: "the early group had significantly less educa-
tion, higher weekly alcoholic beverage use, and higher clinical trial enroll-
ment... All intention to treat analyses were adjusted for baseline values".
Comment: adjustment was probably done.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-
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Who led PC intervention: Multidisciplinary team
Core team: Nurse/social worker. A collaborative care team comprising the nurse and social worker, a
primary care clinician, palliative care physician, and cardiologist provided case review and supervision.
Participants Country and regions: USA, Colorado
Recruitment: Patients with heart failure were identified through the study sites’ electronic health
records.
Inclusion criteria: Patients with chronic heart failure and reduced health status who were likely to
need the additional resources provided by the intervention. The diagnosis was defined using previous-
ly validated administrative data supplemented with data on required diuretic dosing (furosemide ≥
80 mg/d or equivalent), leK ventricular ejection fraction of 40% or less, brain-type natriuretic peptide
(BNP) levels of 250 pg/mL or more, or N-terminal prohormone level of BNP of 1000 pg/mL or more. Dur-
ing the study screening process, patients who reported reduced heart failure–specific health status (a
Kansas City Cardiomyopathy Questionnaire Short Version [KCCQ] score of ≤ 70) or reported at least 1 of
the study’s target symptoms (fatigue, shortness of breath, pain, and/or depression) were targeted for
enrollment. Early in the study, the cut-o,s for diuretic dosing and BNP were relaxed, and both reduced
heart failure–specific health status and 1 of the target symptoms were required to increase the eligible
study population while still enrolling symptomatic patients.
Exclusion criteria: Patients with active substance abuse or serious mental illness were excluded.
Number of patients: N = 314 (157 intervention and 157 control)
Diseases: Symptomatic heart failure
Patient characteristics: Mean age in years (SD): 64.5 (10.9) years in intervention group, 66.5 (11.8)
years in control group; 18.5% female in intervention group, 24.2% female in control group
Deaths at end of study (N (%)): N = 8. 3 (1.9%) in intervention and 5 (3.2%) in control
Withdrawals/other dropouts (N (%)): N = 32. 16 (10.2%) in intervention and 16 (10.2%) in control
Interventions Name: Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) intervention vs usual care
Type: The nurse and social worker who provided the CASA intervention were not specialist palliative
care clinicians. However, they were trained to provide the intervention and they both worked with the
patients’ primary care clinicians and were supervised by a study primary care clinician, cardiologist,
and palliative care physician.
Service base: The CASA trial was a National Institutes of Health–funded trial in 3 health systems (urban
safety net, Veterans Affairs, and academically affiliated health systems).
Team: Core sta, included a nurse and social worker. However, a collaborative care team comprising
the nurse and social worker, a primary care clinician, palliative care physician, and cardiologist provid-
ed case review and supervision.
Intervention condition: The CASA intervention included 3 components. A registered nurse addressed
symptoms, a social worker provided structured psychosocial care, and a team (including the nurse and
social worker, a primary care clinician, palliative care physician, and cardiologist) reviewed patients’
care and provided orders for tests and medications to patients’ clinicians for review and signature. The
patient and nurse selected an initial symptom on which to focus. The nurse assessed and managed
symptoms using structured guidelines developed for the study, including disease-specific, behavioural,
and palliative approaches. The nurse was trained in helping communication, motivational interview-
ing, and the symptom guidelines. Six nurse intervention follow-up assessments by telephone (1-2 per
month) were planned using a structured symptom rating scale. The nurse applied motivational inter-
viewing to promote changes in health behaviours. The nurse had access to a PhD-level clinical nurse
specialist to discuss difficult issues regarding symptom management. The social worker provided a
structured telephone based psychosocial intervention to help patients with heart failure adjust to liv-
ing with illness and address depression symptoms, if present. The psychosocial intervention was op-
erationalised in a treatment manual and was based on interpersonal and behavioural activation psy-
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chotherapies. The following topics were included in approximately 6 counselling sessions: grief and
loss, change in role, behavioural activation, and pacing. The social worker also provided support to
patients’ informal unpaid caregivers as needed. The social worker received psychosocial intervention
training and follow-up supervision. The nurse and the social worker discussed the patients in weekly
collaborative care team meetings with a team that included a palliative care physician.
Duration: 6 months
Control condition: Patients in the usual care group received care at the discretion of their clinicians,
which could include care from cardiology, palliative care and mental health. Patients were also given
an information sheet that outlined self-care for heart failure. Patients who had significant depressive
symptoms were notified of this, and their clinicians were also contacted. Referring clinicians then as-
sumed responsibility for depression care.
Outcomes Primary outcome
Patient-reported heart-failure specific health status assessed using the Kansas City Cardiomyopathy
Questionnaire (KCCQ)
Secondary outcomes
Depression measured by the Patient Health Questionnaire (PHQ-9)
Anxiety measured by the Generalized Anxiety Disorder (GAD-7) Questionnaire
Overall symptom distress measured by the General Symptom Distress Scale (GSDS)
Pain measured by the PEG (3 items derived from the Brief Pain Inventory)
Fatigue measured by the Patient Reported Outcomes Measurement Information System (PROMIS)
Short Form
Shortness of breath measured by the Memorial Symptom Assessment Scale
unpaid caregiver depression assessed using the Patient Health Questionnaire-8 (PHQ-8)




Measures were completed in person, by mail, or by telephone at baseline and at 3, 6, and 12 months by
personnel who did not provide the intervention and were unaware of treatment arm assignment and
intervention activities.
Resource use/costs Number of hospitalisations
Use of other services
Time horizon: enrollment to one year
Notes Funding source: This work was supported by grant R01-013422 from the National Institute of Nursing
Research, National Institutes of Health; grant UL1 TR001082 from the National Institutes of Health/Na-
tional Center for Advancing Translational Sciences Colorado Clinical and Translational Science Award;
and grant CDA 08-022 from the Veterans Affairs Health Services Research and Development Service.
Declarations of interest among primary researchers: None reported
Power considerations: The authors planned a sample size of 312 to detect a change in KCCQ score of 6
to 8 points. They anticipated a 25% dropout rate owing to death etc. As the SD for the KCCQ has ranged
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from 15 to 20 in prior studies, with this sample size, they had 86% power to detect a change of 6 points
(assuming an SD of 15) or 8 points (assuming an SD of 20) (2-sided test, α = .05).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "the randomisation sequence was comput-
er-generated using random block sizes and stratification by study site and was




Low risk Quote from main publication: "the randomisation sequence was comput-
er-generated using random block sizes and stratification by study site and was











Low risk Quote from main publication: "because of the nature of the intervention, par-
ticipants could not be blinded".
Comment: participants were not blinded but this was unlikely to lead to bias in
objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Low risk of bias due to blinding of outcome assessors
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "measures were completed in person, by mail,
or by telephone at baseline and at 3, 6, and 12 months by personnel who did
not provide the intervention and were unaware of treatment arm assignment
and intervention activities".
Comment: participants were not blinded while personnel who sometimes as-
sisted in completing measures were blinded. Given that objective outcomes





Low risk N = 124 (79%) completers in intervention group vs N = 124 (79%) completers
in control group. In the intervention group, 3 (1.9%) patients died, 6 withdrew
and 10 were lost to follow-up. The remaining 14 were not accounted for. In
the control group, 5 (3.2%) patients died, 2 withdrew and 14 were lost to fol-
low-up. The remaining 12 were not accounted for. Missing data were included
in analysis. Maximum likelihood estimates used.
Comment: low risk of bias
Selective reporting (re-
porting bias)
High risk Some outcomes in the protocol were not reported in the study such as the
FACIT-Sp for spiritual well-being, QUAL-E and EQ-5D-5L for quality of life. In ad-
dition, unpaid caregiver outcomes were not reported.
Other bias Unclear risk Quote from main publication: "baseline characteristics were balanced be-
tween groups, except those in the intervention group were significantly more
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likely to have a biventricular pacemaker and to be less short of breath com-
pared with those in the control group".
Comment: it was unclear if baseline differences were controlled for. An unclear
risk of bias was rated.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Multidisciplinary team (intervention was organised in close co-operation
with out-of-hours palliative advanced home care who were fully informed of the identities of the pa-
tients and knew how to respond to calls).
Core team: Physician/nurse. Clinical team comprising specialists in palliative and heart failure care, i.e.
specialised nurses, palliative care nurses, cardiologist, palliative care physician, physiotherapist, and
occupational therapist held regular meetings about the patient twice a month. The team was responsi-
ble for total care.
Participants Country and regions: Sweden
Recruitment: January 2011 to October 2012. Patients with a confirmed diagnosis of CHF and cared for
at the Department of Medicine-Geriatrics or primary healthcare centres and who met the criteria of the
European Society of Cardiology were asked to participate in the study.
Inclusion criteria: CHF with NYHA functional classes III−IV symptoms and at least one of the following:
one hospitalised episode of worsening heart failure that resolved with the injection/infusion of diuret-
ics or the addition of other heart failure treatment in the preceding 6 months and regarded as being
‘optimally treated’ according to the responsible physician; need for frequent or continual IV support;
chronically poor QoL based on a visual analogue scale (VAS) score < 50; signs of cardiac cachexia, de-
fined as an involuntary non-oedematous weight loss ≥ 6% of total body weight within the preceding 6–
12 months; and life expectancy of < 1 year.
Exclusion criteria: Patients who did not want to participate in the study; had severe communication
problems; had severe dementia or other serious diseases in which heart failure was of secondary im-
portance; with other life-threatening illnesses as their primary diagnosis and an expected short survival
time; whose primary care centre responsible for their care was located > 30 km from the hospital; and
who were already participating in another clinical trial.
Number of patients: N = 72 (36 intervention and 36 control)
Diseases: Chronic heart failure (NYHA class III - IV)
Patient characteristics: mean age in years (SD): 81.9 (7.2) years in intervention group, 76.6 (10.2) years
in control group; 27.8% female in intervention group, 30.6% female in control group
Deaths at end of study (N (%)): N = 12. 8 (22.2%) in intervention and 4 (11.1%) in control
Withdrawals/other dropouts (N (%)): Not stated
Interventions Name: Palliative advanced home caRE and heart FailurE caRe (PREFER) vs usual care
Type: Specialist palliative care. Patients in the intervention group were offered a multidisciplinary ap-
proach involving collaboration between specialists in palliative and heart failure care, i.e. specialised
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nurses, palliative care nurses, cardiologist, palliative care physician, physiotherapist, and occupational
therapist.
Service base: County hospital located in Northern Sweden
Team: Clinical team comprised specialists in palliative and heart failure care, i.e. specialised nurses,
palliative care nurses, cardiologist, palliative care physician, physiotherapist, and occupational thera-
pist.
Intervention condition: Patients in the intervention group were offered a multidisciplinary approach
involving collaboration between specialists in palliative and heart failure care. The patients were also
offered structured, person-centred care (PCC) at home. The patient’s narrative was recorded in a struc-
tured manner and a mutual care plan was developed that included the goals and strategies for imple-
mentation and follow-up. The intervention was carried out as follows: (i) after identifying a patient who
fulfilled the inclusion criteria, a responsible physician and nurse were identified for each patient; (ii) the
patient received a thorough medical examination by the physician with identification of comorbidities
and assessment of physiological, social, and spiritual needs; (iii) meeting with nurses who used a mod-
el for person-centred palliative care comprising self-image, self-determination, social relationships,
symptom control, synthesis, and surrender, and continued through; (iv) regular meetings about the pa-
tients’ conditions within the team twice a month; and (v) brief discussions took place between the team
members at the unit and information was shared by the documentation in medical records and phone
calls. The team was responsible for the total care, i.e. including comorbidities.
Duration: 6 months
Control condition: Usual care was provided mainly by general practitioners or doctors and/or the
nurse-led heart failure clinic at the Medicine-Geriatrics department.
Outcomes Outcomes
Symptom burden assessed using the ESAS





Assessment points: After randomisation, prospective assessments were made at baseline and 1, 3,
and 6 months of follow-up using the Edmonton Symptom Assessment Scale (ESAS), Euro Qol (EQ-5D),
and Kansas City Cardiomyopathy Questionnaire (KCCQ).
Resource use/costs Resource utilisation: number of hospitalisations, number of days spent in hospital, number of physi-
cian and nurse visits, phone calls and/or drug prescriptions at the outpatient clinics of the hospitals
and at the primary healthcare centres.
Time horizon: Study enrollment to study completion at 6 months
Data sources: The data were collected over a total of 6 months between 2011 and 2013. Authors calcu-
lated cost based on the time spent for each patient. When services were given as part of our interven-
tion, minutes were documented and used to calculate costs for each sta, category. Healthcare services
offered as part of the standard care (both primary healthcare and hospital care) were calculated simi-
larly but based on assumptions made on timing. These assumptions were based on recommendations
from the county council and according to practice in the area. Costs were calculated by multiplying the
allocated time for given services by the average salaries.
Analytical perspective: Provider perspective
Notes Funding source: This work was supported by the Swedish Association of Local Authorities and Re-
gions, the Swedish Heart and Lung Association, and the Ronnbaret Foundation Skelleftea Municipality.
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Declarations of interest among primary researchers: None declared
Power considerations: The PREFER model was created to improve the mean symptom burden by at
least 25% compared with the control group. With a power of 80%, significance level of P < 0.05, and an
estimated dropout rate of 15%, 31 patients were needed in each arm (total 62 patients). Due to patients
dropping out, mainly due to deaths (12 patients), the number of participants was increased to 36 in
each arm.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "patients were randomized with envelopes in














Low risk Quote from main publication: "this was a prospective randomised study with
an open non-blinded design".
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes such as mortality.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk High risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "this was a prospective randomised study with
an open non-blinded design".
Comment: lack of blinding of outcome assessment was unlikely to lead to bias




High risk N = 28 (77.8%) completers in intervention group vs N = 32 (88.9%) completers
in control group. In the intervention group, 8 (22.2%) patients died while 4
(11.1%) deaths were recorded in the control group during the study. Missing
data appeared to have been excluded from the analysis.
Comment: high risk of bias
Selective reporting (re-
porting bias)
High risk Although primary outcomes and secondary outcomes were specified on the
clinical trials registry NCT01304381, it was not specified in the published pa-
per. Quality of life assessed using the Kansas City Cardiomyopathy Question-
naire (KCCQ), functional class and mortality were outcomes in the published
paper but not mentioned on the clinical trial registry.
Comment: high risk of bias
Other bias Low risk Quote from main publication: "the two groups were balanced with respect to
baseline characteristics except for mean age".
Comment: given that the authors controlled for age, a decision was made not
to rate down for imbalance bias. Rather, a low risk of bias was rated.
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Who led PC intervention: Multidisciplinary team (physicians conduct home visits and are available
along with nursing services on a 24-hour on-call basis)
Core team: Patient/family/physician/nurse/social worker. Additional team members, including spiri-
tual counsellor or chaplain, bereavement co-ordinator, home health aide, pharmacist, dietitian, volun-
teer, physical therapist, occupational therapist, and speech therapist, join the core care team in service
provision as needed.
Participants Country and regions: Hawaii and Colorado, USA.
Recruitment: Discharge planners, primary care physicians, and other specialty physicians referred
potentially eligible terminally ill patients to the study. For those meeting the initial criteria, the in-
take clerk contacted the primary care physician to determine the prognosis. Once eligibility was deter-
mined, the intake clerk gained informed consent from the patient to participate in the study.
Inclusion criteria: Patients with a primary diagnosis of CHF, COPD, or cancer and a life expectancy of
12 months or less, have visited the emergency department or hospital at least once within the previous
year; and scored 70% or less on the Palliative Performance Scale.
Exclusion criteria: Not explicitly stated
Number of patients: N = 297 (145 intervention and 152 control)
Diseases: Cancers (N = 138, 46%), COPD (N = 62, 21%) and CHF (N = 97, 33%)
Patient characteristics:.Mean age in years (SD): 73.9 (11.1) years in intervention group, 73.7 (13) years
in control group; 45% female in intervention group, 53% female in control group
Deaths at end of study (N (%)): N = 8: 8 (5.5%) in intervention and none in control
Withdrawals/other dropouts (N (%)): N = 5: 2 (1.4%) in intervention and 3 (2%) in control
Interventions Name: In-home palliative care plus usual care vs usual care
Type: Specialist palliative care. Includes a palliative care physician.
Service base: Two group-model, closed-panel, non-profit health maintenance organisations (HMOs)
providing integrated healthcare services in Hawaii and Colorado
Team: The IHPC programme uses an interdisciplinary team approach, with the core team consisting
of the patient and family plus a physician, nurse, and social worker with expertise in symptom man-
agement and biopsychosocial intervention. Additional team members, including spiritual counsellor
or chaplain, bereavement co-ordinator, home health aide, pharmacist, dietitian, volunteer, physical
therapist, occupational therapist, and speech therapist, join the core care team in service provision, as
needed.
Intervention condition: The IHPC programme is an interdisciplinary home-based healthcare pro-
gramme. Modelled after hospice programs in that it offers pain management and other comfort care in
the patient’s home, the IHPC programme also features important modifications. Upon admission, the
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team assesses the physical, medical, psychosocial, and spiritual needs of the patient and family. All pa-
tients received initial assessments from physicians, nurses, and social workers. Additional team mem-
bers join the core care team in service provision, as needed. The team convenes to develop a care plan
in accordance with the wishes of the patient and the family. Frequency of subsequent medical visits is
based on the individual needs of the patient. Physicians conduct home visits and are available along
with nursing services on a 24-hour on-call basis. Advanced care planning is provided that involves pa-
tients and their families in making informed decisions and choices about care goals and end-of-life
care.
Duration: Participants enrolled in the IHPC arm received palliative care until death or transfer to a hos-
pice programme.
Control condition: Usual care consisted of standard care to meet the needs of the patients and fol-
lowed Medicare guidelines for home healthcare criteria. These services included home health services,
acute care services, primary care services, and hospice care. Additionally, they received ongoing home
care when they met the Medicare-certified criteria for an acute condition.
Outcomes Outcomes





Assessment points: Interviews were conducted via telephone by undergraduate and graduate-level
research assistants blinded to group assignment within 48 hours of study enrollment and every 30, 60,
90, and 120 days to gather demographic information and satisfaction with services.
Resource use/costs Resource use: emergency department visits, hospitalisation, enrollment and days in hospice
Time horizon: Medical service use data were collected from the time the patient enrolled in the study
until the time of death or the end of the study period.
Data sources: Resource use data for each participant were collected retrospectively from the non-prof-
it HMO mainframe database, from the time the patient enrolled in the study until the time of death or
end of study (2002 to 2004). Costs were calculated using actual costs for contracted medical services
(services provided by non-HMO contracted facilities in Colorado) and proxy cost estimates for all ser-
vices provided within the HMO. Costs were in 2002 USD.
Analytical perspective: Not clear
Notes Funding source: This study was funded by the Kaiser Permanente Garfield Memorial Fund.
Declarations of interest among primary researchers: Richard Brumley, Nora Morgenstern, Sherry
Saito, and Rae Seitz are employed as physician partners in the Permanente Medical Group of South-
ern California, Colorado, and Hawaii, respectively. Susan Enguidanos is employed by Partners in Care
Foundation and conducted this work through a subcontract with the Garfield Memorial Fund. Paula
Jamison and Jorge Gonzalez are employed by Partners in Care Foundation and serve a consultative
role through this employment to Kaiser Permanente. Kristine Hillary is employed by Kaiser Perma-
nente. Janet McIlwaine was employed by Kaiser Permanente.
Power considerations: Based on methods established previously, it was determined that, using a sig-
nificance criterion of.05, a sample size of 300 would be necessary for a statistical power of 0.80, using
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "group assignment was determined by blocked
randomisation using a computer-generated random number chart, stratified














Low risk Participants and personnel were not blinded
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Low risk of bias because outcome assessors were blinded
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "undergraduate- and graduate-level research
assistants, blinded to group assignments, were recruited and trained to con-
duct telephone interviews with the patient or, if the patient was unable to par-
ticipate, the primary unpaid caregiver".




Low risk N = 145 (93.5%) completers in intervention group vs N = 152 (98.1%) com-
pleters in control group. Only completers were included in analysis. In the in-
tervention group, 10 (6.9%) people were lost to follow-up [8 (5.5%) deaths and
2 (1.4%) people withdrew from the study]. In the control group, 3 (2%) people
withdrew.
Comment: low risk because attrition was less than 10%
Selective reporting (re-
porting bias)
Unclear risk Unclear as protocol not available
Other bias Unclear risk Quote from main publication: "there were no significant differences between
study groups in baseline measures other than satisfaction. Satisfaction with
services was measured at baseline after study assignment. Those randomised
to intervention demonstrated significantly higher satisfaction with services at
baseline than those assigned to usual care (P = 0.03)".
Comment: given that the authors did not state that they controlled for differ-
ence in satisfaction levels at baseline, an unclear risk of bias rating was given.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-
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Who led PC intervention: Multidisciplinary team
Core team: Palliative care physician/nurse practitioner. Could include social workers, chaplains, or
other disciplines, as needed.
Participants Country and regions: USA, Northeastern and Southeastern United States
Recruitment: October 2010 to November 2014. Patients were identified by screening of ICU records
and discussion with ICU clinicians.
Inclusion criteria: Patients > 21 years treated in medical ICUs were eligible if they required at least
7 days of mechanical ventilation uninterrupted for 96 hours or longer and were not expected to be
weaned or to die within 72 hours. For the first year of the study, patients were eligible if they required at
least 10 days of mechanical ventilation. Family members were eligible if they had the responsibility of
healthcare decision-making for the patient.
Exclusion criteria: Patients who were mechanically ventilated at an outside hospital for > 7 days or
who had chronic neuromuscular disease, trauma, or burns. Patients were excluded if a surrogate de-
cision-maker was not available or lacked English proficiency, the primary physician refused to grant
permission to investigators to approach the patient or family, or the investigators were the attending
physicians. Patients previously admitted to the study ICU or who had a palliative care consultation pri-
or to screening
Number of family surrogate decision-makers: N = 365 (184 intervention and 181 control)
Number of patients: N = 256 (130 intervention and 126 control)
Diseases: Disease not specified but all patients were adults treated in medical ICUs
Patient characteristics: Mean age in years (95% CI): 58 (55.2 - 60.8) years in intervention group, 57 (54 -
59.7) years in control group; 51% female in intervention group, 52% female in control group
Family surrogate decision-makers characteristics: Mean age in years (95% CI): 51 (48.8 - 52.8) years
in intervention group, 51 (48.6 - 52.7) years in control group; 70% female in intervention group, 72% fe-
male in control group
Deaths among patients at end of study (N (%)): Total N = 8: 8 (6.2%) in intervention and none in con-
trol
Withdrawals/other dropouts among family surrogate decision-makers (N (%)): Total N = 53: 21
(11.4%) intervention and 32 (17.7%) control
Interventions Name: Structured family meetings led by palliative care specialists and provision of an information-
al brochure (intervention) vs provision of an informational brochure and routine family meetings con-
ducted by ICU teams (control)
Type: Specialist palliative care. Included a palliative care physician.
Service base: 4 medical intensive care units
Team: Comprised of a palliative care physician and nurse practitioner and could include social work-
ers, chaplains, or other disciplines, as needed.
Intervention condition: A validated and widely available brochure describing chronic critical illness
was provided to the family surrogate decision-makers. Research co-ordinators then scheduled a min-
imum of 2 meetings with the support and information team. The protocol provided for scheduling of
additional meetings at the request of the family, ICU physician, or support and information team clini-
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cians. Support and information team clinicians conducted pre-meetings with ICU physicians to review
each patient’s condition, prognosis, and previous discussions of goals of care. The support and infor-
mation team clinicians also reviewed estimates of 1-year prognosis based on the ProVent 14 score. The
support and information team meetings were structured according to a set of objectives and recom-
mended topics. Support and information team clinicians were trained by reviewing the main objectives
of the meeting templates that appeared in the original protocol; however, they were allowed some
flexibility for adapting the content to the particular needs of each family. After the meetings with family
members, the support and information team provided feedback to the ICU clinicians not in attendance.
Duration: The first meeting with the support and information team was conducted after 7 days of me-
chanical ventilation at the onset of chronic critical illness and when a tracheostomy is often consid-
ered. The second meeting was conducted after further treatment was provided for a period approxi-
mating the mean duration of mechanical ventilation after tracheostomy for patients who achieved ven-
tilator liberation.
Control condition: The ICU clinicians managed all formal and informal family meetings per their usual
practice without input from the palliative care specialists. Family surrogate decision-makers in the con-
trol group received the same informational brochure as the intervention group. Clinicians were able to
formally consult palliative care clinicians at their discretion, and this was encouraged if they needed as-
sistance with symptom management or for transfer to hospice.
Outcomes Primary outcome:
Anxiety and depression of surrogate assessed using the Hospital Anxiety and Depression Scale (HADS)
Secondary outcomes:
Post-traumatic Stress Disorder (PTSD) of the surrogate assessed using the Impact of Event Scale-Re-
vised (IES-R)
Discussion of patient preferences
Family satisfaction with care assessed using the 24-item Family Satisfaction in the Intensive Care Unit
survey
Hospital length of stay for patients
90-day survival of patients
Assessment points: Research co-ordinators interviewed family surrogate decision-makers prior to pa-
tient randomisation to collect demographics and prehospitalisation activities of daily living and instru-
mental activities of daily living. Research co-ordinators blinded to group assignment interviewed surro-
gate decision-makers immediately after the second support and information team meeting for the in-
tervention group and 10 days after randomisation for the control group, unless the patient had died. All
surrogate decision-makers were interviewed again by telephone for follow-up beginning 90 days after
randomisation.
Resource use/costs This relates to resource use by patients
Hospital length of stay
Number of ICU days
Ventilator days
Time horizon: period of hospitalisation
Notes Funding source: This project was funded by grant R01-NR012413 from the National Institute of Nursing
Research.
Declarations of interest among primary researchers: One of the authors reported having a consult-
ing agreement with the Research Triangle Institute related to quality of care in long-term acute care
hospitals. No other disclosures were reported.
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Power considerations: Based on a previous study, it was determined that 150 family members in the
intervention group and the control group would provide a sufficient sample to detect a minimal clini-
cally important difference of 1.5 for mean total HADS score with 90% power and a type I error of 5%.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "after enrollment of patients and family mem-
bers, patients were randomized to the intervention or the control group using
a computer-generated, web-based randomization system with blinding of al-
location. The randomization was stratified by study site in block sizes varying




Low risk Quote from main publication: "after enrollment of patients and family mem-
bers, patients were randomized to the intervention or the control group using












Low risk Participants were not blinded.
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Study did not state whether outcome assessors were blinded to group alloca-
tion when assessing secondary outcomes.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "observers were blinded to group allocation
for the measurement of the primary outcomes... The research co-ordinator at
each study site who had knowledge of group assignments was not involved in
collection of the primary outcomes through family interviews. A research as-
sistant at each study site who was blinded to group assignments conducted
these interviews".





High risk N = 163 (88.6%) completers (surrogates) in intervention group vs N = 149
(82.3%) completers (surrogates) in control group. In the intervention group, 21
(11.4%) patients refused to participate and 6 (3.3%) were unavailable. In con-
trol group, 15 (8.3%) refused to participate and 17 (9.4%) were unavailable.
Missing data were excluded from the analysis.
Comment: high risk of bias because the study used 'completer' analysis and >
10% of surrogates did not complete the study
Selective reporting (re-
porting bias)
High risk One of the secondary outcomes specified in the protocol (e.g. physician-sur-
rogate discordance score) was not reported. Furthermore, the original proto-
col specified 3 co-primary endpoints for anxiety and depression (HADS scores),
PTSD (IES-R scores), and discussion of patient preferences, it was decided be-
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fore enrollment that total HADS score should be the primary outcome, which
was consistent with the power analysis.
Comment: high risk of bias
Other bias Low risk Study appeared to be free of other biases.






Methods Design: RCT (patient, family and sta,)
Single-centre, unblinded, RCT
Who led PC intervention: Multidisciplinary team
Core team: Physician/registrar/resident/clinical nurse consultant
Participants Country and regions: Australia, regions were not stated.
Recruitment: May 2006 and October 2008 (29 months): patients with a terminal or pre-terminal condi-
tion were eligible if the treating intensivist indicated to the patient or the patient’s surrogate that they
believed treatment should not be escalated or should be withdrawn. Patients were then enrolled in the
study if they met the selection criteria.
Inclusion criteria: Aged 18 years or older; pre-terminal or terminal condition, and the duty intensivist
and parent treating teams believed that continuing current treatment or escalating treatment was un-
likely to result in a significant improvement in the patient’s medical condition; duty intensivist deemed
it appropriate that a not-for-resuscitation (NFR) order be written for the patient; patient was deemed
unlikely to survive more than 1 week if treatment was either withdrawn or not escalated; patient was
expected to stay in the ICU for at least another 48 hours; patient or surrogate was willing to consent to
the completion of two questionnaires during the end-of-life process; no reason to believe that the pa-
tient or family would object to a palliative care team being involved in the patient’s end-of-life care.
Exclusion criteria: Patient unable to give consent or participate in the decision-making process and
had no readily available legal surrogate decision-maker to give consent, or was under control of the
Guardianship Board; palliative care team not available to see the patient within the next 24 hours; pa-
tient unlikely to survive until review by the palliative care team; patient, surrogate or treating medical
teams had already specifically requested palliative care involvement in end-of-life care; no indepen-
dent intensivist was available to approach the patient or family for consent
Number of patients: N = 20 (10 intervention and 10 control)
Diseases: Actual diseases were not specified. However, admission codes were stated. The admission
code for those not admitted from the operating theatre included cardiovascular (N = 3), gastroenterolo-
gy (N = 1), neurology (N = 1), respiratory (N = 6), sepsis (N = 4), trauma (N = 2), other (N = 1). Two patients
were admitted from the operating theatre.
Patient characteristics: Median age in years (IQR): 83 (14) years in intervention group, 74 (20) years in
control group; 50% female in intervention group, 70% female in control group
Deaths at end of study (N (%)): Total N = 16: 9 (90%) intervention and 7(70%) control; differences be-
tween intervention and control not statistically significant
Number of families: N = 9 (5 intervention and 4 control)
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Family characteristics: Not provided
Number of sta: 18 teams of nurses (9 intervention and 9 control): 17 team of intensivists (8 interven-
tion and 9 control)
Sta characteristics: Not provided
Withdrawals/other drop-outs: No patient was lost to follow-up. However, for one patient, neither
questionnaire was given to family or sta, as the patient died suddenly soon after the enrollment dis-
cussion. For another patient, the authors decided not to administer the second questionnaire to family
or sta, as the patient died 24 hours after enrollment. One patient was discharged alive to the ward, and
the authors decided not to administer the second questionnaire to the same intensivist.
Interventions Name: Palliative care consultation in addition to usual ICU end-of-life care vs usual ICU care
Type: Training in palliative care unclear
Service base: 14-bed general ICU in an urban, tertiary hospital
Team: Comprised a physician, registrar, resident and clinical nurse consultant, and undertook ward
rounds daily.
Intervention condition: The intervention was a consultation and subsequent management by a pallia-
tive care team. The first consultation occurred within 24 hours of randomisation. The intervention was
provided in addition to usual ICU care commensurate with the patient’s medical condition.
Duration: From enrollment until after the patient had died or been discharged from the ICU
Control condition: The control group received usual ICU care but no palliative care consultation.
Outcomes Primary outcomes:
ICU and hospital length of stay
Satisfaction with quality of care of families, intensivists, and bedside nursing sta,
Secondary outcomes:
ICU and hospital mortality
Number of medical teams caring or consulting for the patient
Individual domain scores of the satisfaction questionnaire
Assessment points: Questionnaires were administered to patients’ families, nursing sta, and inten-
sivists immediately after randomisation and again after the patient had died or been discharged from
the ICU.
Resource use/costs ICU and hospital length of stay
Time horizon: From enrollment until death for hospital length of stay or enrollment to discharge from
the ICU for ICU length of stay
Notes Funding source: Department of Intensive Care and the Department of Palliative Care, Concord Repatri-
ation General Hospital
Declarations of interest among primary researchers: Apart from funding, no further study author
disclosure statements were made.
Power considerations: No power calculation reported
Risk of bias
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "patients were randomly allocated to an inter-
vention or control group. Allocations were computer-generated by an inde-





Low risk Quote from main publication: "allocations were computer-generated by an in-
dependent statistician using the biased coin technique, and stored sequential-











Low risk Quote from main publication: "the study was a single-centre, unblinded, ran-
domised controlled feasibility trial".
Comment: there was no blinding but this was unlikely to lead to bias in objec-
tive outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Comment: no blinding
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "the study was a single-centre, unblinded, ran-
domised controlled feasibility trial".





High risk Quote from publication: "for one patient, neither questionnaire was given to
family or sta, as the patient died suddenly soon after the enrolment discus-
sion. For another patient, the authors decided not to administer the second
questionnaire to family or sta, as the patient died 24 hours after enrolment...
One patient was discharged alive to the ward 24 hours after the enrolment dis-
cussion, and the authors also decided not to administer the second question-
naire to the same intensivist". Analysis was intention-to-treat except for data
derived from questionnaires.




Low risk The study protocol was available and all of the study’s prespecified (primary
and secondary) outcomes that were of interest in the review have been report-
ed in the prespecified way.
Other bias Unclear risk The authors stated that "patients allocated to standard ICU end-of-life care
were younger, were more likely to be female, and had higher APACHE II scores
than those allocated to receive a consultation with the palliative care team".
However, it was unclear whether these differences were statistically signifi-
cant. The authors did not state whether they controlled for these differences.
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Methods Design: Fast-track RCT
Who led PC intervention: Multidisciplinary team
Core team: A part-time consultant in palliative medicine with a special interest in neurological condi-
tions, a part-time clinical nurse specialist and a full time administrator
Participants Country and regions: UK, Southeast London
Recruitment: June 2004 and July 2005. A consultant in palliative medicine not part of the service ini-
tially screened all referrals. Patients were then sent a letter giving information about the trial and invit-
ing them to participate. The interviewer telephoned patients several days after receipt of the letter,
and arranged to meet them to explain more about the study, agree consent, ask if the nearest car-
er/family member could be approached, and complete the baseline interview.
Inclusion criteria: Patients identified by referring clinicians as potentially benefiting from a specialist
palliative care assessment. Referrers were advised to use a score of > 8 on the Expanded Disability Sta-
tus Scale (EDSS) as a benchmark but were encouraged to refer on the basis of need, rather than disabil-
ity.
Exclusion criteria: There were no specific exclusion criteria for the study.
Number of patients: N = 52 (26 intervention and 26 control)
Diseases: Multiple sclerosis (MS)
Patient characteristics: Mean age in years: 53 years in intervention group, 53 years in control group;
65.4% female in intervention group, 73.1% female in control group
Deaths at end of study (N (%)): Total N = 4: 1 (3.8%) intervention and 3 (11.5%) control
Withdrawals/other dropouts: Total N = 2: none in intervention and 2 (7.7%)
Number of unpaid caregivers: Numbers were unclear. Different numbers reported under unpaid care-
giver outcomes
Family characteristics: Not provided
Interventions Name: Multiprofessional palliative care team assessment and follow-up in addition to usual care vs
usual care
Type: Specialist palliative care. The service comprised a part-time consultant in palliative medicine
with a special interest in neurological conditions, a part-time clinical nurse specialist and a full time ad-
ministrator
Service base: King's College Hospital
Team: Comprised a part-time consultant in palliative medicine with a special interest in neurological
conditions, a part-time clinical nurse specialist and a full time administrator. The consultant and nurse
specialist for the palliative care service had access to a consultant neurologist. Patients thought to ben-
efit from specialist neurological review could be seen in clinic jointly by the neurology and palliative
care consultants and other relevant healthcare professionals. The MS palliative care service worked
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closely with the existing HSPC team, specifically utilising time from the palliative care psychosocial
worker.
Intervention condition: At the initial assessment by a member of the multiprofessional team, the fol-
lowing information was collected: demographics, ability to communicate, main symptom issues, cur-
rent medication, psychological concerns, social issues (including care package and agencies involved),
carer concerns and any advanced care planning issues. Following this, an action plan was formulated
and communicated to the primary healthcare team and other involved professionals as appropriate.
Follow-up telephone calls or visits were arranged depending on clinical need. The clinical team met
weekly to discuss the case-load and for the palliative care consultant to input into the management of
all the patients. Patients with ongoing specialist palliative care needs were referred onto existing spe-
cialist community palliative care teams in the area where the patient lived. Intervention was offered in
addition to standard best practice services.
Duration: 12 weeks
Control condition: People affected by MS received a variety of services, including nurse services (in-
cluding nurses specialising in MS), physiotherapy, neurology and rehabilitation services. In addition,
district nurses, social services and general practitioners provided support in the community. A few pa-
tients received home physiotherapy, occupational therapy and/or attended specialist rehabilitation
services or clinics. Inpatient care, including rehabilitation was available as required, as were other spe-
cialist services, including continence advice, psychiatry and/or psychology. Charities such as the MS
Society provided information on available services and organised support groups.
Outcomes Outcomes:
Patient symptoms and concerns assessed using the Palliative care Outcome Scale (POS) and MS-POS
Quality of life assessed using the physical and psychological subscales of the Multiple Sclerosis Impact
Scale (MSIS)
unpaid caregiver burden assessed using the 12-item Zarit Burden Interview
unpaid caregiver mastery assessed using the modified Lawton positivity questionnaire
Assessment points: Assessments were carried out at baseline (before randomisation), then at 6 weeks,
12 weeks and 24–26 weeks for those in the fast-track group. Usual care patients undertook an addition-
al interview 16–18 weeks post-baseline, after they had received the palliative care service.
Resource use/costs None reported
Notes Funding source: The MS Society
Declarations of interest among primary researchers: None declared
Power considerations: The authors estimated that a sample of 25 patients in each group would en-
able them to detect clinically significant differences of greater than 1.6 on the POS (for individual
items), where items had a standard deviation of less than 2, at P < 0.05, power 80%. Based on the local
patient numbers of people with an EDSS > 8, they estimated that they would identify 3 to 4 patients per
week and be able to recruit and follow-up two of these. Recruitment over a year would therefore give
50–52 patients.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "consenting patients newly referred to the new
service were randomised to receive the palliative care service either immedi-
ately (fast-track, FI) or after a 12-week wait (standard best practice, SI). Ran-
domisation was conducted by independent statistical colleagues using the
minimisation method immediately after baseline interview".
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Low risk Quote from main publication: "consenting patients newly referred to the new
service were randomised to receive the palliative care service either immedi-
ately (fast-track, FI) or after a 12-week wait (standard best practice, SI). Ran-
domisation was conducted by independent statistical colleagues using the






High risk Quote from main publication: "after the baseline interview, details of those pa-
tients randomised to fast track were immediately passed to the palliative care
service. Those patients randomised to standard best practice were notified
and details were kept with the research team until after the third research in-
terview at 12 weeks, when details were passed to the clinical team".
Comment: not done
Blinding of outcome as-
sessment (detection bias),
subjective outcomes




Low risk We rated a low risk of bias because there were 96.1% completers in the inter-
vention group and 80.8% completers in the control group. The authors carried
out the analysis with both imputed and non-imputed data in order to test for
sensitivity; in the results only the non-imputed data were shown as there was
no noticeable difference in the results.
Comment: low risk of bias
Selective reporting (re-
porting bias)
High risk Some prespecified outcomes such as use of health and social services were
not reported.
Other bias Low risk Study appeared to be free of other biases.








Who led PC intervention: Multidisciplinary team
Core team: Palliative care physician/advanced practice nurses
Participants Country and regions: USA, Boston
Recruitment: August 2014 to January 2016. Consecutively eligible patients with planned autologous
or allogeneic haematopoietic stem cell transplantation (HCT) were identified during the weekly trans-
plant team meetings. Research sta, obtained permission from the treating oncologist to approach eli-
gible patients and their unpaid caregivers within 72 hours of their transplant admission (HCT hospitali-
sation).
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Inclusion criteria: Patients aged > 18 years who could speak English or complete questionnaires with
minimal assistance from an interpreter. Enrolled patients were asked to identify a unpaid caregiver
who could be invited to participate in the unpaid caregiver portion of this study. Patients without a un-
paid caregiver were still eligible to participate.
Exclusion criteria: Patients with a history of HCT or those with psychiatric or comorbid disease that
the oncologist believed would interfere with adherence to study procedures were excluded.
Number of patients: N = 160 (81 intervention and 79 control)
Diseases: Adults with haematologic malignancies undergoing autologous/allogeneic HCT
Patient characteristics: Mean age in years (SD): 57.2 (12.7) years in intervention group, 56.9 (14.1)
years in control group; 59.3% female in intervention group, 54.4% female in control group
Deaths at end of study (N (%)): Total N = 3: 3 (3.7%) in intervention and none in control
Withdrawals/other dropouts (N (%)): Total N = 8: 3 (3.7%) intervention and 5 (6.3%) control
Number of unpaid caregivers: N = 94 (49 intervention and 45 control)
unpaid caregivercharacteristics: Mean age in years (SD): 54.4 (14.6) years in intervention group, 54.3
(13.7) years in control group; 66.7% female in intervention group, 73.3% female in control group
Interventions Name: Early palliative care integrated with standard transplant care vs standard transplant care alone
Definition of early PC: Not explicitly defined but palliative care intervention primarily focussed on
managing patients’ physical and psychological symptoms during hospitalisation for HCT.
Type: Specialist palliative care. The three palliative care clinicians (two nurse practitioners and one
board-certified physician) underwent a half-day training focussed on addressing the main topics cov-
ered by the intervention.
Service base: Massachusetts General Hospital
Team: Comprised an inpatient palliative care physician and two advanced practice nurses
Intervention condition: Intervention patients met with the inpatient palliative care physician or ad-
vanced practice nurse within 72 hours of randomisation. The palliative care clinician followed patients
up during their hospitalisation. Patients, unpaid caregivers, and the palliative care clinicians were per-
mitted to initiate additional visits as needed. Participants did not have outpatient palliative care fol-
low-up after discharge. The palliative care intervention primarily focussed on managing patients’ phys-
ical and psychological symptoms during hospitalisation for HCT and did not include advance care plan-
ning, goals-of-care and code status discussions, or end-of-life decision-making. Study investigators cre-
ated an intervention manual that provided guidelines for addressing symptoms and psychological dis-
tress. After each visit, the palliative care clinicians communicated their recommendations in person to
the transplant team and documented their recommendations in the medical record.
Duration: Period of hospitalisation
Control condition: Control patients received standard transplant care with the supportive care mea-
sures instituted by the transplant team. Patients, unpaid caregivers, and transplant clinicians were per-
mitted to request consultation with palliative care clinicians.
Outcomes Primary outcome:
Quality of life assessed using the Functional Assessment of Cancer Therapy – Bone Marrow Transplant
(FACT-BMT)
Secondary outcomes:
Anxiety and depression assessed using the 14-item Hospital Anxiety and Depression Scale (HADS). De-
pression was also assessed using the Patient Health Questionnaire 9 (PHQ-9)
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Fatigue assessed using the 13-item FACT Fatigue subscale
Symptom burden assessed using the Edmonton Symptom Assessment Scale (ESAS)
Post-traumatic Stress Disorder (PTSD) assessed using the 17-item PTSD Checklist–Civilian Version
Distress assessed using the National Comprehensive Cancer Network Distress Thermometer Checklist
Incidence of acute and chronic graK-vs-host disease
Nonrelapse mortality
Overall survival
unpaid caregiver quality of life assessed using the unpaid caregiver Oncology QOL questionnaire
unpaid caregiver's mood (depression and anxiety) assessed using the 14-item Hospital Anxiety and De-
pression Scale (HADS). unpaid caregiver depression was also assessed using the Patient Health Ques-
tionnaire 9 (PHQ-9)
Assessment points: Participants completed study questionnaires prior to randomisation and during
the second week of hospitalisation for HCT (at patients’ blood count nadir; i.e. the period during HCT
hospitalisation when patients experience the lowest blood cell counts and highest toxicity and symp-
tom burden: day 5 after stem cell infusion for autologous and day 8 after stem cell infusion for allogene-
ic HCT, with a 2-day window) and at 3 and 6 months after HCT.
Resource use/costs Number of PC visits
Time horizon: enrollment to discharge from hospital
Notes Funding source: This work was supported by funds from the National Palliative Care Research Founda-
tion and grant K24 CA 181253 from the National Cancer Institute.
Declarations of interest among primary researchers: One of the authors reported receipt of personal
fees for consulting or advisory board membership from Bayer, Millennium, Incyte, Seattle Genetics, and
Insys. No other disclosures were reported.
Power considerations: A sample size of 160 patients (80 patients in each group) was estimated to be
sufficient with 80% power to detect a 6-point change in QoL (FACT-BMT) from baseline to week 2 using
a 2-sample t-test with an α = 0.05 statistical significance level and a rate of attrition of 15%. All reported
P values were 2-sided.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "patients were then randomized to the palliative
care intervention or standard transplant care using a computer-generated 1:1
randomization stratified by type of HCT (autologous, myeloablative allogene-




Unclear risk Quote from main publication: "patients were then randomized to the palliative
care intervention or standard transplant care using a computer-generated 1:1
randomization stratified by type of HCT (autologous, myeloablative allogene-
ic, or reduced intensity allogeneic HCT)."
Comment: allocation concealment not described
Blinding of participants
and personnel (perfor-
High risk Comment: no blinding
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Low risk Quote from main publication: "non-blinded randomized clinical trial among
160 adults with haematologic malignancies undergoing autologous/allogeneic
HCT and their unpaid caregivers".
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk High risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "non-blinded randomized clinical trial among
160 adults with hematologic malignancies undergoing autologous/allogeneic
HCT and their unpaid caregivers".





Low risk N = 75 (92.6%) completers in intervention group vs N = 74 (93.7%) completers
in control group. Multiple imputation was used for missing observations. 80
(98.8%) patients in intervention group and 77 (97.5%) in control group were
included in the primary analysis. Furthermore, because of a clerical error, the
first 38 study patients did not complete the nausea item, which was therefore
omitted from the composite ESAS score analyses (range, 0-90).
Selective reporting (re-
porting bias)
High risk All the study's prespecified outcomes have not been reported and an addition-
al outcome ( unpaid caregiver coping) was added.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Single-centre Phase III fast-track single-blind mixed-method RCT
Who led PC intervention: Multidisciplinary team
Core team: Palliative care medical consultant/clinical specialist occupational therapist/clinical spe-
cialist physiotherapist/administrator
Participants Country and regions: UK, Addenbrooke’s catchment area seeing patients from Cambridgeshire, Hert-
fordshire and Essex and, where practical, further afield
Recruitment: November 2008 to January 2012. Consecutive cancer patients referred to Breathlessness
Intervention Service (BIS) (from primary or secondary care) were invited to participate by letter.
Inclusion criteria: Patients were eligible if they met BIS referral criteria (that is, diagnosed appropri-
ately-treated cause of breathlessness, troubled by breathlessness in spite of optimisation of underly-
ing illness, and might benefit from a self-management programme). Recruited patients were asked to
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identify their informal carers who were also invited to participate. All participating patients and infor-
mal carers gave informed consent.
Exclusion criteria: Patients were excluded if they had received BIS previously. Patients who were un-
willing to participate in the trial continued to have access to BIS.
Number of patients: N = 67 (35 intervention and 32 control)
Diseases: Advanced cancer. Lung (N = 33, 49%), breast (N = 13, 19%) rectal/bowel (N = 4, 6%), prostate
(N = 3, 4%), lymphoma (N = 3, 4%), mesothelioma (N = 3, 4%), gastro-oesophageal junction (N = 2, 3%),
renal (N = 2, 3%), endometrial (N = 1, 2%), hepatocellular (N = 1, 2%), bladder (N = 1, 2%) and unknown
primary (N = 1, 2%).
Patient characteristics:.Mean age in years (SD): 70 (9.4) years in intervention group, 67 (13.3) years in
control group; 59% female in intervention group, 62% female in control group
Number of carers: N = 41 (20 intervention and 21 control)
Carer characteristics: Mean age in years (SD): 65.6 (13.4) years in intervention group, 63.5 (12.2) years
in control group; 70% female in intervention group, 67% female in control group
Deaths at end of study (N (%)): N = 2: 2 (5.7%) in intervention group and 0 in control group
Withdrawals/other dropouts (N (%)): N = 11: 5 (14.3%) in intervention group and 6 (18.8%) in control
group
Interventions Name: Breathlessness Intervention Service (BIS) plus standard care vs standard care
Type: Specialist palliative care. Includes a palliative care medical consultant (with dedicated clinical
sessions and a research interest in breathlessness), a clinical specialist occupational therapist (lead
clinician for the service), a clinical specialist physiotherapist and an administrator.
Service base: Addenbrooke’s Hospital. BIS is a secondary care service which provides care in a com-
munity setting, predominantly seeing patients in their own homes.
Team: A palliative care medical consultant (with a research interest in breathlessness), a clinical spe-
cialist occupational therapist (lead clinician for the service), a clinical specialist physiotherapist and an
administrator
Intervention condition: The Breathlessness Intervention Service (BIS) is a multidisciplinary complex
intervention combining nonpharmacological and pharmacological interventions to support breathless
patients with advanced disease, theoretically underpinned by a palliative care approach. Consultations
usually occur in the patient’s own home. First stage of intervention is mainly nonpharmacological (se-
lection and application as clinically indicated). Second stage interventions likely to be applied concur-
rently with first stage interventions include pharmacological review, referral to specialist services or
acupuncture.
Duration: Two weeks
Control condition: Standard care was defined as specialist outpatient appointments in secondary care
(for example, oncology) which may include specialist nurse input, and primary care services.
Outcomes Primary outcome:
Patient distress due to breathlessness measured using a numerical rating scale
Secondary outcomes:
Disease-specific health-related quality of life assessed using the Chronic Respiratory Questionnaire
(CRQ)
Patient anxiety and depression using the Hospital Anxiety and Depression Scale (HADS)
Carer distress due to patient breathlessness measured using a numerical rating scale
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Carer anxiety and depression using the Hospital Anxiety and Depression Scale (HADS)
Service use assessed using the Client Services Receipt Inventory (CSRI)
Patients and carers' expectations and experiences of BIS explored using qualitative topic-guided inter-
views
For health economic analyses: EQ-5D and measure of service use assessed using the Client Services Re-
ceipt Inventory (CSRI)
Assessment points: Participating patients and carers completed a baseline interview (t1: week 1) be-
fore randomisation. These interviews included the quantitative patient- and carer-reported measures
and qualitative interviews (carers were interviewed separately where possible). A two-week follow-up
interview (t3: week 3) was designed to represent BIS completion for the intervention arm, or end of
waiting-list period prior to BIS for controls. A final interview (t5: week 5) was conducted four weeks
from baseline; this represented two weeks after BIS for intervention arm and completion of BIS for con-
trols.
Resource use/costs Measure of service use assessed using the Client Services Receipt Inventory (CSRI)
Informal care (unpaid hours/week from family/ friends performing specific tasks) was valued at average
UK wages (GBP 11.21/hour). Costs of BIS visits were estimated at GBP 91 (based on specialist nurse con-
tacts which averaged the rehabilitation specialists’ wages) and phone contacts at one-quarter of this.
Time Horizon: Costs were calculated combining service use data (CSRI) for eight weeks and two weeks
prior to baseline and t3, respectively, with UK 2011/2012 unit costs.
Data sources: A generic health status measure (EQ-5D) and measure of service use (Client Services Re-
ceipt Inventory (CSRI) were administered for health economic analyses. Costs were calculated combin-
ing service use data (CSRI) for eight weeks and two weeks prior to baseline and t3, respectively, with UK
2011/2012 unit costs. Informal care (unpaid hours/week from family/ friends performing specific tasks)
was valued at average UK wages (GBP 11.21/hour). Costs of BIS visits were estimated at GBP 91 (based
on specialist nurse contacts which averaged the rehabilitation specialists’ wages) and phone contacts
at one-quarter of this.
Analytical perspective: Not clear
Notes Funding source: The study was supported by the following funders: NIHR Research for Patient Benefit
(for Phase III RCT funding); Macmillan Cancer Support (post-doctoral fellowship); The Gatsby Founda-
tion for the initial funding of BIS; and AT Prevost was supported by the National Institute for Health Re-
search (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s
College London.
Declarations of interest among primary researchers: The authors declared that Sara Booth (SB) was
the founder and one of the clinicians providing BIS but had no role in data collection. The other authors
declared that they had no competing interests.
Power considerations: A sample size of 60 randomised patients (26 analysed per arm, allowing for
dropout) provided 80% power to detect a 2-point difference in mean distress at two weeks between
groups (SD = 2.5, alpha = 5%), with increased precision anticipated from adjustment for baseline.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "participants were randomised to one of two
groups using randomly permuted blocks of random size two, four and six, gen-
erated by the study statistician using a computer programme and concealed
within sealed opaque envelopes until allocation notification
by the intervention deliverer".
Comment: probably done
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Allocation concealment
(selection bias)
Low risk Quote from main publication: "participants were randomised to one of two
groups using randomly permuted blocks of random size two, four and six, gen-
erated by the study statistician using a computer programme and concealed
within sealed opaque envelopes until allocation notification






High risk Comment: no blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Quote from main publication: "data collection-design facilitated re-
searcher-blinding to group allocation for the collection of primary and key sec-
ondary outcomes at the key measurement point, that is, planned unblinding
occurred during the two-week follow-up interview (t3) only after collection of
this outcome data and prior to qualitative data collection about the interven-
tion".




High risk N = 28 (75%) completers in intervention group vs N = 26 (77%) completers in
control group. Missing data were excluded from the analysis: 7 (25%) patients
were missing in the intervention group due to death (N = 2) and deterioration
(N = 5) while 6 (23%) patients were missing in the control group due to deterio-
ration of their condition.
Selective reporting (re-
porting bias)
High risk Some outcomes such as patient and carer social functioning, carer assessment
of patient's breathlessness, carer distress due to patient's breathlessness, car-
er quality of life, carer anxiety and depression and unpaid caregiver burden
were not reported in the study. The trial registration on ClinicalTrials.gov is
NCT00678405.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Single-centre phase III fast-track single-blind mixed method RCT
Who led PC intervention: Multidisciplinary team
Core team: Palliative care medical consultant/clinical specialist occupational therapist/clinical spe-
cialist physiotherapist
Participants Country and regions: UK
Recruitment: Consecutive patients with nonmalignant disease who were referred to BIS (from primary
or secondary care) were invited to participate in the trial, by letter.
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Inclusion criteria: Patients were eligible if they met BIS referral criteria (they had a diagnosed appro-
priately treated cause of breathlessness, were troubled by breathlessness in spite of optimisation of
underlying illness, and might benefit from a self-management programme). Recruited patients were
asked to identify their informal carers who were also invited to participate.
Exclusion criteria: Patients were excluded (from the trial only) if they had received BIS previously.
Number of patients: N = 87 (44 intervention and 43 control)
Diseases: Advanced nonmalignant disease comprising COPD (N = 73, 84%) and other nonmalignant
disease (N = 14, 16%)
Patient characteristics: Mean age in years (SD): 72.3 (10.6) years in intervention group, 72.2 (9.4) years
in control group; 36% female in intervention group, 42% female in control group
Number of carers: N = 57 (29 intervention and 28 control)
Carer characteristics: Mean age in years (SD): 62.5 (14.82) years in intervention group, 62 (12.02) years
in control group; 79% female in intervention group, 79% female in control group
Deaths at end of study (N (%)): N = 2: 1 (2.3%) in intervention and 1 (2.3%) in control
Withdrawals/other dropouts (N (%)): N = 6: 2 (4.5%) in intervention and 4 (9.3%) in control
Interventions Name: Breathlessness Intervention Service (BIS) plus standard care vs standard care
Type: Specialist palliative care. Included a palliative care medical consultant, a clinical specialist occu-
pational therapist and a clinical specialist physiotherapist
Service base: Addenbrooke’s Hospital. BIS is a secondary care service which provides care in a com-
munity setting, predominantly seeing patients in their own homes.
Team: A palliative care medical consultant, a clinical specialist occupational therapist and a clinical
specialist physiotherapist
Intervention condition: The Breathlessness Intervention Service (BIS) is a multidisciplinary complex
intervention combining nonpharmacological and pharmacological interventions to support breathless
patients with advanced disease, theoretically underpinned by a palliative care approach. Consultations
usually occurred in the patient’s own home. First stage of intervention was nonpharmacological (selec-
tion and application as clinically indicated). Second stage of intervention depended on outcome of first
stage interventions and included pharmacological interventions.
Duration: Four weeks
Control condition: Standard care was defined as specialist outpatient appointments in secondary care
(for example, oncology) which may include specialist nurse input, and primary care services.
Outcomes Primary outcome
Patient distress due to breathlessness measured using a numeric rating scale (NRS)
Secondary outcomes
Patient quality of life measured by the Chronic Respiratory Questionnaire (CRQ)
Patient anxiety and depression measured by the Hospital Anxiety and Depression Scale (HADS)
Carer-reported outcome measures included an NRS for carer distress due to patient breathlessness
Carer anxiety and depression measured by the Hospital Anxiety and Depression Scale (HADS)
Patient use of other services assessed using the Client Service Receipt Inventory (CSRI)
Patients and carers' expectations and experiences of BIS explored using qualitative topic-guided inter-
views
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For health economic analyses: EQ-5D and the CSRI
Assessment points: Participating patients completed a baseline interview (t1) prior to randomisa-
tion.This interview included both the quantitative patient-reported measures and the qualitative top-
ic-guided interviews. Carers were interviewed separately, where possible. Similar mixed method fol-
low-up interviews were conducted with both patients and carers at each subsequent follow-up inter-
view (t2–t5) at fortnightly intervals. Interview two (t2; two weeks after baseline) represented the mid-
way point in either receiving the BIS intervention for the intervention arm or the waiting-list period for
the controls; interview three (t3) was designed to represent BIS completion for the intervention arm,
or the end of the waiting-list period prior to commencing BIS for the controls; interview four (t4) repre-
sented the midway point in receiving the BIS intervention for the controls (no t4 was conducted with
patients and carers on the intervention arm); and the final interview (t5; eight weeks from baseline)
was designed to represent four weeks after BIS for the intervention arm, and the completion of BIS for
the controls.
Resource use/costs Measure of service use assessed using the Client Services Receipt Inventory (CSRI)
The cost of the intervention was calculated at GBP 91 per contact based on specialist nursing input
costs, with phone contacts costed at 25% of this.
Time Horizon: Costs were calculated by combining service use data (collected for the two months pri-
or to baseline and at four-week follow-up) with UK 2011/12 unit costs.
Data sources: The EQ-5D and Client Service Receipt Inventory (CSRI) were administered for the health
economic analyses. Costs were calculated by combining service use data (collected for the two months
prior to baseline and at four-week follow-up) with UK 2011/12 unit costs. The cost of the intervention
was calculated at £91 per contact based on specialist nursing input costs, with phone contacts costed
at 25% of this. Costs were combined with the primary outcome and EQ-5D-derived quality-adjusted life
years (QALYs), with uncertainty explored using cost-effectiveness planes.
Analytical perspective: Not clear
Notes Funding source: This paper presented independent research commissioned by the NIHR under its Re-
search for Patient Benefit (RfPB) programme (Grant Reference Number PB-PG-0107-11134).
Declarations of interest among primary researchers: MF, ATP, PM, BBP, AB, IJH, CJT, SB had support
from NIHR (Research for Patient Benefit grant) for the submitted work; MF had support from Macmil-
lan Cancer Support (Post-Doctoral Fellowship) for the submitted work; IJH had support from Cicely
Saunders International; SB had support from Macmillan Cancer Support (funded online learning mod-
ule connected to BIS), the Gatsby Foundation (funded the pilot BIS and its evaluation), and a capaci-
ty building grant from NIHR, and SB was the founder and one of the clinicians providing BIS that may
be relevant to the submitted work and started an MRC methods research programme in collaboration
with IJH, who has published an evaluation of a breathlessness service.
Power considerations: A sample size of 60 randomised patients (26 analysed per arm, with allowance
for dropout) provided 80% power to detect a 2-point difference in mean distress between groups (SD =
2.5, alpha = 5%), with increased precision anticipated from adjustment for baseline.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "participants were randomised to one of two
groups using randomly permuted blocks of random size 2, 4 and 6, generated
using a computer programme by the study statistician and concealed within





Low risk Quote from main publication: "participants were randomised to one of two
groups using randomly permuted blocks of random size 2, 4 and 6, generated
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using a computer programme by the study statistician and concealed within







High risk Comment: no blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Quote from main publication: "data collection was designed to facilitate re-
searcher blinding to group allocation for the collection of primary and key sec-
ondary outcomes at t3. That is, researcher blinding was explained to study
participants on recruitment, they were reminded at the start of t2 not to let the
researcher know their group allocation, and at the start of t3 they were asked
not to let the researcher know their group allocation until the researcher came
to open their group allocation envelope just prior to CSRI completion (after the
collection of primary and key secondary outcomes at t3)".




Low risk N = 41 (93.2%) completers in intervention group vs N = 38 (88.4%) completers
in control group. Missing data were excluded from the analysis: 3 (6.8%) pa-
tients were missing in the intervention group due to death (N = 1) and lost to
study (N = 2) while 5 (11.6%) patients were missing in the control group due to
death (N = 1) and lost to study (N = 4).
Selective reporting (re-
porting bias)
High risk Social functioning was not reported in the study. The trial registration on Clini-
calTrials.gov is NCT00678405.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-





Methods Design: RCT (multicentre RCT)
Who led PC intervention: Multidisciplinary team
Core team: Double-boarded certified oncologists and palliative care physicians and nurses involved
full-time in palliative care
Participants Country and regions: Italy, Emilia-Romagna in Northern Italy
Recruitment: November 2014 to March 2016. Follow-up was completed in November 2016. Consecu-
tively enrolled patients were identified by research personnel.
Inclusion criteria: Age > 18 years; pathologically confirmed NSCLC, pancreatic, gastric or biliary tract
cancer diagnosed within the previous 8 weeks; Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) 0, 1, or 2; metastatic or locally advanced disease (but not susceptible to loco-region-
al treatments); life expectancy > three months; eligibility for first-line chemotherapy and/or biological
therapy; completion of the QoL questionnaire; provision of written informed consent at enrollment
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Exclusion criteria: Patients already receiving care from the palliative care service or previously treat-
ed with chemotherapy and/or biological therapy for advanced disease, as well as patients with NSCLC
with EGFR mutation, were excluded.
Number of patients: N = 281 (142 intervention and 139 control)
Diseases: Advanced cancer: lung (non-small cell), pancreatic, gastric and biliary
Patient characteristics: Median age in years (IQR): 68.5 (12) years in intervention group, 68 (11) years
in control group; 32% female in intervention group, 38% female in control group
Deaths at end of study (N (%)): N = 97: 48 (33.8%) intervention and 49 (35.3%) control had died by six
months.
Withdrawals/other dropouts (N (%)): N = 7: 4 (2.8%) in intervention group and 3 (2.2%) in control
group
Interventions Name: Early palliative care integrated with usual care vs usual care
Early palliative care (EPC): Patients were diagnosed with NSCLC, pancreatic, gastric or biliary tract
cancer within the previous 8 weeks.
Type: Double-boarded certified oncologists and palliative care physicians and nurses involved full-
time in palliative care
Service base: Five University and Community Hospital Cancer Centres in Northern Italy
Team: Composed of an oncologist specialised in palliative care (PC) and a nurse involved full-time in
PC
Intervention condition: Patients met with the PC team within 2 weeks after enrollment, and at least
every 2 weeks thereafter for 24 weeks. After protocol amendment, follow-up visits were scheduled
every 3 weeks. Additional visits with the PC team could be scheduled at the discretion of the patient,
oncologist, or PC provider. General guidelines for the PC visits were adapted from the protocol of the
Temel et al. study. The PC team documented provided care in the patient’s medical record. Physical
and psychosocial symptoms were assessed using validated instruments, and the necessary interven-
tions enacted according to individual patient and family needs.
Duration: Enrollment to 6 months
Control condition: Patients assigned to standard care received anticancer and symptom control treat-
ments provided by oncologists and nurses without formal PC training. They were offered no formal in-
tervention, but PC referral was not denied, if requested. The patients in the control arm who were re-
ferred to the PC team did not cross over to the EPC group or follow the specified PC protocol.
Outcomes Primary outcomes:




Use of end-of-life (EoL) care defined as the percentage of deceased patients who used the following in
the 30 days preceding death: chemotherapy use, hospital admission and emergency room visit
Assessment points:
Patients were assessed at baseline, 12 weeks and 24 weeks
Resource use/costs Percentage of deceased patients who used the following in the 30 days preceding death:
Chemotherapy use
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Hospital admission
Emergency room visit
Time horizon: 30 days before death
Notes Funding source: This work was supported by the Programma di ricerca Regione-Università, Regione
Emilia-Romagna, bando “Ricerca per il Governo clinico” 2013.
Declaration of interest among primary researchers: The authors stated that they had no conflicts of
interest to declare.
Power considerations: To detect a significant between-group difference of at least 6.5 points in the
change in the FACT-G score between t0 and t1, through a two-tail unpaired Student’s t-test with 80%
power and 5% alpha, the authors estimated a sample size of 186 patients. This quota was increased
by 30% (243 patients) based on the estimated number of deaths within 12 weeks (20%) and lost to fol-
low-up (10%) at T1.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "eligible patients were randomised before an-
ticancer treatment to one of the two groups on a 1:1 allocation rate. To take
into account centre heterogeneity, stratified randomisation was performed.
Lists using a permuted block balanced procedure were generated for each par-
ticipating centre with the SAS v8 Statistical Software, and for each list a seed
was defined. Lists were saved and implemented in a web-based e-CRF, to au-





Low risk Quote from main publication: "lists using a permuted block balanced proce-
dure were generated for each participating centre with the SAS v8 Statistical
Software, and for each list a seed was defined. Lists were saved and imple-
mented in a web-based e-CRF, to automatically assign the results of the ran-













Low risk Quote from main publication: "... patients and clinicians could not be blinded
to group assignment".
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes such as survival.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Quote from main publication: "although complete masking of intervention
was not feasible, blinding was ensured for healthcare sta, in charge of data
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Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "although complete masking of intervention
was not feasible, blinding was ensured for healthcare sta, in charge of data






Low risk N = 90 (63.4%) completers in intervention group vs N = 87 (62.6%) com-
pleters in control group. Number of deaths and withdrawals were similar
between groups. 48 (33.8%) deaths and 4 (2.8%) withdrawals/dropouts oc-
curred in the intervention group while 49 (35.3%) deaths and 3 (2.2%) with-
drawals/dropouts occurred in the control group. Imputation method was used
for missing observations as described in the FACIT Administration and Scoring
Guidelines.
Comment: Given that imputation was done for missing observations, a low risk
of bias was rated.
Selective reporting (re-
porting bias)
Low risk All of the study’s prespecified (primary and secondary) outcomes have been
reported.
Other bias Unclear risk Quote from main publication: "Baseline characteristics were well matched be-
tween the two arms. Known prognostic factors, including age, sex, ECOG PS
and presence of metastases were also balanced. Only a greater number of pa-
tients was observed with gastric cancer in the control arm and with biliary can-
cer in the intervention arm".
Comment: Given that it was unclear whether this difference was statistically
significant, an unclear risk of bias rating was given.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-







Who led PC intervention: Multidisciplinary team (PC team was available Monday through Friday and a
palliative care physician was on call after hours)
Core team: Palliative care physician/nurse/hospital social worker/chaplain
Participants Country and regions: USA, Denver, Portland, and San Francisco
Recruitment: June 2002 and December 2003. Eligible patients were members of the same integrated
health plan from three regions: Denver, Colorado, San Francisco, California, and Portland, Oregon. Re-
ferrals were received from all medical services and inpatient units.
Inclusion criteria: Eligible patients were > 18 years, hospitalised with at least one life-limiting diagno-
sis, and whose attending physician indicated they “would not be surprised if the patient died within 1
year.”
Exclusion criteria: Patients were excluded if they had impaired cognitive status and no surrogate or
were currently enrolled in hospice or other PC studies.
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Number of patients: N = 517 (280 intervention and 237 control)
Diseases: Cancer, congestive heart failure (CHF), myocardial infarction (MI), other heart disease, chron-
ic obstructive pulmonary disease (COPD), other pulmonary disease, end-stage renal disease (ESRD), or-
gan failure, stroke, dementia
Patient characteristics: Mean age in years (SD): 73.6 (12.6) years in intervention group, 73.1 (13.2)
years in control group; 59% female in intervention group, 51% female in control group
Deaths at end of study (N (%)): No death
Withdrawals/other dropouts (N (%)): Total N = 5: 5 (1.8%) intervention and none in control.
Interventions Name: Interdisciplinary inpatient palliative care consultative service (IPCS) vs usual hospital care
Type: Specialist palliative care. Included a palliative care physician
Service base: A hospital in Denver, Portland, and San Francisco
Team: The IPCS teams included a palliative care physician and nurse, hospital social worker and chap-
lain.
Intervention condition: All teams provided care in accordance with key palliative care components
which were adapted from Weismann 1997. The teams assessed patients’ needs for symptom manage-
ment, psychosocial and spiritual support, end-of-life planning, and post-hospital care. The team then
met with the patient/family to address symptoms, diagnosis, prognosis, and goals of care. After the pa-
tient/family meeting, the team convened briefly to synthesise a palliative care plan and organise fol-
low-up by team members. IPCS provided consultation on intervention patients to the attending, in-
volved subspecialists and sta, on all aspects of palliative care, including treatment recommendations.
A palliative care physician was on call after hours. The teams collaborated with the attendings and dis-
charge planners in preparing for the patient’s discharge. If intervention patients were readmitted to the
hospital, they were again followed by IPCS for palliative care needs. Each site was visited early in the
study to assess protocol adherence.
Duration: Period of hospitalisation
Control condition: San Francisco and Portland hospitals were part of a managed care organisation’s
(MCO) delivery system. Denver’s community hospital had a contract with the MCO. All hospitals had
MCO hospitalist physicians. At two sites hospitalists served as the attending physicians. Portland’s hos-
pital used a combination of MCO hospitalists and primary care internists. All hospitals had social work-
ers and chaplains on sta, that provided direct patient services to usual care patients.
Outcomes Primary outcomes:
Symptom control assessed using the Physical Area scale of the Modified City of Hope Patient Question-
naires (MCOHPQ).
Levels of emotional and spiritual support assessed using items taken from the MCOHPQ Emotional/Re-
lationship Area and Spiritual Area scales.
Patient satisfaction assessed using the MCOHPQ Place of Care Environment scale and the Doctors,
Nurses/Other Care Providers Communication scale.
Total health services costs at 6 months post-index hospitalisation.
Secondary measures:
Survival
Number of advance directives (ADs) at discharge
Hospice utilisation within the 6 months post-index hospitalisation
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Assessment points: After a baseline questionnaire was administered, the patient was randomly as-
signed to IPCS or usual hospital care. Surveys were administered to patients or proxies at study enroll-
ment and within 2 weeks following index hospitalisation discharge to measure symptom control as
well as emotional and spiritual support. Patient satisfaction was also measured within 2 weeks of index
hospital discharge.
Resource use/costs Healthcare costs
Intensive care admissions
Hospice utilisation
Time horizon: Enrollment to discharge from hospital
Data sources: Costs were computed for all health services used within the 6 months following index
hospitalisation discharge. Costs of health services were assigned using the predetermined internal MCO
rate structure and vendor contracts based on per diem and case rate calculations.
Analytical perspective: Not clear
Notes Funding source: Garfield Memorial Fund
Declarations of interest among primary researchers: Apart from funding, no further study author
disclosure statements were made.
Power considerations: Not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "after a baseline questionnaire was adminis-
tered the patient was randomly assigned to IPCS or UC using a computer-gen-














Low risk Participants and personnel were not blinded but this was unlikely to lead to
bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Unclear risk of bias as there was no mention of blinding of outcome assess-
ment
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk There was no mention of blinding of outcome assessment but this was unlikely




Low risk N = 275 (98.2%) completers in intervention group vs N = 237 (100%) completers
in control group. 5 (1.8%) patients in the intervention group withdrew their
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consent and were dropped from the study. The 275 (98.2%) patients in the in-
tervention and 237 in control group were included in the analysis.
Comment: low risk of bias because of the very small number of dropouts
Selective reporting (re-
porting bias)
Unclear risk Unclear because the protocol of this study was not available
Other bias High risk Quote from publication: "there were no differences in any baseline measures
between the IPCS and UC groups except for the life-limiting diagnoses of
stroke and end-stage renal disease (ESRD)".
Comment: Given that the authors did not control for the highlighted differ-
ences, a decision was made to rate down for imbalance bias.







Who led PC intervention: Multidisciplinary team
Core team: Doctors/nurses/psychologists were part of the team in all the 6 specialised palliative care
centres. 5 teams included physiotherapists, 4 social workers, 3 volunteers, 3 chaplains, 1 pharmacist
and 1 had a secretary.
Participants Country and regions: Denmark
Recruitment: May 2011 to December 2013: consecutive patients who were in oncological treatment or
follow-up at five different Departments of Oncology were screened for palliative care needs by research
nurses if they had cancer stage IV or cancer in the central nervous system grade III/IV; were > 18 years;
lived in the area of one of the participating SPC centres; had no contact with an SPC during the previ-
ous year.
Inclusion criteria: Patients were eligible for the trial if they scored at least 50% of the score represent-
ing maximal symptom or maximally reduced functioning on at least one of the following seven scales:
physical function, role function, emotional function, nausea/ vomiting, pain, dyspnoea or lack of ap-
petite; had at least four additional symptoms (defined as a score of at least 33% of the score corre-
sponding to maximal symptom burden or maximally reduced functioning) as measured by any of the
13 remaining scales (global health status/QoL excluded).
Exclusion criteria: Patients were excluded from the trial if they did not understand Danish well enough
to fill in a questionnaire or were considered incapable of complying with the trial protocol.
Number of patients: N = 297 (145 intervention and 152 control group)
Diseases: Cancer: lung, digestive system, breast, other
Patient characteristics: Mean/median age not presented. The following was the age distribution in
the intervention group: < 50 (10), 50-59 (27), 60-69 (65), 70-79 (36), > 80 (7) and control group < 50 (15),
50-59 (25), 60-69 (58), 70-79 (45), > 80 (9). % of females in intervention group was 57% and 59% in con-
trol group.
Deaths at end of study (N (%)): Total N = 30: 15 (10.3%) intervention and 15 (9.9%) control
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Interventions Name: Early specialist palliative care plus standard care vs standard care
Definition of early PC: Defined as ‘usual SPC’ initiated at an earlier time than would otherwise have
been the case
Type: Training in palliative care unclear
Service base: 6 Danish SPC centres
Team: Doctors, nurses and psychologists were part of the team in all the 6 specialised palliative care
centres. 5 of the teams included physiotherapists, 4 included social workers, 3 had volunteers, 3 had
chaplains, 1 had a pharmacist and 1 had a secretary.
Intervention condition: Patients in the intervention group were referred to a SPC team, and the num-
ber and frequency of contacts with the SPC team and the treatments and other interventions were de-
termined by the patient’s needs, following the European Association for Palliative Care White Paper,
the WHO guidelines and national and local guidelines. The common understanding was that SPC is a
complex and multidisciplinary intervention that is adapted to each patient. The interventions were giv-
en by the sta, normally providing the interventions. Intervention fidelity was not assessed since there
was not a specific manual for the intervention.
Duration: The trial period was eight weeks
Control condition: There was very limited description of standard care. Standard care potentially in-
cluded palliative care provided by the Departments of Oncology, general practitioners (GPs) or home
care services.
Outcomes Primary outcomes:
Change in the patient's primary need (the most severe of the seven EORTC QLQ-C30 scales)
Secondary outcomes:
Change in the seven EORTC QLQ-C30 scales
Survival
Assessment points:
Patients received a questionnaire at baseline and at 3- and 8-week follow-up including the EORTC QLQ-
C3023 and additional instruments.
Resource use/costs Contact with SPC team
Assessment of healthcare service use stated in protocol
Notes Funding source: This work was supported by The Tryg Foundation (7-10-0838A, 7-12-0754) and the
Danish Cancer Society (R16-A695, R114-A7232-14-S3).
Declaration of interest among primary researchers: The author(s) declared no potential conflicts of
interest with respect to the research, authorship and/or publication of this article.
Power considerations: Assuming a difference of 7.5 points in the primary outcome, the planned sam-
ple size was 300 (alpha: 5%; beta: 10%; standard deviation (SD): 20).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "central randomisation via telephone was car-
ried out by the Copenhagen Trial Unit (CTU), which was independent of the tri-
al administration office. The allocation sequence was computer-generated 1:1
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with varying block size of 8 and 12 per strata and was kept unknown for all in-




Low risk Quote from main publication: "central randomisation via telephone was car-
ried out by the Copenhagen Trial Unit (CTU), which was independent of the tri-
al administration office. The allocation sequence was computer-generated 1:1












Low risk Patients were not blinded although investigators and those who analysed the
data were blinded.
Comment: a low risk of bias was given because lack of blinding was unlikely to
lead to bias in objective outcomes such as survival.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Investigators and those who analysed the data were blinded. A low risk of bias
was given.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Investigators and those who analysed the data were blinded.
Comment: low risk of bias was given because blinding or a lack of it would not




Low risk For whole population, missing outcome data not balanced between interven-
tion N = 32 (22%) and control groups N = 39 (26%). The reasons for missing da-
ta also differed between groups with the exception of number of deaths. 20
(13%) people in the control group did not answer the questionnaire compared
to 9 (6.2%) in the intervention group. Higher levels of administrative failure
were recorded in the intervention group (5.5%) compared to the control group
(2%). 89.7% of people in intervention and 90% of control were included in the
primary analysis. Multiple imputations were carried out for missing data with
the exception of people who died.
Selective reporting (re-
porting bias)
High risk Rated "high risk" because some of the secondary outcomes stated in the pro-
tocol were not reported. Examples included cancer patients' satisfaction with
the healthcare system measured using the FAMCARE-p16, anxiety and depres-
sion measured using the Hospital Anxiety and Depression Scale (HAD scale)
and economic consequences per week from the start of the trial to a minimum
of three months after the end of the intervention.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-
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Who led PC intervention: Multidisciplinary team
Core team: Physician/nurse practitioner/social worker/chaplain
Participants Country and regions: USA, New York City
Recruitment: June 2011 to April 2014 (34 months). Research assistants screened the electronic med-
ical record emergency department (ED) track board for patients with the stated specific advanced can-
cer staging criteria 8 to 12 hours daily except Saturdays. Medical oncologists at the institution were
able to opt out of participation.
Inclusion criteria: Patients eligible for participation were those with a known advanced cancer that
met the staging criteria, who were able to speak English or Spanish fluently, and who were being ad-
mitted to or observed in the hospital.
Exclusion criteria: Patients who were unable to answer questions because of severe pain or lethargy,
those who had been seen by palliative care in the past, or if they had evidence of cognitive impairment
based on the 6-item screener. Patients planning to leave the immediate geographic area (i.e. move to
another state or country) were also excluded.
Number of patients: N = 136 (69 intervention and 67 control)
Diseases: Advanced cancer: breast, colorectal, lung and other
Patient characteristics: Mean age in years (SD): 55.1 (13.1) years in intervention group, 57.8 (14.7)
years in control group; 57% female in intervention group, 55% female in control group
Deaths at end of study (N (%)): Total N = 85: 41(59.4%) intervention and 44 (65.7%) control had died
by the one-year mark
Interventions Name: Emergency department-initiated PC consultation vs usual care
Type: Training in PC unclear
Service base: Mount Sinai Hospital (MSH) ED
Team: Comprised a physician, a nurse practitioner, a social worker, and a chaplain
Intervention condition: Inpatient comprehensive palliative care consultation consisted of 3 compo-
nents: (1) symptom assessment and treatment, (2) goals of care and advance care plans, and (3) tran-
sition planning. The team used validated symptom assessments to make recommendations for symp-
tom management to consulting physicians using National Comprehensive Cancer Network (NCCN)
guidelines. The palliative care team met with patients, families, and care teams to identify goals of care,
complete advance directives, and communicate difficult news (if requested) using standardised com-
munication protocols. If admitted, the team saw patients daily to monitor implementation and results
of treatment recommendations and to assess for new and ongoing symptoms. The team also worked
with the patients’ social workers and family to facilitate transition management consistent with goals
of care. If the team found ongoing palliative care needs that were expected to continue after discharge,
they referred patients to the outpatient palliative care clinic.
Duration: Enrollment to discharge from hospital
Control condition: Participants assigned to the usual care arm completed the same baseline inter-
views and follow-up as intervention participants. If requested by the admitting team or oncologist, par-
ticipants may also have received a palliative care consultation.
Outcomes Primary outcomes:
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Quality of life at 12 weeks assessed using the Functional Assessment of Cancer Therapy-General (FACT-
G)
Secondary outcomes:
Survival at one year
Major depressive disorder at 12 weeks assessed using the Patient Health Questionnaire-9 (PHQ-9)
Healthcare utilisation at 180 days (hospital days, hospice use, and ICU admission)
Assessment points:
12 weeks for quality of life and major depressive disorder, one year for survival and 180 days for health-
care utilisation
Resource use/costs Hospital days
Hospice use
ICU admission
Time horizon: Enrollment to 180 days
Notes Funding source: This work was supported by a Mentored Research Scholar Grant from the American
Cancer Society and by a Mid-Career Investigator Award in Patient Oriented Research (K24 AG022345)
from the National Institute on Aging.
Declaration of interest among primary researchers: Apart from funding, no further study author dis-
closure statements were made.
Power considerations: Sample size was estimated based on "time to palliative care" in patients with
advanced cancer. The baseline mean time to consultation for such patients seen by palliative care was
9 days (SD = 12). It was estimated that the intervention would decrease this number by at least 50%, to
4.5 days (estimated SD = 6 days). Calculations employed two-tailed tests (α = 0.05, with β = 0.80). The
authors planned to enroll at least 140 patients. Authors expected to have at least 80% power with α =
0.05 (two-sided) to detect clinically meaningful differences with 70 subjects/group.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "participants were randomized via prespecified
balanced block randomization in blocks of 50".




Low risk Quote from main publication: "after the baseline survey was completed, the
research co-ordinator then relayed the participant information to a separate
research sta, member (the “randomizer”) with no role in study recruitment,
follow-up, or analysis...If the participant was assigned to the intervention
group, the randomizer then paged the palliative care consultation team to re-
lay information about the participant (name, medical record number, ED at-
tending, and oncologist of record) and the reason for consultation. If assigned
to the usual care group, no further action was necessary. The list linking partic-
ipant name and group assignment was stored on a secure network computer




High risk Quote from main publication: "it was not feasible to blind participants or care
providers to participant assignment".
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mance bias), subjective
outcomes





Low risk Quote from main publication: "It was not feasible to blind participants or care
providers to participant assignment".
Comment: there was no blinding of participants and personnel but this was
unlikely to lead to bias for objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Information on blinding of outcome assessment was not provided in the study.
Comment: an unclear risk of bias was given because relevant information was
not provided.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Information on blinding of outcome assessment was not provided in the study.





Low risk N = 53 (77%) completers in intervention group vs N = 43 (64%) completers in
control group. However, all patients were included in the analysis. The authors
stated that "we chose a conservative method of carrying baseline values for-
ward to account for missing depression and QoL follow-up measures".
Selective reporting (re-
porting bias)
High risk All of the study’s prespecified (primary and secondary) outcomes were not re-
ported in the prespecified way. Furthermore, some outcomes such as depres-
sion and survival stated as primary outcomes in the protocol were presented
as secondary outcomes in the main publication.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-





Methods Design: RCT (patient and unpaid caregiver)
Fast-track phase II RCT
Who led PC intervention: Multidisciplinary team
Core team: Part-time consultant in palliative medicine/part-time clinical nurse specialist (PC nurse)/
administrator/psychosocial worker
Participants Country and regions: UK, South East London
Recruitment: Length of recruitment was not stated: patients living with multiple sclerosis (MS) and
deemed (by clinicians) to have one or more unresolved symptoms, psychosocial concerns, end-of-life
issues, progressive illness, or complex needs were referred. Educational seminars informed local health
and social care professionals about the Palliative Care Teams (PCTs). Referrals were screened by a con-
sultant in palliative medicine who was independent from delivering the service.
Inclusion criteria: Patients in South East London, living with MS and deemed (by clinicians) to have
one or more of unresolved symptoms, psychosocial concerns, end-of-life issues, progressive illness, or
complex needs (i.e. palliative care needs). unpaid caregivers were identified through patients.
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Exclusion criteria: Referring sta, or the screening deemed patients had very urgent needs or were de-
teriorating rapidly when immediate referral to the service was offered.
Number of patients: N = 52 (26 intervention and 26 control)
Diseases: Multiple sclerosis
Patient characteristics: Mean age (SD): 53 (10.5) years in intervention group, 53 (10.4) years in control;
65% female in intervention group, 73% female in control.
Deaths at end of study (N (%)): Total N = 4: 1 (3.8%) intervention and 3 (11.5%) control
Withdrawals/other dropouts (N (%)): Total N = 2: none in intervention and 2 (7.7%) control
Interventions Name: Multiprofessional palliative care team in addition to usual care vs usual care
Type: Specialist palliative care. Team included one part-time consultant in palliative medicine and one
part-time clinical nurse specialist (PC nurse)
Service base: The multiprofessional PC team was based in a large teaching hospital.
Team: One part-time consultant in palliative medicine, one part-time clinical nurse specialist (PC
nurse), one administrator and one psychosocial worker
Intervention condition: Patients in the intervention group received the new palliative care service im-
mediately (fast-track). Patients were visited in their own homes or sometimes outpatient clinics, nurs-
ing homes, or hospital. The PCT undertook assessments, suggested ways to improve physical, emo-
tional, social, and other problems, provided specialist welfare benefits advice and bereavement sup-
port, and liaised with and acted as a catalyst for local services, both primary and specialist teams. After
initial assessment, treatment was recommended.
Duration: The intervention was for three months.
Control condition: Control group patients received usual care for 12 weeks, after which they were of-
fered the palliative care service. Community and hospital services (including neurologists, MS nurses,
rehabilitation, neurological, and social services) were offered as usual.
Outcomes Cost
Palliative care needs and concerns assessed using the Palliative care Outcome Scale (POS-8)
Pain item of the POS-8
unpaid caregiver burden assessed using the Zarit Carer Burden Inventory (ZBI)
Assessment points: Baseline (before randomisation) and at 6, 12, 18 (only control group — after they
received PCT), and 24 weeks
Resource use/costs Health, social and voluntary services (district/practice nurse, MS nurse, palliative care nurse, other
nurse, general practice, specialist (home), specialist (hospital), specialist (ward), specialist (other), oc-
cupational therapist/physiotherapist, dietician/chiropodist/dentist, speech therapist, social services,
informal unpaid caregiver, day centre, inpatient care, respite care)
Time horizon: From enrollment to death or study end. Data regarding the use of health and social ser-
vices in the previous three months were collected at each interview using a standard schedule.
Costs: Mean service costs (health, social and voluntary services) in the three months prior to baseline
assessment and 12-week follow-up interviews
Currency: 2005 GBP
Data sources: Research assistants (not blinded to group allocation) collected resource use data in the
last 3 months from patients in face-to-face interview using an adapted version of the Client Service Re-
ceipt Inventory; data were collected at baseline (before randomisation) and at 6 and 12 weeks, at 18
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weeks (the latter only for the control group, after receiving the service) and 24 weeks. Service costs
were calculated by combining resource use data with nationally applicable unit costs. Informal care
costs were estimated by assuming that in the absence of a unpaid caregiver, the help would need to be
provided by a home care worker; the unit costs of the latter were, therefore, used as a “shadow price”.
Costs were in 2005 GBP.
Analytical perspective: Costs were assessed using a broad perspective including costs to health, social
and voluntary services, and informal unpaid caregivers.
Notes Funding source: Multiple Sclerosis Society of Great Britain and Northern Ireland
Declarations of interest among primary researchers: Apart from funding, no further study author
disclosure statements were made.
Power considerations: Study estimated that a sample of more than 25 patients in each arm would en-
able it to detect differences of > 2 on the POS-8 at P < 0.05, power 80% (with SD of 2.25) at 12 weeks.
Cost-effectiveness was assessed only when both cost and outcome data were present.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "the researcher e-mailed relevant data to inde-
pendent statisticians who conducted the randomization using the minimiza-
tion method to give an equal balance of gender, age, date of diagnosis, and ac-




Low risk Quote from publication: "the researcher e-mailed relevant data to indepen-
dent statisticians who conducted the randomization using the minimization







High risk Quote from publication: "we were unable to blind the interviewers or partici-
pants from group allocation".
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from publication: "research assistants (not blinded to group allocation)
collected resource use data in the last 3 months from patients in face-to-face
interview using an adapted version of the Client Service Receipt Inventory".




Unclear risk N = 25 (96.2%) completers in intervention group vs N = 21 (80.8%) completers
in control group. There was one death in the intervention group and three in
the control group. One patient was withdrawn from the control group due to
protocol violation and another due to severe illness. Although, the authors
separately explored missing data and tested imputations (last-value-car-
ried-forward, next-value-carried-backward, and mean value) in a sensitivity
analysis, the number of patients analysed for the POS-8 and POS pain (out-
come measures) differed from the number of patients randomly assigned to
the intervention and control groups.
Selective reporting (re-
porting bias)
Low risk The protocol was available and all stated outcomes were reported.
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Other bias Low risk Study appeared to be free of other biases.







Fast-track phase III RCT
Who led PC intervention: Multidisciplinary team
Core team: Palliative care physician/respiratory medicine physician/physiotherapist/occupational
therapist
Participants Country and regions: South London
Recruitment: October 2010 and September 2012. The authors screened for potential patients across
three large teaching hospitals and via general practitioners.
Inclusion criteria: Patients had to meet all criteria: refractory breathlessness on exertion or rest (MRC
dyspnoea scale score ≥ 2), despite optimum treatment of the underlying disease, as deemed by the
identifying clinician; advanced disease such as cancer, chronic obstructive pulmonary disease (COPD),
chronic heart failure, interstitial lung disease, and motor neuron disease; willing to engage with short-
term home physiotherapy and occupational therapy; and able to provide informed consent
Exclusion criteria: Breathlessness of unknown cause; a primary diagnosis of chronic hyperventilation
syndrome; completely house- (or hospital- or nursing home-) bound, despite offer of free transport to
clinic; or within 2 weeks of treatment for an acute exacerbation. Such patients were reapproached after
2 weeks.
Number of patients: N = 105 (53 intervention and 52 control)
Diseases: Cancer, chronic obstructive pulmonary disease (COPD), heart failure, interstitial lung disease
and other.
Patient characteristics: Mean age (SD): 66 (11) years in intervention group, 68 (11) years in control;
47% female in intervention group, 37% female in control.
Deaths at end of study (N (%)): Total N = 4: 1 (1.9%) intervention and 3 (5.8%) control
Withdrawals/other dropouts (N (%)): Total N = 19: 10 (18.9%) in intervention and 9 (17.3%) control
Interventions Name: Early palliative care integrated with respiratory services for patients with advanced disease and
refractory breathlessness (breathlessness support service) vs usual care.
Early PC: Early palliative care was integrated with respiratory services for patients with advanced dis-
ease and refractory breathlessness. The authors were explicit about early palliative care.
Type: Specialist palliative care. Team included a palliative care physician.
Service base: Hospital
Team: Palliative care physician, respiratory medicine physician, physiotherapist, occupational thera-
pist
Intervention condition: The breathlessness support service (BSS) was a multiprofessional integrat-
ed service that combined respiratory, physiotherapy, occupational therapy, and palliative care assess-
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ment and management. It brought together assessment and treatment of physical, emotional, psycho-
logical, and spiritual concerns, through one point of access. The service comprised a first outpatient
clinic appointment with respiratory medicine and palliative care clinicians assessing present treatment
and concerns. The patient (and family, if present) was given a breathlessness pack including informa-
tion, management, and pacing guidance, a hand-held fan or water spray, and a poem and helped to
agree a crisis plan. A home assessment was done 2–3 weeks after the clinic visit to assess the need for
walking and home aids and adaptations, reinforcement of self-management, and further guidance on
pacing and exercises, including a DVD, when appropriate. A final clinic appointment with a palliative
care specialist was arranged to agree further actions and a discharge plan.
Duration: The intervention was for six weeks.
Control condition: Control group patients continued with optimum management as provided by their
usual services in accordance with relevant UK guidance to ensure best practice. After the 6-week (pri-
mary endpoint) research interview, these patients were offered BSS.
Outcomes Primary outcome
Breathlessness mastery at 6 weeks determined according to one domain of the quality of life measure,
the Chronic Respiratory Disease Questionnaire.
Secondary outcomes
Severity of breathlessness on average, at worst, at rest and on exertion in the previous 24 hours
Activity (assessed by London Chest Activity of Daily Living questionnaire)
Other domains of the Chronic Respiratory Disease Questionnaire (breathlessness, fatigue, and emo-
tional function)
Quality of life assessed using the EQ-5D
Palliative needs assessed using the Palliative care Outcome Scale (POS)
Depression and anxiety assessed using Hospital Anxiety and Depression Scale (HADS)
Spirometry
Patient survival
Assessment points: Research data were collected in face-to-face interviews with patients, usually in
their own homes, at baseline and 6 weeks follow-up (the primary endpoint).
Resource use/costs Hospital inpatient days in previous 3 months
Time horizon: Data regarding hospital inpatient days in the previous three months was collected using
a standard schedule.
Costs: Cost of formal care in the previous 3 months
Currency: 2011-12 unit costs GBP
Data sources: Data regarding hospital inpatient days in the previous three months at baseline was col-
lected using a standard schedule. We calculated costs by combining Client Service Receipt Inventory
data with UK 2011–12 unit costs.
Analytical perspective: Not clear
Notes Funding source: Mainly by a National Institute for Health Research (NIHR) grant from Research for Pa-
tient Benefit (PBPG-0808-17311)
Declarations of interest among primary researchers: The authors declared no competing interests.
Power considerations: On the basis of the primary outcome, the Chronic Respiratory Disease Ques-
tionnaire mastery domain, the authors estimated that more than 34 patients per group would detect a
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mean difference of 0.70 (SD 1), a value of less than 0.05 at power 80%. To allow for a conservative esti-
mated attrition of 40%, the authors planned to recruit at least 110 patients.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "using data from the baseline interview, the
King’s Clinical Trials Unit’s Online randomisation system, independent of re-
search and clinical teams, randomly assigned (1:1) patients to the intervention
(immediate access to breathlessness support service in addition to standard
care) or control group (standard best practice; offered breathlessness support
service after 6 weeks). Allocation was done by minimisation to balance four
potential confounders: cancer versus non-cancer, breathlessness severity (nu-
merical rating scale > 3 or not), presence (or not) of an informal unpaid care-




Low risk Quote from main publication: "randomisation was computer generated cen-
trally by the independent Clinical Trials Unit in a 1:1 ratio, by minimisation to
balance four potential confounders: cancer versus non-cancer, breathlessness





High risk Quote from main publication: "patients were aware of treatment allocation,
and were asked not to disclose this information to interviewers or research
nurses".





Low risk This study was a single-blind RCT in which the research interviewers/nurses
were blinded. Quote from main publication: "Patients were aware of treatment
allocation, and were asked not to disclose this information to interviewers or
research nurses".
Comment: patients were not blinded but this was unlikely to lead to bias in ob-
jective outcomes such as survival.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Quote from main publication: "research nurses/interviewers were masked to
treatment allocation". However, the authors also acknowledged that the re-
search nurse could have seen breathlessness support service equipment (e.g.
hand-held fan and information sheets) in patients' home, which could have bi-
ased their interviews.
Comment: unclear risk because there was the possibility that interviews could
have been biased
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "Research nurses/interviewers were masked to
treatment allocation". However, the authors also acknowledged that the re-
search nurse could have seen breathlessness support service equipment (e.g.
hand-held fan and information sheets) in patients' home, which could have bi-
ased their interviews.
Comment: although there was the possibility that the interviews by research
nurses/interviewers could have been biased, this was unlikely to lead to bias in




High risk N = 42 (79.2%) completers in intervention group vs N = 40 (76.9%) completers
in control group. Missing data were excluded from the analysis: 11 (20.8%) pa-
tients were missing in the intervention group due to death (N = 1), withdrawal
(N = 6), unable to contact (N = 4) and 12 (23.1%) patients were missing in con-
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High risk There were protocol deviations. Economic evaluation was not carried out as
specified in the protocol.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-





Methods Design: RCT (multicentre RCT)
Who led PC intervention: Multidisciplinary team
Core team: Physician/advanced nurse practitioner. Other professionals (chaplains and social workers)
participated as requested.
Participants Country and regions: USA
Recruitment: September 2006 to June 2008. Patients were screened with the use of computer-gener-
ated lists of diagnoses, and charts were reviewed for eligibility criteria.
Inclusion criteria: Participants had an admission diagnosis of acute heart failure (HF) (ICD-9 codes and
subcodes associated with 425 and 428), a 1-year mortality risk of ≥ 33% based on Enhanced Feedback
for Effective Cardiac Treatment (EFFECT) score, and/or New York Heart Association (NYHA) functional
class III or IV.
Exclusion criteria: Cognitive impairment, a life-limiting non-HF illness, acute severe psychiatric illness
other than major depression, symptoms too severe for study consent, anticipated cardiac transplanta-
tion, or an attending physician who rejected the need for palliative care consultation (PCC).
Number of patients: N = 85 (43 intervention and 42 control)
Diseases: Acute heart failure
Patient characteristics: Mean age (SD): 67 (11) years in intervention group, 68 (13) years in control;
39.5% female in intervention group, 57.1% female in control.
Deaths at end of study (N (%)): Total N = 19: 11 (% not presented because denominator was unclear)
intervention and 8 (% not presented because denominator was unclear) control
Withdrawals/other dropouts (N (%)): Not stated
Interventions Name: Hospital-based palliative care consultation vs usual care
Type: Training in palliative care unclear
Service base: 3 hospitals in a predominantly African-American urban community
Team: The Palliative Care Consultation (PCC) team included a physician and advanced nurse practi-
tioner. Other professionals (chaplains and social workers) participated as requested.
Intervention condition: The PCC team included a physician and advanced nurse practitioner. Other
professionals (chaplains and social workers) participated as requested. Clinical interviews assessed
for uncontrolled distressing symptoms, goals of care, advance care planning, code status, and desired
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post-treatment residential setting. All PCC patients had at least 1 palliative care consultation, with the
opportunity for additional meetings, as desired.
Duration: 3 to 6 months after randomisation
Control condition: Not described
Outcomes Primary outcome:
The primary outcome assessed after 3–6 months was a dichotomous (election vs nonelection) measure
of comfort-oriented care, which included
(1) outpatient hospice,
(2) inpatient hospice,
(3) a “do not resuscitate” (DNR) order during the index or a subsequent hospitalisation, or
(4) a DNR order at home or at a nursing home, as assessed by means of telephone interviews and med-
ical records.
Secondary outcomes were not stated.
Assssement point:
After written informed consents were obtained, baseline questionnaires were completed and randomi-
sation to palliative care consultation (PCC) and control groups conducted. 3-6 months after randomisa-
tion
Resource use/costs None reported
Notes Funding source: This work was supported by the Blue Cross/Blue Shield Foundation of Michigan (grant
no. 1074-II PIRAP, Rob Zalenski, Principal Investigator)
Declarations of interest among primary researchers: No disclosures were made by the authors.
Power considerations: The study was powered to detect a moderate to large effect of ≥ 20% absolute
group differences in palliative outcomes (24% PCC vs 4% control). A sample size of 88 had 80% power
to detect the prespecified 20% proportion difference with a significance, or alpha, of 0.05 (P = .05).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "after written informed consents were obtained,
baseline questionnaires were completed and randomisation to PCC and con-
trol groups conducted".









Low risk Quote from main publication: "this was a prospective open-label behavioral
intervention pilot trial of PCC versus usual care in patients with advanced HF
who were hospitalised for an acute HF exacerbation at 1 of 3 hospitals in a pre-
dominantly African American urban community".
Comment: there was no blinding but this was unlikely to lead to bias in objec-
tive outcomes.
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Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "this was a prospective open-label behavioral
intervention pilot trial of PCC versus usual care in patients with advanced HF
who were hospitalised for an acute HF exacerbation at 1 of 3 hospitals in a pre-
dominantly African American urban community".
Comment: there was no blinding but this was unlikely to lead to bias in the as-




High risk It was reported that 19 (23.8%) of 80 patients died 3-6 months after randomi-
sation with no difference by group (11 intervention and 8 control, P = 0.47).
The percentage of attrition for intervention and control group could not be cal-
culated due to lack of clarity on the denominator.




Unclear risk Furthermore, patient satisfaction and quality of life were reported at base-
line but not at follow-up. No information was given regarding how the authors
measured those outcomes. It was unclear if these were part of the outcomes in
this study as the protocol was not available.
Other bias Low risk Study appeared to be free of other biases.






Methods Design: RCT (single-centre RCT)
Who led PC intervention: Multidisciplinary team
Core team: Nurses with experience in palliative care and a palliative care physician
Participants Country and regions: Switzerland, Geneva
Recruitment: September 2013 to July 2016. Patients were recruited among subjects followed by Gene-
va University Hospitals on long-term oxygen therapy (LTOT) and/or home non-invasive ventilation
(NIV), and subjects hospitalised for acute exacerbation of COPD (AECOPD) in our general internal medi-
cine and geriatric wards.
Inclusion criteria: COPD defined according to GOLD (Global Initiative for Obstructive Lung Diseases)
criteria (FEV1/FVC < 70%) stage III or IV (FEV1 < 50% predicted) and LTOT and/or home NIV and/or one
or more hospital admissions in the previous year for an acute exacerbation.
Exclusion criteria: Moderate or severe cognitive impairment (Mini Mental State Examination [MMSE]
score < 23) and cancer.
Number of patients: N = 49 (26 intervention and 23 control)
Diseases: COPD
Patient characteristics: Mean age (SD): 70.8 (8.4) years in intervention group, 71.3 (8.1) years in con-
trol; 46.2% female in intervention group, 60.9% female in control
Deaths at end of study (N (%)): Total N = 8: 4 (15.4%) intervention and 4 (17.4%) control
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Withdrawals/other dropouts (N (%)): Not stated
Interventions Name: Early palliative care (EPC) at home with usual care vs usual care
EPC: The authors reported that they chose patients with LTOT and/or NIV and/or hospitalised with-
in the preceding year. Patients hospitalised for AECOPD are at high risk of subsequent readmission or
post-discharge mortality; those under LTOT and/or home NIV also have a limited survival, justifying the
chosen criteria.
Type: Specialist palliative care. Included nurses with experience in palliative care and a palliative care
physician
Service base: Geneva University Hospitals
Team: Included nurses with experience in palliative care and a palliative care physician who supervised
the PC interventions and defined medical strategies whenever symptom scores were abnormal (ESAS
items > 4).
Intervention condition: EPC group patients met the community ambulatory palliative care team as
soon as possible after inclusion and monthly for 12 months. Home visits by nurses from the palliative
care consultation lasted approximately 90 min and focussed on symptom assessment and manage-
ment using the Edmonton Symptom Assessment Scale (ESAS) (If intensity of pain, dyspnoea, mood,
anxiety, and appetite were > 4/10 and the patient agreed, a consultation with a palliative care physician
(or other specialist) was suggested), nutrition, understanding of illness and coping, anticipation and
decision-making, support of relatives, social-spiritual needs, co-ordination between different health
providers and alternative approaches such as relaxation. All cases were discussed with a physician spe-
cialised in palliative care, whom the patient could consult whenever appropriate. The EPC group also
received standard care throughout the study period.
Duration: 12 months
Control condition: Control group patients had no contact with the palliative care team. For all patients
under LTOT and/or home NIV, specialised nurses provided regular home visits to check on all aspects
related to respiratory support. Treatments prescribed by a primary care physician or pulmonologist
were not modified. Because the palliative care team was distinct from those providing standard care,
the risk of 'contamination' of the control group by the early palliative care intervention was minimal.
Outcomes Primary outcomes




Symptoms assessed using the Edmonton Symptom Assessment Scale (ESAS)
Health-related quality of life (HRQoL) assessed using the SF-36
Mood disturbances assessed using the Hospital Anxiety and Depression Scale (HADS-A and HADS-D)




After written informed consents were obtained and completion of baseline assessments, patients were
randomised to EPC and control groups. Every month, data related to primary outcomes were recorded
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through hospital files, contact with the patient and his/her GP. Data related to the secondary outcomes
were collected every three months.




Notes Funding source: Swiss National Foundation for Research, within a programme focussing on palliative
care. The authors also received additional funding from the Lancardis Foundation and the Pulmonary
League of Geneva, both non-profit organisations devoted to supporting healthcare and research.
Declarations of interest among primary researchers: The authors declared that they had no conflict
of interest to report regarding the study.
Power considerations: Regarding the primary outcome, the authors calculated that a sample size of
80 patients per group would be adequate with an 80% power to detect a difference in hospital admis-
sions of 20% between both groups at an α significance level (2-sided test) of 0.05 (obtained from study
protocol).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "patients were randomly assigned to the early
palliative care group (EPC) or the standard care group (SC) in a 1:1 ratio with-
out stratification and with randomised block sizes ranging from 4 to 6, using
sealed envelopes prepared with a computer program by... a co-investigator




Low risk Quote from main publication: "patients were randomly assigned to the early
palliative care group (EPC) or the standard care group (SC) in a 1:1 ratio with-
out stratification and with randomised block sizes ranging from 4 to 6, using
sealed envelopes prepared with a computer program by... a co-investigator






High risk Information obtained from the trial registry indicated it was open-label.
Comment: participants and personnel were not blinded. Consequently, a high





Low risk Information obtained from the trial registry indicated it was open-label.
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in the objective outcomes assessed.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Information obtained from the trial registry indicated it was open-label.
Comment: Outcome assessors were not blinded. Consequently, a high risk of
bias was rated.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Information obtained from the trial registry indicated it was open-label.
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Comment: Outcome assessors were not blinded but this was unlikely to lead




Low risk It appeared there were N = 22 (84.6%) completers in intervention group vs N =
19 (82.6%) completers in control group. There were 4 (15.4%) deaths in the in-
tervention group and 4 (17.4%) deaths in the control group. Given that missing
data were included in the analysis, a low risk of bias rating was given.
Selective reporting (re-
porting bias)
High risk Some outcomes such as survival and advanced care planning were not stated
a priori in the clinical trial registry.
Other bias Low risk Study appeared to be free of other biases.






Methods Design: RCT (information provided for sections that were translated)
Who led PC intervention: Multidisciplinary team
Core team: Physician/senior nurse/junior nurse
Participants Country and regions: China (foreign language study)
Recruitment: March 2015 to August 2016
Inclusion criteria: Patients who are:
1. Clinically diagnosed to have late-stage lung cancer (stages III and IV)
2. Expected life expectancy > 6 months
3. Radiation therapy post-operation
4. Informed consent to participate
Exclusion criteria: The exclusion criteria are:
1. Inability to adhere to experiment, disagreeable participants
2. Disabilities that can affect visual-auditory understanding, speech
3. Participated in other experiments within recent one month
4. Major mental illnesses and cognitive deficiencies
5. Infectious diseases or immune disorders
Number of patients: N = 106 (53 intervention and 53 control)
Diseases: Advanced lung cancer
Patient characteristics: Mean age (SD): 64.25 (10.41) years in intervention group, 63.34 (10.22) years in
control; 42% female in intervention group, 53% female in control
Deaths at end of study (N (%)): Unclear as not stated in paper
Withdrawals/other dropouts (N (%)): Unclear as not stated in paper
Interventions Name: Palliative care based on the knowledge-belief-action model vs control (routine nursing inter-
vention)
Type: Specialist palliative care. Clinical team was trained by expert in model of knowledge-belief-ac-
tion palliative care
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Service base: Hospital
Team: Clinical team comprised main attending physician, senior nurse and junior nurse who were
equipped with relevant educational qualifications, good communication and co-ordinating skills.
Intervention condition: Intervention included three stages:
1. First stage of model (hospitalisation 1 to 3 days) promoted health knowledge, including family sup-
port
2. Second stage of model (hospitalisation 4 to 6 days) established healthy beliefs/attitudes
3. Third stage of model (hospitalisation 7 days to discharge) addressed behaviour
All patients in the study group were given a 3-month nursing intervention.
Duration: Three months
Control condition: Control patients received a routine nursing intervention.
Outcomes Outcomes
Cancer-related fatigue assessed using the Piper Fatigue Scale
Quality of life assessed using the Chinese version of the EORTC QLQ-C30
Nursing satisfaction assessed using hospital self-made survey questionnaire
Resource use/costs Not reported
Notes Funding source: Funded by Chengde Science and Technology Bureau, Science and Technology Re-
search and Development Plan
Power considerations: Authors did not include a power calculation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "106 patients with advanced lung cancer in our
hospital were selected and divided into the study group and control group ac-









Unclear risk Information not provided in the study
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Information not provided in the study
Blinding of outcome as-
sessment (detection bias),
objective outcomes




Unclear risk Information not provided in the study
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Selective reporting (re-
porting bias)
Unclear risk Unclear as protocol not available
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-







Who led PC intervention: Multidisciplinary team
Core team: Physicians/nurses/social worker/chaplain/volunteers
Participants Country and regions: USA, West Los Angeles
Recruitment: Recruitment period was not stated. For each hospital admission, the primary physician
of each patient on the roster was consulted to ascertain whether the patient’s condition (cancer) was
terminal. When the physician believed that the patient had a terminal prognosis of two weeks to six
months and the patient had been informed of this prognosis, the patient was invited to participate in
the study.
Inclusion criteria: These criteria included 1) diagnosis of cancer, 2) terminal prognosis (life expectancy
of up to 6 months for the inpatients and 1 year for outpatients), 3) residence within a 30-minute driving
range of the Wadsworth Hospital if an outpatient, and 4) sufficient responsiveness to the environment
to be judged capable of providing informed consent for study participation and the potential of bene-
fiting from the hospice programme
Exclusion criteria: Not stated
Number of patients: N = 247 (137 intervention and 110 control)
Diseases: Lung (N = 89, 36%), prostate (N = 26, 10.5%), ear, nose and throat (N = 25, 10.1%), brain (N =
18, 7.3%), other (N = 89, 36%)
Patient characteristics: Mean age (SD): 63.3 years in intervention group, 64 years in control; 2.2% fe-
male in intervention group, 2.8% female in control
Number of survivors of patients: N = 96 (56 intervention and 40 control)
Survivor characteristics: Mean age (SD): 56 (11) years in intervention group, 58 (13) years in control;
87% female in intervention group, 77% female in control
Deaths at end of study (N (%)): Total N = 230: 128 (93.4%) intervention and 102 (92.7%) in control
group
Withdrawals/other dropouts (N (%)): Total N = 10. Numbers in intervention and control group not giv-
en
Interventions Name: Hospice provided both in a special inpatient unit and at home vs usual care
Type: Specialist palliative care as the intervention was a hospice programme
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Service base: The hospice programme studied was based at the Veterans Administration (VA) Medical
Center, West Los Angeles, Wadsworth Division, a university-affiliated teaching hospital
Team: The hospice included an 11-bed inpatient unit sta,ed by 2 physicians, 19 nurses, a social work-
er, a chaplain, and about 30 volunteers; a homecare programme serving about 25 patients at any given
time; and a consultation service for patients awaiting admission to the hospice inpatient unit or need-
ing emergency hospital care when no hospice inpatient beds are available.
Intervention condition: Hospice patients were referred to the hospice programme, which conducted
its own assessment and developed a treatment plan.
Duration: Enrollment to death
Control condition: Control patients continued under their current care.
Outcomes Outcomes
Pain was measured using the McGill Pain Scale.
The symptom scale was adapted from the California Pain Assessment Profile.
Depression was measured using the Centre for Epidemiologic Studies-Depression Scale (CES-D).
Anxiety was measured using a section of the General Well-Being Measure used in the Rand Health In-
surance Study.
Satisfaction with care: interpersonal care measured using the interpersonal care scale adapted from
the Ware scale, question on the degree of satisfaction with involvement in care adapted from the Na-
tional Cancer Institute's Hospice Study and physical environment satisfaction scale adapted from Mc-
Caffree and Harkins
Mortality
Assessment point: Randomisation was followed by baseline interviews. Both hospice and control pa-
tients and their familial unpaid caregivers were interviewed according to a fixed schedule until the pa-
tient's death or until a pre-established number of interviews of each type had been conducted. The in-
tervals between interviews varied with different questionnaires.
Resource use/costs Total inpatient days: general medical, hospice, ICU and intermediate care
Nursing home days
Number of days at home
Radiation treatments
Chemotherapy treatments
Use of surgical procedures: major and minor surgical procedures
Use of diagnostic procedures
Time horizon: Both hospice and control patients and their family unpaid caregivers were interviewed
according to a fixed schedule until the patient’s death or until a pre-established number of interviews
of each type had been conducted.
Data sources: The number of hospital days the patient spent in the hospice ward, the intermediate
care ward, a general medical ward, or an intensive care unit was obtained from the charts of each pa-
tient who died. For patients who had inpatient stays in other hospitals, the authors obtained the to-
tal number of hospital days, but were often unable to obtain the breakdown of days between inten-
sive care unit and other wards. In the cost study, the authors obtained utilisation data from complet-
ed inpatient charts. A total of 144 patients had complete data for all cost elements, but bed-day calcu-
lations were made on a larger sample of 230 patients. Completed inpatient charts were abstracted to
obtain records of the patient’s use of drugs, laboratory, radiology, surgical, and diagnostic procedures,
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chemotherapy, radiation therapy, nuclear medicine, and consultation services. Each of these was as-
signed a price. The number of times each drug was administered was summed and multiplied by the
unit price of the drug to obtain the total drug costs for a given patient over all hospital stays. The au-
thors were able to obtain prices for drugs, major surgical procedures, pathology, and chemotherapy,
as well as the cost of a bed in a general medical or intensive-care unit. However, the VA operated two
classes of beds for which there was no ready equivalent at UCLA. Wadsworth VA operated an intermedi-
ate-care ward for patients not requiring treatment as intensive as that given in a general medical bed.
The authors used the VA cost accounting estimates that an intermediate-care bed costs 70% as much
as a general medical bed. For hospice per diem costs, the authors used two alternate assumptions—(1)
equal to intermediate care; and (2) equal to a general medical bed.
Analytical perspective: Not clear
Notes Funding source: This work was supported by grants from the California chapter of the American Can-
cer Society and the Henry J. Kaiser Family Foundation and by direct assistance from the VA Medical
Center, Wadsworth.
Declaration of interest among primary researchers: Not stated
Power considerations: No sample size calculation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "after informed consent was received from pa-
tients and their FCGs, patients were randomly assigned to receive hospice
or conventional care; the sampling proportion was deliberately weighted to
favour hospice care".
Comment: random sequence generation was unclear.
Allocation concealment
(selection bias)





High risk Participants and personnel were not blinded.





Low risk Participants and personnel were not blinded.
Comment: There was no blinding but this was unlikely to lead to bias in objec-
tive outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Blinding of outcome assessment was unclear.
Comment: an unclear risk of bias was given because blinding of outcome as-
sessment was unclear.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Blinding of outcome assessment was unclear.
Comment: Although blinding of outcome assessment was unclear, this was un-




High risk N = 9 (7%) completers in intervention group vs N = 9 (8.2%) completers in con-
trol group. No information was provided on how missing data was handled.
Comment: high risk of bias
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Selective reporting (re-
porting bias)
Unclear risk Unclear as protocol not available
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Nurse-led intervention
Core team: Nurses. The intervention nurses had a weekly clinical support session with their clinical
palliative care mentor to review complex cases.
Participants Country and regions: Mombasa, Kenya
Recruitment: Period of recruitment not stated. The authors screened patients waiting onsite for rou-
tine clinic appointments. Each day, they drew a random number to select the first waiting patient to
screen, then all consecutive waiting patients were subsequently screened.
Inclusion criteria: Authors enrolled adults taking antiretroviral therapy (ART) for at least 1 month, with
a pain or symptom score of 3–5 (the score ranges from 0 [best] to 5 [worst]) and reporting that their
pain or symptoms had lasted more than 2 weeks.
Exclusion criteria: Authors excluded patients who had pain or symptoms for fewer than 2 weeks, were
receiving ART for prevention of mother-to-child transmission, or did not speak English or Swahili.
Number of patients: N = 120 (60 intervention and 60 control)
Diseases: People with HIV on ART
Patient characteristics: Mean age (SD): 38.3 (8.2) years in intervention group, 40.5 (9.2) years in con-
trol; 80% female in intervention group, 82% female in control
Deaths at end of study (N (%)): Total N = 3: 3 (5%) intervention and none in control group
Withdrawals/other dropouts (N (%)): Total N = 3: 3 (5%) intervention and none in control group
Interventions Name: Nurse-led palliative care intervention vs usual care
Type: Specialist palliative care. Nurses received 2 weeks of full-time palliative care training delivered
by Kenyan experts from the Kenyan Hospice and Palliative Care Association.
Service base: Outpatient HIV clinics in a community hospital
Team: Two experienced nurses employed by the HIV clinic
Intervention condition: These nurses used a standardised multidimensional assessment and care
planning instrument for all patients allocated to the intervention group to provide holistic patient-cen-
tred care. The instrument addressed physical, psychological, social, and spiritual well-being and pa-
tients’ understanding of their illness and adherence to ART. The instrument also included space to plan
and review care against prioritised needs. The intervention nurses had a weekly clinical support ses-
sion with their clinical palliative care mentor to review complex cases. Patients in the intervention
group met the trained nurse immediately after allocation, then at 2 weeks, 4 weeks, and for three sub-
sequent monthly appointments, with a total of six appointments over 4 months.
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Duration: 5 months
Control condition: Patients allocated to the control group received usual care from the HIV clinic, con-
sisting of monthly clinical assessments once ART was established, with investigations and treatment
for any relevant symptoms or problems. Nurses with no exposure to palliative care provided this ser-
vice, because no palliative care was available beyond the hospice. Patients in the control group re-
ceived usual monthly appointments (i.e. five appointments during the study).
Outcomes Primary outcomes:
Pain assessed using the pain item of the African Palliative care Outcome Scale (APOS)
Secondary outcomes
Psychological morbidity assessed using the General Household Questionnaire-12 (GHQ-12)
Palliative care-related problems and concerns assessed using the APOS
Adherence to ART
Quality of life assessed using the Medical Outcomes Study-HIV (MOS-HIV) scale
Assessment points: Baseline data was collected before randomisation; quantitative data was collect-
ed once a month for 5 months.
Resource use/costs None reported in main publication although it was stated that the Client Services Receipt Inventory
was used to record the components of care received by patients.
Notes Funding source: Diana Princess of Wales Memorial Fund
Declaration of interest among primary researchers: The authors declared that they had no compet-
ing interests.
Power considerations: The authors calculated that they would need to enroll 60 participants in each
group, allowing for 6% attrition, to detect a 1 point change in the pain score on APOS with 5% precision
and 80% power.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "participants were randomly assigned (1:1) by block
randomisation (block size 40) to either intervention or control".
Comment: insufficient information about sequence generation process
Allocation concealment
(selection bias)
Unclear risk Quote from publication: "participants selected a folded slip of paper from a
box offered by the researcher, which was unfolded by the researcher and the
assignment (to control or intervention) recorded".
Comment: "unclear risk" was rated because although the slip of paper was
folded, they were not included in sealed envelopes which may have reduced





High risk Quote from publication: "participants and investigators were not masked to
allocation".
Comment: high risk due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from publication: "Participants and investigators were not masked to
allocation".
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Unclear risk N = 54 (90%) completers in intervention group vs N = 60 (100%) completers in
control group. 6 patients in intervention group were excluded from the analy-
sis because they died (3), migrated (2) or withdrew (1) due to time constraints.
Selective reporting (re-
porting bias)
High risk Data collected using the Client Services Receipt Inventory was not reported.
Other bias Unclear risk Study appeared to be free of other biases.






Methods Design: Cluster-randomised crossover trial
Who led PC intervention: Multidisciplinary team
Core team: A physician board-certified in palliative care, nurse practitioners, a palliative care clinical
fellow, a social worker, and a chaplain.
Participants Country and regions: USA
Recruitment: August 2017 to May 2018. A member of the research team who was independent of the
ICU and palliative care teams screened the electronic medical records of MICU admissions within the
previous 24 hours. Up to the first two consecutively screened patients meeting eligibility criteria were
enrolled per MICU each weekday in both the intervention and control arms.
Inclusion criteria: Patients who met any of the following criteria: admitted from long-term skilled
nursing facility or acute care facility, or admitted from home with activities of daily living dependencies
requiring skilled nursing; end-stage neurologic condition; advanced or metastatic cancer; arrest with
neurologic compromise; multiple organ system failure; end-stage organ disease; shock; acute respira-
tory failure and prolonged length of stay or ICU readmission.
Exclusion criteria: History of any stem cell transplant; solid organ transplant within 1 yr of transplant,
or actively undergoing workup for solid organ transplant; non-English speaking patients for whom an
interpreter was unavailable; patients without capacity to participate in palliative care (PC) discussions
with no identifiable surrogate; patients who had received a PC consultation earlier during the same
hospitalisation; patients already determined to be do-not-resuscitate/do-not-intubate (DNR/DNI).
Number of patients: N = 199 (97 intervention and 102 control)
Diseases: Neurologic, CHF, coronary artery or peripheral vascular disease, end-stage renal disease, sol-
id organ transplant, cancer, HIV, COPD, cirrhosis
Patient characteristics: Mean age (SD): 66 (14) years in intervention group, 62 (12) years in control;
51% female in intervention group, 45% female in control
Deaths at end of study (N (%)): Total N = 71: 34 (35.1%) intervention and 37 (36.3%) in control group
Withdrawals/other dropouts (N (%)): Not reported
Interventions Name: Early palliative care consultation vs usual care
Early PC: Early palliative care consultation within 48 hours of medical intensive care unit (MICU) admis-
sion
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Type: Specialist palliative care. Included a physician board-certified in palliative care and a palliative
care clinical fellow
Service base: Barnes-Jewish hospital
Team: A physician board-certified in palliative care, nurse practitioners, a palliative care clinical fellow,
a social worker, and a chaplain
Intervention condition: Intervention arm patients received a palliative care consultation within 48
hours of MICU admission. A palliative care consultation included: chart review of the patient’s hospital-
isation, meeting with the patient and available healthcare proxies, identification of physical and emo-
tional needs of the patient and family, discussion with the primary team on how best to meet those
needs, and communication between all parties with respect to goals, values, and treatment decisions.
Formal meetings including the palliative care team, primary team, and the patient or healthcare prox-
ies were encouraged but not mandatory. A care plan for each consultation was discussed by the entire
palliative care team at rounds, with additional team members participating as appropriate. The pallia-
tive care team continued to follow the patient until discharge from the hospital.
Duration: Hospitalisation to discharge
Control condition: The control arm received standard of care: palliative care could be consulted at the
discretion of the MICU clinicians.
Outcomes Primary outcomes:
Proportion of patients who transitioned to DNR/DNI resuscitation preference before hospital discharge
Secondary outcomes
MICU length of stay
Hospital length of stay
Discharge to hospice





Post-discharge emergency department visits
Hospital readmissions.
Assessment points: During hospitalisation and also post-discharge
Resource use/costs MICU length of stay
Hospital length of stay




Post-discharge emergency department visits
Hospital readmissions
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Cost
Time Horizon: During hospitalisation and also post-discharge
Notes Funding source: The study was supported by The Foundation for Barnes-Jewish Hospital and Wash-
ington University Institute of Clinical and Translational Sciences (ICTS).
Declaration of interest among primary researchers: Drs. Chi, Buettner, Al-Hammadi, and Kollef re-
ceived support for article research from the NIH. Dr. Buettner’s institution received funding from ICTS
Just In Time award. Drs. Buettner’s and Dans’s institutions received funding from Barnes-Jewish Hos-
pital Foundation. Dr. Chen disclosed work for hire. Dr. Kollef’s effort was supported by the Barnes-Jew-
ish Hospital Foundation. Dr. Dans’ institution also received funding from ICTS at Washington Universi-
ty School of Medicine and Barnes Jewish Hospital Foundation, and she received funding from Nation-
al Comprehensive Cancer Network (NCCN). The remaining authors disclosed that they do not have any
potential conflicts of interest.
Power considerations: Based on preliminary data from the first 60 days of the study, a generalised es-
timating equation model was used to determine that 96 patients would be required per arm to detect a
threefold increase (54% vs 18%) in the primary outcome with 80% power and a type 1 error of 5%.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "the two medical ICUs (MICUs) of Barnes-Jewish
Hospital (1,250 beds) comprised of 16 and 18 beds respectively were randomly
assigned to intervention or usual care. A washout period of 6 weeks occurred
halfway through the study during which enrollment was halted and new ad-
missions received usual care, followed by crossover of the MICUs to interven-
tion or usual care".
Comment: random sequence generation was unclear.
Allocation concealment
(selection bias)
Low risk Quote from main publication: "the two medical ICUs (MICUs) of Barnes-Jew-
ish Hospital (1,250 beds) comprised of 16 and 18 beds respectively were ran-
domly assigned to intervention or usual care. A washout period of 6 weeks oc-
curred halfway through the study during which enrollment was halted and
new admissions received usual care, followed by crossover of the MICUs to in-
tervention or usual care... The Washington University School of Medicine Hu-
man Studies Committee approved this investigation and waived the need for
informed consent".
Comment: given that the need for informed consent was waived, it appeared






Low risk Quote from trial registry indicated it was open-label. However, this was unlike-
ly to lead to bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "two trained research study team members in-
dependently collected process and outcome data for each patient’s hospitali-
sation, and a third team member reconciled any discrepancies. Physicians and
study team members were not blinded because of inherent difficulties with
blinding of the palliative care intervention."
Comment: lack of blinding was unlikely to lead to bias in objective outcomes.
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High risk N = 63 (64.9%) completers in intervention group vs N = 65 (63.7%) completers
in control group. Some patients were not included in the analysis of the out-
comes and it was unclear how the authors dealt with missing data.
Selective reporting (re-
porting bias)
High risk One of the secondary outcomes (antibiotic usage and duration) specified in
the trial registry was not reported.
Other bias Low risk Study appeared to be free of other biases.







Pilot phase II RCT
Who led PC intervention: Nurse-led intervention (services provided up to 24 h/day for up to 5 days)
Core team: Nursing services (utilising agency nursing sta,). It also co-ordinates allied health input (oc-
cupational therapy, physiotherapy, pastoral care) if equipment or other services are needed.
Participants Country and regions: Australia, Southwest Sydney, New South Wales
Recruitment: Recruitment sites were an inpatient unit and the community.
Inclusion criteria: Patients were eligible if they had complex or unstable symptom management and
high care needs.
Exclusion criteria: Not stated
Number of patients: N = 31 (23 intervention and 8 control)
Diseases: Predominantly cancer (N = 25, 80.7%), non-cancer (N = 3, 9.7%) and not reported (N = 3,
9.7%)
Patient characteristics: Mean age (SD): 62.8 (14.2) in intervention group, 66 (20.8) in control group;
39.1% female in intervention group, 50% female in control group
Deaths at end of study (N (%)): N = 68%; mean (95% CI): 69.6% (52.2%, 87%) intervention and 62.5%
(25%, 100%) control
Withdrawals/other dropouts (N (%)): None
Interventions Name: Home-based palliative care vs usual care
Type: Training in palliative care unclear
Service base: Hospital
Team: Includes nursing services (utilising agency nursing sta,). It also co-ordinated allied health input
(occupational therapy, physiotherapy, pastoral care) if equipment or other services are needed.
Intervention condition: PEACH was an individualised care package determined by local protocols for
community and inpatients. Services were rapidly mobilised, essential equipment was secured, allied
health was co-ordinated and higher intensity nursing was provided (up to 24 h/day for up to 5 days)
compared with usual care.
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Duration: 28 days
Control condition: Usual care encompassed conventional discharge planning with existing communi-
ty services including specialist palliative care, access to an after-hours number, and equipment from
loan pools.
Outcomes Primary outcome:
Number of days out of institutional care (determined from medical records of admissions to hospital




Assessment points: 28 days
Resource use/costs Number of days at home
PEACH intervention costs (sta, administration, travel and direct patient contact time, overheads and
consumables)
Cost of specialist palliative care service use
Cost of acute hospital and palliative care unit inpatient lengths of stay and outpatient visits
Time horizon: from study enrollment to 28 days
Data sources: Patient-level data were collected prospectively, including: days at home; place of death;
PEACH intervention costs (sta, administration, travel and direct patient contact time, overheads and
consumables); specialist palliative care service use; acute hospital and palliative care unit inpatient
lengths of stay and outpatient visits. Resource use was costed according to the Australian Manual of
Resource Items and their Associated Costs, and inpatient stays as recommended by the Australian Med-
ical Services Advisory Committee guidelines. Specialist palliative care services and PEACH costs were
estimated using hourly rates of local salaries (plus 30% on-costs), agency sta, costs and equipment
hire. PEACH administrative costs were included. Outpatient visits were costed using the National Hos-
pital Cost Data Collection.
Analytical perspective: Healthcare provider perspective
Notes Funding source: This study was funded by the Australian Government Department of Health and Age-
ing under the National Palliative Care Program, Palliative Care for People at Home. NM was also funded
through the National Palliative Care Program and Flinders University.
Declarations of interest among primary researchers: The authors declared no competing interests.
Power considerations: None reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "participants were randomised to receive
PEACH or usual care in a 3:1 ratio, increasing experience with PEACH and aid-
ing recruitment and ethics approval".
Comment: there was insufficient information about the random sequence gen-
eration process.
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Allocation concealment
(selection bias)





Low risk Quote from trial registry: "masking not used"
Comment: masking was not carried out but this was unlikely to lead to bias in
objective outcomes.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from trial registry: "masking not used"
Comment: masking was not carried out but this was unlikely to lead to bias in




Low risk N = 7 (30.4%) completers in intervention group vs N = 3 (37.5%) completers in
control group. In the intervention group, 16 (69.6%) patients died during the
28-day follow-up while 5 (62.5%) died in control group. Complete data were
available and used in cost-effectiveness analysis.
Selective reporting (re-
porting bias)
High risk Some secondary outcomes in the protocol such as change in symptom score,
functional status, unpaid caregiver QoL and modified family inventory of
needs score were not reported in the main publication. Study was retrospec-
tively registered.
Other bias Unclear risk There were differences in age, gender, marital status, recruitment site and the
percentage of patients with different diagnosis between the intervention and
control group at baseline. The authors did not state if these differences were
statistically significant and whether they controlled for them.







Who led PC intervention: Multidisciplinary team
Core team: Advanced practice nurse (APNs)/physician assistants (PAs)/medical social workers (MSWs)/
nurse co-ordinators/medical oncologists/ surgeons/radiation oncologists worked as a palliative care
unit with the study APN overseeing the co-ordination and implementation of the intervention by differ-
ent members of the team.
Participants Country and regions: USA, Connecticut
Recruitment: August 2010 and December 2012. Eligible patients were identified at weekly tumour
boards. Patients’ oncologist asked patients if they were interested in the study. Research sta, met with
interested patients to explain the study, obtain consent, and administer baseline questionnaires.
Inclusion criteria: Eligible patients qualified based on (1) a late-stage cancer diagnosis within 100
days; (2) post-biopsy or surgery with additional treatment recommended; (3) at least one self-reported
chronic condition; and (4) age > 21 years.
Exclusion criteria: Not stated
Number of patients: N = 146 (66 intervention and 80 control)
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Diseases: Gynaecologic (29), lung (37), gastrointestinal (53), and head and neck cancers (27)
Patient characteristics: Mean age (range): 34 (51.5%) were < 65 years and 32 (48.5%) were 65 years
and older in intervention group, 57 (71.3%) were < 65 years and 23 (28.7%) were 65 years and older in
control group; 71.2% female in intervention group, 43.7% female in control group.
Deaths at end of study (N (%)): N = 10: 7 (10.6%) intervention and 3 (3.75%) control
Withdrawals/other dropouts (N (%)): N = 44: 23 (34.8%) intervention and 21 (26.3%) control
Interventions Name: An advanced practice nurse (APN) co-ordinated multidisciplinary intervention vs enhanced usu-
al care (usual multidisciplinary care plus a copy of the symptom management toolkit with instructions
on its use).
Early PC: Eligible patients were those with a late-stage cancer diagnosis within 100 days.
Type: Specialist palliative care. Advanced practice nurses (APNs), physician assistants (PAs), and med-
ical social workers (MSWs) in the two disease-specific clinics participated in three one-hour, one-on-
one training sessions with the study APN co-ordinator. Training included review of evidence-based
symptom protocols, documentation requirements, guidelines on handling adverse events and commu-
nication strategies to enhance patient problem-solving, decision-making, and self-efficacy.
Service base: Four disease-specific multidisciplinary clinics (gynaecologic, lung, gastrointestinal, and
head and neck clinics) at Smilow Cancer Hospital (SCH) at Yale-New Haven, Connecticut
Team: Members of each disease-specific multidisciplinary team (APNs, PAs, MSWs, nurse co-ordina-
tors, medical oncologists, surgeons, and radiation oncologists) worked as a palliative care unit with the
study APN overseeing the co-ordination and implementation of the intervention by different members
of the team.
Intervention condition: The essential components of the intervention included monitoring patients’
status, providing symptom management, executing complex care procedures, teaching patients and
family unpaid caregivers, clarifying the illness experience, co-ordinating care, responding to the family,
enhancing QoL, and collaborating with other providers. In addition, goals of care were discussed. The
study APN trained the clinic sta, (APNs, PAs, MSWs) in the lung and gynaecological clinics prior to the
recruitment of patients. Members of each disease-specific multidisciplinary team worked together as
a palliative care unit, each member taking on different functions to ensure all components of the inter-
vention were addressed. The clinic APN oversaw the co-ordination and implementation of the interven-
tion by different members of the team. Intervention fidelity was assessed and monitored by the study
APN co-ordinator.
Duration: 10 weeks
Control condition: Patients in this group did not receive the APN-co-ordinated intervention but con-
tinued to receive routine oncology care delivered by multidisciplinary members of the head and neck
and gastrointestinal disease-specific clinics. Both groups received a copy of the Symptom Management
Toolkit, a resource manual describing 28 common symptoms and problems associated with cancer
treatment and were instructed on its use.
Outcomes Primary outcome
Symptom distress assessed using the Symptom Distress Scale (SDS)
Health distress assessed using a four-item scale developed by the Stanford Patient Education Research
Center
Depression assessed using Personal Health Questionnaire (PHQ-9)
Functional status assessed using the Enforced Social Dependency Scale (ESDS)
Self-reported health assessed using the first item of the Short Form - 12 (SF-12)
Secondary outcomes
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Quality of life assessed using the Functional Assessment of Cancer Therapy-General (FACT-G)
Anxiety assessed using the Hospital Anxiety and Depression Scale (HADS)
Uncertainty assessed using the Mishel Uncertainty in Illness Scale – Community Form (MUIS-C)
Self-efficacy assessed using the Self-Efficacy for Managing Chronic Disease Scale (SEMCD-6)
Assessment points: Standardised scales were used to collect five primary patient outcomes at all
three data collection points (baseline - after randomisation, one and three months). The four sec-
ondary outcomes were collected at one and three months post-baseline.
Resource use/costs None reported
Notes Funding source: Funded by NIH/NINR grant R01NR011872
Declarations of interest among primary researchers: Apart from funding, no further study author
disclosure statements were made.
Power considerations: Not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "a cluster randomisation procedure was used
to randomise four disease-specific clinics at Smilow Cancer Hospital (SCH) at
Yale–New Haven into two groups: an intervention group (an APN-co-ordinated
multidisciplinary intervention) and an enhanced usual care group (usual multi-
disciplinary care plus a copy of the symptom management toolkit with instruc-
tions on its use). Due to the ongoing interactions of the team members to dis-
cuss and share patients’ treatment plans and management strategies in the
disease-specific clinics, it was important to randomise the clinics and not the
patients... Randomisation was done using the ranuni function in conjunction
with the rank procedure in statistical software SAS (SAS version 9.2 for Win-










High risk Participants and personnel were not blinded.
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Unclear because no mention was made of this





High risk N = 36 (54.5%) completers in intervention group vs N = 56 (70%) completers in
control group. Missing data were not balanced in numbers across intervention
and control group. There were high proportions of loss-to-follow-up and these
were excluded from the analysis. In the intervention group, patients were lost-
to-follow-up because 22 (33.3%) were treated at other facilities, 7 (10.6%) died
and 1 (1.5%) withdrew. In the control group, patients were lost-to-follow-up
because 20 (25%) were treated at other facilities, 3 (3.8%) died and 1 (1.3%)
withdrew.
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Selective reporting (re-
porting bias)
High risk Uncertainty assessed using the Mishel Uncertainty in Illness Scale – Commu-
nity Form (MUIS-C) was specified as the primary outcome on the clinical trial
registry, clinicaltrials.gov (NCT01272024). However, this was reported as a sec-
ondary outcome in the main publication. Other outcomes that were not speci-
fied on the trials registry were also reported.
Other bias Unclear risk The authors reported that "patient characteristics in both groups were simi-
lar, except patients in the intervention group were older, more likely to be fe-
male, had more chronic conditions, and were diagnosed with later-stage can-
cers". The authors did not state whether they controlled for these variables in
the analysis.
Comment: unclear risk of bias
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-





Methods Design: RCT (patient and unpaid caregiver)
Fast-track RCT
Who led PC intervention: Multidisciplinary team (one of the team nurses, with physician back-up, was
available 24 hours a day)
Core team: Palliative care nurses (working one week on, one o,)/physician/part-time social worker
Participants Country and regions: Canada, London, Ontario, metropolitan area
Recruitment: (date and length not stated). From family physicians and home care (HC) nurses (with
“strenuous efforts to attract referrals, including an information sheet for family doctors and presenta-
tions to medical meetings” resulting in short lived increases)
Inclusion criteria: Aged > 18 years; being cared for at home by an eligible unpaid caregiver; having
symptomatic cancer which had metastasised or spread to surrounding tissues; and expected to survive
for two months.
Exclusion criteria: Not explicitly stated
Number of patients (randomised): 146
Diseases: Cancer (146)
Number of unpaid caregivers who completed questionnaires: 74
Patient and unpaid caregivercharacteristics: Not stated
Deaths at end of study: N = 36 (numbers in the intervention and control groups not stated)
Withdrawals/other dropouts: 14 patients (10%) failed to complete the one-month questionnaire and
in 3 patients, the reasons for dropout were not stated.
Interventions Name: Palliative care home support team based on an inpatient unit vs standard care
Type: Specialist palliative care. The palliative care home support team consisted of two experienced
palliative care nurses (working one week on, one o,), one physician, and a part-time social worker.
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Service base: The palliative care home support team was based on a 14-bed palliative care unit.
Team: Two experienced palliative care nurses, one physician, and a part-time social worker
Intervention condition: The team was planned to be a consulting and support service for family physi-
cians and home care nurses. Within three days of referral by a family doctor or nurse, one of the team
nurses carried out a full assessment in the home. The nurse's assessment and recommendations were
discussed with the team doctor, then sent to the family doctor with copies to the visiting nurse and
home care case manager. A consultation by the team doctor was available on request. All new and ac-
tive cases were discussed at the weekly team meeting. The involvement of the team after the initial as-
sessment depended on the wishes of the patient and family and on negotiation with the family physi-
cian and home care nurse. One of the team nurses, with physician back-up, was available 24 hours a
day, and patients were given a number to call if their home care nurse or family doctor could not be
reached.
Duration: Not stated
Control condition: Control patients'waiting list' group waited four weeks for assessment by the team.
Emergency consultation by the team physician was available for patients in the waiting list group if re-
quested by the family physician.
Outcomes Primary outcomes
Pain assessed using the McGill Pain Questionnaire
Nausea assessed using the Melzack Nausea Questionnaire
Secondary outcomes
Patient's quality of life (scale not stated)
unpaid caregiver's health (scale not stated)
Assessment points: After randomisation, a research assistant visited the home to provide more de-
tails, obtain written consent and explain the study questionnaires and then collect them after three
days. Data collection was repeated at one and two months, one month being the main comparison
point.
Resource use/costs None reported
Notes Funding source: This study was supported by a grant from the Ontario Ministry of Health.
Declarations of interest among primary researchers: Not reported
Power considerations: The number of patients was calculated on the basis of a reduction of 33%
in the main outcomes of pain and nausea. With an alpha level of 0.05 and a ß of 0.20, it was calculat-
ed that 110 patients would be required for each group, allowing for 20% attrition;...“because of early
deaths, problems with recruitment, and a low compliance rate for completion of questionnaires, the re-
quired sample size was not attained”.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "the project coordinator assessed eligibility and





Low risk Quote from main publication: "the project coordinator assessed eligibility and
conducted randomisation using a computer generated table of random num-
bers".
McWhinney 1994  (Continued)
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)















High risk Patients and unpaid caregivers were not blinded.
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Research assistant who visited patients and unpaid caregivers at home to col-
lect study questionnaires was blinded.





High risk Of the 146 patients who were randomised in this study, 53 (36.3%) were lost to
follow-up before one month. 36 (24.7%) died, 14 (9.6%) failed to complete the
one month questionnaires and 3 (2.1%) were unaccounted for by the authors.
There were high proportions of loss-to-follow-up.
Selective reporting (re-
porting bias)
Unclear risk Unclear as there was no published protocol
Other bias Unclear risk An unclear risk of bias was rated because the sample characteristics at base-
line was not reported.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was not






Who led PC intervention: Unclear
Core team: Professionals in palliative team were not described.
Participants Country and regions: Mexico
Recruitment: Not stated
Inclusion criteria: Newly diagnosed or relapsed metastatic breast cancer patients were included.
Exclusion criteria: Not stated
Number of patients: N = 53 (33 intervention and 20 control).
Diseases: Breast cancer
Patient characteristics: Not stated
Deaths at end of study (N (%)): Not stated
Withdrawals/other dropouts (N (%)): Not stated
Interventions Name: Early palliative care vs standard care
Early PC: Not described
Type: Training unclear
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Service base: Hospital, Instituto Nacional de Cancerologia in Mexico
Team: Palliative team. However, professionals in palliative team were not described.
Intervention condition: Intervention was provided by a palliative team, which included psychological,
nutritional and symptom support.
Duration: Not clear
Control condition: Standard care was given by the attending physician.
Outcomes Outcomes
Number of emergency room consultations
Number of hospitalisation
Hospitalisation length
Assessment points: Not stated
Resource use/costs Cost of emergency room consultations
Cost of hospitalisation days
Time Horizon: Unclear
Notes Funding source: Not stated
Declarations of interest among primary researchers: Not stated
Power considerations: Not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from abstract: "patients were randomized to standard care given by the
attending physician (control arm) or intervention by palliative team".
Comment: unclear risk of bias due to insufficient information in the abstract
Allocation concealment
(selection bias)










Unclear risk Comment: unclear risk of bias due to insufficient information in the abstract
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Comment: unclear risk of bias due to insufficient information in the abstract
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Blinding of outcome as-
sessment (detection bias),
objective outcomes




Unclear risk Comment: unclear risk of bias due to insufficient information in the abstract
Selective reporting (re-
porting bias)
Unclear risk Comment: unclear risk of bias due to insufficient information in the abstract
Other bias Unclear risk Comment: unclear risk of bias due to insufficient information in the abstract
Size of study High risk High risk of bias because the number of participants in each group was less
than 50





Who led PC intervention: Multidisciplinary team
Core team: The specialised palliative care team comprised physicians, nurses, physiotherapists, psy-
chologists, a part-time social worker, dietician, occupational therapist, and chaplain.
Participants Country and regions: Denmark, Vejle
Recruitment: Eligible patients were informed about the project by a doctor or nurse in the outpatient
clinic.
Inclusion criteria: First-time non-resectable cancer diagnosed less than 8 weeks before enrollment.
Patients with prostatic cancer were eligible, if referred to systemic oncologic treatment for the first
time less than 8 weeks before enrollment (e.g. due to failure of anti-hormone treatment). Patients el-
igible for systemic oncologic treatment at Vejle Hospital and accepted treatment. Patients aged ≥ 18
years of age with the ability to read and understand Danish. Patients who were able to provide written
and oral informed consent.
Exclusion criteria: Other contact with a specialised palliative care unit within 1 year of enrollment and
inability to comply with the protocol due to cognitive or other impairment
Number of patients: N = 281 (132 intervention and 149 control).
Diseases: Cancer
Patient characteristics: Mean age (SD): 66 (9) years in intervention group. % female: 42% female in in-
tervention group. Data not provided for control group.
Deaths at end of study (N (%)): N = 4 (3%) in the intervention group. Data not provided for control
group
Withdrawals/other dropouts (N (%)): N = 6 (4.5%) in the intervention group. Data not provided for
control group
Interventions Name: Palliative rehabilitation alongside standard oncology treatment vs standard treatment alone
Early PC: Patients were diagnosed with non-resectable solid cancer within the last 8 weeks
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Type: Specialist palliative care. Physician and nurse were specialised in palliative care. The specialised
palliative care (SPC) team had 15 years of experience in treating patients with life-threatening illness-
es and their unpaid caregivers, predominately as home-based specialised palliative care and in the late
phases of the disease. The SPC team received a 2-day visit from researchers and palliative rehabilita-
tion clinicians from the British and Irish Health Systems.
Service base: Department of Oncology, Vejle Hospital
Team: Specialised palliative care team consisting of physicians, nurses, physiotherapists, psycholo-
gists, a part-time social worker, dietician, occupational therapist and chaplain.
Intervention condition: The intervention consisted of a 'basic offer' and tailored elements. The basic
offer was two mandatory consultations and the option of contacting a palliative rehabilitation team di-
rectly during the participation period of 12 weeks, if needed. In addition, patients and family unpaid
caregivers could be offered participation in a 12-week patient/ unpaid caregiver school combined with
individually tailored physical exercise in groups, individual consultations with members of the pallia-
tive rehabilitation team, or both. Except for the chaplain, all SPC team members offered individual con-
sultations to patients and family unpaid caregivers in the palliative rehabilitation clinic or over the tele-
phone. The SPC team assembled for weekly multidisciplinary conferences discussing each patient at
least once.
Duration: 12 weeks
Control condition: The control group received standard care at the Department of Oncology. In ad-
dition to anticancer treatment, all patients had access to a number of paramedical services available
through referral. These services were not open for unpaid caregivers.
Outcomes Primary outcomes
Symptom/problem prioritised on an adapted form of the EORTC QLQ-C30 by patients
Secondary outcomes
Quality of life assessed using the EORTC QLQ-C30
Survival
Health service utilisation including number and length of hospital admissions and treatments, visits to
outpatient clinics, emergency rooms, and general practitioners
Assessment points: At baseline (before randomisation), 6 weeks and 12 weeks
Resource use/costs Health service utilisation including number and length of hospital admissions and treatments, visits to
outpatient clinics, emergency rooms, and general practitioners
Time horizon: From enrollment until three months after final data collection
Notes Funding source: This study was supported by the Danish Cancer Society, the Research Council of Lille-
baelt Hospital, the Andreas and Grethe Gullev Hansen Foundation and the Hede Nielsen Family Foun-
dation.
Declarations of interest among primary researchers: The authors declared that they had no conflict
of interest.
Power considerations: Data from other studies using EORTC QLQ-C30 suggested a SD of less than 25
for a difference between the repeated measurements, and a group difference of 10 for clinical rele-
vance. With a risk of type I error of 0.05 and type II error of 0.10, 133 patients were required in each arm.
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from study protocol: "randomisation is subsequently performed by the
clinical trial unit using a randomisation list from randomiser.org. Patients are
randomised 1:1 to the intervention or control group with no further stratifica-




Low risk Quote from study protocol: "the randomisation list is blinded from anyone in-






High risk Quote from study protocol: "blinding of study participants and health profes-






Low risk Quote from study protocol: "Blinding of study participants and health profes-
sionals is not possible".
Comment: Blinding was not carried out but this was unlikely to lead to bias in
assessment of objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Comment: It was unclear whether outcome assessors were blinded.
Blinding of outcome as-
sessment (detection bias),
objective outcomes





Unclear risk Data on attrition was only presented for the intervention group. In the in-




Unclear risk Comment: Unclear risk of bias due to insufficient information in the abstract
Other bias Unclear risk Comment: Unclear risk of bias due to insufficient information in the abstract
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Multidisciplinary team
Core team: Nurse practitioner/physician/social worker/chaplain
Participants Country and regions: USA
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Recruitment: Study recruited inpatients with heart failure (HF) being actively managed during the cur-
rent admission or had been within the past 6 months. Eligible patients were screened by conducting a
review of new inpatient admissions to the medicine and cardiology services. Eligibility was confirmed
through review of the electronic health record (EHR). The research co-ordinator contacted the patient’s
attending physician prior to approaching the patient to obtain informed consent.
Inclusion criteria: Inclusion criteria included:
• HF primary diagnosis or symptomatic/active HF in current hospitalisation or within prior 6 months
• NYHA Class II - IV
• > 18 years of age
• English speaking
• Able to give informed consent and pass Short Portable Mental Status Questionnaire (SPMSQ)
• Medicine, cardiology and HF service
• No previous palliative care or hospice care
Exclusion criteria: Exclusion criteria included:
• Pulmonary hypertension
• Right heart failure
• LeK ventricular device (LVAD)
• Percutaneous coronary intervention (PCI), coronary arterial bypass graK (CABG) or valve replacement
during index admission
• Pre/post heart, liver, lung transplant
• Homeless or live outside bay area
• Active illicit drug use
Number of patients enrolled: N = 39 (22 intervention and 17/18 control)
Number of patients who participated in study: N = 30 (16 intervention and 14 control)
Diseases: Heart failure
Patient characteristics: Mean age (SD): 71 (18) years in intervention group, 59 (19) years in control;
69% female in intervention group, 28% female in control group
Deaths at end of study (N (%)): N = 2: 1 (6.3%) in intervention and 1 (7.1%) in control group
Withdrawals/other dropouts (N (%)): N = 8: 5 (31.3%) in intervention and 3 (21.4%) in control group
Interventions Name: Interdisciplinary palliative care intervention (Symptom Management Service - HF [SMS-HF])
alongside standard cardiology care vs standard care
Type: Training unclear
Service base: Large, urban, academic medical centre in the US
Team: Inpatient palliative care team consisting of a nurse practitioner, physician, social worker and
chaplain
Intervention condition: Patients received a six–month palliative care intervention provided by the in-
terdisciplinary SMS–HF inpatient palliative care team. The SMS–HF team provided direct care to the pa-
tient including prescribing medications for symptoms, discussing advance care planning and complet-
ing appropriate documentation, and providing psychosocial and spiritual support and services. The pa-
tients first contact the SMS-HF team during hospitalisation. They received a one–week, in–person fol-
O'Riordan 2019  (Continued)
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
low–up assessment, and five monthly consultations, of which at least two were in person, with the re-
mainder conducted via telephone and including all members of the SMS-HF team. Additional contacts
with the SMS-HF team were scheduled as needed. Patients in the SMS-HF group who were re-admitted
to the same hospital were followed by the inpatient palliative care team. Standard electronic health
record (EHR) templates were used to document in–person and telephone care and communicate rec-
ommendations to the cardiology team.
Duration: 6 months
Control condition: The patients randomised to usual care received guideline–driven HF treatment. Au-
thors assessed all symptoms and quality of life (QoL) at enrollment and symptoms, QoL, satisfaction,
advance care planning documentation, and resource utilisation at follow-up three and six months lat-
er.
Outcomes Outcomes
Quality of life assessed using the Minnesota Living with HF Questionnaire (MLHFQ) and the Functional
Assessment of Chronic Illness Therapy with the palliative care subscale (FACIT–PAL)
Pain assessed using the Brief Pain Inventory (BPI).
Anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS)
Symptoms assessed using the Edmonton Symptom Assessment Scale (ESAS)
Fatigue assessed using the Brief Fatigue Inventory (BFI)
Dyspnoea assessed using the BORG Scale
Patient satisfaction assessed using an unvalidated scale
Assessment points: Patients were randomised and completed the survey at 3 time points (baseline,
three and six-month follow-up). Patients completed the baseline survey in the hospital. The follow-up
survey was mailed to patients at three and six months for both usual care and intervention groups.
Resource use/costs Number of readmissions to hospital
Number of hospital visits
Time horizon: Study enrollment to six months
Notes Funding source: The National Palliative Care Research Center and the Alafi Family Foundation
Declarations of interest among primary researchers: Not stated
Power considerations: Based on previous research from the HF clinic, the authors projected it would
be feasible to obtain complete baseline and follow-up data from 64 patients over a 24–month peri-
od. Using the SD for the MLHFQ (SD = 25.4) and the BPI (SD = 1.99) and using paired t–tests to estimate
the minimum detectable difference, the authors calculated that with 80% power and P = 0.05, a sam-
ple size of 32 patients in each group would enable them to observe a minimum detectable difference
on the BPI of 1.4 points and on the MLHFQ of 16.4 points, while for pain the detectable difference was
smaller than the clinically meaningful value (2–points).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "patients were randomised within blocks of six
to either SMS–HF or usual care to reduce potential bias and confounding. A
member of the research team with no contact with the study patients conduct-
ed a random assignment procedure to prevent any bias in the allocation to
groups".
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Comment: it was unclear how the random sequence was generated.
Allocation concealment
(selection bias)
Unclear risk Quote from main publication: "a member of the research team with no contact
with the study patients conducted a random assignment procedure to prevent
any bias in the allocation to groups".





High risk Participants and personnel were not blinded.
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Unclear because it was not mentioned





High risk N = 16 (72.7%) completers in intervention group vs N = 14 (77.8%) completers
in control group. In the intervention group, one (6.3%) death occurred, 2
(12.5%) patients dropped out and 3 (18.8%) patients were determined not el-
igible immediately after enrollment. In control group, one (7.1%) death oc-




High risk Information published on the clinical trials registry NCT01461681 indicate that
the primary outcome for the study was depression assessed using the Center
for Epidemiologic Studies Depression Scale (CES-D). However, in the published
study, depression was not specified as the primary outcome. Other additional
outcomes such as quality of life, pain and symptoms were also assessed.
Other bias High risk Quote from main publication: "The intervention group had significantly more
(P = 0.03) women (69%, n = 11) than the usual care group (28%, n = 4)".
Comment: study did not control for difference between intervention and con-
trol group. High risk was rated due to imbalance bias.







Who led PC intervention: Multidisciplinary team
Core team: Medical oncologist/case manager nurse/clinical nurse/algologist/psychiatrist/physical
therapy expert/social services expert/liaison consultant nurse with a doctorate in psychiatry
Participants Country and regions: Turkey, Izmir
Recruitment: September 2009 to September 2011. The authors used the criteria of the National Com-
prehensive Cancer Network clinical practice guide for palliative care for the selection of patients. They
selected inpatients who had an acute need for palliative care.
Inclusion criteria: Older than 18 years, fully conscious, co-operative and oriented, no sight or hearing
problems, capable of verbal communication, patient with advanced stage cancer, life expectancy of be-
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tween 6 and 12 months, a performance level of 50 or less on the Karnofsky Performance Scale (KPS),
patient with cancer having 1 or more uncontrollable symptoms, and patient with cancer receiving pal-
liative care.
Exclusion criteria: Not described
Number of patients: N = 44 (22 intervention and 22 control)
Diseases: Cancers: gastrointestinal, genitourinary, breast, sarcoma, lung and unknown primary tu-
mour
Patient characteristics: Mean age (SD): 52.59 (13.31) in intervention group, 53.63 (12.31) in control
group; 81.8% female in intervention group, 68.2% female in control group
Deaths at end of study (N (%)): No death
Withdrawals/other dropouts (N (%)): No dropout
Interventions Name: Palliative care-based case management model vs usual care
Type: Training in palliative care unclear
Service base: Tulay Aktas Oncology Hospital, Medical Oncology Clinic, Ege University
Team: Included a medical oncologist, a case manager nurse, and a clinical nurse, an algologist, a psy-
chiatrist, a physical therapy expert, a social services expert, and a liaison consultant nurse with a doc-
torate in psychiatry.
Intervention condition: Palliative care was provided by a multidisciplinary team, based on the case
management model. Initially, the patients met with the medical oncologist and the registered nurse
(RN) when they were accepted into the palliative care programme. The case management nurse, along
with the clinical nurse, followed up the patient and family from admission to discharge. The interven-
tion group received immediate consultation and follow-up by the palliative care team based on a phi-
losophy of multidisciplinary care. After a comprehensive symptom diagnosis, effective symptom man-
agement, psychosocial stress management, social support, care and training support, and family coun-
selling services were organised. Symptom follow-up and monitoring were made by case manager nurse
with Edmonton Symptom Assessment System (ESAS). Reconsultation and treatment arrangement
were made for uncontrolled symptoms of the patients. The care and training requirements of the pa-
tient and his family were provided by the case manager nurse and service nurses. Family counselling
was provided by psychiatry nurse. Patients were provided with personal care, and a training book was
used to train both patients and their families. Individualised patient/family education was given by the
case manager nurse. The educational book ‘‘Palliative Care for Cancer Patients and Their Families’’ was
also given to the usual care group, but individualised education was given only to the case manage-
ment group.
Duration: The period of hospitalisation: day of admission to hospital until the day of discharge
Control condition: When usual care patients were admitted to the Oncology Department, an oncolo-
gist obtained a medical history, examined the patient, and ordered various tests. Treatment plans were
then made, and orders were given to the ward nurses. The nurses provided treatment to the patients
according to the doctor’s orders and implemented usual nursing care. The educational book ‘‘Palliative
Care for Cancer Patients and Their Families’’ was also given to the usual care group.
Outcomes Outcomes:
Level of symptoms assessed using the Edmonton Symptom Assessment System (ESAS)
Quality of life assessed using the European Organization for Research and Treatment (EORTC) Quality
of Life Questionnaire C30 (QLQ-C30)
Patient and family satisfaction assessed using Patient and Family Satisfaction Forms that was created
by the researcher based on the FAMCARE questionnaire
Resource use/costs Length of stay in hospital
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Direct costs in USD
Time horizon: Period of hospitalisation
Data sources: The Patient Expenditure Record Form was created by listing direct health expenditure,
which consisted of all expenses incurred while in hospital. Items such as the following appeared in the
form among the direct expenses: medicines used from the start of the patient’s stay in hospital, med-
ical equipment, laboratory and diagnosis tests, consultations, professional care, and hospital stay ex-
penses (including those of companions). On the patient’s discharge from hospital, costs were record-
ed on the form by obtaining the expenses list from the clinic secretary. Total costs for each patient were
calculated in US dollars from the expenses lists.
Analytical perspective: Not clear
Notes Funding source: The authors received no financial support for the research, authorship, and/or publi-
cation of this article.
Declarations of interest among primary researchers: The authors declared no potential conflicts of
interest with respect to the research, authorship, and/or publication of this article.
Power considerations: While the research power that is necessary to show the difference in pallia-
tive care service from routine clinic care was 90%, minimum sample width that was necessary to find a
meaningful difference between the 2 averages in the working group was determined as 18. However,
the authors ended the study with 22 experimental and 22 working group patients.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "in this study, patients with advanced stage can-
cer receiving palliative care who met the specified criteria and agreed to take
part in the research were divided randomly according to age, sex, and educa-
tion level into 2 groups a control group and an experimental group".
Comment: unclear as no mention of how the random sequence was generated
Allocation concealment
(selection bias)





High risk Participants and personnel were not blinded.
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Unclear as blinding of outcome assessment was not stated





Low risk There was no loss to follow-up reported.
Selective reporting (re-
porting bias)
Unclear risk Unclear as the protocol of this study was not available
Other bias Unclear risk There were differences between the intervention and control group in gender,
marital status, educational level, disease duration, tumour type and Karnosfky
performance score. However, no testing for statistically significant differences
was carried out and it was unclear if differences were controlled for.
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Who led PC intervention: Multidisciplinary team
Core team: EASE-psy was delivered by a mental health clinician while the core team in EASE-phys was
a palliative care physician and nurse. Other multidisciplinary team members were involved as needed.
Participants Country and regions: Canada, Toronto
Recruitment: March 2015 to November 2016. Eligible patients were identified through clinical records
and approached for consent to participate within 1 month of admission to Princess Margaret Cancer
Centre (PM), Toronto, Canada.
Inclusion criteria: Newly diagnosed or recently relapsed with acute myeloid leukaemia (AML) or acute
lymphocytic leukaemia (ALL) within 1 month of inpatient admission to PM; receiving (or expected to re-
ceive) induction chemotherapy with curative intent; > 18 years old; fluent in English; and no cognitive
impairment
Exclusion criteria: Cognitive screening test score below cutoff (i.e. Short Orientation-Memory-Concen-
trationTest (SOMC) score < 20); and already receiving psychological/psychiatric counselling or pallia-
tive care services at PM at the time of recruitment
Number of patients: N = 42 (22 intervention and 20 control)
Diseases: Acute leukaemia (AL) (all included patients were newly diagnosed with acute leukaemia)
Patient characteristics: Mean age (SD): 51.59 (16.66) in intervention group and 54.25 (15.19) in control
group; 36.4% female in intervention group, 40% female in control group
Deaths at end of study (N (%)): None
Withdrawals/other dropouts (N (%)): N = 7: 6 (27.3%) intervention and 1 (5%) control
Interventions Name: Emotion And Symptom-focused Engagement (EASE) plus usual care vs usual care alone
Early PC: Eligible patients were newly diagnosed or recently relapsed with acute myeloid leukaemia
(AML) or acute lymphocytic leukaemia (ALL) within 1 month of inpatient admission to PM (all recruited
patients were newly diagnosed with acute leukaemia).
Type: Specialist palliative care. The core team in EASE-phys was a palliative care physician and nurse.
Other multidisciplinary team members were involved as needed.
Service base: Princess Margaret Cancer Centre (PM), University Health Network (UHN), Toronto, Cana-
da
Team: EASE-psy was delivered by a mental health clinician while the core team in EASE-phys was a pal-
liative care physician and nurse. Other multidisciplinary team members were involved, as needed.
Intervention condition: EASE integrated a novel psychotherapeutic intervention (EASE-psy) with sys-
tematic screening of physical symptoms and triggered referral for early palliative care (EASE-phys) to
target traumatic stress and physical symptoms. EASE-psy included 8–12 psychotherapeutic sessions,
approximately 30–60 min each, delivered over 8 weeks by a trained mental health clinician. It was
based on principles of supportive psychotherapy and trauma-focussed CBT applied to patients with
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life-threatening or advanced disease. The first 8 sessions occurred during hospitalisation, adjusted de-
pending on the patient’s ability to participate. The remaining 4 sessions occurred weekly or bi-weekly
after discharge, in co-ordination with outpatient clinic visits. EASE-phys consisted of systematic screen-
ing of physical symptoms with the ESAS-AL, with triggered referral to early palliative care. The ESAS-
AL was administered 2 to 3 times weekly during the inpatient stay and weekly after discharge. When
there was a score ≥ 4 (moderate to severe) on any physical symptom, a palliative care referral was trig-
gered and ESAS-AL screening for that participant was taken over by the EASE-phys team until all symp-
tom scores were < 4. At that point, the research team resumed ESAS-AL administration, with re-referral,
if needed. The EASE-phys team applied symptom management guidelines used routinely in palliative
care at PM. As long as symptom scores were ≥ 4, follow-up from the EASE-phys team occurred 3 times
weekly for inpatients in-person and weekly for outpatients in-person or by telephone.
Duration: 12 weeks
Control condition: Patients receiving induction chemotherapy for AL were admitted to one of three
dedicated AL inpatient wards at PM. Care was provided by a multidisciplinary team including physi-
cians, nurses, and allied health personnel dedicated to the treatment of AL. Participants in the control
group received no formal trial intervention, but any referral to psychosocial or palliative care services
was not delayed or denied. At PM, all newly diagnosed patients with AL are referred to a social worker.
However, these social workers did not routinely provide structured psychotherapy. At the end of the
trial, participants in the control group were offered EASE on compassionate grounds, without further
completion of questionnaires or symptom screening.
Outcomes Primary outcome
Severity of traumatic stress symptoms measured by the 30-item Stanford Acute Stress Reaction Ques-
tionnaire (SASRQ).
Secondary outcomes
Physical symptom burden measured by the Memorial Symptom Assessment Scale (MSAS)
Pain assessed using the Brief Pain Inventory (BPI)
Quality of life (QoL) measured using the Functional Assessment of Chronic Illness Therapy-Spiritual
Well-Being Scale (FACIT-Sp)
Depression assessed by the Beck Depression Inventory-II (BDI-II)
Patient satisfaction with care measured using the 16-item Family Satisfaction with Care - Patient Ver-
sion (FAMCARE-P16)
Attachment security assessed with the Brief Experiences in Close Relationships Scale (ECR-M16)
Emotional support assessed with Clinical Evaluation Questionnaire (CEQ)
Assessment points: Assessments were conducted at baseline (before randomisation) and at 4, 8, and
12 weeks.
Resource use/costs Referral to palliative care, social work and psychiatry
Time horizon: 12 weeks
Notes Funding source: This trial was funded by the Canadian Cancer Society Research Institute (CCSRI grant
no. 702603; GR and CZ, Co-Principal Investigators). This research was also supported in part by the
Princess Margaret Cancer Centre and Princess Margaret Cancer Foundation, University Health Network,
Toronto, Ontario, Canada, and the Ontario Ministry of Health and Long-term Care.
Declarations of interest among primary researchers: One of the authors reported personal fees and
grants outside this submitted work from Novartis, Takeda Pharmaceuticals, Otsuka Pharmaceutical,
Jazz Pharmaceuticals, Medivir, and Abbvie. The remaining authors declared no conflicts of interest.
Power considerations: The main outcome criteria for this phase II trial were related to feasibility.
Therefore, the trial was powered to detect only medium to large effects. The authors planned to recruit
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50 participants, in order to detect a medium effect size of 0.56 (Cohen’s d) between groups at the pri-
mary endpoint on the SASRQ, assuming a correlation between repeated measurements of 0.72 on the
SASRQ observed in their earlier longitudinal study of patients with AL.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "upon providing written informed consent and
completing baseline measures, participants were allocated by permuted block
randomisation (variable block size) either to EASE plus usual care or to usu-
al care alone, with stratification by age (≤ 60 vs. > 60) and type of AL (AML or
ALL)... The PM Department of Biostatistics, which is independent of the trial
team, developed the randomisation procedures, managed the logbook, and
provided the computer-generated randomisation allocation to research sta,




Low risk Quote from main publication: "the PM Department of Biostatistics, which is in-
dependent of the trial team, developed the randomisation procedures, man-
aged the logbook, and provided the computer-generated randomisation allo-






High risk Quote from main publication: "we report here results of an unblinded phase II






Low risk Quote from main publication: "we report here results of an unblinded phase II
randomised controlled trial (RCT) for patients with newly diagnosed AL..."
Comment: there was no blinding but this was unlikely to lead to bias in objec-
tive outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from main publication: "we report here results of an unblinded phase II
randomised controlled trial (RCT) for patients with newly diagnosed AL..."
Comment: not done
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "we report here results of an unblinded phase II
randomised controlled trial (RCT) for patients with newly diagnosed AL..."





Low risk N = 16 (72.7%) completers in intervention group vs N = 19 (95%) completers in
control group. There were no deaths during the trial. Missing data were includ-
ed in the analysis using maximum likelihood estimates.
Comment: low risk of bias
Selective reporting (re-
porting bias)
High risk Some prespecified outcomes such as attachment security and emotional sup-
port by clinical services were not reported.
Other bias Low risk Study appeared to be free of other biases.
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Who led PC intervention: Multidisciplinary team
Core team: Palliative care nurse practitioner/hospice and palliative medicine board-certified physi-
cian. The intervention was performed in collaboration with each patient’s clinical cardiology team.
Participants Country and regions: USA, North Carolina
Recruitment: August 2012 to June 2015. This trial screened and enrolled both hospitalised patients
and recently discharged patients who were at high risk of rehospitalisation and mortality based on
their Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterisation Effectiveness
risk score. Hospitalised patients could be enrolled if they were expected to be discharged within 48 hrs.
Inclusion criteria: Age > 18 y; hospitalisation for acute heart failure (HF) (either systolic HF or HF with
preserved ejection fraction) or within 2 weeks of discharge of a hospitalisation for acute HF; dyspnoea
at rest or minimal exertion plus ≥ 1 sign of volume overload; previous HF hospitalisation within the past
1 yr; ESCAPE risk score ≥ 4 indicating > 50% predicted 6-month mortality; anticipated discharge from
hospital with anticipated ability to return to outpatient follow-up appointments; or subjects aged > 18
y, hospitalised with acute HF with signs/symptoms of volume overload who do not meet all other eligi-
bility criteria may also be considered for enrollment if they can be categorised into one of the following
high-risk groups:
1. Support with chronic inotropes without plans for cardiac transplant or cardiac assist device and an-
ticipated discharge from hospital
2. Multiple hospitalisations for HF in the past 12 months (minimum 3) and anticipated discharge from
hospital
3. No prior hospitalisation for HF in the past 12 months but with an ESCAPE score > 4 and anticipated
discharge from hospital
Exclusion criteria: Failure to meet severity of illness criteria in the Evaluation Study of Congestive
Heart Failure and Pulmonary Artery Catheterisation Effectiveness risk score. Other reasons for exclu-
sion were acute coronary syndrome within 30 days; cardiac resynchronisation therapy within the past
3 months or current plan to implant; active myocarditis, constrictive pericarditis; severe stenotic valvu-
lar disease amendable to surgical intervention; anticipated heart transplant or ventricular assist device
within 6 months; renal replacement therapy; non-cardiac terminal illness; women who are pregnant or
planning to become pregnant; inability to comply with study protocol.
Number of patients: N = 150 (75 intervention and 75 control)
Diseases: Advanced heart failure
Patient characteristics: Mean age (SD): 71.9 (12.4) years in intervention group, 69.8 (13.4) years in con-
trol group. 44% females in intervention and 50.7% females in control group
Deaths at end of study (%)): 29% of patients died but numbers in intervention and control group not
provided
Withdrawals/other dropouts (N (%)): N = 96: 47 (62.7%) intervention and 49 (65.3%) control
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Interventions Name: Interdisciplinary palliative care intervention combined with usual HF management (PAL-HF) vs
usual care
Type: Specialist palliative care. Included a certified palliative care nurse practitioner and a hospice and
palliative medicine board-certified physician
Service base: Duke University Hospital
Team: A certified palliative care nurse practitioner and a hospice and palliative medicine board-certi-
fied physician
Intervention condition: The study team assessed and managed the multiple domains of quality of life
for patients with advanced HF, including physical symptoms, psychosocial and spiritual concerns, and
advance care planning. A certified palliative care nurse practitioner co-ordinated these aspects of the
patient’s care in collaboration with a hospice and palliative medicine board-certified physician. The in-
tervention was performed in collaboration with each patient’s clinical cardiology team and focussed
on shared goal-setting to combine HF symptom amelioration with palliative care goals. After hospital
discharge, the PAL-HF nurse practitioner actively participated in the ongoing management of the pa-
tients. Patients were screened for depression and anxiety with the HADS. Patients who screened posi-
tive were considered for referral to a mental health provider as well as for possible use of symptomatic
medical therapies, stress management resources and psychotherapy. Spiritual concerns were assessed
by the study nurse practitioner, and these details were shared with the intervention team. Goals of care
were iteratively assessed by the intervention nurse practitioner. After the 6-month intervention period
was completed, the nurse practitioner continued to contact the patients in the intervention arm every
3 months to provide ongoing support and clinical care.
Duration: 6 months
Control condition: Usual care patients were managed by a cardiologist-directed team with HF exper-
tise. Inpatient care was focussed on symptom relief and use of evidence-based therapies as detailed in
current guidelines. Inpatient palliative care consultation was not denied to usual care patients. After
discharge, these patients received outpatient follow-up with their general practitioners as well as an
HF cardiologist or nurse practitioner with care focussed on guidelines-based medication titration and
serial monitoring of end-organ function.
Outcomes Primary outcomes:
Quality of life assessed by two different questionnaires, the Kansas City Cardiomyopathy Questionnaire
(KCCQ) and Functional Assessment of Chronic Illness Therapy - Palliative Care (FACIT-Pal) scale
Secondary outcomes:
Depression and anxiety assessed using the Hospital Anxiety and Depression Scale (HADS)




Assessment points: After trial enrollment, subjects underwent reassessment of their clinical status
and primary outcome questionnaires at weeks 2, 6, 12, and 24. Secondary outcomes were assessed at
weeks 2, 12 and 24.
Resource use/costs Number of hospital encounter records
Number of clinic encounter records
Number of primary care contacts
Number of cardiology contacts
Number of telephone contacts
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Number of rehabilitation clinic contacts
Number of emergency department/urgent care contacts
Number of hospitalisations
Time horizon: From enrollment until death or end of the study
Notes Funding source: Funded by the NINR: R01NR013428. RJM was supported by T32GM086330 from the
National Institute of General Medical Sciences.
Declarations of interest among primary researchers: Dr. Johnson received research support from
projects funded by the National Institute on Aging. Dr. Krishnamoorthy has worked on projects funded
by research grants to the Duke Clinical Research Institute from the NIH, Novartis, Daiichi-Sankyo, and
Eli Lilly; and has received support to attend educational conferences from HeartWare, Thoratec, and
Medtronic. Dr. Mark has received consulting fees from Medtronic; and has received research funding
from Eli Lilly, Bristol-Myers Squibb, Pfizer, AstraZeneca, Merck and Company, Oxygen Theraputics, and
Gilead. Dr. Tulsky has received research funding from PCORI. All other authors have reported that they
have no relationships relevant to the contents of this paper to disclose. P.K. Shah served as Guest Edi-
tor-in-Chief for this paper. Barry H. Greenberg served as Guest Editor for this paper.
Power considerations: The KCCQ overall summary and FACIT–PAL scores were selected as the co-pri-
mary endpoints. Assuming a common SD of 12 points for the KCCQ overall summary score, the planned
sample size of 200 subjects (100 per arm) was projected to provide 80% power to detect a difference of
4.8 points. As noted earlier, a 5-point change in this score is the smallest change that is clinically signifi-
cant at the individual patient level. For the FACIT–PAL co-primary endpoint, the sample size of 200 sub-
jects was projected to provide 80% power to detect a difference of 10 points assuming a SD of 25. Sam-
ple size calculations were based on a 2-sample Student t-test with a type I error rate of 0.05. The data
and safety monitoring board, in consultation with the sponsoring agency, recommended a sample size
reduction to 150 subjects, based upon enrollment rates, a mortality rate that was lower than predicted,
and observed outcomes differences at that intermediate time point.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "enrolled patients were randomised in a 1:1 al-
location to usual care (UC) alone or UC plus palliative care intervention (UC +
PAL) using a complete randomisation scheme".
Comment: unclear as random sequence generation was not well described
Allocation concealment
(selection bias)





High risk Quote from main publication: "the trial was unblinded because blinding of the
intervention was not feasible".





Low risk Quote from main publication: "the trial was unblinded because blinding of the
intervention was not feasible".
Comment: there was no blinding but this was unlikely to lead to bias in objec-
tive outcomes such as mortality.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from main publication: "the trial was unblinded because blinding of the
intervention was not feasible".
Comment: high risk of bias due to lack of blinding
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Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "the trial was unblinded because blinding of the
intervention was not feasible".
Comment: there was no blinding but this was unlikely to lead to bias in the as-




High risk N = 28 (37.3%) completers in intervention group vs N = 26 (34.7%) completers
in control group. At the point of primary analysis (6 months), N = 41 (54.7%)
completers in intervention group vs N = 40 (53.3%) in control group. At the end
of the study, 40 (53.3%) patients died and 7 (9.3%) withdrew from the interven-
tion group while in the control group 38 (50.7%) died and 11 (14.7%) withdrew.
Missing data were not included in the analysis. Overall, there was high attrition
across intervention and control groups.
Comment: high risk of bias
Selective reporting (re-
porting bias)
High risk Some outcomes specified in the protocol such as unpaid caregiver satisfac-
tion, quality of care from the family member's perspective and cost were not
reported in the published study.
Other bias Low risk Study appeared to be free from other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Multidisciplinary team
Core team: Physicians board-certified in hospice and palliative medicine/clinical nurse specialists
board-certified in advanced practice palliative care nursing/social worker/chaplain
Participants Country and regions: USA, Minneapolis, Minnesota
Recruitment: April 2012 to February 2013. Potentially eligible patients were identified using reports
from the electronic health record (EHR). Eligibility was verified by reviewing patient records and talking
with a floor nurse if needed. Patients determined to be eligible were visited by the research nurse who
explained the study and enrolled those interested in participating.
Inclusion criteria: Patients were considered eligible for the study if they were adult inpatients with a
diagnosis of acute HF.
Exclusion criteria: Patients in the intensive care unit (ICU), on a ventilator, undergoing evaluation for
a heart transplant or a leK ventricular assist device (LVAD), post-transplant or post-LVAD, determined to
be actively dying, or if they had cognitive impairments such that informed consent and data collection
would not be possible or if they spoke limited English. Patients who had already had a palliative care
order request by their attending physician during the hospital stay were ineligible.
Number of patients: N = 232 (116 intervention and 116 control)
Diseases: Acute heart failure
Patient characteristics: Mean age (SD): 76 (11.9) years in intervention group, 70.9 (13.6) years in con-
trol group. 52.6% females in intervention and 42.2% females in control group
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Deaths at end of study (N (%)): N = 19: 14 (12.1%) intervention and 5 (4.3%) in control group
Withdrawals/other dropouts (N (%)): N = 93: 49 (42.2%) intervention and 44 (37.9%) control
Interventions Name: Inpatient palliative care integrated into care for heart failure (HF) patients vs usual care
Type: Specialist palliative care. Included physicians who were board-certified in hospice and palliative
medicine and nurse specialists board-certified in advance practice palliative care nursing
Service base: Abbott Northwestern Hospital (ANW), 629-bed tertiary-care facility in Minneapolis, Min-
nesota
Team: The ANW inpatient palliative care team at the time of the study included four physicians board-
certified in hospice and palliative medicine, two clinical nurse specialists board-certified in advanced
practice palliative care nursing, a social worker, and a chaplain.
Intervention condition: After patients were randomised to the intervention group, an order for pallia-
tive care was entered, and triaged by the palliative care team with a goal of conducting the palliative
care consult within 24 hours of the order. Providers did an initial consult and then determined whether
further appointments were necessary. The study intervention differed from the standard palliative care
process in two ways. First, baseline study measures of symptom burden, depression, and QoL were
available to the providers to review at the time of the consultation. Second, the study paid only for the
initial palliative care consultation and any subsequent visits were billed to the patient’s insurance as
standard care. Actions of palliative care providers during visits generally included assessment of symp-
tom burdens; emotional, spiritual, and psychosocial aspects of care; co-ordination of care orders; rec-
ommendations for change in current or future treatment; referrals; and future care planning assess-
ment and discussions. All HF patients received a referral to the ACP process through their discharge or-
ders.
Duration: Period of hospitalisation
Control condition: This was not described.
Outcomes Primary outcome
Symptom burden assessed using the Edmonton Symptom Assessment Scale (ESAS)
Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9)
Quality of life assessed using the Minnesota Living with Heart Failure (MLHF) questionnaire
Secondary outcomes




Assessment points: After enrollment and baseline data collection, patients were randomised to the
study group and notified of their groups. Outcomes were assessed at the time of enrollment, and also
at 1 and 3 months. ACP completion, hospice admission and mortality were assessed within 6 months of
the study hospitalisation.
Resource use/costs 30-day inpatient readmission
Hospice use
Time horizon: Readmission to hospital within 30 days was assessed as well as hospice use within 6
months.
Notes Funding source: This study was funded by the Abbott Northwestern Hospital Foundation.
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Declarations of interest among primary researchers: The authors stated that no competing financial
interests existed.
Power considerations: Power calculations were done to identify a sample size using mean baseline
values of summary scores from 26 pilot study patients for each of the three study data collection instru-
ments. Calculations assumed an alpha of 0.05 and 80% power. Results indicated a sample size of 500
(250 per group) would be sufficient to detect an effect size (Cohen’s d) of 0.25, which equates to mini-
mum detectable mean differences between intervention and control groups of 1.5 points in the PHQ-9,
6.4 points in the MLHF Questionnaire, and 3.3 points in the ESAS.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "patients hospitalised with acute HF were ran-
domised to receive a PC consult with follow-up as determined by provider or
standard care".









High risk Quote from main publication: "after enrollment and baseline data collection,
patients were immediately randomised to the study group and notified of
whether they were in the intervention or control group so they would know
whether to expect a visit from a palliative care provider".





Low risk Quote from main publication: "After enrollment and baseline data collection,
patients were immediately randomised to the study group and notified of
whether they were in the intervention or control group so they would know
whether to expect a visit from a palliative care provider".
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk Unclear risk of bias because blinding of outcome assessment was unclear
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk It was unclear whether there was blinding of outcome assessment.
Comment: Although blinding of outcome assessment was unclear, this was un-




High risk N = 65 (56%) completed all surveys in intervention group vs N = 78 (67.2%)
completed all surveys in control group. In the intervention group, 14 (12.1%)
patients died, 20 (17.2%) withdrew/dropped out for other reasons, 15 (12.9%)
and 14 (12.1%) surveys were not completed for unknown reasons at 1-month
and 3-month data collection, respectively. In the control group, 5 (4.3%) pa-
tients died, 5 (4.3%) withdrew, 21 (18.1%) and 18 (15.5%) surveys were not
completed for unknown reasons at 1-month and 3-month data collection, re-
spectively. Missing data were excluded from the analysis. Overall, there was
high attrition (> 10%) across intervention and control groups.
Comment: high risk of bias
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Selective reporting (re-
porting bias)
Unclear risk Unclear as the protocol was not available
Other bias Low risk There was a statistically significant difference in age between intervention and
control groups at baseline. However, the authors adjusted for age, gender and
marital status.
Comment: Given that the authors controlled for the highlighted difference, a
decision was made not to rate down for imbalance bias. Rather a low of bias
was rated.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-





Methods Design: RCT (multicentre RCT)
Who led PC intervention: Multidisciplinary team
Core team: Physician (neurologist or psychiatrist), a nurse (case manager and team leader), a psychol-
ogist, and a social worker
Participants Country and regions: Italy: Milan, Rome and Catania
Recruitment: January 2015 to November 2015. Patients were recruited from three Italian centres.
Inclusion criteria: Participants were non-institutionalised adults (age > 18 years) with severe multiple
sclerosis (MS) and their primary carers. Other patient inclusion criteria were primary or secondary pro-
gressive MS. Expanded Disability Status Scale (EDSS) score > 8.0, complex symptoms, and > 2 unmet
care needs. The carer was his or her next of kin and was designated by the patient except for patients
with severe cognitive compromise.
Exclusion criteria: Hospitalised/institutionalised patients, patients already receiving palliative care
and dyads living out of study area
Number of adult-carer dyads: N = 78 (52 intervention and 26 control)
Diseases: Severe multiple sclerosis
Patient characteristics: Mean age (SD): 60.5 (9.7) years in intervention group, 56.8 (9.5) years in control
group. 62% females in intervention and 46% females in control group
Carer characteristics: Mean age (SD): 60.1 (13.9) years in intervention group, 60.8 (11.1) years in con-
trol group. 62% females in intervention and 61% females in control group
Deaths at end of study (N (%)): N = 4: 4 (7.7%) intervention and 0 (0%) in control group
Patient withdrawals/other dropouts (N (%)): N = 5: 3 (5.8%) intervention and 2 (7.7%) control
Carer withdrawals/other dropouts (N (%)): N = 4: 2 (3.8%) intervention and 2 (7.7%) control
Interventions Name: Home-based palliative approach (HPA) combined with usual care vs usual care
Type: Specialist palliative care. Nurses of the Milan and Rome centres had degrees and worked full-
time in palliative care; the Catania nurse attended a week-long individual training course. Prior to study
start, all team members were trained in the HPA intervention.
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Service base: Three Italian centres
Team: Each centre had a HPA team consisting of a physician (neurologist or psychiatrist), a nurse (case
manager and team leader), a psychologist, and a social worker.
Intervention condition: After a comprehensive assessment of the dyad needs based on direct ob-
servation and on visit 1 information, the HPA team defined the contents of the intervention, involv-
ing the dyad and the patient caring physician. Subsequently, the team verified programme implemen-
tation and reviewed it as necessary. The team was not on call for dyads. In the event of emergencies,
dyads contacted the patient caring physician or emergency medical services. All team activities were
recorded in the PeNSAMI patient study record, which was kept at the patient’s home and available to
all health professionals/ unpaid caregivers. Three and six months after trial initiation, the HPA team
met again to share experiences, fine-tune the protocol, and discuss difficult cases.
Duration: Six months
Control condition: Usual care consisted of the health and social services provided by the Italian Na-
tional Health Service in the study area. Dyads assigned to usual care received the three examiner vis-
its (visits 1–3) and the monthly telephone interviews, but not the HPA team visits (except visit 0). At the
end of the study, dyads who received usual care were offered the HPA.
Outcomes Primary outcome
Health-related quality of life assessed using the Schedule for the Evaluation of Individual Quality of Life
- Direct Weighting (SEIQoL-DW)
Symptom burden assessed using the Palliative Care Outcome Scale-Symptoms-MS, POS-S-MS
Secondary outcomes
Quality of life assessed using the European Quality of life Five Dimensions (EQ-5D-3L)
Anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS)
Functional independence assessed using the Functional Independence Measure (FIM)
Carer quality of life assessed using the Short Form 36 (SF-36) and the EQ-5D-3L
Carer depression and anxiety assessed using the Hospital Anxiety and Depression Scale (HADS)
Carer burden assessed using the Zarit Burden Interview (ZBI)
Adverse events
Assessment points: After enrollment, patients were randomised (2: 1) to receive HPA or usual care.
Outcomes were assessed at baseline, and after three and six months.
Resource use/costs Direct and indirect tangible costs assessed by the MS Foundation Costs Questionnaire (MSCQ)
Time horizon: Six telephone interviews are performed on a monthly basis by a trained interviewer who
administered the full MSCQ (at three and six months) and pertinent MSCQ sections (at one, two, four
and five months).
Notes Funding source: The Fondazione Italiana Sclerosi Multipla (FISM)
Declarations of interest among primary researchers: A.S. has been a board member of Biogen Idec,
Merck Serono and Novartis and has received speaker honoraria from Genzyme, Merck Serono, and Ex-
cemed. F.P. received honoraria for speaking activities from Bayer Schering, Biogen Idec, Merck Serono,
Novartis, and Sanofi Aventis. He has served as advisory board member of Bayer Schering, Biogen Idec,
Merck Serono, and Novartis. M.G.G. has received research funding from Merck Serono and consult-
ing and speaking fees from Biogen Idec. P.C. has been a board member of Biogen Idec, received trav-
el grants from Sanofi Aventis, Biogen Dompe, and Merck Serono. P.Z. and M.A.B. are board members of
the Fondazione Italiana Sclerosi Multipla (charitable organisation). All other authors declared that they
had no competing interests.
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Power considerations: The authors set a power of 80% for the SEIQoL-DW and 85% for the POS-S-
MS. For the POS-S-MS, the authors calculated that a sample size of 62 patients would yield a power of
85% to detect a mean score change of −0.4 (SD, 0.5) in the HPA group compared to a change of 0.2 (SD,
0.8; null hypothesis) in the usual care group, at an α level of 0.05. Assuming 20% dropout, 49 patients
were required in the HPA group and 25 patients in the usual care group (total sample size 74). For the
SEIQoL-DW, the authors calculated that a sample size of 32 patients would yield a power of 80% to de-
tect a mean score change of 12.1 (SD, 12.8) in the HPA group compared to a change of −7.4 (SD, 19.3) in
the usual care group, at an α level of 0.05. Assuming 20% dropout, 25 patients were required in the HPA
group and 13 in the usual care group (total sample size 38).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "dyads were randomly assigned (2:1) to receive
HPA or usual care. Allocation to treatment groups was done using a third-par-
ty, web-based computerised randomisation procedure with stratified minimi-
sation for expanded disability status scale (EDSS) score, presence of severe




Low risk Quote from main publication: "allocation to treatment groups was done using
a third-party, web-based computerised randomisation procedure with strati-
fied minimisation for expanded disability status scale (EDSS) score, presence












Low risk Quote from main publication: "in this randomised, examiner-blind, controlled
study, we recruited patients from three Italian centers".
Comment: participants and personnel were not blinded (only the outcome as-
sessors 'examiners' were blinded) but this was unlikely to lead to bias in objec-
tive outcomes such as serious adverse events.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Low risk Quote from main publication: "in this randomised, examiner-blind, controlled
study, we recruited patients from three Italian centers".
Comment: probably done
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "in this randomised, examiner-blind, controlled





Low risk N = 50 dyads completers in intervention group vs N = 26 dyads completers in
control group. In the intervention group, 4 (7.7%) intervention patients died
and 3 (5.8%) withdrew/dropped out for other reason. 2 (3.8%) carers in the in-
tervention group also withdrew. In the control group, no patients died and 2
(7.7%) withdrew consent. 2 (7.7%) carers in the control group also withdrew
consent.
Comment: low risk of bias because attrition was less than 10%
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Selective reporting (re-
porting bias)
High risk Some outcomes such as EQ-5D, Core-POS and MSCQ were not reported.
Other bias Unclear risk There appeared to be differences between the intervention and control groups
in gender, age and occupation. However, no testing for statistically significant
differences was carried out.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Nurse-led intervention
Core team: Palliative care nurse consultant. Other members of the team were not described.
Participants Country and regions: Australia, Department of Medical Oncology, Royal Prince Alfred Hospital (RPAH)
Camperdown, New South Wales
Recruitment: April 2003 to January 2005: ambulatory patients with newly detected incurable metasta-
tic cancer attending a medical oncology clinic with a life expectancy of less than 12 months were invit-
ed to take part.
Inclusion criteria: Ambulatory patients with newly detected incurable metastatic cancer attending a
medical oncology clinic with a life expectancy of less than 12 months
Exclusion criteria: Previous contact with palliative care
Number of patients: N = 120 (60 intervention and 60 control)
Diseases: Gastrointestinal cancer (44), lung cancer (23), gynaecological cancer (19), breast cancer (17),
prostate cancer (2) and other primary sites (15)
Patient characteristics: Mean age (SD): 63 (11.2) years in intervention group, 64 (11.1) in control
group; 47% female in intervention group, 57% female in control group
Deaths at end of study (N (%)): Total N = 70: 39 (65%) intervention and 31 (51.7%) in control group.
Withdrawals/other dropouts (N (%)): Unclear
Interventions Name: Early contact with palliative care services plus standard oncologic care vs standard oncologic
care
Early PC (EPC): Early contact with a palliative care nurse consultant with ongoing oncologist care
Type: Specialist palliative care. Included a palliative care nurse consultant
Service base: Medical oncology clinic
Team: Palliative care nurse consultant who served as a link to palliative care services in the hospital
and community
Intervention condition: Patients met with a palliative care nurse consultant (PC nurse), a member of
the hospital palliative care team. She outlined available palliative care services including advice about
symptom control, and she offered to arrange review by a palliative care physician, and provided con-
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tact details for the palliative care service. The PC nurse offered to telephone the patient monthly to
check on their well-being, or, if the patient preferred, provided her contact details.
Duration: Intervention continued during the lifespan of the patient.
Control condition: Standard oncologic care was given in line with the oncologist’s recommendation.
Control patients were referred to the palliative care service when recommended by the oncologist.
Outcomes Primary outcome
Quality of life assessed using the McGill Quality of Life (MQoL) questionnaire
Symptom severity assessed using the Rotterdam Symptom Checklist (RSC)
Feeling supported assessed using the Supportive Care Needs - Short Form Questionnaire (SCNS - Short)
Secondary outcomes
End-of-life experiences
Number of lines of chemotherapy
Place of death
Survival
Assessment points: Baseline (after randomisation); the following baseline study questionnaires (MQoL
and RSC) were completed monthly whilst the SCNS was to be completed every 4 months until death.
Resource use/costs Contact with palliative care services: palliative care nurse and physician
Time horizon: From study enrollment to death
Notes Funding source: Supported by an NHMRC strategic palliative care research grant no: 219141
Declarations of interest among primary researchers: Apart from funding, no further study author
disclosure statements were made.
Power considerations: A sample size of 150 patients was sought to provide over 80% power to detect
an effect size of 0.50 (SD) at the two-sided 5% level of significance based on a two-sample t-test.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "for allocation of the participants, a comput-




Low risk Quote from main publication: "allocation was concealed using sequentially






High risk Quote from trial registry: "masking not used"
Comment: high risk of bias due to lack of blinding
Blinding of participants
and personnel (perfor-
Low risk Quote from trial registry: "masking not used"
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mance bias), objective
outcomes
Comment: although masking was not carried out, this was unlikely to lead to
bias in objective outcomes such as place of death.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from trial registry: "masking not used"
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from trial registry: "masking not used"
Comment: although masking was not carried out, this was unlikely to lead to




High risk N = 11 (18.3%) completers in intervention group vs N = 18 (30%) completers
in control group. 10 (16.7%) patients in the intervention group and 11 (18.3%)
in control were alive but did not complete the questionnaire battery at 12
months. The reasons for non-completion were not stated. Overall, there was
high attrition across intervention and control groups.
Comment: high risk of bias
Selective reporting (re-
porting bias)
Low risk Study appeared to be free of reporting bias as all the outcomes listed in the tri-
al registry were reported.
Other bias Low risk The authors reported that there were differences between the groups in the
time since initial cancer diagnosis (mean of 29 versus 34 months in the early
referral and standard care groups, respectively), and the oncologists’ estimate
of likely survival (e.g. 11 versus 20 patients with estimates of > 12 months like-
ly survival in the early referral and standard care groups, respectively). The au-
thors controlled for these variables in subsequent analyses.
Comment: given that the authors controlled for the highlighted differences,
a decision was made not to rate down for imbalance bias. Rather a low risk of
bias was rated.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Multidisciplinary team
Core team: Board-certified palliative care physicians/advanced practice nurses
Participants Country and regions: USA, Massachusetts
Recruitment: June 2006 to July 2009. Patients who presented to the outpatient thoracic oncology clin-
ic were invited by their medical oncologists to enroll in the study. Physicians were encouraged, but not
required, to offer participation to all eligible patients; no additional screening or recruitment measures
were used.
Inclusion criteria: Patients were eligible to participate if they had pathologically confirmed metasta-
tic non–small-cell lung cancer diagnosed within the previous 8 weeks and an Eastern Cooperative On-
cology Group (ECOG) performance status of 0, 1, or 2 and were able to read and respond to questions in
English.
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Exclusion criteria: Patients who were already receiving care from the palliative care service were not
eligible..
Number of patients: N = 151 (77 intervention and 74 control)
Diseases: Metastatic non-small-cell lung cancer
Patient characteristics: Mean age (SD): 64.98 (9.73) years in intervention group, 64.87 (9.41) years in
control; 42 (55%) female in intervention group, 36 (49)% female in control
Deaths at end of study (N (%)): N = 27: 10 (13%) intervention and 17 (23%) control
Withdrawals/other dropouts (N (%)): N = 17: 7 (9.1%) intervention and 10 (13.5%) control
Interventions Name: Early palliative care integrated with standard oncologic care vs usual oncologic care
Early PC (EPC): Patients were eligible to participate if they had pathologically confirmed metastatic
non–small-cell lung cancer diagnosed within the previous 8 weeks.
Type: Specialist palliative care. Included board-certified palliative care physicians and advanced-prac-
tice nurses
Service base: Massachusetts General Hospital (MGH), Boston
Team: Board-certified palliative care physicians and advanced practice nurses
Intervention condition: Patients met with a member of the palliative care team, which consisted of
board-certified palliative care physicians and advanced-practice nurses, within 3 weeks after enroll-
ment and at least monthly in the outpatient setting until death. Additional visits with the palliative care
service were scheduled at the discretion of the patient, oncologist, or palliative care provider. General
guidelines for the palliative care visits in the ambulatory setting were adapted from the National Con-
sensus Project for Quality Palliative Care. Using a template in the electronic medical record, palliative
care clinicians documented the care they provided according to these guidelines with particular atten-
tion to assessing physical and psychosocial symptoms, establishing goals of care, assisting with deci-
sion-making regarding treatment, and co-ordinating care on the basis of the individual needs of the pa-
tient. All the participants continued to receive routine oncologic care throughout the study period.
Duration: Intervention group patients met with a member of the palliative care team within 3 weeks af-
ter enrollment and at least monthly thereafter in the outpatient setting until death.
Control condition: Patients who were randomly assigned to standard care were not scheduled to meet
with the palliative care service unless a meeting was requested by the patient, the family, or the oncol-
ogist.
Outcomes Primary outcome
Change in quality of life (QoL) from baseline to week 12 assessed using the Functional Assessment of
Cancer Therapy–Lung (FACT-L) scale
Secondary outcomes





Assessment points: Participants completed baseline questionnaires before randomisation. Follow-up
assessments of quality of life and mood were performed at 12 weeks. Participants who had no sched-
uled clinic visits within this period received the questionnaires by mail.
Temel 2010  (Continued)
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
Resource use/costs Number of palliative care visits
Use of health services and end-of-life care including anticancer therapy, medication prescriptions, re-
ferral to hospice, hospital admissions, emergency department visits
Time horizon: Study enrollment until death or date of censoring (Dec 1, 2009)
Data sources: Data were collected from the electronic medical record on the use of health services and
end-of-life care, including anticancer therapy, medication prescriptions, referral to hospice, hospital
admissions, emergency department visits, and the date and location of death.
Analytical perspective: Not clear
Notes Funding source: Funded by an American Society of Clinical Oncology Career Development Award and
philanthropic giKs from the Joanne Hill Monahan Cancer Fund and Golf Fights Cancer.
Declarations of interest among primary researchers: Dr. Temel reported receiving payment for de-
veloping continuing medical education (CME) programs from Informedical; and Dr. Lynch served on the
board of Infinity Pharmaceuticals, receiving consulting fees from Roche, Boehringer Ingelheim, Merck,
AstraZeneca, Bristol-Myers Squibb, and Sanofi-Aventis, royalties from Partners HealthCare, and pay-
ment for developing CME programs from Informedical. No other potential conflict of interest relevant
to this article was reported.
Power considerations: The authors estimated that with 120 patients, the study would have 80% pow-
er to detect a significant between-group difference in the change in the TOI score from baseline to 12
weeks, with a medium effect size of 0.5 SD. The protocol was amended to allow for the enrollment of an
additional 30 participants in order to compensate for the loss of any patients to follow-up.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "eligible patients were enrolled within 8 weeks
after diagnosis and were randomly assigned to one of the two groups in a 1:1
ratio without stratification".









High risk Quote from main publication: "We enrolled ambulatory patients with newly di-
agnosed metastatic non–small-cell lung cancer in a nonblinded, randomised,
controlled trial of early palliative care integrated with standard oncologic care,
as compared with standard oncologic care alone".





Low risk Quote from main publication: "We enrolled ambulatory patients with newly di-
agnosed metastatic non–small-cell lung cancer in a nonblinded, randomised,
controlled trial of early palliative care integrated with standard oncologic care,
as compared with standard oncologic care alone".
Comment: there was no blinding but this was unlikely to lead to bias in objec-
tive outcomes such as survival.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from main publication: "We enrolled ambulatory patients with newly di-
agnosed metastatic non–small-cell lung cancer in a nonblinded, randomised,
controlled trial of early palliative care integrated with standard oncologic care,
as compared with standard oncologic care alone".
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Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "We enrolled ambulatory patients with newly di-
agnosed metastatic non–small-cell lung cancer in a nonblinded, randomised,
controlled trial of early palliative care integrated with standard oncologic care,
as compared with standard oncologic care alone".
Comment: there was no blinding but this was unlikely to lead to bias in assess-




Low risk N = 60 (78%) completers in intervention group vs N = 47 (64%) completers in
control group. 17 (22%) patients in the intervention group did not complete
12-week follow-up assessment for a number of reasons: died (n = 10), trans-
ferred care (n = 1), form mailed but not returned (n = 1), and refused, hospi-
talised or too ill (n = 5). 27 (36%) in control group did not complete 12-week
follow-up assessment for a number of reasons: died (n = 17), withdrew (n = 1),
form mailed but not returned (n = 3), and refused, hospitalised or too ill (n =
6). For intention-to-treat analyses, a conservative method of carrying baseline
values forward to account for all missing patient-reported outcome data, in-
cluding data that were missing owing to death was used.
Comment: low risk of bias was rated because the study used baseline observa-
tion-carried-forward to deal with missing patient-reported outcome data.
Selective reporting (re-
porting bias)
High risk One of the outcomes, family unpaid caregiver satisfaction, has not been re-
ported in any of the publications for this study.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Multidisciplinary team
Core team: Physicians/advanced practice nurses
Participants Country and regions: USA, Massachusetts
Recruitment: May 2011 to July 2015. Study sta, screened consecutive patients who presented to the
oncology clinics and notified clinicians via email when patients were eligible to participate. Oncology
clinicians invited their patients to enroll in the study.
Inclusion criteria: Patients were eligible to participate if they were within 8 weeks of a diagnosis of in-
curable lung (NSCLC, small-cell, or mesothelioma) or noncolorectal GI (pancreatic, oesophageal, gas-
tric, or hepatobiliary) cancer. Patients were also required to receive their care at Massachusetts General
Hospital (MGH), be > 18 years of age, have no history of therapy for metastatic disease, have an Eastern
Cooperative Oncology Group performance status of 0 to 2, and be able to read and respond to ques-
tions in English or complete questionnaires with minimal assistance.
Exclusion criteria: Patients who were already receiving palliative care services, needed immediate re-
ferral for palliative care or hospice, or who had significant psychiatric or other comorbid disease pro-
hibiting participation
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Number of patients: N = 350 (175 intervention and 175 control)
Diseases: Lung (non-small-cell, small-cell, neuroendocrine, mesothelioma, epidermal growth factor re-
ceptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation) and noncolorectal cancer
(pancreatic, oesophageal/GE junction, gastric, hepatobiliary)
Patient characteristics: Mean age (SD): 65.64 (11.26) years in intervention group, 64.03 (10.46) years in
control; 48% female in intervention group, 44% female in control
Deaths at end of study (N (%)): N = 59: 27 (15.4%) intervention and 32 (18.3%) control
Withdrawals/other dropouts (N (%)): N = 49: 30 (17.1%) intervention and 19 (10.9%) control
Interventions Name: Early integrated PC and oncology care vs usual oncology care
Early PC (EPC): Patients were eligible to participate if they were within 8 weeks of a diagnosis of incur-
able lung (NSCLC, small-cell, or mesothelioma) or noncolorectal GI (pancreatic, oesophageal, gastric,
or hepatobiliary) cancer.
Type: Specialist palliative care. Included palliative care clinicians
Service base: Massachusetts General Hospital (MGH), Boston
Team: Physicians and advanced practice nurses
Intervention condition: Patients assigned to early palliative care met with a member of the outpatient
palliative care team within 4 weeks of enrollment and at least once per month until death. Consisting
of physicians and advanced practice nurses, the MGH outpatient team practices per guidelines of the
National Consensus Project for Quality Palliative Care. Palliative care clinicians contacted patients via
telephone when an in-person visit was not possible. The patient, oncologist, or palliative care clinician
could schedule additional palliative care visits at their discretion. Finally, for patients who were admit-
ted to MGH, the inpatient palliative care team observed them throughout their hospitalisation.
Duration: Intervention continued at least once per month until the patient's death.
Control condition: Patients assigned to usual oncology care were able to meet with a palliative care
clinician only upon request by the oncologist, patient, or family. All patients, regardless of group as-
signment, continued to receive routine oncology care throughout the study period.
Outcomes Primary outcome
Change in quality of life (QoL) from baseline to week 12 assessed using the Functional Assessment of
Cancer Therapy - General (FACT-G) scale
Secondary outcomes
Change in QoL from baseline to week 24 assessed using the Functional Assessment of Cancer Therapy -
General (FACT-G) scale
Depression assessed using the Patient Health Questionnaire-9 (PHQ-9)
Anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS)
Differences in end-of-life communication assessed using the Prognosis and Treatment Perceptions
Questionnaire
Assessment points: Patients completed a demographic questionnaire and baseline self-report mea-
sures after providing written informed consent and before random assignment. Follow-up assessments
occurred at 12 weeks and 24 weeks.
Resource use/costs Number of palliative care visits
Time horizon: Study enrollment to 24 weeks
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Notes Funding source: Supported by the National Institutes of Health Grant No. NCT01401907 and National
Institute of Nursing Research Grant No. R01- NR012735
Declarations of interest among primary researchers: Four of the authors provided disclosure infor-
mation.
Power considerations: The primary outcome was change in FACT-G score from baseline to 12 weeks;
a 4- to 5-point change in FACT-G score is considered clinically meaningful. The authors estimated that
with 280 patients, the study would have 80% power to detect a 4-point difference in the change in
FACT-G scores from baseline to 12 weeks between study groups (with P < 0.05). Given the rate of miss-
ing data observed in a previous study by the authors, the sample size was increased to 350 patients.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "the Office of Data Quality randomly assigned
patients in a 1:1 fashion to receive early integrated PC and oncology care ver-
sus usual oncology care, stratified by cancer type, using a computer-generated




Low risk Quote from main publication: "the Office of Data Quality randomly assigned
patients in a 1:1 fashion to receive early integrated PC and oncology care ver-
sus usual oncology care, stratified by cancer type, using a computer-generated






High risk Quote from main publication: "we enrolled patients with newly diagnosed in-
curable cancers from Massachusetts General Hospital (MGH) in a nonblinded,
randomized trial of early palliative integrated with oncology care compared
with usual oncology care".
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from main publication: "we enrolled patients with newly diagnosed in-
curable cancers from Massachusetts General Hospital (MGH) in a nonblind-
ed, randomized trial of early PC integrated with oncology care compared with
usual oncology care".




High risk N = 118 (67.4%) completers in intervention group vs N = 124 (70.9%) com-
pleters in control group. 30 (17.1%) patients in the intervention group did
not complete 24-week follow-up assessment for a number of reasons: hos-
pitalised/hospice (n = 8), transferred care (n = 9), withdrew consent (n = 7),
mailed and not returned (n = 1) and refused (n = 5). 19 (10.9%) in control group
did not complete 24-week follow-up assessment for a number of reasons: hos-
pitalised/hospice (n = 7), transferred care (n = 3), withdrew consent (n = 1),
mailed and not returned (n = 2), refused (n = 5) and clinic sta, missed patient
(n = 1). Missing data were excluded from the analysis.
Comment: high risk of bias
Selective reporting (re-
porting bias)
High risk Quote from main publication: "we also compared patient-reported out-
comes between the two groups by using a terminal decline joint modeling ap-
proach, which models the trend in outcomes backward from death, rather
than prospectively from enrollment. We did not prespecify the use of this ap-
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proach in our protocol as it was first published in 2013, after initiation of this
study".
Comment: post hoc analysis
Other bias Low risk Quote from main publication: "to examine QoL and mood we used indepen-
dent-samples t-tests and analysis of covariance (ANCOVA) models that con-
trolled for baseline criterion scores and potential confounders such as age and
comorbidity, which were imbalanced between groups and associated with
outcomes of interest". The authors therefore controlled for baseline criterion
scores and potential confounders.
Comment: Given that the authors controlled for the highlighted differences,
a decision was made not to rate down for imbalance bias. Rather a low risk of
bias was rated.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Nurse-led intervention
Core team: Palliative care physicians/palliative care nurses
Participants Country and regions: Belgium, Flanders
Recruitment: April 2013 to February 2016. Study recruited patients with advanced cancer from the
Medical Oncology, Thoracic Oncology, and Digestive Oncology departments of Ghent University Hospi-
tal in Flanders, Belgium. Patients were identified for recruitment by a trained clinical research assistant
and the treating oncologists. Both outpatients and inpatients were considered for inclusion. Oncolo-
gists described the study to patients and all participants provided written informed consent.
Inclusion criteria: Eligible patients were > 18 years, and had an advanced cancer diagnosis due to a
solid tumour, a European Cooperative Oncology Group performance status of 0 – 2, an estimated life
expectancy of 12 months, were within the first 12 weeks of a new primary tumour or had a diagnosis of
progression, and were able to read and respond to questions in Dutch. Patients recruited from a hos-
pital other than Ghent University Hospital had to be within the first 12 weeks of a disease progression
event or still on first-line treatment.
Exclusion criteria: Patients with haematological malignancies because they have a less predictable
disease trajectory than those presenting with solid tumours. Patients who had received one or more
palliative care consultations at any time, or one palliative care consultation in the 6 months before di-
agnosis or disease progression. Patients deemed cognitively impaired at the discretion of the oncolo-
gist and psychologist
Number of patients: N = 186 (92 intervention and 94 control)
Diseases: Gastrointestinal [pancreas (N = 25), biliary tract (N = 11), oesophagus (N = 6), gastro-oe-
sophageal (N = 7), gastric (N = 7), colorectal (N = 15)], lung (N = 51), head and neck (N = 19), breast (N =
14), melanoma (N = 15), genitourinary [prostate (N = 6), bladder (N = 4), kidney (N = 6)]
Patient characteristics: Median age (IQR): 64.5 (57.3 - 71) years in intervention group, 65 (57 - 71) years
in control; 36% female in intervention group, 27% female in control
Deaths at end of study (N (%)): N = 47: 22 (23.4%) intervention and 25 (27.2%) control
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Withdrawals/other dropouts (N (%)): N = 106: 44 (47.8%) intervention and 62 (66%) control
Interventions Name: Systematic early integration of palliative care in oncological care vs usual oncology care
Early PC (EPC): Patients were within the first 12 weeks of a new primary tumour or had a diagnosis of
progression. Patients recruited from a hospital other than Ghent University Hospital had to be within
the first 12 weeks of a disease progression event or still on first-line treatment.
Type: Specialist palliative care. Included specialist palliative care nurse and palliative care physician.
The palliative care physician involved in this study has a specialty degree in anaesthesiology and was a
trained professional in specialised palliative care.
Service base: Medical Oncology, Thoracic Oncology, and Digestive Oncology departments of Ghent
University Hospital in Flanders, Belgium
Team: Palliative care physicians and palliative care nurses
Intervention condition: Patients had a first consultation with a specialised palliative care nurse with-
in 3 weeks of enrollment. Hospital consultations between patients and palliative care nurses were or-
ganised monthly until the patient’s death, and coincided with planned oncological sta, meetings. The
palliative care physician visited patients after referral from the palliative care nurse. The early palliative
care intervention used a previously published study (Temel 2010) as a guide, with the intervention con-
sisting of four major components:
(1) training sessions for palliative care nurses and physician about cancer treatments, use of the inter-
vention documents and the administration of the Edmonton Symptom Assessment Scale (ESAS)
(2) semi-structured, monthly palliative care consultations by palliative care nurses allowed for individ-
ualised patient care. These consultations focussed on illness understanding and perception, symptom
burden, psychological coping, spiritual coping, and medical decision-making. If needed, patients were
referred to other health-care professionals.
(3) Monthly symptom assessments using ESAS by palliative care nurses
(4) Integration of palliative care into oncological care through participation of palliative care nurses in
the weekly multidisciplinary oncology meetings and their reporting in the electronic patient file.
Duration: Hospital consultations between patients and palliative care nurses were organised monthly
until the patient’s death.
Control condition: Standard oncology care was provided by a multidisciplinary team, including oncol-
ogists, other medical specialists, psychologists, social workers, dieticians, and specialist nurses. In rou-
tine clinical practice, the palliative care team is only involved on demand, often late in the disease tra-
jectory, and their services are not systematically offered to all patients from oncology departments. All
patients could have further consultations with the specialist nurse, dietician, and psychologist on de-
mand.
Outcomes Primary outcomes
Quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire Core 30 items (EORTC QLQ-C30)
Secondary outcomes
Quality of life assessed using the McGill Quality of Life (MQOL) Questionnaire
Patient’s mood assessed using the Hospital Anxiety and Depression Scale (HADS)
Depression assessed using the Patient Health Questionnaire-9 (PHQ-9)
Understanding of illness assessed using the questionnaire used by Temel and colleagues
European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30
items (EORTC QLQ-C30 functioning and symptoms scales)
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McGill Quality of Life (MQOL) Questionnaire functioning scales
Overall survival
Assessment points:
Enrolled patients completed follow-up questionnaires administered by the data manager at 12, 18, and
24 weeks, and 6 weekly thereafter until death. Patients who were not willing or able to complete the
questionnaires at the hospital received them by mail.
Resource use/costs Number of consultations with the palliative care team
Frequency of contact with a psychologist, dietician, social worker, or a specialist nurse
Time horizon: from study enrollment to 24 weeks
Notes Funding source: Research Foundation Flanders, Flemish Cancer Society (Kom Op Tegen Kanker).
Declarations of interest among primary researchers: The authors declared no competing interests.
Power considerations: With 59 patients in each group, the study had a power of 80% to detect a 12-
point difference in the global health status/quality of life scale EORTC QLQ-C30 score from baseline to
12 weeks between both study groups assuming a SD of 23.0. Based on a previous study, the authors ex-
pected an overall dropout rate of 35%, accounting for the planned inclusion of 182 patients.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from main publication: "patients were randomly assigned (1:1) to either
systematic early integration of palliative care in oncological care or to usu-
al oncological care. We generated the randomisation list using the permuted
block method (block size of 4), stratified according to treating department.
Computer generated sequences were created by a statistician using the PLAN




Low risk Quote from main publication: "the allocation sequence was only available to
an independent administrative assistant and was unknown to the investiga-
tors. The research assistant enrolled the patients and obtained patient study






High risk Quote from main publication: "in this non-blinded, randomized, controlled tri-
al..."





Low risk Quote from main publication: "in this non-blinded, randomized, controlled tri-
al..."
Comment: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes such as survival.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
High risk Quote from main publication: "masking those individuals giving the interven-
tion, those assessing the outcomes and analysing the data was not possible".
Comment: high risk of bias due to lack of blinding
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Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk Quote from main publication: "masking those individuals giving the interven-
tion, those assessing the outcomes and analysing the data was not possible".
Comment: outcome assessors were not blinded but this was unlikely to lead to




Low risk N = 51 (55.4%) completers in intervention group vs N = 45 (47.9%) completers
in control group. Multiple imputation was carried out for missing data and
they were included in the analysis.
Comment: given the fact that multiple imputations were carried out, a low risk
of bias was rated.
Selective reporting (re-
porting bias)
Unclear risk Quote from main publication: "Additional protocol-specified secondary end-
points not reported here include patient illness trajectory and end-of-life care;
unpaid caregiver’s mood, understanding of the patient’s illness, satisfaction
with care, and impact on quality of life; and impact on advance-care planning
and end-of-life decision-making, as reported by the patient’s physician". How-
ever, the authors stated that "Data regarding whether physicians discussed
advance-care planning and end-of-life care with their patients, patient quali-
ty of life near death, and unpaid caregiver-reported outcomes will be reported
elsewhere".
Comment: the above highlighted secondary endpoints were not reported but
will be reported subsequently.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Multidisciplinary team
Core team: Full-time attending physicians/nurse practitioners/nurse thanatologist/physician fellow in
Hospice and Palliative medicine. The extended team included spiritual ministry, social work, recreation
therapy, counselling, nutrition, acupuncture, acupressure, massage, reiki, rehabilitation medicine.
Participants Country and regions: USA, Bethesda, Maryland
Recruitment: Patients with advanced malignancies who were undergoing surgical procedures in Na-
tional Cancer Institute (NCI) Surgery Branch clinical trials were recruited.
Inclusion criteria: Not described
Exclusion criteria: Not described
Number of patients: N = 152 (76 intervention and 76 control)
Diseases: Advanced cancer
Patient characteristics: Mean age (SD): 52.43 (10.42) years in intervention group, 52.38 (3.01) in con-
trol group. Gender distribution in the intervention and control group was not described.
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Deaths at end of study (N (%)): Number of deaths was not provided.
Withdrawals/other dropouts (including deaths) (N (%)): N = 102: 54 (71.1%) intervention and 48
(63.2%) control
Interventions Name: Hospital-based early palliative care vs standard oncology care
Early PC (EPC): Early palliative care was begun postoperatively. The philosophy of the palliative care
team was to provide comfort care for symptom burden earlier in the disease process to improve quality
of life.
Type: Specialist palliative care. Included professionals with training in palliative care
Service base: National Institutes of Health Clinical Centre, Bethesda
Team: Two full-time attending physicians, three nurse practitioners, a nurse thanatologist, and one
physician fellow in Hospice and Palliative medicine. The extended team included spiritual ministry, so-
cial work, recreation therapy, counselling, nutrition, acupuncture, acupressure, massage, reiki, rehabil-
itation medicine.
Intervention condition: The hospital-based pain and palliative care service (PPCS) was a consult team
available to all patients who were actively participating in research studies throughout the National In-
stitutes of Health (NIH) Clinical Centre. The patients were seen as inpatients as well as in an outpatient
clinic setting. Each consult included a full assessment of pain and other symptoms, what treatments
had been implemented, and what were the most bothersome and disruptive to the patient. The con-
sult also covered emotional and spiritual distress. The patient was usually offered varied modalities of
treatment, pharmacologic as well as complementary therapies.
Duration: The intervention was provided until 12 months: interviews were conducted pre-surgically
and at follow-up visits up to 1 year.
Control condition: Standard pain and symptom management provided to the control group includ-
ed individual consultations such as nutrition, social work, spiritual ministry, recreation therapy, occu-
pational therapy, physical therapy, and/or clinical psychiatry. If standard pain and symptom manage-
ment were insufficient to meet the needs of a patient, study participants were permitted to cross over
to the treatment arm of the study at the clinical discretion of the attending physician.
Outcomes Primary outcomes
Pain intensity and unpleasantness assessed using the Gracely Pain Scale
Symptom burden assessed using the Symptom Distress Scale
Secondary outcomes
Mood assessed using the Centre for Epidemiologic Studies - Depression Scale (CES-D)
Social support
Satisfaction with pain and symptom management
Assessment points: After randomisation, face-to-face interviews were conducted prior to surgery,
within the first 24 hrs postoperatively, and during follow-up staging visits at 4–6 weeks, 3, 6, 9, and 12
months. Pain and symptom outcomes were assessed at all time intervals. Secondary outcomes were
assessed less frequently with mood assessed at baseline, 6 and 12 months.
Resource use/costs None reported
Notes Funding source: Not reported
Declarations of interest among primary researchers: Not reported
Power considerations: Not reported
Wallen 2012  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from main publication: "once written consent was obtained, patients
were randomized to the standard care (control) or early palliative care (treat-
ment) group".
Comment: unclear as random sequence generation was not well described
Allocation concealment
(selection bias)





High risk Participants and personnel were not blinded.
Comment: high risk of bias due to lack of blinding
Blinding of outcome as-
sessment (detection bias),
subjective outcomes





High risk N = 22 (28.9%) completers in intervention group vs N = 28 (36.8%) completers
in control group. In the intervention group 54 patients dropped out due to
death or disease progression while 48 patients in the control group dropped
out for these reasons.
Comment: given the high levels of attrition, a high risk of bias was rated.
Selective reporting (re-
porting bias)
High risk Data for mood measured using the Centre for Epidemiologic Studies Depres-
sion Scale (CES-D) was not presented at baseline and also during follow-up. Al-
so, the protocol included the palliative care outcome scale (POS) as one of the
outcome measures but this was not presented in the published study.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-






Who led PC intervention: Multidisciplinary team
Core team: Nurses and physicians
Participants Country and regions: South Korea
Recruitment: Patients who presented to the outpatient cancer clinic between April 2012 and May
2016 were invited by their physicians to enroll in the study; all the physicians in the clinic agreed to ap-
proach, recruit, and obtain consent from their patients.
Inclusion criteria: Patients were eligible to participate if they had pathologically confirmed locally
advanced or metastatic pancreatic or biliary tract cancer diagnosed within the previous 8 weeks, a
Woo 2019 
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Karnofsky performance rating scale ≥ 50% and cancer-related pain (BPI worst pain score > 3) and/or de-
pression (CES-D > 16).
Exclusion criteria: Not stated
Number of patients: N = 288 (144 intervention and 144 control)
Diseases: Pancreatic or biliary tract cancer
Patient characteristics: Median age (range): 66 (40 - 86) years in intervention group, 67 (42 - 89) in con-
trol group. 56% female in intervention group, 55% female in control
Deaths at end of study (N (%)): N = 207: 100 (69.4%) intervention and 107 (74.3%) control
Withdrawals/other dropouts (N (%)): N = 48: 25 (17.4%) intervention and 23 (16%) control
Interventions Name: Early palliative care (EPC) integrated with usual oncologic care vs usual oncology care
Early PC (EPC): Patients were eligible to participate if they had pathologically confirmed locally ad-
vanced or metastatic pancreatic cancer or biliary tract cancer diagnosed within the previous 8 weeks.
Type: Training in palliative care unclear
Service base: National Cancer Centre, Korea
Team: Nurses and two physician experts in pancreatic cancer or biliary tract cancer
Intervention condition: EPC included: (1) Nursing assessment of pain and depression, (2) pain con-
trol based on National Comprehensive Cancer Network (NCCN) guidelines, (3) depression control by
psychoeducation and/or consultation with a psychiatric specialist, and (4) patient education. Nursing
assessment of pain included a brief evaluation of each patient’s mood state with the CES-D. Patients
with CES-D scores > 25 were referred to psychiatric specialists. The interventions was delivered by tele-
phone or during regularly scheduled outpatient care. Follow-up intervention visits or telephone coach-
ing were scheduled daily until BPI worst pain score was ≤ 3. In addition, telephone calls were triggered
when patients reported inadequate symptom improvement, nonadherence to medication, adverse ef-
fects, or suicidal ideation, or when patients requested to be contacted.
Duration: Participants were contacted at baseline and at 1, 3, 6, 9, and 12 months.
Control condition: The control group received no formal intervention but were informed of their de-
pressive and pain symptoms. Their screening results were provided to their physician. Usual oncology
care (UOC) was directed by an attending physician and consisted of anticancer and symptom control
treatments and consultation with psychiatric and pain care specialists. The latter were provided when-
ever requested, regardless of group assignment.
Outcomes Primary outcomes
Pain assessed using the Brief Pain Inventory
Depression assessed using the Centre for Epidemiological Studies — Depression Scale (CES-D)
Secondary outcomes
Quality of life assessed using the European Organisation for Research and Treatment of Cancer Core
Quality of Life questionnaire (EORTC QLQ-C30) Korean version
Sleep disturbance assessed using the Insomnia Severity Index (ISI)
Satisfaction with pain control assessed on a 5-point scale (1 = very good; 5 = very poor)
Patient and investigator's global assessment
Clinical global impression score assessed using the Clinical Global Impression-Improvement (CGI-I
scale)
Woo 2019  (Continued)
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Survival
Assessment points: Participants were contacted at baseline and at 1, 3, 6, 9 and 12 months.
Resource use/costs None reported
Notes Funding source: The study was supported by grants from the National Cancer Center, Korea.
Declarations of interest among primary researchers: The authors indicated that they had no poten-
tial conflicts of interest.
Power considerations: The target sample size, calculated for a power of 80% and a corrected two-
sided alpha of 0.025 and allowing a dropout rate of 18–20%, was 144 per group.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "patients...were randomised 1:1 within 8 weeks after
diagnosis to receive either EPC or usual oncology care. Patients were stratified
based on tumor type (PC or BTC) and symptom type (pain only, depression on-
ly, and pain and depression)".









High risk Quote from publication: "lack of blinding is always an issue in clinical research
regarding early palliative care for patients with advanced cancer. This bias
could not be avoided due to the lack of patient blinding in this prospective,
randomised controlled trial".





Low risk Quote from publication: "lack of blinding is always an issue in clinical research
regarding early palliative care for patients with advanced cancer. This bias
could not be avoided due to the lack of patient blinding in this prospective,
randomised controlled trial".
Comments: participants and personnel were not blinded but this was unlikely
to lead to bias in objective outcomes such as survival.
Blinding of outcome as-
sessment (detection bias),
subjective outcomes
Unclear risk It was not stated whether outcome assessors were blinded.
Blinding of outcome as-
sessment (detection bias),
objective outcomes
Low risk It was not stated whether outcome assessors were blinded but this was unlike-




Low risk N = 19 (13.2%) completers in intervention group vs N = 14 (9.7%) completers
in control group. In the intervention group 125 patients (86.8%) dropped out
due to death and other reasons while 130 patients (90.3%) in the control group
dropped out for these reasons.
Comment: given that there was imputation of missing values, a low risk of bias
was rated.
Woo 2019  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Study protocol was not available.
Other bias Low risk Study appeared to be free of other biases.
Size of study Unclear risk Unclear risk of bias because the number of participants in each group was be-
tween 50 and 199
Woo 2019  (Continued)
ACP: advanced care planning
AL: acute leukemia
BIS: Breathlessness Intervention Service
BPI: Brief Pain Inventory
CHF: chronic heart failure
CI: Confidence interval
COPD: chronic obstructive pulmonary disease
CT: Computerised Tomography
DVD: Digital Versatile Disc
D12: Dyspnoea 12 breathlessness scale
EGFR: epidermal growth factor receptor





HSPC: Hospital Specialist Palliative Care
ICD: International Classification of Disease
ICU: intensive care unit
IHPC: In Home Palliative Care
ILD: Interstitial Lung Disease
km: kilometers
mg/d: milligram/day
MICU: medical intensive care unit
MRC: Modified Research Council breathlessness scale
NIHR: National Institute for Health Research
NSCLC: non-small cell lung cancer
NYHA: New York Heart Association
N/n: Number
PC: palliative care
PCT: palliative care team
pg/mL: picogram/milliliter
QoL: quality of life
RCT: randomised controlled trial
SD: Standard deviation
SPC: specialist palliative care
UCLA: University of California, Los Angeles
v: versus
WHO: World Health Organization
y / yrs: years
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Bakitas 2017 This study was not a randomised controlled trial.
Berglund 2019 Intervention was not provided by a multidisciplinary team.
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Study Reason for exclusion
Bonsignore 2018 This study was not a randomised controlled trial.
Brims 2019 The control group included palliative care as part of routine usual care.
Do 2017 Study compared a psychosocial intervention combined with early palliative care vs early pallia-
tive care vs standard cancer treatment. The control group included palliative care as part of routine
usual care.
Fischer 2019 Intervention was not provided by a multidisciplinary team.
Hanks 2002 This study compared the effectiveness of a multidisciplinary specialist palliative care team (PCT)
('full-PCT') with limited telephone advice ('telephone-PCT', the control group). The control group
included palliative care as part of routine usual care.
Hartman 2019 This study was not a randomised controlled trial as it used an alternate day assignment to allocate
participants to the intervention and control groups.
Hoek 2017 This study compared weekly teleconsultations from a hospital-based specialist palliative care con-
sultation team (SPCT) with palliative home care provided by GPs (supported by the SPCT) accord-
ing to the standard referral procedures. The control group included palliative care as part of rou-
tine usual care.
Jordhoy 2001 This study did not conceal its allocation sequence. It was a cluster-RCT.
Kimbell 2018 This study was not a randomised controlled trial.
Maltoni 2016 The intervention was not provided by a multidisciplinary team.
Nordly 2019 Study included both hospital-based and hospice-based specialist palliative care and did not sepa-
rate their results.
O'Mahony 2017 This study was not a randomised controlled trial.
Pantilat 2010 This study was not a randomised controlled trial as it used an alternate day assignment to allocate
participants to the intervention and control groups.
Rabow 2004 This study did not conceal its allocation sequence. It was a cluster-RCT.
Scarpi 2019 The intervention was not provided by a multidisciplinary team.
Schenker 2018 The intervention was not provided by a multidisciplinary team.
Spatuzzi 2017 This study was not a randomised controlled trial.
Sussman 2018 The intervention was not provided by a multidisciplinary team.
Ullrich 2017 This study was not a randomised controlled trial.
Veronese 2017 The intervention was not hospital-based specialist palliative care. It was home palliative care.
Wong 2016 The control group included palliative care as part of routine usual care.
Yang 2018 The intervention was not provided by a multidisciplinary team.
Zimmermann 2014 This study did not conceal its allocation sequence. It was a cluster-RCT.
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GP: General Practitioners
PCT: Palliative Care Team
RCT: Randomised Controlled Trial
SPCT: Specialist Palliative Care Consultation Team
vs: versus
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods RCT
Participants Patients with newly diagnosed non-small-cell lung cancer
Interventions Early palliative care integrated with standard oncological care
Outcomes Primary outcome measured: quality of life at 12 weeks assessed using the Edmonton Symptom As-
sessment Scale (ESAS)
Notes Only the abstract was published. We found no preregistration entry for this study and the author
could not be contacted. Consequently, there was insufficient information as to the nature of pallia-
tive care team and setting.
Aljohani 2015 
RCT: Randomised Controlled Trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Collaborative supportive care for life-limiting chronic conditions: a prospective randomised con-




Number of patients: Unknown as study is ongoing
Diseases: Adults with life-limiting chronic conditions
Patient characteristics: Patients aged 18 years and over
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Specialist palliative care
Service base: Hospital
Team: Palliative care, renal medicine, general medicine, cardiac failure medicine, social work, ad-
vance care planning and complex care nurse practitioners
Description: Multidisciplinary supportive care clinic management and ongoing follow-up as clini-
cally required. Face-to-face consultations with patients and their carers with a palliative care physi-
cian and/or general medicine physician, nurse practitioner, and social work. Medical issues will be
reviewed, symptoms managed, and care planning issues reviewed. The clinic review will be on an
as-required basis after the initial review. These may be up to weekly if needed. All participants are
reviewed until death. Patients' family physicians will be provided with a summary of the consulta-
ACTRN12618001045202 
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tion and a care plan to each patient. Each clinic will also have a multidisciplinary meeting to dis-
cuss each patient's needs.
Duration: Unclear
Outcomes Primary outcomes:
Health professional-rated score for symptom severity
Quality of life assessed using the McGills Quality of Life Questionnaire




General practitioner episodes of contact
Hospital admissions
Number of community service referrals
Number of episodes of contact with other healthcare professionals
Number of patient/carer episodes of contact (composite score)










Number of patients: 90: 45 intervention and 45 control
Diseases: Heart failure
Patient characteristics: Patients aged 18 years or older
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
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Study name The randomised evaluation of default access to palliative services (REDAPS) trial
Methods Multicentre pragmatic, stepped-wedge cluster-RCT
Participants Country: USA
Recruitment: An electronic health record (EHR)-based algorithm to identify eligible patients was
constructed based on ICD-9 and -10th Revisions, Clinical Modification codes (67 - 69) that are
present on admission. In addition, nurses complete a 5-item electronic checklist during intake to
denote the disease-specific eligibility criteria. The eligibility criteria were chosen to include pa-
tients (1) with sufficiently complex needs that they are likely to benefit from specialty palliative
care, (2) who could be identified relatively easily from the electronic health record, and (3) who dif-
fer from the populations most commonly included in prior or ongoing studies of palliative care.
Number of patients: Unknown as study is ongoing
Diseases: Advanced chronic obstructive pulmonary disease, dementia or end-stage renal disease
Patient characteristics: Patients aged 65 years or older
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Specialist palliative care
Service base: Hospital
Team: Palliative care team
Description: REDAPS is a pragmatic, stepped-wedge cluster-randomised trial in which hospitals
adopt the intervention of electronically triggered, default palliative care consultation orders for el-
igible patients at randomly assigned times (wedges). During the intervention phase of the trial at
each hospital, a palliative care consult order is entered by default for all eligible patients. It is ini-
tially an inactive “standing order” that is generated with a future start date. Physicians caring for
Courtright 2016 
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patients who trigger the default order are notified and instructed on how to cancel it if they wish.
If it is not cancelled within 24 hours, the standing order becomes active. In keeping with the prin-
ciples of pragmatic trials testing real-world effectiveness of interventions, palliative care teams re-
tain discretion regarding prioritisation of patients, provision of services, and documentation prac-
tices within a standardised palliative care consultation form.
Duration: All hospitals contribute at least 3.5 months of control data before adopting the interven-
tion. Similarly, the end of the 31-month study period includes a 3.5-month period during which all
hospitals are using the intervention. This design enables comparisons of outcomes before and af-
ter implementation within hospitals as well as comparisons among hospitals at given time points.
Outcomes Primary outcome:
Composite measure of in-hospital mortality and length of stay.
Secondary outcomes:
Palliative care process measures
Documentation of goals of care
Documentation of family meetings
Documentation of durable power of attorney, surrogate, or proxy
Documentation of pain assessment
Palliative care team visits per patient
Use of bowel regimen for patients on opioids
Clinical outcomes:
Pain scores (excluding patients with dementia)
Dyspnoea
Code status (most recent at time of death or discharge)
Hospital mortality
Intensive Care Unit (ICU) mortality
Transfer to ICU after randomisation
Cardiopulmonary resuscitation after randomisation




Direct cost per hospitalisation
Direct cost per day
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Number of patients: 200
Diseases: Heart failure
Patient characteristics: Patients aged 18 years or older
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Specialist palliative care
Service base: Unclear
Team: Palliative care team
Description: Early Integration of Palliative Care (EIPC, proactive) with monthly visits with monitor-
ing of symptoms and treatment, psychological support in addition to treatment of control group
Duration: Unclear
Outcomes Primary outcome:
Health-related quality of life assessed at 12 months and measured by the Functional Assessment
of Chronic Illness Therapy; Palliative Care scale (FACIT–PAL) and the Kansas City Cardiomyopathy
Questionnaire (KCCQ)
Secondary outcomes:
Depression and anxiety score (HADS-D) every 3 months
Symptom burden score (MIDOS) at baseline and end of study
Spiritual well-being (measured via the FACIT–Spiritual Well-Being scale (FACIT-Sp)) at baseline and
end of study
Number of hospital readmissions
Total number of hospital days due to heart failure (end of study)
Overall survival (end of study)







Study name Advancing symptom alleviation with palliative treatment (ADAPT) trial to improve quality of life: a
study protocol for a randomized clinical trial
Methods Multisite RCT
Participants Country: USA
Recruitment: Eligible subjects at both study sites will be identified electronically using validated
combinations of diagnostic codes. Study personnel will screen individual medical records to con-
firm eligibility. After confirmation, patients’ primary care providers will be contacted to confirm
the study team can contact their patients and to explain the study. With primary care provider ap-
proval, veterans will be mailed letters describing the study and providing contact information for
Graney 2019 
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study sta, if they are interested in participating. If an eligible veteran does not contact the study
team, they are contacted by telephone.
Number of patients: 300
Diseases: Chronic heart failure (CHF), interstitial lung disease (ILD) and COPD
Patient characteristics: Study to include veterans with CHF, ILD and COPD
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Specialist palliative care
Service base: Hospital
Team: Palliative care team comprising a registered nurse (RN) and Master’s level social worker
(MSW) who integrate into a larger collaborative care team ('Team') that includes a representative
primary care provider (PCP) and palliative care specialist. Specialist support with a cardiologist or
pulmonologist is available for the Team for additional management recommendations, if needed.
Description: The intervention is a multidisciplinary, team-based approach to addressing symptoms
and psychosocial needs of participants. The team-based approach is based on the evidence-based
collaborative care model of healthcare delivery.
Duration: 6 months
Outcomes Primary outcome:
Patient-reported quality of life assessed using the Functional Assessment for Chronic illness Thera-
py-General (FACT-G) questionnaire
Secondary outcomes:
Symptom experience measured using the General Symptom Distress Scale (GSDS)
Depression assessed using the Patient Health Questionnaire-8 (PHQ-8)
Health-related quality of life assessed using the Quality of Life at the End of Life (QUAL-E) ques-
tionnaire, Kansas City Cardiomyopathy Questionnaire (KCCQ-12); the Clinical COPD Questionnaire
(CCQ); or the King’s Brief Interstitial Lung Disease (K-BILD)
Hospitalisations
Advanced care planning communication and documentation






Study name The EPIC trial
Methods Multicentre RCT
Participants Country: France
Recruitment: Patients will be recruited nationwide from 17 university hospitals or cancer centres in
France. Inclusion criteria: patients must:
Hutt 2018 
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- have an upper GI metastatic cancer, including pancreatic cancer, biliary tract cancer or gastric
cancer (including junctional Siewert 2 and 3 cancers) (an amendment is being submitted to our
ethics committee in order to include other oesophageal cancers, too),
- be 18 years of age or older,
- have an ECOG performance status ≤ 2,
- be planned for treatment with first-line Ct,
- have a life expectancy of more than 4 weeks,
- have a good understanding of the French language,
- have health insurance coverage,
- sign and date a written informed consent form.
Exclusion criteria:
Patients with any of the following conditions or characteristics are excluded from the study:
- locally advanced cancer,
- junctional Siewert one oesophago-gastric cancer (an amendment is being submitted to our ethics
committee in order to include these cancers together with other oesophageal cancers),
- gastric or junctional oesophago-gastric cancer with dysphagia,
- gastric or junctional oesophago-gastric cancer with unknown or positive HER2 status,
- compression of the biliary tract without any bypass procedure.
Number of patients: Sample size of 480 patients proposed
Diseases: Metastatic upper GI cancers
Patient characteristics: Unknown as study is ongoing
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Early palliative care
Service base: Hospital
Team: Palliative care specialists
Intervention: Medical oncologists will be in charge of the patient for chemotherapy (Ct) adminis-
tration and for supportive care, in accordance with professional practices. PC specialists will be in
charge of PC/EPC visits. In the experimental arm (Ct + EPC), five PC visits are scheduled. The first
visit (V1) will be scheduled within the first 3 weeks after randomisation. The remaining four visits
will be scheduled every month. The content of each of the five PC visits will be described by the PC
physician and documented in the database following a specific checklist developed by PC physi-
cians.
Duration: 24 weeks
Control: In order to match with standard practice in France, participants allocated to the standard
arm (Ct alone) are not scheduled to meet with the PC service, but a PC visit can be performed any-
time if requested by the patient, the family or the oncologist.
Outcomes Primary outcome:
Overall survival (as intent-to treat analysis)
Secondary outcomes:
Hutt 2018  (Continued)
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Overall survival (per protocol analysis)
One-year survival rate (intent-to treat and per protocol analyses)
Quality of Life assessed with the QLQ-C30 questionnaire at baseline, and after inclusion, every 8
weeks until patient withdrawal from the study
Depression and anxiety assessed with the HADS scale (Hospital Anxiety and Depression Scale) at
baseline, and after inclusion, every 8 weeks during 24 weeks
Time Until Definitive Deterioration (TUDD) for quality of life scores was defined as the time from
randomisation to the first observation of a definitive deterioration of QLQ-C30 score or death
Presence or lack of advanced directives
Actual description of the PC package
Number of patients receiving chemotherapy in their last 30 days of life










Number of patients: 48
Diseases: Chronic heart failure
Patient characteristics: Unknown as study is ongoing
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Unclear
Service base: Unclear as not stated
Team: Unclear
Intervention: Participants will be trained for 6 weeks according to the WHO protocol, in groups of 6
to 8 people, once a week. The educational content included physical problems management and
strategies for promoting physical activity, self-care (diet, sleep pattern, proper use of drugs and no
smoking) and psychological and spiritual care and social communication.
Duration: 6 weeks
Control: Routine care without any intervention
Outcomes Primary outcome:
Self-efficacy assessed using Sullivan's cardiac self-efficacy questionnaire
Starting date June 2018
IRCT20160521027993N1 
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Number of patients: 60
Diseases: COPD
Patient characteristics: Unknown as study is ongoing
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Unclear
Service base: Unclear as not stated
Team: Unclear
Intervention: COPD patients will receive palliative care using the training and implementation of
the protocol from the time of admission. Training sessions will include: first day - giving pamphlets
and training on smoking cessation methods and diet, day two - teaching effective breathing tech-
niques, day three - lung physiotherapy, day four - cold steaming.
Duration: Not stated
Control: Receives routine nursing care.
Outcomes Primary outcome
Quality of life assessed using the SF-12






Study name The effect of palliative care program on the quality of life of children with leukaemia
Methods Country: Iran
Recruitment: Not stated.
Number of patients: 60
Diseases: Leukaemia
Patient characteristics: Unknown as study is ongoing
Deaths at end of study: Unknown as study is ongoing
IRCT20180531039925N1 
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Withdrawals/other dropouts: Unknown as study is ongoing
Participants Type: Unclear
Service base: Unclear as not stated
Team: Unclear












Study name Does outpatient palliative care improve patient-centered outcomes in Parkinson's disease: ratio-
nale, design, and implementation of a pragmatic comparative effectiveness trial
Methods Country: USA
Recruitment: Included: 1) Referrals from colleagues within academic practices; 2) Referrals from
community physicians notified about the study through personal connections, solicitations
through email and letters, and continuing medical education (CME) events; 3) Community talks giv-
en to patients by investigators or patient/ unpaid caregiver advisors sponsored by support groups
or local PD organisations; 4) Advertisements through local PD organisations (e.g. newsletters); and
5) Postings on clinical research websites
Number of patients: 210
Diseases: Parkinson's disease
Patient characteristics: Unknown as study is ongoing
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Participants Type: Unclear
Service base: Unclear as not stated
Team: Neurologist with PC experience and informal training with a board-certified palliative medi-
cine specialist
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Inclusion criteria: (1) Histologically or cytologically proven lung cancer (2) Stage IV non-small cell
lung cancer or extensive-disease small cell lung cancer (3) Negative or unknown of EGFR gene mu-
tation (4) Negative or unknown of ALK fusion gene (5) Undergoing first-line chemotherapy at insti-
tutions participating in this study (6) Not performed anticancer therapy (chemotherapy, radical
surgery, definitive radiotherapy) (7) Initial administration of the first-line chemotherapy in inpa-
tient hospital setting (8) Age >= 20 years (9) Written informed consent for participation in this study
Exclusion criteria: (1) Already consulted outpatient palliative medicine clinic or outpatient psy-
cho-oncology clinic before entry to this study, and scheduled to receive the medical care subse-
quently (2) Already received intervention of specialty palliative care service before diagnosis (3)
With severe cognitive impairment (4) Unable to read and respond to questions in Japanese (5) Par-
ticipated in other intervention studies which prohibits participation in this study (6) Judged to be
inappropriate for participation to this study
Number of patients: Unknown as study is ongoing
Diseases: Advanced lung cancer
Patient characteristics: Unknown as study is ongoing
Deaths at end of study: Unknown as study is ongoing
Withdrawals/other dropouts: Unknown as study is ongoing
Interventions Type: Early specialist palliative care
Service base: Unclear as not stated
Team: Information obtained from contacting the author indicates that the nurse-led, screen-
ing-triggered early specialist palliative care intervention involves other healthcare professionals
such as doctors or psychologists
Intervention: Nurse-led screening-triggered early specialised palliative care (ESPC) intervention
Duration: Not stated
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Control: Usual care
Outcomes Primary outcome:
Change in the score on the Functional Assessment of Cancer Therapy-Lung Trial Outcome Index
(FACT-L TOI) from baseline to 3 months
Secondary outcomes:
FACT-L score
FACT-L Lung Cancer Subscale (LCS) score
Proportion of patients with depression assessed by Patient Health Questionnaire 9 (PHQ-9)
PHQ-9 score
Proportion of patients with anxiety assessed by generalised anxiety disorder 7-item (GAD-7)
GAD-7 score
EuroQol-5 Dimension (EQ-5D) score
Proportion of responses to each item in the questionnaire about illness understanding
Proportion of responses to each item in the questionnaire about medical services received
One-year survival rate
Overall survival
Visiting time with patients taken for each profession belonging to specialised palliative care service
to meet with patients
Place of death as a ratio outcome
Days from the last chemotherapy to death
Days of hospital stay in general wards during one month before death
Days of hospice usage during one month before death
Proportion of hospice usage during one month before death
Proportion of cardiopulmonary resuscitation
Starting date January 2017
Contact information  
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• Patients diagnosed with solid tumours who are eligible for participation in phase I clinical trials
of investigational cancer therapies
• Patients who have signed an informed consent for participation in phase I clinical trials
• Able to read or understand English - this is included because the intervention and study materials
(including outcome measures) are only in English
• Ability to read and/or understand the study protocol requirements, and provide written informed
consent
Exclusion Criteria:
• Patients diagnosed with haematologic (as a population distinct from solid tumours and different
trials) cancers
Number of patients: Sample size of 480 participants proposed
Disease: Patients diagnosed with solid tumours
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Integration of palliative care for cancer patients
Service base: Not stated
Team: Interdisciplinary team
Intervention: Patients receive part I of the Palliative Care Intervention (PCI) comprising quantita-
tive surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care
discussions beginning prior to administration of the first dose of phase I treatment. Patients then
receive part II of the PCI comprising recommendations from the interdisciplinary team, patient ed-
ucational sessions, and supportive care referrals following the first dose of phase I treatment and
which is completed within one month of the first treatment.
Duration: Unclear
Usual care: Delayed PCI
Outcomes Primary outcomes:
Change in overall QoL scores, assessed by the Functional Assessment of Cancer Therapy-General
(FACT-G) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp)
Change in psychological distress, assessed using the Psychological Distress Thermometer
Satisfaction with communication, measured by the Family Satisfaction with Advanced Cancer Care
(FAMCARE)
Patients' symptom intensity and symptom interference with daily activities
Total numbers of supportive care referrals (social work, dietitian, chaplaincy, psychologist/psychi-
atrist)
Total number of unscheduled outpatient encounters and inpatient admissions
Total number of hospice referrals
Retention on the phase I trial
Patient satisfaction with the PCI
Secondary outcomes:
NCT01828775  (Continued)
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Change in overall QoL scores, assessed by FACT-G and FACIT-Sp
Change in psychological distress, assessed using the Psychological Distress Thermometer
Satisfaction with communication, measured by FAMCARE
Patients' symptom intensity and symptom interference with daily activities
Total numbers of supportive care referrals (social work, dietitian, chaplaincy, psychologist/psychi-
atrist)
Total number of unscheduled outpatient encounters and inpatient admissions
Total number of hospice referrals
Retention on the phase I trial
Patient satisfaction with the PCI






Study name A randomized trial of a family unpaid caregiver palliative care intervention
Methods Country: USA
Participants Recruitment: Inclusion Criteria:
• Primary family unpaid caregivers of cancer patients with gastrointestinal (colorectal, pancreatic,
gastric), gynaecologic, urinary or lung cancers who are entering the City of Hope for treatment or
follow-up
• Primary family unpaid caregivers of cancer patients who are diagnosed with stage II-IV disease
• Primary family unpaid caregivers of cancer patients with > 6 months prognosis
• Living within a 50 mile radius of the City of Hope
Number of family unpaid caregivers: Sample size of 200 participants proposed
Diseases: Patients with stage II-IV gastrointestinal, gynaecologic, urologic and lung cancers
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Family unpaid caregiver Palliative Care Intervention (FCPCI)
Service base: Unclear
Team: Advanced practice nurse
Intervention: Participants receive FCPCI with an advanced practice nurse (APN), comprising 4
home education sessions once weekly followed by 4 telephone support sessions for 30 minutes
once monthly and 24-hour telephone support available for 6 months.
Duration: 6 months
NCT01846520 
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Control: Usual care
Outcomes Primary outcomes:
Effects of Family unpaid caregiver Palliative Care Intervention (FCPCI) on unpaid caregiver burden
Effects of FCPCI on caregiving skills preparedness
Effects of FCPCI on Quality of Life (QoL)
Effects of FCPCI on psychological distress
Secondary outcomes:
unpaid caregiver's self-care behaviour
unpaid caregivers' resource use
Identification of subgroups of family unpaid caregivers who benefit most from the FCPCI in relation
to sociodemographic, health status, and patient characteristics
Family unpaid caregivers' satisfaction with the FCPCI
unpaid caregiver out-of-pocket costs






Study name A structured early palliative care intervention for patients with advanced cancer - a randomized




• Diagnosed within the last 16 weeks
• Metastatic or locally advanced, not amenable to curative treatment, non-small cell lung cancer
(NSCLC), or
• Metastatic or locally advanced, not amenable to curative treatment, colorectal cancer, or
• Metastatic or locally advanced, not amenable to curative treatment, prostate cancer, or
• Metastatic or locally advanced, not amenable to curative treatment, breast cancer with visceral
and/or brain metastasis, or
• Metastatic or locally advanced, not amenable to curative treatment, bladder/ urothelium cancer,
or
• Metastatic or locally advanced, not amenable to curative treatment, pancreatic cancer
• Diagnosis is histologically confirmed
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
• At least 18 years of age at the time of enrollment
• Signed informed consent with understanding of the study procedures and the investigational na-
ture of the study
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Exclusion Criteria:
• Presence of delirium or dementia or other reason for lack of ability to give informed consent
• Inability to communicate adequately in German
• Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of
the study and to formulate his/her own wishes correspondingly
• Patients already receiving care from an inpatient palliative care service
Number of patients: Sample size of 150 patients proposed
Diseases: Advanced cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Early Palliative Care Intervention
Service base: Unclear
Team: Palliative care physicians and nurses
Intervention: The structured approach intervention with the SENS model is based on the biopsy-
chosocial-spiritual model of care and the WHO definitions of palliative care as well as the NCCN
Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of con-
cerns from the patient perspective, determines the priority and structures the support needed. The
intervention is performed by palliative care physicians and nurses collaboratively. It is utilised as
baseline assessment and afterwards integrated in each routine oncology care outpatient and inpa-
tient visit. Depending on the goals, it may be applied between routine visits. In addition, patients
will receive usual oncology care throughout the study period.
Duration: Unclear
Control: Patients in the usual care group will receive routine oncology care throughout the study.
This incorporates a routine assessment according to the standard SAKK - protocol which assess-
es overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clin-
ic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nurs-
ing sta, of the palliative care unit are familiar with using the SENS-assessment instrument. Partic-
ipants assigned to usual care may meet with the palliative care service on request according to es-
tablished practice.
Outcomes Primary outcomes:
Distress over six months as measured with the National Comprehensive Cancer Network (NCCN)
Distress thermometer
Secondary outcomes:
Quality of life as measured by Functional Assessment of Cancer Therapy - General (FACT-G)




Starting date December 2013
Contact information  
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Study name Effects of a transitional palliative care model on patients with end-stage renal failure (ESRF)
Methods RCT
Participants Country: Hong Kong
Recruitment:
Inclusion Criteria:
• Patient with chronic kidney disease and diabetic mellitus with creatinine ≥ 350 milli mole (uM) or
those without diabetic mellitus with creatinine ≥ 450 milli mole (uM) who refused renal replace-
ment therapy (RRT);
• Patient not suitable for long-term renal replacement therapy (RRT) after assessment by renal
team (e.g. multiple comorbidities, poor functional status and social support)
• Identified as ESRF patient eligible for palliative care without prior renal replacement therapy
• Ability to speak Cantonese
• Living within the hospital service area
• Ability to be contacted by phone
Exclusion Criteria:
• Discharged to nursing home or other institution
• Inability to communicate
• Cognitive impairment, mini-mental stage examination (MMSE) < 20
• Diagnosed with severe psychiatric disorders such as schizophrenia and bipolar disorder
Number of patients: 176 participants proposed
Diseases: end-stage renal failure (ESRF)
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Transitional Palliative Care Model
Service base: Unclear
Team: Unclear
Intervention: Transitional palliative care includes:-
• telephone follow-up for early identification of signs and symptoms
• home visit for spiritual support
Duration: Unclear
Control: Customary care receives care:-
• hospital based medical follow-up
• general nursing assessment and advice
Outcomes Primary outcomes:
NCT02139917 
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Healthcare utilisation composite - The dates of rehospitalisations, length of stay, and number of
other hospital services used, including clinics and emergency room visits, will be extracted from
the hospital administrative systems.
Secondary outcomes:
Perceived outcomes composite (quality of life, unpaid caregiver burden, satisfaction with care).
Quality of life will be measured by an ESRF-specific quality of life measure. The unpaid caregiver
burden will be measured by the Zarit unpaid caregiver Burden Scale (ZCBS).
Satisfaction with care will be measured by the 15-item questionnaire






Study name Impact of early palliative care on quality of life and survival of patients with non-small-cell
metastatic lung cancer in Northern France
Methods RCT
Participants Country: Northern France
Recruitment: Inclusion Criteria:
• Being diagnosed with non-small cell lung cancer
• Proven histologically
• Metastatic proven imaging (MRI, CT Scanner, PET scan) Stage IV (any T, any N, M1)
• Prior to secondary chemotherapy treatment.
• Age > 18 years
• PS ≤ 2
• Patient able to understand the nature, purpose and methodology of the study
• Signed informed consent
Exclusion Criteria:
• Age < 18 years
• Patient already supported by palliative care
• Patient with an activating EGFR mutation or EML4-ALK rearrangement or ROS1 gene translocation
• Patient under trusteeship/guardianship
Number of patients: Sample size of 144 patients proposed
Diseases: Metastatic lung cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Early palliative care
Service base: Unclear
NCT02308865 
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Team: Multidisciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist
and possibility of a physical therapist and a chaplain
Intervention: Multidisciplinary palliative care monthly consultations with a doctor, a nurse, a psy-
chologist and possibility of a physical therapist and a chaplain in addition to standard onco-pneu-
mologic care
Duration: Unclear
Control: Patient supported by the Oncology Respiratory service for the treatment of their disease
by chemotherapy and for the treatment of complications
Outcomes Primary outcome:
Quality of life measured at 12 weeks by the TOI score
Secondary outcomes:
Survival
Events - Presence of any of the following: chemotherapy, use of resuscitation or no treatment-lim-
iting decision 14 days before death
Quality of life measured by the score TOI at 12 weeks and by the Echelle SCNS - SF34 scale, FACT-L,
PHQ-9 and HADS questionnaires at 12 and 21 weeks






Study name Early palliative care with standard oncology care versus standard oncology care alone in metastat-





• Having signed informed consent
• Age ≥ 18 years old
• Histologically confirmed esophageal squamous carcinoma and gastric adenocarcinoma,
metastatic disease.
• Measurable disease according to the RECIST criteria (diameter of the lesion should be more than
10 mm by spiral CT or MRI, more than 20 mm by common CT, the date of image should be less
than 15 days before enrollment)
• Karnofsky performance status ≥ 80
• Life expectancy of ≥ 3 month
• WBC > 3000/mm3, absolute neutrophil count ≥ 1500/mm3, platelet > 100,000/mm3, Hb > 9 g/dL
(within 14 days before enrollment)
• ALT and AST < 2.5 times ULN (≤ 5 times ULN in patients with liver metastases)
• Bilirubin level < 1.0 times ULN
NCT02375997 
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• Serum AKP < 2.5 times ULN
• Serum creatinine < 1.5 times ULN
• No severe complications, such as active gastrointestinal bleeding, perforation, jaundice, obstruc-
tion, non-cancerous fever > 38℃；
• Normal ECG and heart function
• Fertile patients must use effective contraception
• Good compliance
Exclusion Criteria:
• Previous treatment of palliative chemotherapy
• Only with brain or bone metastasis
• No measurable lesions, e.g. pleural fluid and ascites
• Suffers from severe heart disease or disease with other important organs
• Chronic diarrhoea or renal dysfunction
• Pregnancy or lactation period
• Other previous malignancy within 5 years, except non-melanoma skin cancer
• Abnormal or disabled cognition, including CNS metastasis
Number of patients: Sample size of 592 participants proposed
Disease: Metastatic Esophageal Squamous Carcinoma (ESCC) and gastric cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Early palliative care
Service base: Unclear
Team: Unclear
Intervention: Standard oncology care plus palliative care
Duration: Unclear
Control: Standard oncology care
Outcomes Primary outcomes:
Overall survival. Time from randomisation to death
Secondary outcomes:
Quality of life scores measured on the quality of life form
Overall response rate: complete response rate plus partial response rate
Adverse events: number of participants with adverse events as a measure of safety and tolerability
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• Fluent in English
• UK Brain Bank criteria for diagnosis of probable PD or Multiple Systems Atrophy (MSA) or Cor-
ticobasal Degeneration (CBD) or Progressive Supranuclear Palsy (PSP) or Lewy Body Dementia
(LBD)
• At high risk for poor outcomes as identified by the Palliative Care Needs Assessment Tool (PC-NAT)
Exclusion Criteria:
• Immediate and urgent palliative care needs
• Unable or unwilling to commit to study procedures including: randomisation, study visits or the
addition of a neurologist to their care team
• Presence of additional chronic medical illnesses which may require palliative services
• Already receiving palliative care and/or hospice services.
Number of patients: Sample size of 210 participants proposed
Diseases: Parkinson's disease
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Outpatient palliative care
Service base: Hospital
Team: Interdisciplinary outpatient palliative care team
Intervention: Usual care augmented by an outpatient interdisciplinary palliative care team
Duration: 6 months
Control: Usual care as in including both a Primary Care Physician (PCP) and neurologist
Outcomes Primary outcomes:
Changes in the subjects quality of life (QoL). The QOL-AD (Quality of Life in Alzheimer's Disease) sur-
vey will be used to measure the differences in the quality of life between groups.
Changes in unpaid caregiver distress. The Zarit unpaid caregiver Burden Interview Form (ZBI) will
be used to measure differences in unpaid caregiver Distress between groups.
Secondary outcomes:
Changes in patient and unpaid caregiver mood. The Hospital Anxiety and Depression Scale (HADS)
will be used to quantify changes in anxiety and depression.
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Study name A pilot study of structured palliative care for patients enrolled on phase I clinical trials
Methods RCT
Participants Country: USA
Recruitment: Patient Inclusion Criteria:
• Patients must be enrolled in a phase 1 clinical trial and be within 2 weeks of starting the experi-
mental therapy or intervention.
• Patients are eligible to enroll on this study with or without the enrollment of their unpaid care-
giver.
Patient Exclusion Criteria:
• Patients diagnosed with a haematologic malignancy
unpaid caregiver Inclusion Criteria:
• Any unpaid caregiver is considered eligible for this study; the unpaid caregiver is the person iden-
tified by the patient as the one who provides the most regular physical and/or emotional support.
• unpaid caregivers must be willing to complete surveys at baseline and on a monthly basis.
unpaid caregiver Exclusion Criteria:
• unpaid caregivers who are solely professional, paid unpaid caregivers
Number of participants: Sample size of 132 participants proposed
Diseases: Cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Structured palliative care
Service base: Hospital
Team: A team of trained specialists which include doctors, nurses, social workers and spiritual care
providers. The team can make referrals to other specialists such as psychologists or nutritionist, if
needed.
Intervention: Supportive care for the patient and unpaid caregiver will be provided by the outpa-
tient palliative care team which includes clinicians with specialised palliative care training, social
workers, spiritual care specialists and mental health clinical nurse specialist.
Duration: Unclear
Control: Supportive care for the patient and unpaid caregiver will be provided by the treating on-
cologist.
Outcomes Primary outcomes:
Average total MSAS score: assessment of patient burden
Average total FACT-G score: measure of patient quality of life
Reason for study discontinuation (patient-reported outcome): measure of central tendency for why
patients discontinued the phase I study. Patient-reported outcomes for the reason for study dis-
continuation will be qualitatively assessed
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Duration on study: measure of central tendency of the duration patients were on the phase I study.
Duration on study will serve as the primary objective for sample size determination.
Adverse events: measure of central tendency of adverse events
Secondary outcomes:
Mean number of hours of palliative care services: mean number of hours utilised by patients and
unpaid caregivers who received structured palliative care
Type of palliative care services: measure of central tendency for the type of palliative care services
utilised by patients and unpaid caregivers who received structured palliative care
Other Outcome Measures:
Frequency of adverse events of patients receiving structured and usual supportive care
Average days on study
Change in FACT-G score: change in patient symptom burden when compared to baseline between
patients who received structured palliative care and those who received standard supportive care
Change in MSAS score: change in quality of life when compared to baseline between patients who
received structured palliative care and those who received standard supportive care
Change in CRA score: change in unpaid caregiver burden when compared to baseline between
those who received structured palliative care and those who received standard supportive care
Change in QOLLTI-F score: change in unpaid caregiver quality of life as assessed through change in
QOLLTI-F score when compared to baseline between those who received structured palliative care
and those who received standard supportive care











• > 18 years old
• Acute lymphoblastic or myeloblastic leukaemia at first relapse and diagnosed within 8 weeks be-
fore inclusion
• Patients in whom a curative strategy (transplant) is not considered
• Patients older that 75 years at the diagnosis
• Informed signed consent
Exclusion Criteria:
• Unable to answer the questionnaire
• Psychiatric disorders other than depression
• Persons under guardianship
Number of participants: Sample size of 80 participants proposed
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Diseases: Acute leukaemia
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Early palliative care
Service base: Hospital
Team: A multidisciplinary palliative specialist team of physician, nurse and psychologist.
Intervention: Patients will be seen by palliative care team at least once a month until the 12th
week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative
specialist team of physician, nurse and psychologist. Physical, psychological, social and existential
suffering will be addressed.
Duration: 12 weeks
Control: Patients will be supported by the support care team if asked by the oncologist.
Outcomes Primary outcome:
Measure of quality of life: quality of life measured by FACT-Leu questionnaire (compared between
the 2 groups)
Secondary outcomes:
Measure of symptoms intensity: symptom intensity measured by ESAS questionnaire (compared
between the 2 groups)
Measure of depression: score of depression measured by HADS questionnaire (compared between
the 2 groups)
Measure of anxiety: score of anxiety measured by HADS questionnaire (compared between the 2
groups)
Measure of the quality of the end-of-life: within the last month of life, several parameters will be
studied to evaluate the quality of the end-of-life like number of admissions in emergency unit.
Overall survival










Recruitment: Participants will be
• (1) patients with advanced cancer receiving care at a participating clinic;
• (2) their unpaid caregivers;
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• (3) their oncology sta, nurses, oncologists, and practice managers.
Patient eligibility criteria. Inclusion criteria:
(1) adults (≥ 21 years old);
(2) the oncologist "would not be surprised if the patient died in the next year";
(3) Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤ 2;
(4) planning to receive ongoing care from a participating oncologist and willing to be seen at least
monthly.
Exclusion criteria:
(1) unable to read and respond to questions in English;
(2) cognitive impairment or inability to consent to treatment, as determined by the patient's oncol-
ogist;
(3) unable to complete baseline interview;
(4) ECOG PS of 3 (capable of limited self-care; confined to bed or chair > 50% of waking hours) or 4
(cannot carry on any self-care; totally confined to bed or chair);
(5) haematologic malignancy.
unpaid caregiver eligibility criteria. Inclusion criteria:
(1) adults (≥ 21 years old);
(2) family member or friend of an eligible patient.
Exclusion criteria:
(1) unable to read and respond to questions in English;
(2) unable to complete the baseline interview. Patients will be asked to select as unpaid caregiver
the person who is most likely to accompany them to visits or help with their care should they need
it.
Clinician eligibility criteria:
Oncology sta, nurses who undergo training to deploy CONNECT, oncologists, and practice man-
agers at participating sites will be eligible to participate.
Number of participants: Sample size of 672 patients and their unpaid caregivers proposed
Diseases: Advanced cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: A primary palliative care intervention (CONNECT)
Service base: Hospital
Team: Care management by oncology nurses
Intervention: At clinics randomised to the CONNECT intervention, oncology nurses will be select-
ed by a nurse advisory panel to receive standardised primary palliative care training. A multi-step
deployment strategy will be employed to orient oncologists and implement CONNECT processes.
CONNECT nurses will administer CONNECT to enrolled patients and unpaid caregivers. An inter-
vention fidelity monitoring and maintenance plan will be implemented to ensure high quality and
consistent delivery of the intervention.
Duration: Unclear
NCT02712229  (Continued)
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Control: At clinics randomised to usual care, enrolled patients and unpaid caregivers will continue
to receive supportive oncology care according to usual practice.
Outcomes Primary outcomes:
Quality of Life - patient. The investigators will compare change in the 3-month FACIT-Pal scores be-
tween enrolled patients at intervention clinics and enrolled patients at usual care clinics.
Secondary outcomes:
Symptom burden - patient. The investigators will compare change in the 3-month Edmonton
Symptom Assessment Scale (ESAS) scores between enrolled patients at intervention clinics and en-
rolled patients at usual care clinics.
Depression and anxiety symptoms - patient. The investigators will compare change in the 3-month
Hospital Anxiety and Depression Scale (HADS) scores between enrolled patients at intervention
clinics and enrolled patients at usual care clinics.
Depression and anxiety symptoms - unpaid caregiver. The investigators will compare change in the
3-month Hospital Anxiety and Depression Scale (HADS) scores between enrolled unpaid caregivers
at intervention clinics and enrolled unpaid caregivers at usual care clinics.
unpaid caregiver burden - unpaid caregiver. The investigators will compare change in the 3-month
Zarit Burden Interview-Short scores between enrolled unpaid caregivers at intervention clinics and
enrolled unpaid caregivers at usual care clinics.
Healthcare utilisation. To inform future dissemination efforts and aid in understanding optimal fi-
nancing models, the investigators will calculate implementation costs of the intervention and de-
termine the effects of CONNECT on healthcare utilisation, including hospitalisations, chemothera-
py use, and hospice use.
Survival - patients. The investigators will calculate survival time from date of enrollment using the
Kaplan-Meier method.
Other Outcome Measures:
Patient-oncologist therapeutic relationship. The investigators will compare change in the 3-month
Human Connection Scale scores between enrolled patients at intervention clinics and enrolled pa-
tients at usual care clinics.
Hope - patients and unpaid caregivers. The investigators will compare change in the 3-month
Herth Hope Index scores between enrolled patients and unpaid caregivers at intervention clinics
and enrolled patients and unpaid caregivers at usual care clinics.
Self-efficacy - patients and unpaid caregivers. The investigators will compare 3-month scores on
the Cancer Behavior Inventory-Brief (patients) and the unpaid caregiver Inventory ( unpaid care-
givers) between enrolled patients and unpaid caregivers at intervention clinics and enrolled pa-
tients and unpaid caregivers at usual care clinics.
Satisfaction - unpaid caregivers. The investigators will compare change in the 3-month FAMCARE-2
scores between enrolled unpaid caregivers at intervention clinics and enrolled unpaid caregivers at
usual care clinics.
Distress - patients. The investigators will compare change in the 3-month scores on the Distress
Thermometer between enrolled patients at intervention clinics and enrolled patients at usual care
clinics.
Illness understanding, care preferences, advance care planning - patients. The investigators will
compare change in patient illness understanding, care preferences, and advance care planning be-
tween enrolled patients at intervention clinics and enrolled patients at usual care clinics.
Burnout - clinicians. The investigators will compare burnout (Maslach Burnout Inventory) between
clinicians at intervention clinics and usual care clinics.
Satisfaction with CONNECT and recommendations for improvement. The investigators will assess
satisfaction with CONNECT and recommendations for improvement among clinicians at interven-
tion clinics annually.
Starting date July 2016
NCT02712229  (Continued)
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• Diagnosis of dementia from Alzheimer's or other underlying cause
• Global Deterioration Scale (GDS) Stage 5, 6 or 7
• Acute illness hospitalisation
Exclusion Criteria:
• No English-speaking family decision-maker
• Primary physician expects study to be too stressful for family unpaid caregiver
Number of participants: Sample size of 120 participants proposed
Diseases: Advanced dementia
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Triggered palliative care
Service base: Hospital
Team: Interdisciplinary Palliative Care consultation during hospitalisation with post-discharge col-
laborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician
Intervention: Specialty interdisciplinary Palliative Care consultation during hospitalisation with
post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary





Hospital transfers: includes emergency department visits and hospital admissions during mea-
sured interval
Secondary outcomes:
Comfort: comfort at the End of Life in Dementia (CAD-EOLD) instrument, consisting of 14 Lik-
ert-scaled items measuring comfort in the final phase of life with dementia. Scores range from
14-42, with higher scores indicating greater comfort.
unpaid caregiver Strain: Family Distress in Advanced Dementia instrument, a 21-item questionnaire
designed to detect strain in family unpaid caregivers in dementia. unpaid caregivers are asked a
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series of items about emotional distress, preparedness, and relations with healthcare providers
scored 1-5.
Access to hospice or palliative care: percent with access to specialty palliative care healthcare
provider or hospice within 30 days post-discharge
POLST (Physician Orders for Life Sustaining Treatment): percent with POLST form completed and
signed
Palliative care domains: number of palliative care domains addressed in treatment plan, using the
Palliative Care Domain score which is scored 0 (not addressed) or 1 (addressed) for each of 10 pos-
sible domains of a palliative care treatment plan - prognosis, overall goals of care, physical symp-
toms, psychiatric symptoms, spiritual needs, and 5 treatment preferences: resuscitation, artificial
feeding, intravenous fluids, antibiotics, and hospitalisation. Scores are summed for a total possible
score of 0-10, with higher scores indicating greater attention to palliative care needs in the treat-
ment plan.
Burdensome treatment: number of burdensome treatments per patient, defined as a count per pa-
tient of use of the following treatments: feeding tube, central intravenous line, surgical procedure,
intensive care transfer, ventilator use, cardiopulmonary resuscitation use at any time during the
time frame of measurement






Study name A randomized study to evaluate the effect of outpatient symptom management on symptom bur-





• 18 years of age or older
• Diagnosis of Stage III, IV, or recurrent gynaecologic malignancy (uterine, ovarian, cervical, vulvar,
vaginal, fallopian tube, primary peritoneal)
• Receiving active intravenous, intraperitoneal, or oral chemotherapy
• Patient at University of Michigan Gynecologic Oncology Clinic
Exclusion Criteria:
• Male
• Less than 18 years of age
• Patients without a diagnosis of a gynaecologic malignancy
• Patients not receiving intravenous, intraperitoneal or oral chemotherapy at the time of enroll-
ment
• Patients receiving radiation therapy with chemo-sensitization.
Number of participants: Sample size of 180 participants proposed
Diseases: Gynaecologic malignancies
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
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Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Specialised symptom management and supportive care intervention
Service base: A specialised symptom management and supportive care clinic
Team: Symptom management providers
Intervention: Patients randomised to this arm are referred to a specialised symptom management
and supportive care clinic and seen within two weeks. Patients will be seen in follow-up as recom-
mended by the symptom management providers, and at each visit they will complete the ESAS-r
and NCCN distress thermometer and return their responses either in person or by mail to the study
team in a pre-addressed postage-paid envelope.
Duration: Unclear
Control: Patients randomised to this arm receive standard symptom management care by their pri-
mary gynaecologic oncologist and complete the NCCN distress thermometer and ESAS-r at each
visit, every 3-4 weeks.
Outcomes Primary outcomes:
Change in patient-reported symptom burden as determined by the Edmonton Symptom Assess-
ment System: To determine if referral to a symptom management clinic improves the symptom
burden quantified by the patients' Edmonton Symptom Assessment System (ESAS) scores
Change in patient-reported symptom burden as determined by the National Comprehensive Can-
cer Network Distress Screening Tool: To determine if referral to a symptom management clinic im-
proves the symptom burden quantified by the patients' National Comprehensive Cancer Network
(NCCN) Distress Screening Tool scores
Secondary outcomes:
Baseline symptom burden and palliative care needs: To determine the baseline symptom burden
and palliative care needs upon enrollment of patients with advanced stage or recurrent gynaeco-
logic malignancies receiving chemotherapy
Change in patient-reported distress: To measure changes in patient-reported distress using the NC-
CN Distress Thermometer
Change in symptom burden: To evaluate changes in patients' symptom burden with the ESAS-r to
evaluate the ongoing sustained effect of the intervention
Change in patient adherence to symptom management programme: To analyse patients in the
symptom management arms with a 3-item questionnaire to determine what factors are associated
with adherence to a symptom management programme
Barriers to symptom management and supportive care: To analyse barriers that prevented patients
from attending the Symptom Management and Supportive Care Clinic, as identified in a 3-item
questionnaire
Overall survival rate: Overall survival will be compared between the two study arms.
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Study name Pilot study of a transdisciplinary intervention integrating geriatric and palliative care with oncology




• Age 65 or older
• Diagnosed with incurable (defined as metastatic or receiving chemotherapy with palliative intent)
esophageal, gastric, pancreas, hepatobiliary, colorectal, or lung cancer within the prior 8 weeks
(including patients with prior diagnosis of cancer who developed incurable disease)
• Verbal fluency in English
• Planning to receive care at Massachusetts General Hospital (MGH)
Exclusion Criteria:
• Unwilling or unable to participate in the study
• Significant psychiatric, cognitive or other comorbid disease which the treating clinician believes
prohibits informed consent or participation in the study
• No medical problems for geriatric clinician to address (e.g. comorbidities, polypharmacy, etc.)
Number of participants: Sample size of 62 participants proposed
Diseases: Incurable cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Transdisciplinary Intervention Integrating Geriatric And Palliative Care With Oncology Care
Service base: Unclear
Team: Board-certified geriatric clinician. Unclear if other professionals involved
Intervention: Patients randomised to the transdisciplinary intervention will undergo evaluation
with a board-certified geriatric clinician, who will tailor their care based on the results of a brief
geriatric screening tool, completed prior to their visit. A two-visit transdisciplinary intervention
will be tested with the first visit occurring within four weeks of enrollment and the second visit four
weeks after the initial visit.
Duration: Unclear
Control: Participants receiving usual oncology care will not meet routinely with geriatric clinicians,
though they may receive a geriatrics consult at their request or at the discretion of their treating
team.
Outcomes Primary outcome:
Perceptions of the necessary components of a transdisciplinary intervention integrating geriatrics
and palliative care with oncology care for older patients with incurable GI and lung cancers. Investi-
gators will use qualitative assessment methods to characterise the sample and explore participant
perceptions of the supportive care needs of older patients with cancer.
Secondary outcomes:
Rates of study enrollment (proportion of eligible patients who enroll in the study; to demonstrate
feasibility)
Rates of study completion (the proportion of participants who complete both study visits; to
demonstrate feasibility)
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Mean change in quality of life (measured with the Functional Assessment of Cancer Therapy (FACT)
- General) scores between treatment groups from baseline to week 12. Investigators will compare
mean change in QoL scores between treatment groups from baseline to week 12.
Mean change in symptom scores (measured continuously with the Edmonton Symptom Assess-
ment System-revised (ESAS-r)) between treatment groups from baseline to week 12. Investigators
will compare mean change in symptom scores between treatment groups from baseline to week
12.
Mean change in depression scores (measured continuously with the Geriatric Depression Scale
(GDS)) between treatment groups from baseline to week 12. Investigators will compare mean
change in depression scores between treatment groups from baseline to week 12.
Rates of post-intervention moderate/severe symptoms (measured as presence or absence of mod-
erate/severe symptoms using the Edmonton Symptom Assessment System-revised (ESAS-r)) be-
tween treatment groups. Investigators will compare rates of post-intervention moderate/severe
symptoms (defined as ESAS scores ≥ 4) between treatment groups.
Rates of post-intervention depression symptoms (measured as presence or absence of depression
symptoms using the Geriatric Depression Scale (GDS)) between treatment groups. Investigators
will compare rates of post-intervention depression symptoms (defined as GDS scores > 5) between
treatment groups.
Mean change in activities of daily living (measured continuously using a subscale of the Medical
Outcomes Study (MOS) Physical Health) between treatment groups from baseline to week 12. In-
vestigators will compare mean change in activities of daily living between treatment groups from
baseline to week 12.
Mean change in instrumental activities of daily living (subscale of the Multidimensional Functional
Assessment Questionnaire from the Older American Resources and Services (OARS)) between treat-
ment groups from baseline to week 12. Investigators will compare mean change in instrumental ac-
tivities of daily living between treatment groups from baseline to week 12.
Mean change in illness perceptions (measured continuously using the Brief Illness Perceptions
Questionnaire (BIPQ)) between treatment groups from baseline to week 12. Investigators will com-
pare mean change in illness perceptions between treatment groups from baseline to week 12.
Mean change in self-efficacy (measured continuously using the Perceived Efficacy in Patient-Physi-
cian Interactions (PEPPI)) between treatment groups from baseline to week 12. Investigators will
compare mean change in self-efficacy between treatment groups from baseline to week 12.
Rates of post-intervention deficits in activities of daily living (measured as presence or absence of
deficits in activities of daily living using a subscale of the Medical Outcomes Study (MOS) Physical
Health) between treatment groups. Investigators will compare rates of post-intervention deficits in
activities of daily living between treatment groups.
Rates of post-intervention deficits in instrumental activities of daily living (subscale of the Multidi-
mensional Functional Assessment Questionnaire from the Older American Resources and Services
(OARS)) between treatment groups. Investigators will compare rates of post-intervention deficits in
instrumental activities of daily living between treatment groups.
Rates of hospice enrollment prior to death (measured as rates of hospice enrollment prior to death)
between treatment groups. Investigators will compare rates of hospice enrollment prior to death
between treatment groups.
Acceptability of the Transdisciplinary Intervention to older patients with incurable GI and lung can-
cers. Investigators will evaluate acceptability using exit assessment data. Participants will rate
their satisfaction with the structure, timing and content of the intervention, using Likert-type scale
responses.
Starting date October 2016
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• diagnosis of idiophathic pulmonary fibrosis
• resting partial arterial oxygen pressure (PaO2) < 60 mmHg
• decline in Forced Vital Capacity (FVC) > 10% in the last 6 months
• stage 3 according to the GAP index
Exclusion Criteria:
• active treatment with antifibrotic drug
• concomitant cancer
Number of participants: Sample size of 50 participants proposed
Diseases: Idiopathic pulmonary fibrosis
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Early palliative care integrated with standard respiratory care
Service base: Unclear
Team: Unclear
Intervention: The patients will receive the usual respiratory care that included both the 'classical'
treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care programme that in-
cludes psychological support, spiritual care and respiratory therapist support.
Duration: Unclear
Control: The patients will receive the usual respiratory care that included both the 'classical' treat-
ments with antifibrotic drugs and oxygen therapy
Outcomes Primary outcome:
Quality of life assessed using the Maugeri Respiratory Questionnaire reduced form
Depression assessed using the Centre for Epidemiologic Studies Depression score (CES-D)
Dyspnoea score assessed using the Borg scale
Secondary outcomes:
Survival
Starting date July 2016
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• Hospitalised patients with high-risk AML, defined as:
• Newly diagnosed patients with AML ≥ 60 years of age
• Newly diagnosed AML with antecedent haematologic disorder
• Newly diagnosed therapy-related AML
• Relapsed AML
• Primary refractory AML
Exclusion Criteria:
• Patients already receiving palliative care
• Major psychiatric illness or comorbid conditions prohibiting compliance with study procedures
• A diagnosis of acute promyelocytic leukaemia (APML)
Number of patients: Sample size of 160 patients proposed
Diseases: Acute myeloid leukaemia
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Collaborative palliative care and oncology care
Service base: Hospital
Team: Palliative care and oncology clinicians
Intervention: Collaborative care from palliative care and leukaemia will be given
Duration: Unclear
Control: Standard leukaemia care
Outcomes Primary outcome:
Change in patients' FACT-Leukemia score from baseline to week-2 between study arms
Secondary outcomes:
Change in FACT-Leukemia scores from baseline to months 1, 3, and 6, and longitudinally between
the study arms
Patients' depressive symptoms (as per HADS), and major depressive syndrome (as per PHQ-9) at
baseline, week 2, months 1, 3, and 6, and longitudinally between the two arms
Change In patients' fatigue scores (as per FACT-fatigue) from baseline to week 2, baseline to
months 1, 3, and 6, and longitudinally between study arms
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Symptom burden (as per ESAS) at baseline, week 2, months 1, 3, and 6, and longitudinally between
study arms
Patient-reported PTSD (as per PCL) at week 2, months 1, 3, and 6, and longitudinally between study
arms
Patient-report of discussion of end-of-life (EoL) care preferences between study arms (time frame:
6 months)
Rates of documentation of EoL care preferences (i.e. code status yes, documented vs. no) In the
electronic health record between the two study arms within 30 days of death
Rates of chemotherapy administration within 3, 7, 14, and 30 days of death between the two study
arms
Rates of hospitalisations within 3, 7, 14, and 30 days of death between the study arms
Rates of hospice utilisation and length-of-stay in hospice at the EoL between the study arms






Study name The Creation Of Models for Palliative Assessments to Support Severe iIllness (COMPASS) investiga-





• Inpatient at Vanderbilt University Medical Center with advanced cirrhotic liver disease, whose
treating hepatologist indicates a 'No' response to the question, "Would you be surprised if this
patient died within 1 year?"
Exclusion Criteria:
• Age < 18 years
• Receipt of liver transplant at the time of potential enrollment
• Inability to give written informed consent (patient or surrogate decision-maker)
• Inability to respond to questions in English
• Treating hepatologist denies permission to enroll
• Receiving hepatology care at non-Vanderbilt sites (to ensure appropriate follow-up)
Number of participants: Sample size of 63 participants proposed
Diseases: Liver disease
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Integrated comprehensive palliative care services
Service base: Hospital
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Team: A palliative care physician or nurse practitioner
Intervention: Participants who are randomly assigned to the intervention arm will receive infor-
mational materials, comprehensive inpatient palliative care consultations with a palliative care
physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged,
follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone
contacts will occur on a flexible schedule (e.g. weekly, bi-weekly, monthly) based on the needs and
wishes of the patient, at a minimum frequency of once a month. If a need for further care is iden-
tified from a telephone contact, appropriate follow-up (referral, appointment, clinical communi-
cation, etc.) will occur per standard procedures. If the participant is readmitted, the consultation
schedule will restart.
Standard care will be provided as per the hospital guideline.
Duration: 1 year
Control: Participants randomised to the usual care arm will not be scheduled to meet with the pal-
liative care service unless a consult is requested by the patient, the family, or treating physician.
These consultations would include the same palliative care services as the intervention arm, ex-
cluding the informational patient materials and telephone consultations.
Outcomes Primary outcome:
Time to first hospital readmission within 1-year post randomisation. Assessment of the impact of
palliative care services on time to first hospital readmission
Secondary outcomes:
Days alive out of hospital: from randomisation to 6 months post-randomisation compared across
arms
Total days in hospital: from randomisation to 1 year post-randomisation compared across arms
Total days in ICU: from randomisation to 1 year post-randomisation compared across arms
Number of hospital readmissions: from randomisation to 1 year post-randomisation compared
across arms
Median length of hospital stay per admission: from randomisation to 1 year post-randomisation
compared across arms
Hospice Referral: number of transfers to hospice within 1 year post-randomisation compared
across arms
Time to hospice placement: number of days from hospice referral to time to hospice placement
Chronic Liver Disease Questionnaire (CLDQ). Change in liver disease-related quality of life: the
CLDQ is a 29-item questionnaire measuring 6 domains. Item scores range from 1 to 7 with higher
scores indicating better quality of life.
EQ-5D-5L. Change in generic health status: the EQ-5D-5L is a 5-item questionnaire with responses
ranging from absence of symptom to extreme experience of the symptom.
PROMIS Emotional Distress - Anxiety - Short Form 4a. Change in mood (anxiety): the PROMIS Emo-
tional Distress - Anxiety - Short Form 4a contains 4 items that measure anxiety on a 5-point Likert
scale with higher scores indicating increased symptomatology.
PROMIS Emotional Distress - Depression - Short Form 4a. Change in mood (depression): the
PROMIS Emotional Distress - Depression - Short Form 4a contains 4 items that measure depression
on a 5-point Likert scale with higher scores indicating increased symptomatology.
Satisfaction with care (Quality of End-of-Life Care: Questionnaire for Patient). Change in patient
satisfaction with care: the Quality of End-of-Life Care: Questionnaire for Patient is an 11-item ques-
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tionnaire, with items scored on a 10-point Likert type scale with higher scores indicating better
quality of care.
Kingston unpaid caregiver Stress Scale: will be used to measure unpaid caregiver stress (lay unpaid
caregivers, not institutional sta,) and was designed to monitor change in an individuals stress over
time. Ten items are grouped into three categories: caregiving, family, and financial issues.
Satisfaction with care (Quality of End-of-Life Care: Questionnaire for Patient adapted for unpaid
caregiver); measures change in unpaid caregiver satisfaction with care with wording modified to
apply to unpaid caregivers. The questionnaire is an 11-item questionnaire, with items scored on a
10-point Likert type scale with higher scores indicating better quality of care.
Liver Transplant Status: number of deferred, listed, and declined listing for liver transplant com-
pared across arms
MELD Score: change in MELD score compared across arms
Completed liver transplants: number of patients with completed liver transplants compared across
arms
Physical symptoms: number of documented physical symptoms (ascites, variceal bleeding, en-
cephalopathy, etc.) compared across arms
Presence of advance directives: percentage of patients with documented advance care directives
compared across arms
Survival: survival rate compared across arms
Provider satisfaction: the 'ICU Provider Satisfaction Survey with the Palliative Care Program:Veter-
ans Affairs of Ann Arbor' instrument is available online and has been modified for the current study
by removing the 'ICU' reference and revising 'pain' to symptoms more relevant to the current pop-
ulation.






Study name PALLiON - PALLiative Care In ONcology - a cluster-randomized trial to improve the care for cancer




• A verified metastatic or locally advanced cancer of the upper GI tract, lower GI tract, pancreas,
liver, breast, bladder, prostate, kidney, cholangiocarcinoma, or malignant melanoma
• Defined as a palliative care patient, with expected life expectancy of < 12 months
• Scheduled to start what is perceived as last-line chemotherapy (definition: tumour-directed med-
ical therapy). Observe: different time points for inclusion and line of treatment apply for the spe-
cific diagnoses
• Age > 18 years
• Fluency in written and oral Norwegian
• Physically and cognitively able to provide written informed consent, based on clinical judgement
NCT03088202 
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
• Scheduled to receive all oncological and specialised palliative treatment at the participating hos-
pital
• World Health Organization (WHO) performance status 0-2
Exclusion Criteria:
• Any serious psychiatric diagnosis (e.g. psychotic, bipolar disorder), substance abuse or cognitive
impairment as judged by standard clinical criteria (disturbed consciousness, disorientation to
time/place and attention deficits) at the discretion of the attending physician that precludes com-
pletion of PROs
• A cancer diagnosis other than the ones above
• Multiple malignancies
• Serious substance abuse
• Already included in a palliative care programme
Number of participants: Sample size of 600 participants proposed
Diseases: Advanced cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing




• Educational programme: E-learning lectures, group exercises, skills training
• Standardised care pathways: Pathways for systematic follow-up




Use of chemotherapy: number of patients who receive chemotherapy during their last 3 months of
life
Use of chemotherapy: number of patients who receive chemotherapy during their last month of life
Secondary outcomes:
Use of artificial nutrition: number of patients who receive artificial nutrition during their last month
of life
Use of concomitant medication: number of patients who receive concomitant medication during
their last month of life
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• New York Heart Association Class III or IV heart failure
• 2 or more hospitalisations in the past year due to heart failure
Exclusion Criteria:
• Less than 40 years old
• Currently awaiting a transplant
• Received palliative care within the past 12 months
• Pregnant or intends to be within the next 12 months
• No regular phone access
• Not fluent in English
• Failed the Callahan 6-item Screener
• Does not intent to regularly attend clinic for the next 12 months
Number of participants: Sample size of 30 participants proposed
Diseases: Advanced heart failure
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Primary palliative care plus usual care
Service base: Hospital
Team: Cardiology nurses with training in palliative care. The nurse will act as a liaison to communi-
cate concerns to the patient's cardiologist and primary care physician
Intervention: The intervention will be delivered through four primary mechanisms. First, an ex-
isting HF nurse will deliver the intervention to patients during regularly scheduled visits. Second,
telephone calls will reinforce topics. Third, patients will regularly report symptoms through the
MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the pa-
tient's cardiologist and primary care physician, as well as facilitating other resources (e.g. home
health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks
post-intervention delivery. unpaid caregivers will complete surveys during the first in-person visit
and then during the follow-up assessments.
Duration: Unclear
Control: Patients randomised to the control arm of this study will continue to receive the standard
of high-quality HF care provided to all patients. Control patients may still receive palliative care
outside of the study.
Outcomes Primary outcome:
Feasibility of enrolling 30 patients via attempting to enroll 30 patients
Secondary outcomes:
Intervention acceptability through interviews with patients, unpaid caregivers, and healthcare
providers.
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Intervention fidelity via the Intervention Fidelity Monitoring Report. This will be by assessing inter-
vention fidelity by audio-recording the interventions and having independent reviewers listen to
them and complete the Intervention Fidelity Monitoring Report.






Study name Randomized controlled trial of integrated early palliative care for advanced cancer patients
Methods RCT
Participants Country: South Korea
Recruitment: Inclusion Criteria:
• Subject 20 years and older.
• Subject who has an advanced cancer diagnosis (histologically or cytologically confirmed) due to
a solid tumour
• Subject whose ECOG performance status is between 0 to 2
• Subject with an estimated life expectancy of 12 months and less (assessed by the treating oncol-
ogist)
• Subject who volunteers
Exclusion Criteria:
• Inability to speak, understand or write Korean
• Medical conditions that would limit adherence to participation of the clinical trial (as confirmed
by their referring physician; e.g. dyspnoea)
• Suspension of all cancer treatment
• Palliative care consultation at any time or in palliative care
Number of participants: sample size of 144 participants proposed
Diseases: advanced cancer
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Integrated early palliative care
Service base: Unclear
Team: Palliative care team (PCT). PCT doctor mentioned but unclear if other health and care pro-
fessionals will be involved
Intervention: Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3
months and once in 2 weeks for another 3 months
Duration: 6 months
Control: Usual palliative care can be provided if desired.
Outcomes Primary outcome:
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Change in level of EORTC QLQ-C15-PAL. A questionnaire developed to assess the quality of life of
palliative cancer care patients
Secondary outcomes:
Change in level of MQOL: a questionnaire that measures psychological, existential well-being, and
support
Change in level of EQ-5D of EuroQoL: a questionnaire that measures mobility, self-care, daily activi-
ty, pain/discomfort, and anxiety/depression
Change in level of PHQ-9: 9-question instrument given to patients in a primary care setting to
screen for the presence and severity of depression
Change in level of understanding the illness: 2 questions to assess how patients understand the
prognosis of their illness
Change in level of crisis overcoming capability (SAT-SF). A questionnaire about goal of life, current
crisis/goal, positivity, preparation and practice
Change in advance care preference: questions about advance directive and treatment preference
in case of terminal condition
Medical cost and utilisation of CAM: overall medical cost savings (cost-effectiveness) and use of
complementary and alternative medicine
1-year survival
Changes of CQOL: a questionnaire that measures quality of life and burden for family unpaid care-
givers
Change in level of PHQ-9 of family unpaid caregivers: 9-question instrument given to unpaid care-
givers in a primary care setting to screen for the presence and severity of depression
Change in level of understanding the illness by family unpaid caregivers: 2 questions to assess how
family unpaid caregivers understand the prognosis of patients' illness
Change in level of crisis overcoming capability (SAT-SF) of family unpaid caregivers: a questionnaire
about goal of life, current crisis/goal, positivity, preparation and practice of family unpaid care-
givers
Change in advance care preference of family unpaid caregivers: questions about family unpaid
caregivers' preference on advance directive and treatment in case of terminal condition
Change in Quality Care questionnaire






Study name Impact of a systematic palliative care on quality of life in advanced idiopathic pulmonary fibrosis
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• Age > 40 years
• Patient with confirmed diagnosis of IPF according to the American Thoracic Society (ATS)/Euro-
pean Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic As-
sociation (ALAT) criteria. The patient may be included regardless of the date of diagnosis
• Advanced IPF with forced vital capacity (FVC) < 50%" of predicted value and/or diffusing capacity
for carbon monoxide ((DLCO) < 30% of predicted value or inability to achieve the functional res-
piratory investigations (EFR) due to respiratory severity. EFR dated less than 3 months
• Absence of argument for acute or subacute exacerbation in the last 6 months
• Patient who can be followed in ambulatory consultation/outpatient consultation
• Informed consent signed (signed by the patient or in the presence of a third party for patients who
are poorly fluent in French)
• Affiliation to the social security system
Exclusion Criteria:
• Patient unable to respond to quality of life questionnaires
• Inability (physical or mental) to give a written informed consent
• Acute exacerbation of fibrosis in the previous 6 months
• Patient eligible for a pulmonary transplant
• Participation in other therapeutic trial
• Patient cannot be followed in ambulatory consultation
• Patient under trustee
Number of participants: Sample size of 120 participants proposed
Diseases: Advanced idiopathic pulmonary fibrosis
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Systematic palliative care
Service base: Unclear
Team: A palliative intervention sta, and a chest physician team
Intervention: Supportive care jointly with pneumological consultation, monthly, starting at month
0 and continuing up to month 6
Duration: 6 months
Control: Pneumological consultation performed at months 0, 3 and 6
Outcomes Primary outcome:
The benefit of a systematic, formalised and joint intervention of palliative intervention sta, and a
chest physician team on quality of life, evaluated after 6 months by the Short Form (36) Health Sur-
vey
Secondary outcomes:
The benefit of the systematic, formalised and joint intervention of a supportive care and a pneu-
mologist team on mood and depression evaluated by the Hospital Anxiety and Depression ques-
tionnaire
The benefit of the systematic, formalised and joint intervention of a supportive care and a pneu-
mologist team on understanding of diagnosis and therapeutic objectives and frequency of drafting
of advance directives will be evaluated by the illness understanding questionnaire.
The benefit of the systematic, formalised and joint intervention of a supportive care and a pneu-
mologist team on respiratory symptoms (dyspnoea) will be evaluated by St George's respiratory
questionnaire (SGRQ) and Transition Dyspnea Index (TDI).
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The benefit of the systematic, formalised and joint intervention of a supportive care and a pneu-
mologist team on the course of care, the use of palliative care stays and the duration of hospital
stays (number and duration of hospitalisations)
The benefit of the systematic, formalized and joint intervention of a supportive care and a pneu-
mologist team on the overall survival (survival follow-up visit at month 12).
The benefit of the systematic, formalised and joint intervention of a supportive care and a pneu-
mologist team on the overall survival measured between inclusion and date of death or last news
Carrying out a medico-economic study evaluating the incremental cost-utility and cost-effective-
ness ratio (overall survival criterion) evaluated by the medico-economic questionnaire: EuroQol
five dimensions questionnaire (EQ-5D)






Study name Randomized trial of a collaborative palliative and leukemia care model for patients with acute




• Patients with AML receiving non-intensive therapy including hypomethylating agents, sin-
gle-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents
offered on a clinical trial, including the following populations: newly diagnosed AML, relapsed
AML, primary refractory AML
• The ability to provide informed consent
• The ability to comprehend English or complete questionnaires with minimal assistance of an in-
terpreter
Exclusion Criteria:
• Patients not receiving care at MGH
• Patients receiving intensive chemotherapy (requiring 4-6 week hospitalisation)
• Patients receiving supportive care alone
• Major psychiatric illness or comorbid conditions prohibiting compliance with study procedures
• Patients already receiving palliative care
Number of patients: Sample size of 320 patients proposed
Diseases: Acute myeloid leukaemia
Patient characteristics: Unknown as still ongoing
Deaths at end of study: Unknown as still ongoing
Withdrawals/other dropouts: Unknown as still ongoing
Interventions Type: Collaborative palliative care and oncology care
Service base: Hospital
Team: Physicians and advanced practice nurses trained in the care of patients facing serious illness
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Intervention: Collaborative palliative and oncology care comprises the following:
• 1st palliative care visit within 96 hours of randomisation in the outpatient or hospital
• In outpatient setting: at least once weekly for the first 30 days and then at least twice per month;
thereafter palliative care clinic visits or contact via telephone
• During hospital admissions to MGH: at least twice weekly palliative care visits
Standard care will be provided as per the hospital guideline.
Duration: 2 years
Control: Standard care will be provided as per the hospital guideline and may involve palliative
care consults only upon request.
Outcomes Primary outcomes:
Time from documentation of end-of-life care preferences to death
Secondary outcomes:
Rates of documentation of end-of-life care preferences at least one week prior to death
Patient report of discussing end-of-life care preferences based on an item from the perception of
treatment and prognosis questionnaire
Comparison of rate of hospitalisation between the study arms
Rate of hospice utilisation and length-of-stay in hospice
Change in quality of life using the FACT-Leuk
Quality of end-of-life care using the FAMCARE
Symptom burden using the ESAS
Mood using the HADS
Other outcome measures:
Chemotherapy administration
Rates of death in hospital
unpaid caregiver-reported discussion of end-of-life care preferences as measured by the percep-
tion of treatment and prognosis questionnaire
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• Age ≥ 50 years
• Acute respiratory failure requiring invasive mechanical ventilation, non-invasive mechanical ven-
tilation (continuous or bi-level positive pressure), or high flow nasal cannula for greater than 24
hours in a Columbia University Medical Center medical or surgical ICU
Exclusion Criteria:
• Hospital discharge directly from ICU
• Already received palliative care consultation during the hospitalisation
• Planned discharge to hospice or home hospice
• Respiratory failure due to neurologic diagnosis (intracranial haemorrhage, stroke, or coma)
• Pre-existing neurologic disease or stroke with motor deficits. Older adults with motor diseases
(e.g. Parkinson's disease) will be excluded from frailty measurements because they could present
with frailty characteristics from a single disease
• Psychiatric history of bipolar disorder, schizoaffective disorder, or schizophrenia
• Current alcoholism or drug abuse
• Not English or Spanish speaking. Many surveys are not validated in other languages besides Eng-
lish or Spanish.
• No healthcare proxy or surrogate also consenting to participate
• Expected to be discharged to a location > 20 miles from Columbia University Medical Center
• Status post-heart, -lung, or -liver transplantation. These patients are not representative of the
larger population of older adult survivors of acute respiratory failure.
Number of participants: Sample size of 80 participants proposed
Diseases: Acute respiratory failure
Patient characteristics: Unknown as results have not been published
Deaths at end of study: Unknown as results have not been published
Withdrawals/other dropouts: Unknown as results have not been published
Interventions Type: Palliative care consultation
Service base: Hospital
Team: Palliative care consultation team will be led by one of the board-certified palliative care
physicians.
Intervention: The palliative care consultation team will be led by one of the board-certified pallia-
tive care physicians at Columbia University Medical Center. Over one or more visits, the palliative
care consultation team will first review intervention participants' medical records and baseline Ed-
monton Symptom Assessment System (ESAS) scores. They will also directly assess participants'
physical and psychological symptoms. They will provide supportive counselling, make treatment
recommendations for burdensome symptoms to the primary team of physicians, and will address
goals of care. They will document these activities in structured electronic medical record consulta-
tion notes.
Duration: Unclear
Control: Patient-surrogate pairs randomised to usual care will not have a palliative care consulta-
tion intervention offered, and will receive care by their primary physicians. However, if a palliative
care consultation is requested after randomisation to usual care by the primary team of physicians
and/or the patient/surrogate, it will be provided.
Outcomes Primary outcomes:
Annual enrollment rate: the number of patients who enroll compared to the number of patients
who enroll and decline enrolling over 1 year
Adherence to the palliative care consultation intervention: proportion of patient-surrogate pairs
randomised to a palliative care consultation who actually agree to have the palliative care consul-
tation prior to hospital discharge
NCT03456323  (Continued)
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Crossover from usual care to post-ICU palliative care: proportion of patient-surrogate pairs ran-
domised to usual care who end up receiving a post-ICU palliative care consultation prior to hospital
discharge
Fidelity of the palliative care intervention: documentation in electronic medical record consulta-
tion notes of (a) burdensome symptoms, (b) supportive counselling, (c) symptom treatment rec-
ommendations, and (d) addressing goals-of-care
Secondary outcomes:
Change in Edmonton Symptom Assessment System (ESAS) scores: changes in patients' ESAS symp-
toms (best (0) to worse (10)) from randomisation to hospital discharge, and from hospital discharge
to 1-month follow-up. ESAS symptoms are: pain, fatigue, drowsiness, nausea, lack of appetite, de-
pression, anxiety, shortness of breath, and well-being.
Change in Hospital Anxiety and Depression Scores (HADS) for surrogates: changes in surrogates'
HADS scores (best (0) to worst (42)) from randomisation to hospital discharge, and from hospital
discharge to 1-month follow-up
Other outcome measures:
Number of patients with moderate-to-severe fatigue (ESAS fatigue scores greater than or equal to
4) who are recommended for and receive methylphenidate treatment
New limitation of life-sustaining therapy: number of patients who elect DNR after randomisation
Enrollment in hospice: number of patients who enroll in inpatient hospice or home hospice
Acute-care readmissions: number of patients who are re-admitted to an acute care hospital within
1 month and 3 months






Study name Early palliative care for patients with severe and very severe chronic obstructive pulmonary dis-
ease (COPD)
Methods RCT
Participants Country: Geneva, Switzerland
Recruitment: Potential participants will receive information from the research nurse and will be ad-
vised as to what is involved if participating in the trial. The study nurse will arrange an appointment
for the baseline assessment with the interested patient. This first appointment will take place in
the patient’s home or at the hospital, according to the patient’s choice. At this appointment, writ-
ten informed consent for participation in the study will be obtained from participants. The inclu-
sion criteria are: COPD defined according to GOLD criteria (FEV1/FVC < 70%) stage III or IV (FEV1 <
50% predicted)
- and/or long-term treatment with either domiciliary oxygen or home mechanical ventilation
– and/or one or more hospital admissions in the previous year for an acute exacerbation
The exclusion criteria are:
• Patients in their last days of life (patient bedbound and/or semi comatose and/or takes only fluid
and/or no longer able to take oral drugs)
Weber 2014 
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
• Patients with cognitive impairment: Mini Mental status Examination ≤ 23 at the day of inclusion
of patients
• Patients with active cancer
Number of patients: Sample size of 90 patients/group proposed
Diseases: Chronic Obstructive Pulmonary Disease
Patient characteristics: Unknown as results have not been published
Deaths at end of study: Unknown as results have not been published
Withdrawals/other dropouts: Unknown as results have not been published
Interventions Type: Early specialist palliative care
Service base: Hospital
Team: Psychiatrist, pulmonologist, nurse and specialised palliative care physician
Intervention: Patients assigned to the early palliative care group will meet a nurse attached to the
community ambulatory palliative care unit of the HUG (USPC) within three weeks of inclusion and
at least monthly thereafter during one year after inclusion. This nurse has a long experience in pal-
liative care. The first consultation will take place at the patient’s home, unless the patient prefers
to have the consultation at the pulmonary division. It will take approximately 1.5 h to assess and
discuss the different items. The subsequent monthly consultations will last approximately 30 min-
utes according to the needs of the patients. A consultation with a specialised palliative care physi-
cian or another specialist (psychiatrist, pulmonologist) will be organised if intensity of pain, dysp-
noea, mood, anxiety and appetite disturbances are > 4/10 on visual analogic scales (VAS) and both
the patient and his/her physician agree. The individualised palliative care assessment and treat-
ment plan will be forwarded in writing to the physician in charge of the patient within 24 hours of
the consultation. At the end of each consultation, the items discussed during the consultations will
be collected. Participants who refuse to attend one or more palliative care interventions will be
contacted by phone by the palliative care nurse to understand their reasons. If the patient, agrees a
new appointment will be fixed.
Duration: One year
Control: Patients randomised to the control group, i.e. who receive standard care alone, will not
meet with the palliative support team unless the patient himself, his family or his treating physi-
cian request a meeting. These patients will remain in the control group, as this is already part of
present practice. Patients who present acute exacerbations will be treated by the participant’s GP
or pulmonologist or by the emergency division according to usual practices and recommendations
of our institution.
Outcomes Primary outcomes:
Hospital, ICU and emergency admissions will be collected in both groups from the medical records
once a month. Length of stay in the different divisions, type of divisions (i.e. internal medicine, re-
habilitation) and reasons for admissions will be collected.
Secondary outcomes:
Mood and anxiety of patients will be measured with the self-assessment instrument: the Hospital
Anxiety and Depression Scale (HADS).
Quality of life will be measured with the SF-36 short form: a self-assessment scale validated in this
population, and the COPD Assessment Test (CAT): a short, simple instrument for quantifying the
symptom burden of COPD in routine practice.
Use of antibiotics during the last three months will be recorded.
Completion of advance directives, documented preferences for resuscitation, or nomination of sur-
rogate decision-maker will also be recorded.
Starting date September 2013
Weber 2014  (Continued)
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CAM: Complementary and Alternative Medicine
COPD: chronic obstructive pulmonary disorder
CQOL: unpaid caregiver Quality of Life




ECOG: Eastern Cooperative Oncology Group
EGFR: Epidermal Growth Factor Receptor
EML4-ALK: echinoderm microtubule associated protein-like 4- anaplastic lymphoma kinase
EoL: End of Life
EORTC: European Organization for Research and Treatment of Cancer
EPC: early palliative care
EQ-5D: EuroQol-5 Dimension
ESAS-r: Edmonton Symptom Assessment System Revised
FACT-G: Functional Assessment of Cancer Therapy-General
FACT-L: Functional Assessment of Cancer Therapy-Lung (FACT-L)
FACT-Leu: Functional Assessment of Cancer Therapy - Leukemia
FACIT-Pal: Functional Assessment of Chronic Illness Therapy - Palliative Care
FAMCARE: Family Care
FEV1/FVC: Forced Expiratory Volume in the first one second/Forced Vital
g/dL: grams/decilitre
GAP: Gender Age Physiology
GI: gastrointestinal
GOLD: Global Initiative for Chronic Obstructive Lung Disease
h: hour/s
Hb: Haemoglobin
HER2: human epidermal growth factor receptor 2
HF: heart failure
ICD: International Classification of Diseases
ICU: intensive care unit
M: Metastasis
MELD: Model for End-Stage Liver Disease
mm: millimetre
mmHg: millimetre of mercury
MRI: Magnetic Resonance Imaging
MSAS: Memorial Symptom Assessment Scale
MQOL: McGill Quality of Life Questionnaire
N: Number / Node




PET: Positron Emission Tomography
PHQ-9: Patient Health Questionnaire-9
PRO: patient reported outcomes
PROMIS: Patient-Reported Outcomes Measurement Information System
PS: Performance Status
QLQ-C15-PAL: Quality of Life Questionnaire Core 15 Palliative Care
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QoL: quality of life
QOLLTI-F: Quality of Life in Life-Threatening Illness -Family carer version
RCT: randomised controlled trial
RECIST: Response Evaluation Criteria in Solid Tumours
ROS1: Receptor Tyrosine Kinase
SAT-SF: Crisis Overcoming Capability
SCNS: Supportive Care Needs Survey
SF-12: Short Form Survey 12
T: Tumour
ULN: Upper Limit of Normal
WBC: White Blood Cells
WHO: World Health Organization
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Patient health-related quality of life





Statistical method Effect size
1.1 HSPC versus usual care on patient HRQoL: adjusted
endpoint values




1.2 HSPC versus usual care on patient HRQoL: adjusted
endpoint values (excluding McCorkle 2015)




1.3 HSPC versus usual care on patient HRQoL: unad-
justed endpoint values




1.4 HSPC versus usual care on patient HRQoL: unad-
justed endpoint values (excluding McCorkle 2015)




1.5 HSPC versus usual care on patient HRQoL: unad-
justed change values
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Analysis 1.1.   Comparison 1: Patient health-related quality of life, Outcome













Heterogeneity: Tau² = 0.00; Chi² = 9.30, df = 9 (P = 0.41); I² = 3%
Test for overall effect: Z = 4.67 (P < 0.00001)




















































































IV, Random, 95% CI
0.38 [0.15 , 0.62]
0.19 [-0.13 , 0.51]
0.38 [0.06 , 0.69]
-0.23 [-0.74 , 0.27]
0.20 [-0.52 , 0.92]
0.41 [-0.20 , 1.02]
-0.37 [-1.15 , 0.40]
0.42 [0.03 , 0.80]
0.20 [-0.03 , 0.43]
0.31 [0.02 , 0.60]
0.26 [0.15 , 0.37]
Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours control Favours HSPC
 
 
Analysis 1.2.   Comparison 1: Patient health-related quality of life, Outcome 2: HSPC












Heterogeneity: Tau² = 0.00; Chi² = 5.35, df = 8 (P = 0.72); I² = 0%
Test for overall effect: Z = 5.12 (P < 0.00001)













































































IV, Random, 95% CI
0.38 [0.15 , 0.62]
0.19 [-0.13 , 0.51]
0.38 [0.06 , 0.69]
0.20 [-0.52 , 0.92]
0.41 [-0.20 , 1.02]
-0.37 [-1.15 , 0.40]
0.42 [0.03 , 0.80]
0.20 [-0.03 , 0.43]
0.31 [0.02 , 0.60]
0.29 [0.18 , 0.40]
Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours control Favours HSPC
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Analysis 1.3.   Comparison 1: Patient health-related quality of life, Outcome












Heterogeneity: Tau² = 0.16; Chi² = 46.98, df = 8 (P < 0.00001); I² = 83%
Test for overall effect: Z = 2.66 (P = 0.008)













































































IV, Random, 95% CI
0.59 [0.00 , 1.17]
0.41 [-0.11 , 0.92]
0.70 [0.38 , 1.03]
0.03 [-0.24 , 0.30]
0.05 [-0.15 , 0.24]
0.20 [-0.23 , 0.64]
1.45 [1.02 , 1.88]
-0.04 [-0.54 , 0.46]
0.36 [-0.08 , 0.80]
0.41 [0.11 , 0.70]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours control Favours HSPC
Footnotes
(1) 95% CI were estimated from graph
 
 
Analysis 1.4.   Comparison 1: Patient health-related quality of life, Outcome 4: HSPC versus











Heterogeneity: Tau² = 0.17; Chi² = 45.18, df = 7 (P < 0.00001); I² = 85%
Test for overall effect: Z = 2.77 (P = 0.006)






































































IV, Random, 95% CI
0.59 [0.00 , 1.17]
0.41 [-0.11 , 0.92]
0.70 [0.38 , 1.03]
0.03 [-0.24 , 0.30]
0.05 [-0.15 , 0.24]
0.20 [-0.23 , 0.64]
1.45 [1.02 , 1.88]
0.36 [-0.08 , 0.80]
0.46 [0.13 , 0.78]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours control Favours HSPC
Footnotes
(1) 95% CI were estimated from graph
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Analysis 1.5.   Comparison 1: Patient health-related quality of life, Outcome












Heterogeneity: Tau² = 0.56; Chi² = 146.25, df = 8 (P < 0.00001); I² = 95%
Test for overall effect: Z = 2.60 (P = 0.009)













































































IV, Random, 95% CI
0.35 [-0.23 , 0.93]
0.16 [-0.09 , 0.42]
0.32 [0.00 , 0.63]
0.29 [-0.04 , 0.63]
1.24 [0.59 , 1.89]
0.33 [-0.11 , 0.77]
2.99 [2.54 , 3.43]
0.40 [0.02 , 0.79]
0.11 [-0.12 , 0.34]
0.67 [0.16 , 1.18]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours HSPC
 
 
Comparison 2.   Patient symptom burden





Statistical method Effect size
2.1 HSPC versus usual care on patient symptom bur-
den: adjusted endpoint values




2.2 HSPC versus usual care on patient symptom bur-
den: unadjusted endpoint values




2.3 HSPC versus usual care on patient symptom bur-
den: unadjusted endpoint values (excluding McCorkle
2015)




2.4 HSPC versus usual care on patient symptom bur-
den: adjusted change values




2.5 HSPC versus usual care on patient symptom bur-
den: adjusted change values (excluding McCorkle 2015)




2.6 HSPC versus usual care on patient symptom bur-
den: unadjusted change values
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Analysis 2.1.   Comparison 2: Patient symptom burden, Outcome 1: HSPC









Heterogeneity: Tau² = 0.00; Chi² = 2.94, df = 5 (P = 0.71); I² = 0%
Test for overall effect: Z = 3.60 (P = 0.0003)
























































IV, Random, 95% CI
-0.15 [-0.38 , 0.09]
-0.30 [-0.62 , 0.02]
-0.39 [-0.71 , -0.07]
-0.27 [-0.88 , 0.34]
0.09 [-0.68 , 0.86]
-0.42 [-0.80 , -0.03]
-0.26 [-0.41 , -0.12]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
Footnotes
(1) Data from the severity subscale of the Memorial Symptom Assessment Scale (MSAS) was used in meta-analysis
 
 
Analysis 2.2.   Comparison 2: Patient symptom burden, Outcome 2: HSPC









Heterogeneity: Tau² = 0.17; Chi² = 29.87, df = 5 (P < 0.0001); I² = 83%
Test for overall effect: Z = 0.90 (P = 0.37)
























































IV, Random, 95% CI
-0.65 [-1.24 , -0.07]
-0.79 [-1.12 , -0.46]
-0.06 [-0.26 , 0.15]
-0.04 [-0.47 , 0.39]
0.50 [0.12 , 0.87]
-0.05 [-0.55 , 0.45]
-0.17 [-0.54 , 0.20]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
Footnotes
(1) 95% CI estimated from graph
 
 
Analysis 2.3.   Comparison 2: Patient symptom burden, Outcome 3: HSPC versus usual








Heterogeneity: Tau² = 0.20; Chi² = 29.73, df = 4 (P < 0.00001); I² = 87%
Test for overall effect: Z = 0.88 (P = 0.38)

















































IV, Random, 95% CI
-0.65 [-1.24 , -0.07]
-0.79 [-1.12 , -0.46]
-0.06 [-0.26 , 0.15]
-0.04 [-0.47 , 0.39]
0.50 [0.12 , 0.87]
-0.19 [-0.62 , 0.24]
Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours HSPC Favours control
Footnotes
(1) 95% CI estimated from graph
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Analysis 2.4.   Comparison 2: Patient symptom burden, Outcome 4: HSPC







Heterogeneity: Tau² = 3.90; Chi² = 162.38, df = 3 (P < 0.00001); I² = 98%
Test for overall effect: Z = 1.31 (P = 0.19)










































IV, Random, 95% CI
-0.75 [-1.35 , -0.15]
0.13 [-0.37 , 0.63]
-4.32 [-4.88 , -3.76]
-0.31 [-0.79 , 0.17]
-1.31 [-3.27 , 0.64]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
 
 
Analysis 2.5.   Comparison 2: Patient symptom burden, Outcome 5: HSPC versus usual






Heterogeneity: Tau² = 4.80; Chi² = 126.75, df = 2 (P < 0.00001); I² = 98%
Test for overall effect: Z = 1.41 (P = 0.16)



































IV, Random, 95% CI
-0.75 [-1.35 , -0.15]
-4.32 [-4.88 , -3.76]
-0.31 [-0.79 , 0.17]
-1.79 [-4.29 , 0.70]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
 
 
Analysis 2.6.   Comparison 2: Patient symptom burden, Outcome 6: HSPC









Heterogeneity: Tau² = 0.32; Chi² = 41.18, df = 5 (P < 0.00001); I² = 88%
Test for overall effect: Z = 1.74 (P = 0.08)
























































IV, Random, 95% CI
-0.67 [-1.26 , -0.08]
0.04 [-0.21 , 0.29]
-0.32 [-0.64 , 0.00]
0.11 [-0.47 , 0.70]
-2.47 [-3.27 , -1.66]
0.13 [-0.25 , 0.51]
-0.44 [-0.94 , 0.06]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
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Comparison 3.   Patient satisfaction with care





Statistical method Effect size
3.1 HSPC versus usual care on patient satisfaction with
care: adjusted endpoint values






Analysis 3.1.   Comparison 3: Patient satisfaction with care, Outcome 1: HSPC





Heterogeneity: Tau² = 0.00; Chi² = 0.33, df = 1 (P = 0.57); I² = 0%
Test for overall effect: Z = 3.24 (P = 0.001)




























IV, Random, 95% CI
0.38 [0.15 , 0.61]
0.19 [-0.42 , 0.80]
0.36 [0.14 , 0.57]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours HSPC
 
 
Comparison 4.   Achieving patient preferred place of death




Statistical method Effect size
4.1 HSPC versus usual care on home
deaths
7 861 Odds Ratio (M-H, Random, 95% CI) 1.63 [1.23, 2.16]
 
 
Analysis 4.1.   Comparison 4: Achieving patient preferred place











Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 6 (P = 0.53); I² = 0%
Test for overall effect: Z = 3.38 (P = 0.0007)

















































M-H, Random, 95% CI
2.67 [0.43 , 16.39]
1.37 [0.81 , 2.31]
1.30 [0.61 , 2.77]
2.39 [1.40 , 4.09]
0.43 [0.07 , 2.62]
1.63 [0.61 , 4.30]
1.59 [0.78 , 3.25]
1.63 [1.23 , 2.16]
Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours control Favours HSPC
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Comparison 5.   Pain





Statistical method Effect size
5.1 HSPC versus usual care on pain: adjusted
endpoint values




5.2 HSPC versus usual care on pain: adjusted
change values




5.3 HSPC versus usual care on pain: unadjusted
change values













Heterogeneity: Tau² = 0.00; Chi² = 2.96, df = 3 (P = 0.40); I² = 0%
Test for overall effect: Z = 1.84 (P = 0.07)










































IV, Random, 95% CI
-0.12 [-0.36 , 0.12]
0.07 [-0.64 , 0.79]
-0.66 [-1.28 , -0.03]
-0.15 [-0.44 , 0.13]
-0.16 [-0.33 , 0.01]
Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours HSPC Favours control
 
 





Heterogeneity: Tau² = 0.00; Chi² = 0.34, df = 1 (P = 0.56); I² = 0%
Test for overall effect: Z = 3.44 (P = 0.0006)




























IV, Random, 95% CI
-0.62 [-1.18 , -0.06]
-0.43 [-0.74 , -0.12]
-0.47 [-0.74 , -0.20]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
 
 





Heterogeneity: Tau² = 2.26; Chi² = 29.38, df = 1 (P < 0.00001); I² = 97%
Test for overall effect: Z = 0.86 (P = 0.39)




























IV, Random, 95% CI
0.12 [-0.13 , 0.37]
-2.04 [-2.78 , -1.30]
-0.93 [-3.05 , 1.19]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
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Comparison 6.   Patient anxiety





Statistical method Effect size
6.1 HSPC versus usual care on patient anxiety:
adjusted endpoint values
5 384 Mean Difference (IV, Random, 95%
CI)
-0.63 [-2.22, 0.96]
6.2 HSPC versus usual care on patient anxi-
ety: adjusted endpoint values (excluding Mc-
Corkle 2015)




6.3 HSPC versus usual care on patient anxiety:
unadjusted endpoint values
4 273 Mean Difference (IV, Random, 95%
CI)
-0.90 [-2.52, 0.71]
6.4 HSPC versus usual care on patient anxiety:
unadjusted endpoint values (excluding Mc-
Corkle 2015)
3 209 Mean Difference (IV, Random, 95%
CI)
-1.48 [-3.52, 0.56]
6.5 HSPC versus usual care on patient anxiety:
unadjusted change values




6.6 HSPC versus usual care on patient anxiety
in different populations: adjusted endpoint
values
5 384 Mean Difference (IV, Random, 95%
CI)
-0.63 [-2.22, 0.96]
6.6.1 Cancer populations 3 275 Mean Difference (IV, Random, 95%
CI)
-0.65 [-3.03, 1.74]
6.6.2 Non-cancer populations 2 109 Mean Difference (IV, Random, 95%
CI)
-0.82 [-2.45, 0.80]
6.7 HSPC versus usual care on patient anxiety
in different populations: adjusted endpoint
values (excluding McCorkle 2015)








6.7.2 Non-cancer populations 2 109 Mean Difference (IV, Random, 95%
CI)
-0.82 [-2.45, 0.80]
6.8 EPC vs LPC on patient anxiety: adjusted
endpoint values
5 384 Mean Difference (IV, Random, 95%
CI)
-0.63 [-2.22, 0.96]
6.8.1 Early palliative care (EPC) 2 221 Mean Difference (IV, Random, 95%
CI)
-0.57 [-3.94, 2.79]
6.8.2 Late palliative care (LPC) 3 163 Mean Difference (IV, Random, 95%
CI)
-0.81 [-2.14, 0.52]
6.9 Effect of MDT-led services on patient anxi-
ety: adjusted endpoint values
5 384 Mean Difference (IV, Random, 95%
CI)
-0.63 [-2.22, 0.96]
6.9.1 MDT-led services 5 384 Mean Difference (IV, Random, 95%
CI)
-0.63 [-2.22, 0.96]
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Statistical method Effect size
6.10 Effect of MDT-led services on patient anx-
iety: adjusted endpoint values (excluding Mc-
Corkle 2015)








6.11 HSPC versus usual care on patient anxi-
ety in different countries: adjusted endpoint
values
5 384 Mean Difference (IV, Random, 95%
CI)
-0.63 [-2.22, 0.96]
6.11.1 Studies from USA 3 251 Mean Difference (IV, Random, 95%
CI)
-0.32 [-3.04, 2.39]
6.11.2 Studies from UK 2 133 Mean Difference (IV, Random, 95%
CI)
-1.02 [-2.45, 0.42]
6.12 HSPC versus usual care on patient anxi-
ety in different countries: adjusted endpoint
values (excluding McCorkle 2015)




6.12.1 Studies from USA 2 187 Mean Difference (IV, Random, 95%
CI)
-1.45 [-3.90, 1.00]





Analysis 6.1.   Comparison 6: Patient anxiety, Outcome 1: HSPC








Heterogeneity: Tau² = 2.28; Chi² = 16.60, df = 4 (P = 0.002); I² = 76%
Test for overall effect: Z = 0.78 (P = 0.43)

















































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
-0.78 [-3.10 , 1.54]
-1.16 [-2.98 , 0.66]
1.18 [-0.22 , 2.58]
0.50 [-3.11 , 4.11]
-0.63 [-2.22 , 0.96]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
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Analysis 6.2.   Comparison 6: Patient anxiety, Outcome 2: HSPC versus usual







Heterogeneity: Tau² = 0.19; Chi² = 3.62, df = 3 (P = 0.31); I² = 17%
Test for overall effect: Z = 3.28 (P = 0.001)










































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
-0.78 [-3.10 , 1.54]
-1.16 [-2.98 , 0.66]
0.50 [-3.11 , 4.11]
-1.60 [-2.56 , -0.65]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
 
 
Analysis 6.3.   Comparison 6: Patient anxiety, Outcome 3: HSPC







Heterogeneity: Tau² = 1.75; Chi² = 8.96, df = 3 (P = 0.03); I² = 67%
Test for overall effect: Z = 1.10 (P = 0.27)










































IV, Random, 95% CI
-2.70 [-5.47 , 0.07]
0.10 [-1.09 , 1.29]
0.71 [-1.23 , 2.65]
-2.50 [-4.44 , -0.56]
-0.90 [-2.52 , 0.71]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
 
 
Analysis 6.4.   Comparison 6: Patient anxiety, Outcome 4: HSPC versus usual






Heterogeneity: Tau² = 2.25; Chi² = 6.94, df = 2 (P = 0.03); I² = 71%
Test for overall effect: Z = 1.42 (P = 0.15)



































IV, Random, 95% CI
-2.70 [-5.47 , 0.07]
0.10 [-1.09 , 1.29]
-2.50 [-4.44 , -0.56]
-1.48 [-3.52 , 0.56]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
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Analysis 6.5.   Comparison 6: Patient anxiety, Outcome 5: HSPC







Heterogeneity: Tau² = 0.12; Chi² = 11.72, df = 3 (P = 0.008); I² = 74%
Test for overall effect: Z = 2.99 (P = 0.003)










































IV, Random, 95% CI
-0.69 [-1.28 , -0.10]
-0.21 [-0.46 , 0.04]
-0.54 [-0.86 , -0.23]
-1.36 [-2.02 , -0.70]
-0.62 [-1.02 , -0.21]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
 
 
Analysis 6.6.   Comparison 6: Patient anxiety, Outcome 6: HSPC versus usual







Heterogeneity: Tau² = 3.76; Chi² = 15.84, df = 2 (P = 0.0004); I² = 87%





Heterogeneity: Tau² = 0.00; Chi² = 0.65, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI)
Heterogeneity: Tau² = 2.28; Chi² = 16.60, df = 4 (P = 0.002); I² = 76%
Test for overall effect: Z = 0.78 (P = 0.43)























































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
-0.78 [-3.10 , 1.54]
1.18 [-0.22 , 2.58]
-0.65 [-3.03 , 1.74]
-1.16 [-2.98 , 0.66]
0.50 [-3.11 , 4.11]
-0.82 [-2.45 , 0.80]
-0.63 [-2.22 , 0.96]
Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
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Analysis 6.7.   Comparison 6: Patient anxiety, Outcome 7: HSPC versus usual care on patient






Heterogeneity: Tau² = 0.26; Chi² = 1.31, df = 1 (P = 0.25); I² = 24%





Heterogeneity: Tau² = 0.00; Chi² = 0.65, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 3.62, df = 3 (P = 0.31); I² = 17%
Test for overall effect: Z = 3.28 (P = 0.001)
















































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
-0.78 [-3.10 , 1.54]
-1.91 [-3.12 , -0.70]
-1.16 [-2.98 , 0.66]
0.50 [-3.11 , 4.11]
-0.82 [-2.45 , 0.80]
-1.60 [-2.56 , -0.65]
Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
 
 
Analysis 6.8.   Comparison 6: Patient anxiety, Outcome 8: EPC vs LPC on patient anxiety: adjusted endpoint values
Study or Subgroup




Heterogeneity: Tau² = 5.51; Chi² = 15.75, df = 1 (P < 0.0001); I² = 94%
Test for overall effect: Z = 0.34 (P = 0.74)





Heterogeneity: Tau² = 0.00; Chi² = 0.65, df = 2 (P = 0.72); I² = 0%
Test for overall effect: Z = 1.19 (P = 0.23)
Total (95% CI)
Heterogeneity: Tau² = 2.28; Chi² = 16.60, df = 4 (P = 0.002); I² = 76%
Test for overall effect: Z = 0.78 (P = 0.43)























































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
1.18 [-0.22 , 2.58]
-0.57 [-3.94 , 2.79]
-0.78 [-3.10 , 1.54]
-1.16 [-2.98 , 0.66]
0.50 [-3.11 , 4.11]
-0.81 [-2.14 , 0.52]
-0.63 [-2.22 , 0.96]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
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Analysis 6.9.   Comparison 6: Patient anxiety, Outcome 9: Eect









Heterogeneity: Tau² = 2.28; Chi² = 16.60, df = 4 (P = 0.002); I² = 76%
Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI)
Heterogeneity: Tau² = 2.28; Chi² = 16.60, df = 4 (P = 0.002); I² = 76%
Test for overall effect: Z = 0.78 (P = 0.43)




















































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
-0.78 [-3.10 , 1.54]
-1.16 [-2.98 , 0.66]
1.18 [-0.22 , 2.58]
0.50 [-3.11 , 4.11]
-0.63 [-2.22 , 0.96]
-0.63 [-2.22 , 0.96]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
 
 
Analysis 6.10.   Comparison 6: Patient anxiety, Outcome 10: Eect of MDT-led








Heterogeneity: Tau² = 0.19; Chi² = 3.62, df = 3 (P = 0.31); I² = 17%
Test for overall effect: Z = 3.28 (P = 0.001)
Total (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 3.62, df = 3 (P = 0.31); I² = 17%
Test for overall effect: Z = 3.28 (P = 0.001)













































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
-0.78 [-3.10 , 1.54]
-1.16 [-2.98 , 0.66]
0.50 [-3.11 , 4.11]
-1.60 [-2.56 , -0.65]
-1.60 [-2.56 , -0.65]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
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Analysis 6.11.   Comparison 6: Patient anxiety, Outcome 11: HSPC versus
usual care on patient anxiety in dierent countries: adjusted endpoint values
Study or Subgroup





Heterogeneity: Tau² = 4.66; Chi² = 16.53, df = 2 (P = 0.0003); I² = 88%
Test for overall effect: Z = 0.23 (P = 0.81)




Heterogeneity: Tau² = 0.00; Chi² = 0.06, df = 1 (P = 0.80); I² = 0%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI)
Heterogeneity: Tau² = 2.28; Chi² = 16.60, df = 4 (P = 0.002); I² = 76%
Test for overall effect: Z = 0.78 (P = 0.43)























































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
1.18 [-0.22 , 2.58]
0.50 [-3.11 , 4.11]
-0.32 [-3.04 , 2.39]
-0.78 [-3.10 , 1.54]
-1.16 [-2.98 , 0.66]
-1.02 [-2.45 , 0.42]
-0.63 [-2.22 , 0.96]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
 
 
Analysis 6.12.   Comparison 6: Patient anxiety, Outcome 12: HSPC versus usual care on
patient anxiety in dierent countries: adjusted endpoint values (excluding McCorkle 2015)
Study or Subgroup




Heterogeneity: Tau² = 1.97; Chi² = 2.09, df = 1 (P = 0.15); I² = 52%
Test for overall effect: Z = 1.16 (P = 0.25)




Heterogeneity: Tau² = 0.00; Chi² = 0.06, df = 1 (P = 0.80); I² = 0%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 3.62, df = 3 (P = 0.31); I² = 17%
Test for overall effect: Z = 3.28 (P = 0.001)
















































IV, Random, 95% CI
-2.25 [-3.20 , -1.30]
0.50 [-3.11 , 4.11]
-1.45 [-3.90 , 1.00]
-0.78 [-3.10 , 1.54]
-1.16 [-2.98 , 0.66]
-1.02 [-2.45 , 0.42]
-1.60 [-2.56 , -0.65]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours HSPC Favours control
 
 
Comparison 7.   Unpaid caregiver anxiety





Statistical method Effect size
7.1 HSPC versus usual care on unpaid caregiver anxiety:
unadjusted endpoint values




The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
 
 
Analysis 7.1.   Comparison 7: Unpaid caregiver anxiety, Outcome 1: HSPC





Heterogeneity: Tau² = 5.30; Chi² = 4.44, df = 1 (P = 0.04); I² = 77%
Test for overall effect: Z = 0.39 (P = 0.70)




























IV, Random, 95% CI
-2.90 [-6.18 , 0.38]
0.80 [-0.23 , 1.83]
-0.71 [-4.27 , 2.85]
Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
 
 
Comparison 8.   Patient depression





Statistical method Effect size
8.1 HSPC versus usual care on patient depression: ad-
justed endpoint values




8.2 HSPC versus usual care on patient depression: un-
adjusted endpoint values




8.3 HSPC versus usual care on patient depression: un-
adjusted endpoint values (excluding McCorkle 2015)




8.4 HSPC versus usual care on patient depression: ad-
justed change values




8.5 HSPC versus usual care on patient depression: un-
adjusted change values




8.6 HSPC versus usual care on patient depression as a
binary outcome
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Analysis 8.1.   Comparison 8: Patient depression, Outcome 1: HSPC











Heterogeneity: Tau² = 0.00; Chi² = 6.84, df = 7 (P = 0.45); I² = 0%
Test for overall effect: Z = 3.63 (P = 0.0003)






































































IV, Random, 95% CI
-0.26 [-0.49 , -0.02]
0.06 [-0.25 , 0.38]
-0.44 [-0.76 , -0.12]
-0.00 [-0.54 , 0.53]
-0.36 [-0.81 , 0.08]
-0.27 [-0.99 , 0.45]
-0.48 [-1.09 , 0.14]
-0.18 [-0.41 , 0.04]
-0.22 [-0.34 , -0.10]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
 
 
Analysis 8.2.   Comparison 8: Patient depression, Outcome 2: HSPC








Heterogeneity: Tau² = 0.05; Chi² = 7.53, df = 4 (P = 0.11); I² = 47%
Test for overall effect: Z = 1.68 (P = 0.09)

















































IV, Random, 95% CI
-0.71 [-1.30 , -0.12]
-0.37 [-0.81 , 0.06]
0.11 [-0.39 , 0.62]
-0.45 [-0.89 , -0.01]
0.08 [-0.37 , 0.53]
-0.25 [-0.55 , 0.04]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
Footnotes
(1) data approximated from graph
 
 
Analysis 8.3.   Comparison 8: Patient depression, Outcome 3: HSPC versus usual







Heterogeneity: Tau² = 0.04; Chi² = 5.15, df = 3 (P = 0.16); I² = 42%
Test for overall effect: Z = 2.12 (P = 0.03)










































IV, Random, 95% CI
-0.71 [-1.30 , -0.12]
-0.37 [-0.81 , 0.06]
-0.45 [-0.89 , -0.01]
0.08 [-0.37 , 0.53]
-0.34 [-0.65 , -0.03]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
Footnotes
(1) data approximated from graph
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Analysis 8.4.   Comparison 8: Patient depression, Outcome 4: HSPC





Heterogeneity: Tau² = 0.29; Chi² = 12.71, df = 1 (P = 0.0004); I² = 92%
Test for overall effect: Z = 0.82 (P = 0.41)




























IV, Random, 95% CI
0.07 [-0.23 , 0.37]
-0.72 [-1.03 , -0.41]
-0.32 [-1.10 , 0.45]
Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
 
 
Analysis 8.5.   Comparison 8: Patient depression, Outcome 5: HSPC







Heterogeneity: Tau² = 0.01; Chi² = 3.40, df = 3 (P = 0.33); I² = 12%
Test for overall effect: Z = 3.75 (P = 0.0002)










































IV, Random, 95% CI
-0.32 [-0.90 , 0.26]
-0.30 [-0.55 , -0.04]
-0.36 [-0.68 , -0.04]
-0.93 [-1.55 , -0.30]
-0.38 [-0.58 , -0.18]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
 
 
Analysis 8.6.   Comparison 8: Patient depression, Outcome 6:







Heterogeneity: Tau² = 0.09; Chi² = 2.96, df = 2 (P = 0.23); I² = 32%
Test for overall effect: Z = 3.24 (P = 0.001)





























M-H, Random, 95% CI
0.30 [0.12 , 0.76]
0.29 [0.15 , 0.56]
0.76 [0.30 , 1.96]
0.38 [0.21 , 0.68]
Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HSPC Favours control
 
 
Comparison 9.   Unpaid caregiver depression





Statistical method Effect size
9.1 HSPC versus usual care on unpaid caregiver depres-
sion: adjusted endpoint values
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Statistical method Effect size
9.2 HSPC versus usual care on unpaid caregiver depres-
sion: unadjusted endpoint values






Analysis 9.1.   Comparison 9: Unpaid caregiver depression, Outcome 1: HSPC





Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 1 (P = 0.76); I² = 0%
Test for overall effect: Z = 0.17 (P = 0.86)




























IV, Random, 95% CI
0.00 [-0.22 , 0.22]
-0.07 [-0.46 , 0.32]
-0.02 [-0.21 , 0.18]
Std. Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours HSPC Favours control
 
 
Analysis 9.2.   Comparison 9: Unpaid caregiver depression, Outcome 2: HSPC






Heterogeneity: Tau² = 0.08; Chi² = 5.42, df = 2 (P = 0.07); I² = 63%
Test for overall effect: Z = 1.37 (P = 0.17)



































IV, Random, 95% CI
-0.68 [-1.34 , -0.02]
-0.42 [-0.90 , 0.05]
-0.00 [-0.23 , 0.22]
-0.29 [-0.70 , 0.12]
Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours HSPC Favours control
 
 
Comparison 10.   Unpaid caregiver quality of life





Statistical method Effect size
10.1 HSPC versus usual care on unpaid caregiver quality of
life: unadjusted endpoint values
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Analysis 10.1.   Comparison 10: Unpaid caregiver quality of life, Outcome 1: HSPC





Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 1 (P = 0.73); I² = 0%
Test for overall effect: Z = 2.10 (P = 0.04)




























IV, Random, 95% CI
7.80 [-3.24 , 18.84]
5.50 [-1.15 , 12.15]
6.11 [0.42 , 11.81]
Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours control Favours HSPC
 
 
Comparison 11.   Unpaid caregiver burden





Statistical method Effect size
11.1 HSPC versus usual care on unpaid caregiver burden:
adjusted change values






Analysis 11.1.   Comparison 11: Unpaid caregiver burden, Outcome 1: HSPC






Heterogeneity: Tau² = 0.00; Chi² = 1.29, df = 2 (P = 0.53); I² = 0%
Test for overall effect: Z = 3.66 (P = 0.0002)



































IV, Random, 95% CI
-4.50 [-7.67 , -1.33]
-4.46 [-7.87 , -1.05]
-1.50 [-6.10 , 3.10]
-3.88 [-5.95 , -1.80]
Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours HSPC Favours control
 
 
Comparison 12.   Patient breathlessness





Statistical method Effect size
12.1 HSPC versus usual care on patient breathlessness:
adjusted endpoint values




12.2 HSPC versus usual care on patient breathlessness:
unadjusted endpoint values




12.3 HSPC versus usual care on patient breathlessness:
unadjusted change values
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Analysis 12.1.   Comparison 12: Patient breathlessness, Outcome 1: HSPC








Heterogeneity: Tau² = 0.00; Chi² = 2.33, df = 4 (P = 0.68); I² = 0%
Test for overall effect: Z = 0.45 (P = 0.65)

















































IV, Random, 95% CI
-0.33 [-0.87 , 0.21]
-0.01 [-0.45 , 0.43]
-0.07 [-0.31 , 0.17]
-0.19 [-0.91 , 0.53]
0.11 [-0.18 , 0.39]
-0.04 [-0.19 , 0.12]
Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours HSPC Favours control
 
 
Analysis 12.2.   Comparison 12: Patient breathlessness, Outcome 2: HSPC





Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 1.97 (P = 0.05)




























IV, Random, 95% CI
-0.32 [-0.90 , 0.26]
-0.37 [-0.80 , 0.07]
-0.35 [-0.70 , -0.00]
Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours HSPC Favours control
 
 
Analysis 12.3.   Comparison 12: Patient breathlessness, Outcome 3: HSPC





Heterogeneity: Tau² = 0.55; Chi² = 10.04, df = 1 (P = 0.002); I² = 90%
Test for overall effect: Z = 0.86 (P = 0.39)




























IV, Random, 95% CI
0.04 [-0.21 , 0.29]
-1.06 [-1.70 , -0.43]
-0.47 [-1.55 , 0.61]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours HSPC Favours control
 
 



























Bajwah 2015 Yes Yes Yes Yes Yes
Table 1.   Taxonomy of the components of hospital-based specialist palliative care in studies that either included
certified experts in palliative care or those described as palliative care clinicians 
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Bakitas 2009 Yes Yes Yes Yes Yes
Bakitas 2015 Yes Yes Yes Yes Yes
Bekelman 2018 Yes Yes No Yes Yes
Brannstrom 2014 Yes Yes No Yes Yes
Brumley 2007 Yes Yes Yes Yes Yes
Carson 2016 No Yes No Yes No
Edmonds 2010 Yes Yes Yes Yes Yes
El-Jawahri 2016 Yes No No Yes No
Farquhar 2014 Yes Yes Yes Yes No
Farquhar 2016 Yes Yes Yes Yes No
Franciosi 2019 Yes Yes No Yes Yes
Gade 2008 Yes Yes Yes Yes No
Higginson 2009 Yes No Yes Yes Yes
Higginson 2014 Yes Yes Yes Yes Yes
Janssens 2019 Yes Yes Yes Yes Yes
Kane 1984 Yes No Yes Yes No
Lowther 2015 Yes Yes Yes Yes No
Ma 2019 Yes Yes No Yes Yes
McCorkle 2015 Yes Yes No Yes Yes
McWhinney 1994 Unclear Unclear Unclear Yes Unclear
Nottelmann 2018 Yes Yes Yes Yes Yes
Rodin 2019 Yes No No Yes No
Rogers 2017 Yes Yes Yes Yes Yes
Sidebottom 2015 Yes Yes Yes Yes Yes
Solari 2018 Unclear Unclear Unclear Yes Unclear
Tattersall 2014 Yes No No Yes No
Temel 2010 Yes Yes No Yes Yes
Temel 2017 Yes Yes No Yes Yes
Table 1.   Taxonomy of the components of hospital-based specialist palliative care in studies that either included
certified experts in palliative care or those described as palliative care clinicians  (Continued)
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Vanbutsele 2018 Yes Yes No Yes Yes
Wallen 2012 Yes No No Yes No
Table 1.   Taxonomy of the components of hospital-based specialist palliative care in studies that either included
























Ahronheim 2000 Yes No Yes Yes No
Cheung 2010 Unclear Unclear Unclear Unclear Unclear
Groenvold 2017 Unclear Unclear Unclear Unclear Unclear
Grudzen 2016 Yes Yes Yes Yes No
Hopp 2016 Yes Yes Yes Yes No
Jingfen 2017 Yes Yes No Yes No
McCaffrey 2013 Unclear Unclear Unclear Unclear Yes
Mendoza-Galindo 2018 (ab-
stract only)
Yes No No Yes No
O'Riordan 2019 Yes No Yes Yes No
Ozcelik 2014 Yes No Yes Yes No
Woo 2019 Yes No No Yes No
Table 2.   Taxonomy of the components of hospital-based specialist palliative care in studies that were unclear about











KBILD (used in meta-
analysis)
SGRQ
KBILD is a 15-item questionnaire consisting of three domains (breathlessness and
activities, chest symptoms and psychological) - secondary outcome
SGRQ is a 50-item instrument designed to measure impact on overall health, dai-
ly life, and perceived well-being in patients with obstructive airways disease. Part 1
has a symptoms component (frequency and severity) with a 1, 3 or 12 month recall
(several scales); Part 2 has an activities component looking at activities that cause
or are limited by breathlessness and an impact component looking at social func-
tioning, psychological disturbances resulting from airways disease and referring to
Table 3.   Health-related quality of life scales and dimensions covered 
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current state as the recall (dichotomous (true/false) except last question (4-point




FACIT-Pal Measures physical, emotional, social, and functional well-being in addition to con-
cerns relevant to persons with life-threatening illness (e.g. feeling peaceful, recon-








Measures physical, emotional, social, and functional well-being and additional con-
cern subscales – study did not specify whether primary or secondary outcome




KCCQ KCCQ is a valid, reliable measure of heart failure–specific health status that is re-




EQ-5D (used in meta-
analysis)
KCCQ
A generic, single index that defines health in the five dimensions of mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression - did not specify pri-
mary or secondary outcomes




MSIS Multiple Sclerosis Impact Scale (MSIS) is a 29-item measure of disease impact. It has




FACT-BMT The 47-item Functional Assessment of Cancer Therapy–Bone Marrow Transplant
which includes subscales assessing physical, functional, emotional, social well-be-
ing, and bone marrow transplant–specific concerns during the past week, was used




FACT-G Functional Assessment of Cancer Therapy-General (FACT-G) scale. It is a 27-item in-
ternationally validated questionnaire divided into four primary HRQoL domains:
physical well-being, social/family well-being, emotional well-being, and functional
well-being. The total FACT-G score is the sum of the 4 subscale scores.
Gade 2008





MCOHPQ MCOHPQ Physical Area scale, emotional/relationship area and spiritual area scales
and MCOHPQ place of care environment scale. Physical Area scale addresses pain,
fatigue, sleep changes, nausea, constipation, diarrhoea, dry mouth, change in ap-
petite, and shortness of breath. Emotional support items included: anxiety, burden
to family, support they received, isolation, opportunity to discuss illness and possi-
ble death, and treatment wishes/goals. Spiritual support included: the importance
of participation in spiritual or religious experiences from the Spiritual Area scale,
and two items developed by the investigators: ability to find meaning in one’s life,
and support given by religion or spiritual belief.
MCOHPQ Place of Care Environment scale addressed experiences receiving pain
management and symptom relief, psychological and social support, discharge plan-
ning, and end-of-life planning – primary outcome.
Grudzen 2016
PEP: 12 weeks
FACT-G Functional Assessment of Cancer Therapy-General Measure (not specified in study)
– primary outcome
Table 3.   Health-related quality of life scales and dimensions covered  (Continued)
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Measures breathlessness mastery, breathlessness, fatigue, and emotional function
– secondary outcome
A generic, single index that defines health in the five dimensions of mobility, self-




SF-36 A generalised self-assessment scale assessing different dimensions including vitali-
ty, mental health, general health, physical functioning, role physical, role emotional,






Not specified as primary or secondary outcome
McCorkle 2015
PEP: not stated but





SF-12 (not used in
meta-analysis be-
cause only its first
item was used)





EORTC QLQ-C30 The EORTC QLQ-C30 consists of 30 items in 15 scales. In the present study addition-
al items measuring role functioning, cognitive functioning, social functioning, dysp-
noea, pain, fatigue, insomnia, appetite loss, nausea/vomiting and constipation were
added to the questionnaire to expand these scales to at least four items in each
scale.
O'Riordan 2019
PEP: not stated but
appeared to be 6
months. 6 months
was used in meta-
analysis
Heart failure
MLHF questionnaire MLHF questionnaire measures heart failure–specific health–related quality of life.




EORTC QLQ-C30 The scale consists of the 2 subscales 'functional' and ‘symptom'. The functional sec-
tion is divided into 6 subsections: physical, role, cognitive, emotional, social, and
global quality of life. The symptom section includes the following symptoms: fa-
tigue, nausea and vomiting, pain, dyspnoea, sleep disorders, loss of appetite, con-











Assesses quality of life in several domains, including physical well-being, social/fam-
ily well-being, emotional well-being, functional well-being, and palliative care – pri-
mary outcome
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Heart failure The overall summary score is derived from the physical function, symptom, social
function, and quality-of-life domains.
Sidebottom 2015
PEP: not stated but
data presented at
3 months used in
meta-analysis
Heart failure
MLHF questionnaire The MLHF Questionnaire was created to be representative of the ways HF and treat-
ments can affect key physical, emotional, social, and mental dimensions of QoL. It
assess how much a person’s HF has affected many aspects of their life during the





Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-
DW). The SEIQoL-DW is administered in an interview in which respondents nominate
the five areas of life that are most important in determining their QoL, and rate the
satisfaction/functioning and weight/importance in each of these areas. The SEIQoL-






Physical symptoms, psychological symptoms, outlook on life, and meaningful exis-








Assesses multiple dimensions of the quality of life (physical, functional, emotional,
and social well-being) during the previous week. In addition, the lung cancer sub-





FACT-G Assesses four dimensions of QoL (physical, functional, emotional, and social well-









Global health status/quality of life scale of the European Organisation for Research
and Treatment of Cancer Quality-of-Life Questionnaire Core 30 items (EORTC QLQ-
C30; version 3)
Single item scale and overall summary score of the McGill Quality of Life question-
naire (MQoL). The MQoL incorporates a single item scale of global quality of life and
four subscales, measuring four relevant domains of quality of life (i.e. physical, psy-






EORTC QLQ-C30 (Korean version) assesses multiple dimensions of QoL (physical,
functional, emotional and social well-being) during the previous week.





FACIT-Pal: Functional Assessment of Chronic Illness Therapy for Palliative Care
FACIT-Sp: Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being (FACIT-Sp)
FACT-BMT: Functional Assessment of cancer Therapy – Bone Marrow Transplant
FACT-G: Functional Assessment of Cancer Therapy-General Measure/Functional Assessment of Chronic Illness Therapy–General Measure
FACT-L:
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HF:
HRQoL:
KBILD: Kings Brief Interstitial Lung Disease
KCCQ: Kansas City Cardiomyopathy Questionnaire
LCS:
MCOHPQ: Modified City of Hope Patient Questionnaires













Author Results for Mortality/Survival P value








Bakitas 2009 Number of deaths in the sample
Intervention: 112 (69.6%)
Control: 119 (73.9%)
Survival time (median, 95% CI)
Intervention: 14 months (10.6 to 18.4)
Control: 8.5 months (7 to 11.1)
Cox proportional hazards model estimate
demonstrated a reduced relative risk of
death (HR, 0.67 (95% CI: 0.496 to 0.906) P
= .009) in the HSPC group during the first
year of the study and a greater relative risk
after one year, (HR, 1.56 (95% CI: 0.908 to
2.655)).
P for survival time = 0.14
Bakitas 2015 Number of deaths (authors stated that there were 109
deaths (52.7%)
Intervention: numbers not provided




Kaplan-Meier curves illustrated a 15% differ-
ence in survival at 1 year (HSPC, 63% vs con-
trol, 48%; P = 0.038). However, for the over-
all log-rank test, P = 0.18), suggesting a con-
vergence in overall survival after 12 months.
Bekelman 2018 Number of deaths in the sample
Intervention: 10 (6.4%)
0.52
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Control: 13 (8.3%)




Brumley 2007 Number of deaths (authors highlighted 75% deaths among
participants)
Intervention: numbers not provided
Control: numbers not provided
Survival time (mean (SD))
Intervention: 196 days (SD:164)
Control: 242 days (SD:200)
P = 0.03
However, results of the Kaplan-Meier sur-
vival analysis did not show differences in
survival time between study groups (P =
0.08).
Carson 2016 Survival time (median, IQR)
Intervention: 19 days (12 to 37)
Control: 23 days (12 to 39)
P for survival time = 0.51
90-day survival (HR, 0.95 (95% CI: 0.65 to
1.38), P = 0.96). Post hoc adjustment for
baseline activities of daily living and study
site did not alter the outcome (HR,1.01 (95%
CI; 0.69 to 1.47), P = 0.96)




Edmonds 2010 Number of deaths in the sample
Intervention: 1 (70%)
Control: 3 (11.5%)
P value not stated
El-Jawahri 2016 Number of deaths in the sample
Intervention: 3 (3.7%)
Control: 0
P value not stated
Farquhar 2014 Number of deaths in the sample
Intervention: 2 (5.7%)
Control: 0
P value not stated
Farquhar 2016 Number of deaths in the sample
Intervention: 1 (2.3%)
Control: 1 (2.3%)
P value not stated
Franciosi 2019 Number of deaths in the sample
Intervention: 52 (37.4%)
P value not stated
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Control: 30 (36.6%)
Gade 2008 Number of deaths in the sample
Intervention: 173 (63%)
Control: 132 (56%)
Survival time (median, IQR)
Intervention: 30 days (6 to 104)
Control: 36 days (13 to 106)
P (for difference in number of deaths) = 0.08
P (for difference in survival time) = 0.08






P (for difference in survival time) = 0.16, but
in the adjusted analysis P = 0.39
Grudzen 2016 Number of deaths in the sample
Intervention: 41 (59.4%)
Control: 44 (65.7%)
Survival time (median, 95% CI)
Intervention: 289 days (128 to 453)
Control: 132 days (80 to 302)
The P value for difference in median survival
was 0.20 (log-rank test)
Higginson 2009 Number of deaths in the sample
Intervention: 1 (3.8%)
Control: 3 (11.5%)
P value not stated
Higginson 2014 Number of deaths in the sample
Intervention: 3 (5.7%)
Control: 13 (25%)
Survival time (median, range)
Intervention: 745 (338 to1075)
Control: 711 (345 to1045)
P (for survival rate) was 0.048. In subgroup
analysis, this pattern was not recorded for
patients with cancer (P = 0·97); but it be-
came more marked for patients with dis-
eases other than cancer (P = 0·01).




Janssens 2019 Number of deaths in the sample
Intervention: 4 (15.4%)
Survival did not differ between groups (log-
rank test, P = 0.913).
Table 4.   Studies that reported on mortality/survival  (Continued)
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Control: 4 (17.4%)
Survival time (unclear if mean or median reported)
Intervention: 454 days (95% CI: 382 to 525)
Control: 425 days (95% CI: 339 to 509)
Kane 1984 One-third of the sample died within 45 days after enroll-
ment, the second third within 120 days but numbers were
not provided for the intervention and control groups
Authors reported no difference in the sur-
vival patterns of HSPC and control patients
Lowther 2015 Number of deaths in the sample
Intervention: 3 (5%)
Control: 0
P value not stated




McCaffrey 2013 Number of deaths in the sample
Intervention: 16 (69.6%)
Control: 5 (62.5%)
Increment (95% CI) reported as 7 (-45.1 to
30.4)
McCorkle 2015 Number of deaths in the sample
Intervention: 7 (10.6%)
Control: 3 (3.8%)
P value not stated
McWhinney 1994 Authors reported that 36 (24.7%) patients died before one
month but did not provide numbers in the intervention and
control group.
 
O'Riordan 2019 Number of deaths in the sample
Intervention: 1 (4.5%)
Control: 1 (5.6%)
P value not stated
Rogers 2017 Number of deaths in the sample
Intervention: 23 (30.7%)
Control: 20 (26.7%)
P value not stated
Sidebottom 2015 Number of deaths in the sample
Intervention: 14 (12.1%)
Control: 5 (4.3%)
Results of the survival analysis found no as-
sociation between study group assignment
and death within 6 months after adjustment
for age, gender, and marital status.
Solari 2018 Number of deaths in the sample
Intervention: 3 (3%)
Control: 0
P value not stated
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Tattersall 2014 Number of deaths in the sample
Intervention: 39 (65%)
Control: 31 (51.7%)
Survival time (median, 95% CI)
Intervention: 7 months (5.2 to 9.8)
Control: 11.7 months (9.8 to 18.8)
P (log rank) = 0.014.
The estimated HR was 1.6 (95% CI: 1.1 to
2.3; P = 0.015). This estimate changed to 1.5
(95% CI 0.99 to 2.2; P = 0.06) when adjust-
ed for the oncologist’s baseline estimate of
likely survival, diagnosis, months since diag-
nosis, and gender.
Temel 2010 Number of deaths (authors stated 105 participants (70%)
had died by the time of analysis)
Intervention: numbers not provided
Control: numbers not provided
Survival time (median, 95% CI)
Intervention: 11.6 (6.4 to 16.9) months
Control: 8.9 (6.3 to 11.4) months
Log-rank P = 0.02
After adjustment for age, sex, and baseline
Eastern Cooperative Oncology Group per-
formance status, the group assignment re-
mained a predictor of survival (HR for death
in the standard care group, 1.70; 95% CI,
1.14 to 2.54; P = 0.01).
Temel 2017 Number of deaths in the sample
Intervention: 33 (18.9%)
Control: 41 (23.4%)
P value not stated
Vanbutsele 2018 Number of deaths (authors stated that 121 (65%) of partici-
pants had died by the end of the study)
Intervention: numbers not provided
Control: numbers not provided
Survival time (median, 95% CI)
Intervention: 312 days (190 to 434)
Control: 343 days (253 to 433)
P = 0.97
Woo 2019   Authors reported that there was no differ-
ence in survival between HSPC and usual
care but did not present any data








Studies Participants Adverse effects in patients/caregivers
Bajwah 2015 Patients and care-
givers
Authors reported no worsening of any outcome after receiving the intervention.
Table 5.   Studies that reported on adverse events in patients and/or caregivers 
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Bekelman 2018 Patients There were no harmful adverse events attributed to the intervention.
Groenvold 2017 Patients Authors did not observe any harmful effect of the intervention.
Higginson 2014 Patients (and care-
givers if present)
Authors did not observe any harmful effect of the intervention.
Lowther 2015 Patients Authors did not observe any harmful effect of the intervention.
Rodin 2019 Patients Authors reported no adverse events during the study.
Solari 2018 Patients and care-
givers
Authors reported 15 serious adverse events in 13 patients in the HSPC group and 7
in 7 patients in the control group. Serious adverse events reported included aspi-
ration pneumonia, generalised anxiety, breathing difficulty, urine retention/infec-
tion, anarthria, contact dermatitis, dysphagia, vomiting, bladder catheter malfunc-
tioning, fever, arrhythmia, necrotising fasciitis, traumatic wound, macrohaematuria,
constipation, abdominalgia and bronchitis. Three patients in the HSPC group died
but this was considered to be unrelated to the intervention.
Tattersall 2014 Patients Authors reported that more patients in the HSPC group had poorer appetite com-
pared to the control group (P = 0.04).




Study Time horizon Significance and direction Details
Bakitas 2009 During study
period




Note: not clear if the figures were means or
medians




Poisson generalised linear model
P = 0.32 for baseline (total sample of 207)
P = 0.21 for total use in 109 decedents
Intervention for baseline sample (days, 95%
CI): 0.16 (0.1 to 0.25)
Control for baseline sample:
0.21 (0.15 to 0.31
Intervention (total use in 50 decedents):
0.14 (0.09 to 0.2)
Control (total use in 59 decedents):
0.19 (0.14 to 0.26)
Brumley 2007 During study
period
Reduced ED use in intervention group
Cramer’s V 0.15; P = 0.01
linear regression adjusted for survival, age
and severity of illness showed intervention re-
duced ED visits by 0.35 (P = 0.02)
Intervention: 20% had ED visits
Control: 33% had ED visits
Table 6.   Emergency department (ED) use 
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
Admissions to
the emergency
ward in the year
before study
enrollment
There was no difference in admissions to the
emergency ward in the intervention group
compared to the control group (Incidence
rate ratio 1.27, 95% CI: 0.72 to 2.26, P = 0.384).






Admission to the emergency ward was twice
as often in the intervention group compared
to the control group (incidence rate ratio 2.05,
95% CI: 1.11 to 3.94, P = 0.014). However, after
the Benjamini and Hochberg correction for
multiple testing, this difference was not sig-
nificant.
Number of admissions to emergency ward
Intervention: 37
Control: 16
Ma 2019 During study
period and
post-discharge
Patients in the intervention group had fewer
ED visits compared to usual care (P = 0.0067)







Unclear P = 0.074 Intervention: 39
Control: 50
Rogers 2017 During study
period
P value not stated Frequency of interactions occurring between
patients and providers
Emergency department/urgent care:
Intervention, mean (SD): 0.4 (0.12)
Control, mean (SD): 0.5 (0.11)
During study
period















Study Time horizon Significance and direction Details
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Note: not clear if the figures were means or
medians
Bakitas 2015 Total use covering
period before and af-
ter enrollment
Poisson generalised linear model
P = 0.10 for baseline (total sample of 207)
P = 0.49 for total use in 109 decedents
Intervention for baseline sample (days,
95% CI): 0.52 (0.28 to 0.95)
Control for baseline sample:
0.22 (0.1 to 0.5)
Intervention (total use in 50 decedents):
0.1 (0.04 to 0.24)
Control (total use in 59 decedents):
0.15 (0.07 to 0.3)
Carson 2016 Interviewed surro-
gate decision-mak-
ers immediately















90 days after ran-
domisation.
Differences between groups for other pa-
tient outcomes were analysed based on t
tests, nonparametric tests, χ2 tests (includ-
ing the Fisher exact test), or log-rank tests
as appropriate.
For total ICU days, P = 0.51
P value for after randomisation, P = 0.72
ICU days
Total:
Intervention, median (IQR): 19 (15 to 26)
Control, median (IQR): 20 (15 to 30)
After randomisation:
Intervention, median (IQR): 9 (6 to 15)
Control, median (IQR): 10 (5 to 17)
Cheung 2010 Enrollment to ICU
discharge
Fisher’s exact test and the Mann-Whitney
test
P = 0.97
Intervention: median (IQR) ICU length of
stay: 3 (7) days
Control: median (IQR) ICU length of stay: 5
(8) days
Grudzen 2016 During study period Index-admission
Fisher exact test P > 0.99
Up to 180 days
Fisher exact test P > 0.99
Hospital days at 180 days
Index-admission:
Since only 1 participant had more than 1
ICU admission, the authors treated the ICU
admission as a binary outcome. During the
index-admission, there was no difference
between the 2 groups. (Fisher exact test P
> 0.99)
Up to 180 days:
Table 7.   Intensive care unit (ICU) use  (Continued)
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There was no difference between the 2
groups (Fisher exact test, P > 0.99).
Gade 2008 6 months post-index
hospitalisation
P = 0.04
Continuous measures for intervention and
usual care patients were compared using
t tests for normally distributed measures
and Wilcoxon two-sample tests for mea-
sures with skewed distributions.
ICU admissions, median n:
Intervention: 12
Control: 21
Admissions to ICU for
respiratory failure in
the year before study
enrollment
There was no difference in ICU admissions
for respiratory failure in the intervention
group compared to the control group (Inci-
dence rate ratio 0.88, 95% CI: 0.26 to 2.96,
P = 0.82).
Number of ICU admissions for respiratory




During study period There was no difference in ICU admissions
for respiratory failure in the intervention
group compared to the control group (Inci-
dence rate ratio 4.42, 95% CI: 0.49 to 20.92,
P = 0.16).
Number of ICU admissions for respiratory
failure during the study period:
Intervention: 5
Control: 1
Kane 1984 During study period P value not stated Mean number of ICU days per patient:
Intervention, mean per patient: 0.2
Control, mean per patient: 0.3
Ma 2019 During study period No difference in ICU duration between in-
tervention and control group (P = 0.38)
ICU duration in days, median (IQR):
Intervention: 5 (3 - 8)
Control: 5.5 (3 - 10)
P: 0.38






Study Time horizon Significance and direction Details
Carson 2016 Interviewed surrogate
decision-makers imme-
diately after the sec-
ond support and in-
formation team meet-
ing for the intervention
group and 10 days af-
ter randomisation for
the control group, un-
less the patient had
died. All surrogate de-
cision-makers were in-
terviewed again by tele-
Differences between groups
for other patient outcomes
were analysed based on t
tests, nonparametric tests, χ2
tests (including the Fisher ex-
act test), or log-rank tests as
appropriate.
Mechanical ventilation, P =
0.41
Dialysis, P = 0.64
Nutrition, P = 0.60
Limitations of ICU treatment
Mechanical ventilation:
Intervention, median (IQR): 40 (31)
Control, median (IQR): 33 (26)
Dialysis:
Intervention, median (IQR): 13 (10)
Control, median (IQR): 15 (12)
Nutrition:
Table 8.   Resource use in intensive care unit (ICU) 
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phone for follow-up be-
ginning 90 days after
randomisation.
Vasopressors, P = 0.86 Intervention, median (IQR): 18 (14)
Control, median (IQR): 21 (17)
Vasopressors:
Intervention, median (IQR): 18 (14)
Control, median (IQR): 19 (15)
Ma 2019 During study period The following were lower in
the intervention group com-
pared to the control group:
tracheostomy (P = 0.035) and
days on mechanical ventila-
tion (P = 0.042).




















Number of days on mechanical ventilation, median
(IQR):
Intervention: 4 (3 - 7)
Control: 6 (3 - 13)
P: 0.042
Number of days on vasopressors, median (IQR):
Intervention: 3 (1 - 6)
Control: 3 (2 - 6)
P: 0.91
Table 8.   Resource use in intensive care unit (ICU)  (Continued)
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)



















P = 0.92 Mean number of total admissions
Intervention: 1.94
Control: 1.90
Bekelman 2018 During study
period
P = 0.61 Number of hospitalisations
Intervention:
18 patients had 1 hospitalisation
9 patients had 2 or more hospitalisations
Control:
30 patients had 1 hospitalisation





P = 0.009 Number of hospitalisations, mean (SD)
Intervention: 0.42 ± 0.60
Control: 1.47 ± 1.81
Total number of hospitalisations:
Intervention: 15
Control: 53
Brumley 2007 During study
period
Reduced hospitalisation in intervention group
Cramer’s V 0.23; P < 0.001
Intervention: 36% were admitted
Control: 59% were admitted
Farquhar 2014 During study
period
P value not stated Inpatient:
Intervention, n (%), mean (SD) contacts: 2
(7%), 3.0 (2.8)
Control, n (%), mean (SD) contacts: 3
(12%), 6.3 (6.8)
Farquhar 2016 During study
period
P value not stated Inpatient:
Intervention, n (%), mean (SD) contacts: 6
(15%), 11.5 (8.3)
Control, n (%), mean (SD) contacts: 4
(11%), 6.0 (3.4)
Janssens 2019 Hospital admis-
sions for respi-
ratory failure
in the year be-
There was no difference in hospital admissions
for respiratory failure in the intervention group
compared to the control group (incidence rate
ratio 1.18, 95% CI: 0.61 to 2.31, P = 0.60).
Number of hospital admissions for respira-
tory failure in the year before inclusion:
Intervention: 24
Table 9.   Hospital admission 
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Hospital admission for respiratory failure was
almost twice as often in the intervention group
compared to the control group (incidence rate
ratio 1.87, 95% CI: 1.04 to 3.48, P = 0.026). How-
ever, after the Benjamini and Hochberg correc-
tion for multiple testing, this difference was not
significant.
Number of hospital admissions for respira-






in the year be-
fore study en-
rollment
There was no difference in hospital admissions
for respiratory failure in the intervention group
compared to the control group (incidence rate
ratio 1.18, 95% CI: 0.36 to 4.12, P = 0.77).






There was no difference in hospital admissions
for respiratory failure in the intervention group
compared to the control group (incidence rate
ratio 1.01, 95% CI: 0.32 to 3.28, P = 0.99).
Other hospitalisations during study period:
Intervention: 8
Control: 7
Ma 2019 During study
period and
post-discharge
Patients in the intervention group had fewer
hospital readmissions compared to usual care (P
= 0.024)







Unclear There was no difference in number of hospitali-
sations. P value not given
Intervention: 48%
Control: 51%
Rogers 2017 During study
period
During the 6-month follow-up, 30% of patients
were hospitalised for HF. No differences were
seen between the 2 treatment groups in this
clinical endpoints through the 6-month fol-
low-up point. For hospitalisation for non-heart
failure/cardiovascular and hospitalisation for

















Survival analysis using proportional hazards re-
gression
P = 0.50
There was no association between study
group assignment and 30-day inpatient
readmission (adjusting for age, gender,
and marital status).
Temel 2010 During study
period
P value not stated Any admission from enrollment to death:
Intervention: 73.5%
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Control: 76.8%
  P value not stated Any admission within 30 days of death:
Intervention: 36.7%
Control: 53.6%












Student’s t-test was used
P = 0.46
Intervention (mean (range)): 8.8 (1 - 93)
Control (mean (range)): 9.7 (1 - 63)
Bakitas 2009 During the
study
Wilcoxon rank sum test
P = 0.14








Poisson generalised linear model
P = 0.03 for baseline (total sample of
207)
P = 0.26 for total use in 109 decedents
Intervention for baseline sample (days, 95% CI):
0.69 (0.4 to 1.18)
Control for baseline sample:
1.39 (0.97 to 1.97)
Intervention (total use in 50 decedents):
0.95 (0.61 to 1.46)
Control (total use in 59 decedents):





P value for total hospital days = 0.011.
The number of days spent in hospital
was also significantly lower in the inter-
vention group at the Departments of
Medicine-Geriatrics (100, range 1–45 vs.
242, range 2–46 days) and Surgery (0 vs.
56, range 2–21 days). Days in other de-
partments did not differ significantly.
Total hospital days, mean (SD)
Intervention: 2.9 (8.3)
Control: 8.5 (12.4)
Days in Department of Medicine-Geriatrics:
Intervention: 100 (range 1 - 45)
Control: 242 (range 2 - 46)
Days in Department of Surgery:
Intervention: 0
Control: 56
Days in other departments:
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Intervention: 3 (range 1 - 2)
Control: 7 (1 - 6)
Brumley 2007 During the
study
Fewer hospital days in intervention
group. Linear regression adjusted for
survival, age and severity of illness
showed intervention reduced hospital
days by 4.36 (P < 0.001)


























Differences in the number of hospital
days were analysed using nonparamet-
ric methods.
P value for total hospital days, P = 0.78
P value for deceased patients, P = 0.60
P value for after randomisation, P = 0.51
Hospital days
Total hospital days:
Intervention, median (IQR): 35 (23 to 52)
Control, median (IQR): 36 (23 to 54)
For deceased patients:
Intervention (49 deaths), median (IQR): 25 (18 to
36)
Control (51 deaths), median (IQR): 24 (14 to 39)
After randomisation:
Intervention, median (IQR): 19 (12 to 37)
Control, median (IQR): 23 (12 to 39)
Cheung 2010 During study
period
Fisher’s exact test and the Mann-Whit-
ney test
P = 0.44
Intervention: median (IQR) hospital length of stay:
5 (8) days
Control: median (IQR) hospital length of stay: 11
(27) days
El-Jawahri 2016 During study
period
P value not stated Duration of HCT hospitalisation, median (range):
Intervention: 20 (12 – 102) days
Control: 21 (13 – 40) days
Gade 2008 6 months post-
index hospitali-
sation
P value for admission to study enroll-
ment (days), P = 0.36
P value for study enrollment to dis-
charge or death in the hospital (days), P
= 0.10
P-value for index hospital length of stay
(days), P = 0.57
Continuous measures for intervention
and usual care patients were compared
using t tests for normally distributed
Admission to study enrollment (days), median
(IQR):
Intervention: 3 (2, 7)
Control: 4 (2, 7)
Study enrollment to discharge or death in the hos-
pital (days), median (IQR):
Intervention: 3 (1, 6)
Control: 2 (1, 5)
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measures and Wilcoxon two-sample
tests for measures with skewed distribu-
tions.
Index hospital length of stay (days), median (IQR):
Intervention: 7 (4, 12)
Control: 7 (4, 12)





Up to 180 days
Wilcoxon test P = 0.14
Hospital days at 180 days
Index-admission:
The authors found no difference in hospital days
between the intervention and usual care groups
during the index-admission (Wilcoxon test P =
0.67).
Up to 180 days:
The intervention group had slightly more hospital
days at 180 days than the usual care group (Wilcox-
on test P = 0.14).
Higginson 2009 12 weeks fol-
lowing enroll-
ment
Authors stated increased institutional
days in control group but P value was
not stated.
“The control care patients were more
likely to be (...) admitted to or seen in
hospital”.
Intervention: 4/26 (17%) were institutionalised for
mean 19.0 days (SD 21.6)
Control: 6/28 (29%) were institutionalised for mean
30.7 days (SD 32.1)
Higginson 2014 Three months
before baseline
interview
P value not stated Hospital inpatient days
Intervention, mean (SD): 4.5 (6.8)
Control, mean (SD): 4.6 (7.6)
Kane 1984 During study
period
P value for general medical inpatient
days, P < 0.05
P value for intermediate care inpatient
days P < 0.05
Total inpatient days:
Intervention, mean per patient: 51
Control, mean per patient: 47.5
General medical:
Intervention, mean per patient: 13.2
Control, mean per patient: 20.7
Intermediate care:
Intervention, mean per patient: 8.3
Control, mean per patient: 26.5
Ma 2019 During study
period
No difference in hospital duration be-
tween intervention and control group (P
= 0.43)
Hospital duration in days, median (IQR)
Intervention: 10 (6 - 15)
Control: 11 (6 - 19)
P: 0.43
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Unclear P = 0.808 Intervention: 78 days
Control: 90 days
Ozcelik 2014 During study
period
P = 0.07 Intervention, mean (SD): 9.4 (6.27) days
Control, mean (SD): 13.9 (11.5) days
Temel 2010 During study
period
P value not stated Median inpatient days (range) from enrollment to
death:
Intervention: 5 (0 – 50)
Control: 7 (0 – 45)





Study Time horizon Significance
and direction
Details




Palliative care visits, median (range):
All intervention patients had at least 2 palliative care visits during the first
2 weeks of their hospitalisation (median number of visits, 4; range, 2-7). In-
tervention participants had at least 4 palliative care visits during their en-
tire hospitalisation (median number of visits, 8; range, 4-40). Two control
patients received a palliative care consultation. A total of 41.8% (146/349) of
palliative care visits occurred while a family member was present.
Tattersall 2014 During study
period
P = 0.37 Palliative care contact during the last acute hospital admission:
Intervention: 42 patients (86%)
Control: 29 patients (78%)
Table 11.   Palliative care visits during hospitalisation 
 
 
















nurse visits, P =
0.003
Hospital outpatient clinic
Physician visit, n, median (range):
Intervention: 27, 1 (4 – 30)
Control: 133, 3 (2 -11)
Physician, phone calls and prescriptions, n, median (range):
Intervention: 42, 3 (0 – 8)
Control: 86, 3 (0 -10)
Nurse visits, n, median (range):
Table 12.   Outpatient clinic visits 
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Intervention: 4, 1 (0 – 4)
Control: 60, 2 (0 -27)
Nurse, phone calls and prescriptions, n, median (range):
Intervention: 8, 1 (0 – 4)
Control: 44, 2 (0 - 8)




Contact with the HSPC team, (numbers):
Intervention: 138 patients had at least one face-to-face contact
Control: 13 patients had at least one face-to-face contact









Intervention: 8 patients (35%) received; mean 1.0 contacts (SD 0.0)
Control: 16 patients (76%) received; mean 1.3 contacts (SD 0.7)




Frequency of interactions occurring between patients and providers
Total number of clinic encounter records:
Intervention, mean (SD): 21.9 (1.99)
Control, mean (SD): 20.8 (1.92)
Cardiology:
Intervention, mean (SD): 2.3 (0.55)
Control, mean (SD): 3.2 (1.0)
Rehabilitation clinic:
Intervention, mean (SD): 1.4 (0.68)
Control, mean (SD): 0.9 (0.48)




Contact with palliative care physician consultant:
Intervention: 51 patients (85%)
Control: 8 patients (13.3%)
Contact with palliative care physician in the last month of life:
Intervention: 16 patients (26.7%)
Control: 6 patients (10%)





All the patients assigned to early palliative care, except for one patient who
died within 2 weeks after enrollment, had at least one visit with the pal-
liative care service by the 12th week. The average number of visits in the
palliative care group was 4 (range, 0 to 8). Ten patients who received stan-
dard care (14%) had a palliative care consultation in the first 12 weeks of the
study, primarily to address the management of symptoms, with seven pa-
tients having one visit and three having two visits.
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Mean number of palliative care visits:
Intervention, mean (range): 6.54 (0 to 14)
Control, mean (range): 0.89 (0 to 7)
Number of palliative care visits split on lung and GI cancer:
The authors stated that “we explored characteristics between patients with
lung and GI cancer and found no differences in baseline measures or in the
number of PC visits among those patients who received intervention. How-
ever, the GI cancer cohort had a higher proportion of male patients and
a greater number of hospitalisations (P = 0.038) from baseline to week 24


















ogist (P = 0.02)
Number of consultations from the palliative care team
nurse at 18 weeks:
Intervention, median (IQR): 3 (1 – 4). 82 patients (89%) had at least one con-
sultation
Control, median (IQR): 17 patients (18%) had at least one consultation
PC physician at 18 weeks:
Intervention: 25 patients (27%)
Control: 1 patient (1%)
Nurses at 24 weeks:
Intervention, median (IQR): 3 (2 – 5). 55 patients (60%) had at least 3 consul-
tations
Control, median (IQR): 12 patients (13%) had at least 3 consultations
PC physician at 24 weeks:
Intervention: 32 patients (35%) had at least one consultation
Control: 1 (1%) had one consultation
Number of consultations with a psychologist:
18 weeks:
Intervention: 34 patients (37%) had at least one consultation
Control: 21 patients (22%) had at least one consultation
24 weeks:
No difference was found between intervention and control groups.
Number of consultations with other professionals:
There were no differences between study groups in the number of consul-
tations with a social care nurse (P = 0·87), dietician (P = 0·32), or specialist
nurse (P = 0·28) between 18 weeks and baseline; or between 24 weeks and
baseline with social care nurse (P = 0·07), dietician (P = 0·95), or specialist
nurse (P = 0·99).




Consultation with a psychiatrist:
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The proportions that consulted a psychiatrist (12% vs 12%) were similar in
the intervention and control groups.
Table 12.   Outpatient clinic visits  (Continued)






Study Time horizon Significance and direction Details




Poisson generalised linear model
P = 0.62
Hospice use:
Intervention, rate 95% CI: 0.68 (0.55 to 0.84)






P-value for physician, primary healthcare
centre (PHC), P = 0.027
P value for physician, phone calls and
prescriptions, P = 0.000
P-value for nurse visits, PHC, P = 0.25
P value for nurse visits, phone calls and
prescriptions P = 0.010
Home:
P-value for physician visits, home, P not
stated
P value for nurse visits, home, P = 0.032
Within the PREFER team there were 158
additional physician visits and 1031 nurse
visits at the patient’s home, and 36 phone
call and/or drug prescriptions by the
physician and 225 phone calls and/or pre-
scriptions by the nurses. Summarising
all this, the most striking difference was
found between nurse visits in the PREFER
group and the usual care group (1075 vs.
230; P =0.000). On the other hand, phone
calls and prescriptions by doctors were
more common in the usual care group
(108 vs. 231), while physician’s visits were
somewhat similar (194 vs. 201).
Primary Healthcare Centre
Physician, primary healthcare centre (PHC), n,
median (range):
Intervention: 9, 1 (0 – 3)
Control: 54, 2 (0 - 8)
Physician, phone calls and prescriptions, n, medi-
an (range):
Intervention: 30, 1 (0 – 5)
Control: 145, 1 (1 - 14)
Nurse visits, PHC, n, median (range):
Intervention: 29, 1 (0 – 12)
Control: 61, 2 (0 - 14)
Nurse, phone calls and prescriptions, n, median
(range):
Intervention: 59, 3 (0 – 9)
Control: 153, 4 (1 - 21)
Home:
Physician visits, home, n, median (range):
Intervention: 0, 0 (0 – 0)
Control: 14, 2 (1 - 5)
Nurse visits, home, n, median (range):
Intervention: 11, 2 (1 – 3)
Control: 109, 5 (1 - 23)
Brumley 2007 During study
period
Days in hospice care (1of 2 sites only) Days in hospice care (1 of 2 sites only):
Table 13.   Community care 
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t 0.52
P = 0.60
descriptive data not provided
During study
period
P values not stated Breathlessness intervention service:
Intervention, n (%), mean (SD) contacts: 27 (96%),
1.9 (2.0)
Control, n (%), mean (SD) contacts: 2 (8%), 1.5
(0.7)
Farquhar 2014
  P values not stated GP:
Intervention, n (%), mean (SD) contacts: 10 (36%),
1.2 (0.6)




P values not stated Breathlessness intervention service:
Intervention, n (%), mean (SD) contacts: 39 (95%),
2.1 (1.0)
Control, n (%), mean (SD) contacts: 2 (5%), 1.5
(0.7)
Farquhar 2016
  P values not stated GP:
Intervention, n (%), mean (SD) contacts: 25 (61%),
1.8 (1.2)






Continuous measures for intervention
and control patients were compared us-
ing t tests for normally distributed mea-
sures and Wilcoxon two-sample tests for
measures with skewed distributions
Study enrollment to hospice admission (days),
median (IQR):
Intervention: 2 (0, 23)
Control: 3 (0, 37)
  P = 0.04
Continuous measures for intervention
and control patients were compared us-
ing t tests for normally distributed mea-
sures and Wilcoxon two-sample tests for
measures with skewed distributions.
Hospice length of stay (days), median (IQR)
Intervention: 24 (7, 94)
Control: 12 (4, 48)
Gade 2008
  P = 0.5
Categorical measures were tested using 2
tests or Fisher’s exact test.
Patients admitted to hospice, n (%):
Intervention: 103 (37.1%)
Control: 96 (40.7%)
Grudzen 2016 During study
period
Fisher’s exact test P = 0.85
Chi2 test P = 0.93
Hospice use at 180 days:
Intervention: 28%
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Control: 25%




Authors stated less GP contact in inter-
vention group but P values not stated
District/practice nurse:
P values not stated
MS nurse:
Authors stated there were no differences
(P values not stated)
Social services:
P values not stated
Specialist home visit:
P values not stated
General practice:
Intervention: 8 (35%) received; M 3.8 contacts (SD
0.5)
Control: 11 (52%) received; M 3.4 contacts (SD 1.2)
“Control care patients were more likely to be in
contact with general practitioners”
District/practice nurse:
Intervention: 20 (87%) received; M 12.3 contacts
(SD 19.7)
Control: 13 (62%) received; M 31.9 contacts (SD
50.7)
MS nurse:
Intervention: 11 (48%) received; M 1.8 contacts
(SD 1.8)
Control: 7 (33%) received; M 1.1 contacts (SD 0.2)
“Receipt of MS nurses was similar in the two
groups”.
Social services:
Intervention: 10 (43%) received; M 6.4 contacts
(SD 7.7)
Control: 8 (38%) received; M 4.1 contacts (SD 2.4)
Specialist home visit:
Intervention: 5 (22%) received; M 5.2 contacts (SD
4.5)
Control: 0 received
Note: authors stated that specialist home visits
were most likely to be from the intervention home
palliative care team.
Kane 1984 During study
period
P value not stated Days at home:
Intervention, mean per patient: 44.8
Control, mean per patient: 37.9
McCaffrey 2013 During study
period
No difference as increment, mean (95%
CI) = 1 (-6.8, 8.6)
Days at home:
Intervention, mean (95% CI): 13.1 (8.5, 17.7)
Control, mean (95% CI): 12.1 (5.9, 18.4)
Rogers 2017 During study
period
P values not stated Frequency of interactions occurring between pa-
tients and providers
Primary care:
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Intervention, mean (SD): 4.4 (0.93)








Survival analysis using proportional haz-
ards regression
P = 0.36
There was no significant association between
study group assignment and hospice use within
6 months (adjusting for age, gender, and marital
status).
Temel 2010 During study
period
P = 0.09 Median duration of hospice care:
Intervention: 11 days
Control: 4 days











Study Time horizon Significance
and direction
Details





Intervention, n (%), mean (SD) contacts: 22 (79%), 20.3 (20.8)
Control, n (%), mean (SD) contacts: 25 (96%), 23.4 (25.2)





Care by informal caregiver:
Intervention: 15/23 (65%) received; Mean 152.5 contacts (SD 53.7)
Control: 16/21 (76%) received; Mean 151.1 contacts (SD 57.7)
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Control: 34 (66.7%)





  Not calculated be-
cause expected
frequencies < 5 in




  Not calculated be-
cause expected
frequencies < 5 in




  Pearson chi2 test
P = 0.16
Systemic antibiotics (unclear if mean or median presented)
Intervention: 73 (79.3)
Control: 69 (70.4)
    Interventions during 190 admissions
  Pearson chi2 test
P = 0.025
IV for entire admission (unclear if mean or median presented)
Intervention: 61 (66)
Control: 79 (81)
  Pearson chi2 test
P = 0.30
Indwelling urinary catheter (unclear if mean or median presented)
Intervention: 41 (44.6)
Control: 51 (52)
  Pearson chi2 test
P = 0.33





Days with restraints (mean)
Intervention: 5.18
Control: 6.56
  Pearson chi2 test
P = 0.089




  Pearson chi2 test
P = 0.461
Daily sc/im injection for at least 50% of admission (unclear if mean or
median presented)
Intervention: 16 (17.4)
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>1 invasive test (unclear if mean or median presented)
Intervention: 5 (4.3)
Control: 2 (2)
  Pearson chi2 test
P = 0.15
Number of fingersticks per day in patients receiving insulin (unclear
if mean or median presented)
Intervention: 1.56
Control: 2.01
    Decisions to forgo treatments
  Not calculated be-
cause expected
frequencies < 5 in




  Not calculated be-
cause expected
frequencies < 5 in




  Not calculated be-
cause expected
frequencies < 5 in




  Not calculated be-
cause expected
frequencies < 5 in




  Not calculated be-
cause expected
frequencies < 5 in




  Pearson chi2 test
P = 0.65
CPR in-hospital (unclear if mean or median presented)
Intervention: 62 (67.4)
Control: 63 (64.3)
  Pearson chi2 test
P = 0.10
CPR nonhospital (unclear if mean or median presented)
Intervention: 47 (51.1)
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Control: 38 (38.8)





Fisher exact test P
= 0.75
Referral to palliative care
Intervention: 34/145 (23.4%)
Control: 39/134 (29.1%)
Referral to hospice care
Intervention: 6/161 (3.7%)
Control: 4/161 (2.5%)








Chemotherapy in last 2 weeks of life
Intervention, rate (95% CI): 0.08 (0.03 to 0.2)
Control, rate (95% CI): 0.05 (0.02 to 0.15)




(1of 2 sites only)
Chi2 P = 0.15
Days in hospice




Referral to hospice care
(1 of 2 sites only)
Intervention: 25%
Control: 36%
Days in hospice care (1 of 2 sites only)



























days, P = 0.59
After randomisa-
tion, P = 0.42
Ventilator days
Total
Intervention, median (IQR): 19 (15 to 31)
Control, median (IQR): 21 (14 to 35)
After randomisation
Intervention, median (IQR): 10 (5 to 20)
Control, median (IQR): 12 (5 to 27)
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P = 0.62 Hospital discharge disposition (81 patients discharged from the hos-
pital in intervention group and 75 in control group).
Home
Intervention, median (IQR): 15 (19)
Control, median (IQR): 18 (24)
Home with paid assistance:
Intervention, median (IQR): 10 (12)
Control, median (IQR): 7 (9)
Hospice
Intervention, median (IQR): 3 (4)
Control, median (IQR): 4 (5)
Acute rehabilitation facility
Intervention, median (IQR): 22 (27)
Control, median (IQR): 15 (20)
Long-term acute care hospital
Intervention, median (IQR): 12 (15)
Control, median (IQR): 12 (16)
Other acute care facility
Intervention, median (IQR): 0
Control, median (IQR): 1 (1)
Skilled nursing facility
Intervention, median (IQR): 19 (23)
Control, median (IQR): 16 (21)
Other
Intervention, median (IQR): 0
Control, median (IQR): 2 (3)
During study
period
P value not stated Other hospital care
Intervention, n (%), mean (SD) contacts: 15 (54%), 1.5 (0.8)
Control, n (%), mean (SD) contacts: 14 (54%), 1.4 (0.6)
  P value not stated Nurse
Intervention, n (%), mean (SD) contacts: 11 (39%), 3.0 (3.8)
Control, n (%), mean (SD) contacts: 12 (46%), 1.8 (1.6)
Farquhar 2014
  P value not stated Other health professionals
Intervention, n (%), mean (SD) contacts: 5 (18%), 1.2 (0.4)
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Control, n (%), mean (SD) contacts: 3 (12%), 1.0 (0.0)
    Social care
Intervention, n (%), mean (SD) contacts: 4 (14%), 4.3 (6.5)
Control, n (%), mean (SD) contacts: 3 (12%), 15.7 (22.9)
During study
period
P value not stated Other hospital services
Intervention, n (%), mean (SD) contacts: 20 (49%), 1.7 (1.0)
Control, n (%), mean (SD) contacts: 19 (50%), 2.5 (3.5)
  P value not stated Nurse
Intervention, n (%), mean (SD) contacts: 21 (51%), 2.7 (3.3)
Control, n (%), mean (SD) contacts: 16 (42%), 2.5 (2.5)
  P value not stated Other health services
Intervention, n (%), mean (SD) contacts: 14 (34%), 1.5 (1.1)
Control, n (%), mean (SD) contacts: 4 (11%), 1.0 (0.0)
Farquhar 2016
  P value not stated Social and other care
Intervention, n (%), mean (SD) contacts: 8 (20%), 5.4 (4.6)
Control, n (%), mean (SD) contacts: 9 (24%), 11.3 (22.8)
Groenvold 2017 During study
period
P value not stated Telephone contact with the HSPC team, n
Intervention: 116 patients had at least one telephone contact
Control: 9 patients had at least one telephone contact
Higginson 2009 12 weeks after
enrollment
P value not stated Palliative care nurse
Intervention: 9 (39%) received; M 3.0 (SD 1.5)
Control: 0 received
Other nurse
Intervention: 7 (30%) received; M 40.0 (SD 63.8)
Control: 7 (33%) received; M 95.0 (SD 79.6)
Specialist (ward)
Intervention: 5 (22%) received; M 1.0 (SD 0.0)
Control: 7 (33%) received; M 9.6 (SD 12.1)
Specialist (other)
Intervention: 4 (17%) received; M 1.1 (SD 0.3)
Control: 5 (24%) received; M 1.0 (SD 0.0)
Occupational therapist/physiotherapist
Intervention: 16 (70%) received; M 10.6 (SD 9.9)
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Control: 14 (67%) received; M 22.5 (SD 47.7)
Dietitian/chiropodist
Intervention: 12 (52%) received; M 3.5 (SD 2.5)
Control: 13 (62%) received; M 2.6 (SD 1.3)
Day centre
Intervention: 5 (22%) received;M 20.2(SD 21.0)
Control: 5 (24%) received; M 20.4 (SD 15.9)
Respite care
Intervention: 2 (9%) received; M 9.5 (SD 0.7)
Control: 5 (24%) received; M 10.0 (SD 5.9)
Janssens 2019 During study
period
P = 0.819 Use of antibiotics
The use of antibiotics (for exacerbations not leading to hospital admis-




cedures P < 0.05
Major surgical procedures
Intervention, mean per patient: 0.09
Control, mean per patient: 0.01
Minor surgical procedures
Intervention, mean per patient: 0.42
Control, mean per patient: 0.30





those few who did




Intervention, mean per patient: 7.4
Control, mean per patient: 7.7
Kane 1984
  P = 0.03 Chemotherapy treatments
Intervention, mean per patient: 1.3









ing full target dos-




(P = 0.0009) in the
intervention arm
than in the control
arm.
Prescribed medication use
In the intervention arm, the percentages of angiotensin converting en-
zyme inhibitors (ACEIs) and mineralocorticoid receptor antagonists
(MRAs) increased at the end of the study from baseline, while loop di-
uretics decreased. Beta-receptor blockers (BBs) decreased somewhat in
both groups. The number of patients treated with MRAs differed the most
between groups, and increased from 10 (28%) to 15 (48%) in the PRE-
FER arm compared with 13 (35%) vs 13 (39%) in the control group. The
change in patients receiving full target doses (+8 vs. +1) of the ACEIs/an-
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giotensin receptor blockers, BBs and MRAs were higher (P = 0.0009) in the
intervention arm than in the control arm.
O'Riordan 2019 During study
period
CRT device, P = 0.3
ACE1/ARB device,
P = 0.2





































Pain medication (NSAIDS and opioids)
Intervention: 53.3%
Table 15.   Medications and other resources  (Continued)
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)

















Rodin 2019 During study
period
P value not stated Referral to palliative care
Intervention: 22 (100%)
Control: 1 (5%)






Rogers 2017 During study
period
P value not stated Frequency of interactions occurring between patients and providers
Total number of hospital encounter records
Intervention, mean (SD): 2.5 (0.45)
Control, mean (SD): 2.4 (0.35)
Telephone contact
Intervention, mean (SD): 12.6 (1.2)
Control, mean (SD): 10.6 (0.88)
During study
period
P = 0.05 Aggressive end-of-life care among 105 decedents (chemotherapy with-
in 14 days before death, no hospice care, or admission to hospice 3 days




    Chemotherapy within 30 days of death
Intervention: 32.5%
Control: 42%





The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)

































































Patients and carers interviewed valued the
case conference as they felt that it "laid
everything on the table" and importantly
addressed concerns and anxieties that had
been playing on patients’ and carers’ minds.
The qualitative work also identified lack of
early referral to palliative care by commu-
nity health professionals, despite requests
from patients and carers, and some gate-
keeping by hospital health professionals.
Themes from patients:
Support in the community
Crisis management
Palliative care, psychological support
Advance care planning
Themes from health professionals:
GPs - collaboration of care and efficiency
Community palliative care clinical nurse
specialist – individual care plans and practi-
cal problems addressed
ILD consultant – symptom control
ILD CNS – empowering health professionals
Primary outcome:
Symptom burden
Mean (SD) POS scores at 4 weeks were -5.7
(7.5) fast-track vs -0.4 (8.0) control, (mean
change difference between the two arms
was -5.3 (95% CI -9.8 to -0.7) independent t
test P = 0.02); effect size (95% CI) -0.7 (-1.2 to
-0.1).
Secondary outcomes:
The secondary outcomes of quality of life,
anxiety and depression were superior in the




























Oncologists believed that integrating pallia-
tive care at the time of an advanced cancer
diagnosis enhanced patient care and com-
plemented their practice. Five themes com-
prised oncologists' views on the comple-
mentary role of palliative care: (1) “refer ear-
ly and often,” (2) referral challenges: “pallia-
tive” equals “hospice”; “Heme patients are
Primary outcomes:
Quality of life:
The estimated treatment effects (interven-
tion minus usual care) for all participants
were a mean (SE) of 4.6 (2) for quality of life
(P = 0.02)
Symptom intensity
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different,” (3) palliative care as consultants
or co-managers, (4) palliative care “shares
the load,” and (5) ENABLE II facilitated pal-
liative care integration. Self-assessment
of their practice with advanced cancer pa-
tients comprised four themes: (1) treating
the whole patient, (2) focussing on quality
versus quantity of life, (3) “some patients
just want to fight,” and (4) helping with tran-
sitions; timing is everything.
The estimated treatment effects (interven-
tion minus usual care) for all participants
were a mean (SE) of -27.8 (15) for symptom
intensity (P = 0.06)
Resource use:
Intensity of service did not differ between
the 2 groups.
Secondary outcomes:
The estimated treatment effects (interven-
tion minus usual care) for all participants
were a mean (SE) of -1.8 (0.81) for depressed






















Participants' perceptions of intervention
benefits were represented by four themes:
enhanced problem-solving skills, better
coping, feeling empowered, and feeling sup-
ported or reassured.
Three themes related to trial participation:
helping future patients and contributing to
science, gaining insight through comple-
tion of questionnaires, and trial/interven-
tion aspects to improve. Participants did not
describe participation as burdensome but
rather described some inconveniences or
disappointments such as non-attendance
of meetings by other participants and disap-




The estimated treatment effects (interven-
tion minus usual care) for all participants
were a mean (SE) of 4.6 (2) for quality of life
(P = 0.02)
Symptom intensity
The estimated treatment effects (interven-
tion minus usual care) for all participants
were a mean (SE) of -27.8 (15) for symptom
intensity (P = 0.06)
Intensity of service did not differ between
the 2 groups.
Secondary outcomes:
The estimated treatment effects (interven-
tion minus usual care) for all participants
were a mean (SE) of -1.8 (0.81) for depressed

























Two themes and a total of five categories
were identified. The first theme was feel-
ing secure and safe through receiving care
at home with the categories: having access
to readily available care at home, being fol-
lowed up continuously and having trust in
the team members' ability to help. The sec-
ond theme was being acknowledged as both
a person and a patient, with the following
two categories: being met as a person, par-
ticipating in decisions about one's care and
receiving help for symptoms of both HF and
comorbidities. The team also offered rela-
tives support, which patients appreciated.
Outcomes:
Quality of life:
Between-group analysis revealed that pa-
tients receiving HSPC had improved HRQoL
compared with controls (57.6 ± 19.2 vs. 48.5
± 24.4, age-adjusted P = 0.05). Within-group
analysis revealed a 26% improvement in the
HSPC group for HRQoL (P = 0.046) compared
with 3% (P = 0.82) in the control group.
Quality of life improved by 24% (P = 0.047).
Symptom burden:
Total symptom burden improved by 18% (P
= 0.035)
Resource use:
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Fifteen rehospitalisations (103 days) oc-
curred in the HSPC group, compared with 53




















Breathlessness intervention service (BIS) re-
duced fear and worry, and increased confi-
dence in managing breathlessness. Patients
and carers consistently identified specif-
ic and repeatable aspects of the BIS mod-
el and interventions that helped. The mul-
tidisciplinary sta, expertise was repeated-
ly noted. How interventions were delivered
was important with a suggestion that the in-
tervention was delivered through the provi-
sion of knowledge, with specialist expertise,
which increased patients’ and carers’ confi-
dence. BIS legitimised breathlessness and
increased knowledge whilst making patients
and carers feel ‘not alone’.
Primary outcome:
BIS reduced patient distress due to breath-
lessness (primary outcome: −1.29; 95% CI
−2.57 to −0.005; P = 0.049) significantly more
than the control group; 94% of respondents
reported a positive impact (51/53)
Secondary outcomes:
Mean CRQ mastery scores improved only
negligibly in the intervention arm and re-
mained stable for controls. No differences
were found between trial arms on other CRQ
domains (dyspnoea, fatigue or emotional
function). Mean anxiety scores (HADS) re-
mained fairly stable (both arms). Mean de-
pression scores decreased slightly in the in-
tervention arm, increasing slightly for con-
trols. There was little change in other pa-
tient or carer outcomes.
BIS had a 66% likelihood of better outcomes
in terms of reduced distress due to breath-
lessness at lower health/social care costs






















Patients with non-malignant conditions
and their carers described a range of im-
pacts including reduced fear, anxiety, wor-
ry, and feelings of panic, as well as feeling
more confident about breathlessness. They
valued the multidisciplinary sta, expertise
(their knowledge and understanding of life
with breathlessness), the characteristics of
the BIS sta, (their approachability and at-
tentiveness) and their reassuring and posi-
tive approach, and the time BIS gave them
to talk about breathlessness with an expert.
They reported that being seen at home was
especially helpful. The findings suggest that
it was not only the provision of these inter-
ventions that was important, but also that
how they were delivered was key to their im-
pact: delivery of interventions through the
provision of knowledge (why and how inter-
ventions work or specific guidance on how
and when to use a particular intervention)
increased patients’ and carers’ confidence.
Primary outcome:
There was no difference between groups
in the primary outcome ("distress due to
breathlessness"), when compared to stan-
dard care, of –0.24 (95 % CI: –1.30, 0.82).
Secondary outcomes:
Mean CRQ mastery scores improved slight-
ly on both arms with greater improvement
in the intervention arm. No differences were
found between trial arms on other CRQ
domains (dyspnoea, fatigue or emotional
function). Mean patient anxiety scores de-
creased slightly for the intervention arm and
increased slightly for the control arm and
mean depression scores decreased slightly
in the intervention arm and remained stable
for controls; no between-group difference
was found. Mean anxiety scores for carers
achieved a greater, 1.65-point, reduction in
the intervention arm compared with a 0.15-
point reduction for controls, adjusted dif-
ference of –1.22 (95 % CI: –2.84 to 0.40), P =
0.14. There was little change in other patient
or carer secondary outcomes.
Carers of patients randomised to the inter-
vention arm achieved a greater, 1.03-point,
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reduction in their distress due to their pa-
tient’s breathlessness compared with a 0.2-
point increase for controls, adjusted dif-
ference of –0.42 (95 % CI: –1.86 to 1.02), P
= 0.56. BIS resulted in extra mean costs of





















Patients expressed concerns about hospital
palliative care as it might prevent them from
receiving more aggressive treatment. Most
patients did not engage with advanced care
options.
Primary outcome:
There was no difference between groups in
the primary outcome (election vs non-elec-
tion of measure of comfort-oriented care)























Patients described poor recollection of the
RCT and difficulties understanding the pal-
liative care intervention. No major differ-
ences were observed between patients who
received the specialised intervention and
those who did not. Content analysis em-
phasised that although they experienced
disabling symptoms, participants tended
to attribute their limitations to problems
other than COPD and some declared that
they were not sick. Patients reported restric-
tions due to oxygen therapy, and the bur-
den of becoming dependent on it. This de-
pendence resulted in intense anxiety, lead-
ing participants to focus on the present on-
ly. A strong feeling of perceived helplessness
emerged from the patients' interviews.
Primary outcomes:
Patients in the HSPC group were hospi-
talised for respiratory failure (incidence
rate ratio (IRR) 1.87, 95% CI 1.04 to 3.48, P =
0.026) and admitted to the emergency ward
(IRR 2.05, 95% CI 1.11 to 3.94, P = 0.014)
twice as often during follow-up than the
control group. However, after the Benjami-
ni and Hochberg correction for multiple
testing, none of these differences was sig-
nificant. Furthermore, median values were
identical in both groups (hospitalisation:
median (IQR): 0.0 (1 to 2) vs. 1.5 (1 to 4), P =
0.219; admissions to emergency wards: 1.0
(0; 3) vs. 1.0 (0; 4), P = 0.484).
Secondary outcomes:
There was no difference in HRQoL assessed
using the SF-36 between the HSPC and con-
trol group. There was no difference in anxi-
ety and depression measured by the HADS-
anxiety and HADS-depression between the
intervention and control group. At inclu-
sion, 3 patients in each group had complet-
ed their advanced care planning (ACP) direc-
tives (P = 1.00). At the end of the study, 9 pa-
tients (35%) of the intervention group versus
3 (13%) of the control group had completed
ACP directives (P = 0.194). There was there-
fore a difference in the number of patients
who wrote their ACP directives in favour
of the intervention group (P = 0.023). Sur-
vival did not differ between the groups (P =
0.913). 8 deaths occurred, 4 in each group.
In the intervention group, survival was 454
days (1.24 years; 95% CI: 382 to 525 vs. 425
days (1.16 years; 95% CI: 339 to 509) in the
control group; P = 0.592.
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Patients reported that having time to talk,
appropriate pain medication and effective
health education was of therapeutic value
for their psychological well-being. Integra-
tion of mixed method findings suggested
that positive effect in quantitative measures
of mental health and well-being were attrib-
utable to the active ingredients of: appropri-
ate medication, effective health education
and counselling, and having time to talk in
clinical encounters. Mechanisms of action
included symptom relief, improved under-
standing of illness and treatment, and sup-
port focussed on articulated concerns.
Participants whose quality of life remained
static or deteriorated reported concurrent
intractable physical or social problems
which prevented them from fulfilling their
social roles and led to financial difficulties.
This in turn led to stress, which was a barrier
to positive psychological well-being.
Primary outcome:
In the control group, median pain score
on the pain item of the APOS (range: 0 to
5; 0 indicates worst pain) improved from
1.0 (IQR 0.0 to 2.0) at baseline to 5.0 (3.0 to
5.0) at 4 months; in the HSPC group, it im-
proved from 1.0 (0.0 to 2.0) at baseline to
4.5 (3.0 to 5.0) at 4 months. There was no be-
tween-group difference (coefficient -0.01,
95% CI -0.36 to 0.34, P = 0.95).
Secondary outcomes:
Person-centred assessment and care deliv-
ered by sta, who had received additional
training had positive effects on self-reported




























Three themes emerged from the interviews:
'expectations,' 'met and unmet needs', and
'barriers'. Participants described benefits
from the intervention such as improved con-
trol of symptoms and reduced sense of iso-
lation of the patient-caregiver dyads. Pa-
tient-caregiver dyads valued the expertise of
the HSPC team. Limitations identified that
included factors related to experimental de-
sign (difficulty of dyads in identifying exam-
iner and team roles, additional burden for
caregivers); team issues (insufficient team
building/supervision, competing priorities);
limitations of the intervention itself (insuf-
ficient length, lack of rehabilitation input);
and external factors (resource limitations,
under-responsive services/professionals).
The referring physician focus groups provid-
ed little experiential data.
Primary outcomes:
There was greater reduction in symptom
burden (POS-S-MS) in the HSPC group com-
pared to usual care (P = 0.047). Effect size
was 0.20 at 3 months and 0.32 at 6 months.
Changes in quality of life (SEIQoL-DW index)
did not differ between the two groups.
Secondary outcomes:
There were no differences between the sec-
ondary patient (POS, HADS, FIM total score)
and carer outcomes (ZBI) at three and six
months. There were 22 serious adverse
events in 20 patients, 15 events in 13 pa-
tients in the HSPC group (30%) and 7 events































Patients identified consistent communi-
cation, emotional support, and pain and
symptom management as positive contribu-
tions delivered by the intervention. Consis-
tent communication was described in terms
of the team as a whole and their focus on
individualising patients’ pain and comfort
needs. When describing emotional support
or 'being there' participants emphasised the
support and reassurance they felt knowing
the Pain and Palliative Care Team was avail-
Primary outcomes and
secondary outcomes:
There was no difference between HSPC and
control group. However, for those who re-
mained on study for 12 months, the HSPC
group performed better than their standard
of care counterparts.
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able across time. They saw team members
as their advocates.
Table 16.   Studies with qualitative components  (Continued)
ACP:
APOS: African Palliative Care Outcome Scale
BIS:
CI:
CNS: Clinical Nurse Specialist
COPD:
CRQ: Chronic Respiratory Questionnaire
ENABLE II:
FIM:
GBP: Great British Pounds
GP: General Practitioner
HADS: Hospital Anxiety and Depression Scale
HF:
HIV:












SEIQoL-DW index: Schedule for the Evaluation of Individual Quality of Life-Direct Weighting index
SF-36:
ZBI: Zarit Burden Inventory
 
 
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1.exp Palliative Care/
2 exp Terminal Care/
3 exp Terminally Ill/
4 palliat*.mp.
5 (terminal* adj5 (care or caring)).mp.
6 ((advanced or terminal) adj5 (ill* or disease*)).mp.
7 (end stage or end of life or last year of life or LYOL or life's end).mp.
8 or/1-7
9 (home adj5 (hospital or palliat*)).mp.
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10 ((outreach or hospital at home or outpatient or out-patient or ambulatory or posthospital or post-hospital or consult*) adj2 (care or




14 ((hospital* or inpatient*) adj2 (base* or care or center* or centre* or interven* or management or model* or nurs* or program* or service*
or team* or therap* or treat*)).mp.
15 hospice*.mp.
16 or/9-15
17 8 and 16
18 (child* or adolescent* or infant* or baby or babies or neonat* or juvenil* or pediatric* or paediatric* or young person* or young people
or youth* or young adult*).ti.
19 17 not 18
20 randomized controlled trial.pt.






27 (random* or control* or intervention* or evaluat*).tw.
28 ("before and aKer" or case control* or cohort study or quasi experiment* or time series).tw.
29 or/20-28
30 19 and 29
31 exp budgets/ or exp "costs and cost analysis"/ or economics/ or exp economics, hospital/ or exp economics, medical/ or economics,
nursing/ or exp "fees and charges"/ or exp resource allocation/ or value of life/
32 (cost* or economic*).ti. or (cost* adj2 (e,ective* or utilit* or benefit* or minimi*)).ab. or economic model*.tw. or (budget* or fee* or
financ* or price* or pricing or resourc* allocat* or (value adj2 (monetary or money))).ti,ab.
33 31 or 32
34 19 and 33
35 30 or 34
36 (animals not (humans and animals)).sh.
37 35 not 36
Appendix 2. Embase search strategy
1 exp palliative therapy/
2 exp terminal care/
3 exp terminally ill patient/
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4 palliat*.tw.
5 (terminal* adj5 (care or caring)).tw.
6 ((advanced or terminal) adj5 (ill* or disease*)).tw.
7 (end stage or end of life or last year of life or LYOL or life's end).tw.
8 or/1-7
9 (home adj5 (hospital or palliat*)).tw.
10 ((outreach or hospital at home or outpatient or out-patient or ambulatory or posthospital or post-hospital or consult*) adj2 (base* or




14 12 or 13
15 exp hospital/
16 exp hospital patient/
17 ((hospital* or inpatient*) adj2 (base* or care or center* or centre* or interven* or management or model* or nurs* or program* or service*
or team* or therap* or treat*)).tw.
18 or/15-17
19 14 or 18
20 (child* or adolescent* or infant* or baby or babies or neonat* or juvenil* or pediatric* or paediatric* or young person* or young people
or youth* or young adult*).tw.







28 (doubl$ adj blind$).tw.






35 randomized controlled trial/
36 single blind procedure/
The eectiveness and cost-eectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers
(Review)









Cochrane Database of Systematic Reviews
37 ("before and aKer" or case control* or cohort study or quasi experiment* or time series).tw.
38 or/22-37
39 8 and 21 and 38
40 exp budgets/ or exp "costs and cost analysis"/ or economics/ or exp economics, hospital/ or exp economics, medical/ or economics,
nursing/ or exp "fees and charges"/ or exp resource allocation/ or value of life/
41 (cost* or economic*).ti. or (cost* adj2 (e,ective* or utilit* or benefit* or minimi*)).ab. or economic model*.tw. or (budget* or fee* or
financ* or price* or pricing or resourc* allocat* or (value adj2 (monetary or money))).ti,ab.
42 40 or 41
43 8 and 21 and 42
44 39 or 43
45 (animal/ or nonhuman/) not human/
46 44 not 45
Appendix 3. PsycINFO search strategy
 
1 exp Palliative Care/
2 exp Terminally Ill Patients/
3 palliat*.tw.
4 (terminal* adj5 (care or caring)).tw.
5 ((advanced or terminal) adj5 (ill* or disease*)).tw.
6 (end stage or end of life or last year of life or LYOL or life's end).tw.
7 or/1-6
8 (home adj5 (hospital or palliat*)).tw.
9 ((outreach or hospital at home or outpatient or out-patient or ambulatory or posthospital or post-
hospital or consult*) adj2 (base* or care or center* or centre* or interven* or management or mod-




13 11 or 12
14 exp HOSPITALS/
15 exp Hospitalized Patients/
16 ((hospital* or inpatient*) adj2 (base* or care or center* or centre* or interven* or management or
model* or nurs* or program* or service* or team* or therap* or treat*)).tw.
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17 or/14-16
18 13 or 17
19 (child* or adolescent* or infant* or baby or babies or neonat* or juvenil* or pediatric* or paedi-
atric* or young person* or young people or youth* or young adult* or matern*).tw.
20 18 not 19
21 exp Clinical Trials/
22 (randomis* or randomiz*).tw.
23 (random$ adj3 (allocat$ or assign$)).tw.
24 ((clinic$ or control$) adj trial$).tw.
25 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
26 (crossover$ or "cross over$").tw.
27 exp Random Sampling/
28 exp Experiment Controls/
29 exp PLACEBO/
30 placebo$.tw.
31 exp Program Evaluation/
32 exp Treatment Effectiveness Evaluation/
33 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
34 or/21-33
35 ("before and after" or case control* or cohort study or quasi experiment* or time series).tw.
36 34 or 35
37 7 and 20 and 36
38 (cost* or economic*).ti. or (cost* adj2 (effective* or utilit* or benefit* or minimi*)).ab. or econom-
ic model*.tw. or (budget* or fee* or financ* or price* or pricing or resourc* allocat* or (value adj2
(monetary or money))).ti,ab.
39 exp BUDGETS/
40 exp health care costs/ or exp "costs and cost analysis"/
41 exp Resource Allocation/
42 exp Health Care Economics/
43 or/38-42
  (Continued)
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44 7 and 20 and 43
45 37 or 44
46 limit 45 to human
  (Continued)
 
Appendix 4. CINAHL search strategy
 
S45 S43 not S44
S44 TI (animals not (humans and animals))
S43 S33 or S42
S42 S8 and S21 and S41
S41 S34 or S35 or S36 or S37 or S38 or S39 or S40
S40 MH economic value of life
S39 MH resource allocation
S38 MH fees and charges
S37 MH economics
S36 MH costs and cost analysis
S35 MH budgets
S34 TX ((cost* or economic*)) OR AB ((cost* N2 (effective* or utilit* or benefit* or minimi*)) OR ((eco-
nomic model* or (budget* or fee* or financ* or price* or pricing or resourc* allocat* or (value N2
(monetary or money))
S33 S8 and S21 and S32
S32 S30 or S31
S31 TX ("before and after" or case control* or cohort study or quasi experiment* or time series)
S30 S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29
S29 TX (allocat* random*)
S28 MH quantitative studies
S27 MH placebos
S26 TX placebo*
S25 TX (random* allocat*)
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S24 MH random assignment
S23 TX (Randomi?ed control* trial*)
S22 TX (singl* blind*) or (doubl* blind*) or (tripl* blind*) or (trebl* blind*) or (trebl* mask*) or (tripl*
mask*) or (doubl* mask*) or (singl* mask*)
S21 S19 not S20
S20 TI (child* or adolescent* or infant* or baby or babies or neonat* or juvenil* or pediatric* or paedi-
atric* or young person* or young people or youth* or young adult*)
S19 S14 or S18
S18 S15 or S16 or S17
S17 TX ((hospital* or inpatient*) N2 (base* or care or center* or centre* or interven* or management or
model* or nurs* or program* or service* or team* or therap* or treat*))
S16 MH inpatients
S15 MH hospitals
S14 S12 or S13
S13 TX hospice*
S12 S9 or S10 or S11
S11 MH outpatients
S10 TX (outreach or hospital at home or outpatient or out-patient or ambulatory or posthospital or
post-hospital or consult*) and (base* or care or center* or centre* or interven* or management or
model* or nurs* or program* or service* or team* or therap* or treat*))
S9 TX home and (hospital or palliat*)
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
S7 TX (end stage or end of life or last year of life or LYOL or life's end)
S6 TX ((advanced or terminal) N5 (ill* or disease*))
S5 TX (terminal* N5 (care or caring))
S4 TX palliat*
S3 MH terminally ill patients
S2 MH terminal care
S1 MH palliative care
  (Continued)
 
Appendix 5. Cochrane Library (CENTRAL, CDSR, DARE, HTA, NHS EDD) search strategy
#1 MeSH descriptor: [Palliative Care] explode all trees
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#2 MeSH descriptor: [Terminal Care] explode all trees
#3 MeSH descriptor: [Terminally Ill] explode all trees
#4 palliat*:ti,ab,kw
#5 (terminal* near/5 (care or caring)):ti,ab,kw
#6 ((advanced or terminal) near/5 (ill* or disease*)):ti,ab,kw
#7 (end stage or end of life or last year of life or LYOL or life's end):ti,ab,kw
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 (home near/5 (hospital or palliat*)):ti,ab,kw
#10 ((outreach or hospital at home or outpatient or out-patient or ambulatory or posthospital or post-hospital or consult*) near/2 (base*
or care or center* or centre* or interven* or management or model* or nurs* or program* or service* or team* or therap* or treat*)):ti,ab,kw
#11 MeSH descriptor: [Outpatients] explode all trees
#12 #9 or #10 or #11
#13 hospice*:ti,ab,kw
#14 #12 or #13
#15 MeSH descriptor: [Hospitals] explode all trees
#16 MeSH descriptor: [Inpatients] explode all trees
#17 ((hospital* or inpatient*) near/2 (base* or care or center* or centre* or interven* or management or model* or nurs* or program* or
service* or team* or therap* or treat*)):ti,ab,kw
#18 #15 or #16 or #17
#19 #14 or #18
#20 #8 and #19
#21 (child* or adolescent* or infant* or baby or babies or neonat* or juvenil* or pediatric* or paediatric* or young person* or young people
or youth* or young adult*):ti
#22 (#20 and not #21)
Appendix 6. CareSearch search strategy
1. Inpatient
2. Hospital
3. #1 OR #2
4. (((Palliative) OR Terminal) OR End stage) OR End of life
5. #3 AND #4
6. Outpatient
7. Outreach
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12. #6 OR #7 OR #8 OR #9 OR #10 OR #11
13. Hospice
14. 12 or 13
15. (((Palliative) OR Terminal) OR End stage) OR End of life
16. #14 AND #15
17. #5 OR #16
Appendix 7. Items to be included in the data extraction form
Study details
• publication details (author(s), year, journal);
• country of origin;
• verification of the study eligibility;
• aim/hypothesis;
• type of hospital.
Study design and methods
• study design;
• type of intervention and control (if used);
• inclusion/exclusion criteria;
• allocation sequence procedures;
• allocation concealment;
• type of blinding;
• details of blinding (including instances of blinding being compromised);
• data collection period;
• baseline measurement(s);
• number of follow-ups;
• time that follow-ups occurred;
• sample size (number in each group);
• sample size calculations;
• outcome measures used (di,erentiating primary and secondary);
• recruitment rate;
• method of analysis;
• method of managing missing data;
• study participant characteristics for patient and unpaid caregiver (e.g. age, sex, race, sexual orientation, diagnosis);
• selective reporting.
Intervention(s) and comparator(s)
• setting of intervention;
• type of intervention;
• sta, composition;
• sta, training and experience;
• components of intervention;
• frequency of intervention;
• duration of intervention.
Primary outcome
• Patient health-related quality of life
• Patient symptom burden
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Secondary outcomes
• Patient satisfaction with care;
• unpaid caregiver/family satisfaction with care;
• Achieving patient's preferred place of death;
• Achieving patient's preferred place of care;
• Patient mortality/survival;
• Pain;
• Patient anxiety and depression;
• Breathlessness;
• Adverse events in participants and unpaid caregivers;
• unpaid caregiver symptom control, specifically physical, psychological (e.g. anxiety and depression), social or spiritual domains,
reported through validated assessment scales and burden, including emotional strain, burden, distress, mastery or positive aspects of
caregiving; and
• Unpaid caregiver pre- and post-bereavement outcomes, reported using outcome scales of multidimensional caregiving experiences
(strain, distress, positive appraisals, and family well-being), unpaid caregiver prolonged grief, multidimensional grief responses
(despair, panic behaviour, blame and anger, detachment, disorganisation and personal growth), quality of life.
Costs (resource use)
• Resource use: institutional care services use, outpatient clinic services use, community care services use, unpaid caregiver's care, and
medications and other resources;
• Costs and cost-e,ectiveness.
Appendix 8. Quality assessment of economic evaluations with total costs
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1. The research question is stated Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
2. The economic importance of the research question is
stated
Yes No No Yes Yes Yes No Yes Un-
clear
Yes Yes No Yes










No Yes No No Yes
4. The rationale for choosing the alternative programmes
or interventions compared is stated
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes






























Yes No No Yes
7. The choice of form of economic evaluation is justified in
relation to the questions addressed
Un-
clear
No No No Yes No No No No Yes No No Yes
                           
Data collection                          
8. The source(s) of effectiveness estimates used are stated Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
9. Details of the design and results of effectiveness study
are given
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
10. The primary outcome measure(s) for the economic
evaluation are clearly stated
Un-
clear
Yes Yes Yes Yes Yes No Un-
clear
No Yes No No Yes
11. Methods to value health states and other benefits are
stated














































































































































































12. Details of the subjects from whom valuations were ob-
tained are given
n/a Yes Yes n/a Yes Yes n/a Yes n/a n/a n/a n/a Yes
13. Productivity changes (if included) are reported sepa-
rately
n/a n/a n/a n/a No No n/a n/a No n/a n/a n/a No
14. The relevance of productivity changes to the study
question is discussed
No No No No No No No n/a No No No No No




Yes Yes Yes Yes Yes No Yes Yes Yes No No No
16. Methods for the estimation of quantities and unit costs
are described
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes
17. Currency and price data are recorded Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
18. Details of currency of price adjustments for inflation or
currency conversion are given
No Yes Yes No No No No No No No No No No
19. Details of any model used are given n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
20. The choice of model used and the key parameters on
which it is based are justified
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
                           
Analysis and interpretation of results                          
21. Time horizon of costs and benefits is stated Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
22. The discount rate(s) is stated n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
23. The choice of rate(s) is justified n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
24. An explanation is given if costs or benefits are not dis-
counted
No No No n/a n/a n/a No n/a n/a Yes n/a n/a n/a
25. Details of statistical tests and confidence intervals are





Yes Yes Yes No No No Yes No No Yes














































































































































































27. The choice of variables for sensitivity analysis is justi-
fied
n/a No n/a n/a n/a n/a n/a n/a Yes Yes n/a n/a Yes
28. The ranges over which the variables are varied are
stated
n/a No n/a n/a n/a n/a n/a n/a Yes Yes n/a n/a Yes
29. Relevant alternatives are compared Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
30. Incremental analysis is reported Yes Yes Yes No Yes No No No Yes Yes No No Un-
clear
31. Major outcomes are presented in a disaggregated as
well as aggregated form
No Yes Yes Yes No Yes No No Yes Yes Yes No Un-
clear
32. The answer to the study question is given Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
33. Conclusions follow from the data reported Yes Yes Yes Yes Yes Yes Yes Un-
clear
Yes Yes Yes Yes Yes
34. Conclusions are accompanied by the appropriate
caveats
Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes No Yes





































































Cochrane Database of Systematic Reviews
Notes:
n/a: not applicable
Appendix 9. Assessment of methodological quality of economic studies using the CHEC list
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1. Is the study population clearly described? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
2. Are competing alternatives clearly described? No No No No No Yes Yes No No No No No No
3. Is a well-defined research question posed in answer-
able form?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
4. Is the economic study design appropriate to the stated
objective?
No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
5. Is the chosen time horizon appropriate in order to in-
clude relevant costs and consequences?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
6. Is the actual perspective chosen appropriate? No No No No Yes No No Yes No No Yes No No
7. Are all important and relevant costs for each alternative
identified?
Yes Yes Yes Yes Yes No Yes No Yes No Yes Yes No
8. Are all costs measured appropriately in physical units? Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No No
9. Are costs valued appropriately? No Yes Yes Yes Yes Yes Yes Yes Yes No Yes No No
10. Are all important and relevant outcomes for each al-
ternative identified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
11. Are all outcomes measured appropriately? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
12. Are outcomes valued appropriately? No Yes Yes No No No No Yes Yes No Yes No No
13. Is an incremental analysis of costs and outcomes of al-
ternatives performed?
No Yes Yes No Yes No No No No No Yes No No
14. Are all future costs and outcomes discounted appro-
priately?














































































































































































15. Are all important variables, whose values are uncer-
tain, appropriately subjected to sensitivity analysis?
No Yes Yes No Yes No No No No No Yes No No
16. Do the conclusions follow from the data reported? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
17. Does the study discuss the generalisability of the re-
sults to other settings and patient/client groups?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
18. Does the article indicate that there is no potential con-
flict of interest of study researcher(s) and funder(s)?
No Yes Yes No No Yes Yes Yes Yes No Yes No Yes
19. Are ethical and distributional issues discussed appro-
priately?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes
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There are a number of di,erences between the published protocol (Bajwah 2017), and this review.
Study design
In the published protocol, we stated that we will include a number of study designs including randomised trials, non-randomised trials,
controlled before-and-aKer studies, interrupted time series studies and repeated measures studies. Due to the expansion of our review
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from only inpatient specialist palliative care to include other models of HSPC (HSPC) and given that RCTs are the most rigorous study
design, we refrained from analysing studies that were not RCTs in order to reduce heterogeneity and allow meta-analyses where possible.
We initially wanted to minimise cross-contamination by including only cluster-randomised studies. However, our project advisory group
suggested that both cluster and non-cluster-RCTs should be included to capture the breadth of evidence from RCTs that met our eligibility
criteria.
Intervention
The published protocol was focussed on assessing the e,ectiveness and cost-e,ectiveness of inpatient specialist palliative care in acute
hospitals for adults with advanced illness and their unpaid caregivers. However, we expanded the scope of our review from inpatient
specialist palliative care to all models of HSPC, and the title has been amended to reflect this. Given that models of HSPC are evolving,
we broadened the review to increase relevance for clinical practice and policy makers with the potential to aid the future development,
funding and implementation of evidence-based HSPC. As a result of expanding the scope of our review to cover models of HSPC, we also
expanded the scope of usual care to "inpatient or outpatient hospital care without specialist palliative care input at the point of entry into
the study, community care or hospice care provided outside of the hospital setting".
In our protocol, we stated that the intervention should be administered by hospital sta, who have completed specialist training in palliative
care or who had obtained clinical competencies and professional characteristics required for the delivery of inpatient specialist palliative
care through clinical experience. Experts in our project advisory group recommended that we include studies where the training of the
palliative care team was unclear, with eligibility informed by activity of delivering specialist palliative care rather than level of specialist
training. In order to capture this di,erence, we included studies where the training/clinical competence of the palliative care team was
described as well as studies that simply stated the involvement of a palliative care team.
Outcomes
We changed our primary outcome from pain to two primary outcomes, patient HRQoL (previously, a secondary outcome) and patient
symptom burden assessed using a composite measure of two or more symptoms (a new outcome we introduced following expert advice).
The clinical experts on our project advisory group suggested that pain may not be an appropriate outcome for those with non-malignant
conditions, where pain may be less prevalent compared to patients with cancer. Furthermore, the aim of palliative care is to improve quality
of life, while also ensuring e,ective symptom management.
We have further provided clarity around the outcomes we presented in our protocol.
• We included number of home deaths in the review as a proxy for achieving patient preferred place of death, as people’s preference is
mostly to die at home (Gomes 2012).
• In our protocol, one of our secondary outcomes was patient's other symptoms (e.g. physical, psychological, social or spiritual domains).
We specifically presented data on patient anxiety and patient depression for this outcome.
• Another secondary outcome in our protocol was satisfaction with care, which we reported as patient satisfaction with care and unpaid
caregiver satisfaction with care in this review.
• We had unpaid caregiver symptom control (e.g. physical, psychological, social or spiritual domains) as an outcome in our protocol. In
this review, we presented unpaid caregiver anxiety and caregiver depression for caregiver symptom control.
• For the caregiver pre- and post-bereavement outcome we reported in the protocol, we presented caregiver grief and caregiver quality
of life.
• Although we presented achieving preferred place of care or death as one outcome in the protocol, we split it into two outcomes in the
review: achieving patient preferred place of death and achieving patient preferred place of care.
• We added a new secondary outcome (breathlessness) to this review because of the recommendations we received from clinical experts
in our project advisory group on its relevance as an appropriate outcome in non-malignant conditions.
Given the expansion of these outcomes, there has been a change in the order of the outcomes reported in this review compared to
the protocol. Compared to our protocol, we now have two economic outcomes: resource use; costs and cost-e,ectiveness. Resource
use encompasses institutional care services use, outpatient clinic services use, community care services use, unpaid caregiver care and
medication and other resources. Where possible, we summarised data on cost and cost-e,ectiveness of HSPC.
Data analysis and assessments
We added early versus late palliative care as a subgroup analysis which was recommended for inclusion in our review by clinical experts
because of its relevance to practice. Although we had initially specified that pain and other outcomes presented as binary data will be
treated as binary outcomes in our published protocol, this was not possible as most studies presented their outcomes as continuous data.
The only outcome where we were able to calculate an odds ratio and 95% confidence intervals in addition to standardised mean di,erences
was patient depression.
We expanded our risk of bias (ROB) methods by carrying out separate assessments for all subjective outcomes (e.g. health-related quality
of life) and all objective outcomes (e.g. mortality). Where studies did not include either subjective or objective outcomes, we leK the domain
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that was not included blank. We added the domain 'Other bias (other sources of bias)' in the full review in order to assess whether groups
were balanced at baseline and whether di,erences at baseline were adjusted for. We further expanded on the response options for 'size
of study bias'. In particular, we assessed the following as unclear risk of bias under 'size of study bias': studies that had < 50 participants
in one treatment arm and 50 to 199 participants in another treatment arm; and studies that had 50 to 199 participants in one treatment
arm and > 200 participants in another treatment arm.
We had planned to use either a fixed-e,ects or random-e,ects model for meta-analysis. Due to the di,erent models of HSPC in our review,
we presented only random-e,ects models as we are estimating the average e,ect across HSPC rather than any single true e,ect. We
had planned to estimate an intra-class correlation coe,icient (ICC) where the authors of cluster-RCTs did not carry out adjustment or
provide an ICC. However, we decided to use an estimate of ICC we obtained from a previous Cochrane Review in adjusting for clustering
in McCorkle 2015. We contacted the authors of McCorkle 2015 for their ICC but at the time of publication they have not responded. In
our protocol we stated that we would contact the original investigators for missing data and describe any strategy used for imputing
missing data. We decided to only contact authors for missing data without carrying out imputations as this is the preferred method for
dealing with missing data (Higgins 2011). We initially wanted to explore reasons for heterogeneity in sensitivity analysis. However, Cochrane
editors recommended the use of subgroup analysis for assessing heterogeneity. Consequently, we explored heterogeneity using subgroup
analysis, while we used sensitivity analysis to test the estimate we used in adjusting for clustering in the cluster-RCT. As we did not include
nonrandomised studies, we did not have to pay particular attention to selection bias and reporting bias in such studies. We did not carry
out a subgroup analysis assessing provision of single or few components of HSPC because very few studies provided a single component
of HSPC. One of our subgroup analyses in the protocol was models of specialist palliative care. In our protocol, we have clarified this as
models of HSPC because we expanded our review to include more models of HSPC.
Given that combining endpoint scores and change scores is not recommended when using standardised mean di,erences (SMDs) and also
that Cochrane does not recommend pooling adjusted and unadjusted estimates together, we pooled studies presenting adjusted endpoint
scores as our main meta-analysis, while we carried out sensitivity analyses with studies reporting unadjusted endpoint scores, adjusted
change scores and unadjusted change scores. This is a change from our protocol based on advice from Cochrane editors.
In our protocol, we planned to include three 'Summary of Findings' tables: inpatient hospital specialist palliative care and usual care versus
inpatient hospital care without any specialist palliative care input (e.g. oncological care only); inpatient hospital specialist palliative care
and usual care versus community care (e.g. primary or specialist care provided in the patient’s place of residence); and inpatient hospital
specialist palliative care and usual care versus hospice care provided outside of the hospital setting. We decided to present only one
'Summary of Findings' (SoF) table, rather than three, for the comparison of HSPC (plus or minus usual care) versus usual care as experts
in our project advisory group advised us this comparison alone would be the most informative for decision-makers. We expanded usual
care to "inpatient or outpatient hospital care without specialist palliative care input at the point of entry into the study, community care or
hospice care provided outside of the hospital setting". We presented results on both cost and cost-e,ectiveness in our SoF table as opposed
to only cost-e,ectiveness in our protocol.
We initially stated that we would rate the strength of the evidence using a tool by Van Tulder 2003. However, we decided to use the GRADE
approach in accordance with Cochrane standards.
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